UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 20-F
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2017
Commission File No.: 001-38370
CollPlant Holdings Ltd.
(Exact name of registrant as specified in its charter)
Translation of registrant’s name into English: Not applicable
State of Israel
(Jurisdiction of incorporation or organization)
3 Sapir Street, Weizmann Science Park
Ness Ziona 74140, Israel
Tel: +972 73 232 5600
(Address of principal executive offices)
Yehiel Tal
Chief Executive Officer
+972 73 232 5600
Yehiel@collplant.com
3 Sapir Street, Weizmann Science Park
Ness Ziona 74140, Israel
(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)
Securities registered or to be registered pursuant to Section 12(b) of the Act:
Title of each class to be registered
American Depositary Shares, each representing fifty (50) ordinary
shares, par value NIS 0.03 per share
Name of each exchange on which each class is to be
registered
The Nasdaq Stock Market LLC
Ordinary shares, par value NIS 0.03 per share*
The Nasdaq Stock Market LLC*
* Not for trading, but only in connection with the registration of the American Depositary Shares pursuant to requirements of the Securities
and Exchange Commission.
Securities registered or to be registered pursuant to Section 12(g) of the Act: None
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None
Number of outstanding shares of each of the issuer’s classes of capital or common stock as of December 31, 2017: 166,816,287 ordinary
shares.
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Yes ☐ No ☒
If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or
15(d) of the Exchange Act of 1934.
Yes ☐ No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act
during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.
Yes ☐ No ☒
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months.
Yes ☐ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth
company.
Large accelerated filer
☐
Accelerated filer
☐
Non-accelerated filer
Emerging Growth Company
☒
☒
If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing.
U.S. GAAP ☐
International Financial Reporting Standards as issued by the International Accounting Standards Board ☒
Other ☐
If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has
elected to follow.
☐ Item 17 ☐ Item 18
If this is an annual report, indicate by check mark whether the registrant is a shell company.
Yes ☐ No ☒
TABLE OF CONTENTS
INTRODUCTION
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
EXPLANATORY NOTE
ITEM 1.
ITEM 2.
ITEM 3.
A.
B.
C.
D.
ITEM 4.
A.
B.
C.
D.
ITEM 4A.
ITEM 5.
A.
B.
C.
D.
E.
F.
ITEM 6.
A.
B.
C.
D.
E.
ITEM 7.
A.
B.
C.
ITEM 8.
A.
B.
ITEM 9.
A.
B.
C.
D.
E.
F.
PART I
IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS
OFFER STATISTICS AND EXPECTED TIMETABLE
KEY INFORMATION
Selected Financial Data
Capitalization and Indebtedness
Reasons for the Offer and Use of Proceeds
Risk Factors
INFORMATION ON THE COMPANY
History and Development of the Company
Business Overview
Organizational Structure
Property, Plants and Equipment
UNRESOLVED STAFF COMMENTS
OPERATING AND FINANCIAL REVIEW AND PROSPECTS
Operating Results
Liquidity and Capital Resources
Research and Development, Patents and Licenses
Trend Information
Off-Balance Sheet Arrangements
Tabular Disclosure of Contractual Obligations
DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES
Directors and Senior Management
Compensation
Board Practices
Employees
Share Ownership
MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS
Major Shareholders
Related Party Transactions
Interests of Experts and Counsel
FINANCIAL INFORMATION
Consolidated Statements and Other Financial Information
Significant Changes
THE OFFER AND LISTING
Offer and Listing Details
Plan of Distribution
Markets
Selling Shareholders
Dilution
Expenses of the Issue
i
Page
iii
iii
v
1
1
1
1
3
3
3
45
45
46
71
71
71
71
77
81
84
84
84
84
85
85
88
93
106
106
108
108
110
113
113
113
114
115
115
116
116
116
116
116
Table of Contents
ITEM 10.
A.
B.
C.
D.
E.
F.
G.
H.
I.
ITEM 11.
ITEM 12.
A.
B.
C.
D.
ADDITIONAL INFORMATION
Share Capital
Articles of Association
Material Contracts
Exchange Controls
Taxation
Dividends and Paying Agents
Statement by Experts
Documents on Display
Subsidiary Information
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES
Debt Securities
Warrants and rights
Other Securities
American Depositary Shares
PART II
DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES
ITEM 13.
MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS
ITEM 14.
CONTROLS AND PROCEDURES
ITEM 15.
AUDIT COMMITTEE FINANCIAL EXPERT
ITEM 16A.
CODE OF ETHICS
ITEM 16B.
PRINCIPAL ACCOUNTANT FEES AND SERVICES
ITEM 16C.
EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES
ITEM 16D.
PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS
ITEM 16E.
CHANGE IN REGISTRANT’S CERTIFYING ACCOUNTANT
ITEM 16F.
ITEM 16G.
CORPORATE GOVERNANCE
ITEM 16H. MINE SAFETY DISCLOSURE
ITEM 17.
ITEM 18.
ITEM 19.
SIGNATURES
FINANCIAL STATEMENTS
FINANCIAL STATEMENTS
EXHIBITS
PART III
ii
116
116
116
122
126
126
138
138
138
138
138
139
139
139
139
139
140
140
140
141
141
141
142
142
142
142
142
143
144
144
144
147
Table of Contents
INTRODUCTION
We are a regenerative medicine company focused on developing and commercializing tissue repair products, initially for 3D-bio
printing of tissues and organs, orthobiologics, and advanced wound care markets. Our products are based on our recombinant type I human
collagen, or rhCollagen, a form of human collagen produced with our proprietary plant based genetic engineering technology.
On January 31, 2018, our American Depositary Shares, or ADSs, each representing fifty of our ordinary shares commenced
trading on The Nasdaq Capital Market under the symbols “CLGN”. Our ordinary shares have been trading on the Tel Aviv Stock
Exchange, or TASE, since May 2010. The ADSs were quoted on the OTCQX from March 2015 to May 25, 2017, and, prior to listing on
The Nasdaq Capital Market, quoted on the OTCQB from May 26, 2017 to January 30, 2018.
Unless the context requires otherwise, the terms “CollPlant,” “we,” “us,” “our,” “the Company,” and similar designations refer to
CollPlant Holdings Ltd. and its wholly owned subsidiary CollPlant Ltd. References to “ordinary shares”, “ADSs”, “warrants” and “share
capital” refer to the ordinary shares, ADSs, warrants and share capital, respectively, of CollPlant.
References to “U.S. dollars” and “$” are to currency of the United States of America, and references to “NIS” are to New Israeli
Shekels. References to “ordinary shares” are to our ordinary shares, par value NIS 0.03 per share. We report financial information under
International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB, and none of the
financial statements were prepared in accordance with generally accepted accounting principles in the United States.
Unless otherwise indicated, U.S. dollar translations of NIS amounts presented in this annual report on Form 20-F for the year
ended on December 31, 2017 are translated using the rate of NIS 3.467 to $1.00, the exchange rate reported by the Bank of Israel on
December 31, 2017, U.S. dollar translations of NIS amounts presented in this annual report on Form 20-F for the year ended on December
31, 2016 are translated using the rate of NIS 3.845 to $1.00, the exchange rate reported by the Bank of Israel on December 31, 2016, and
U.S. dollar translations of NIS amounts presented in this annual report on Form 20-F for the year ended on December 31, 2015 are
translated using the rate of NIS 3.902 to $1.00, the exchange rate reported by the Bank of Israel on December 31, 2015.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Certain information included or incorporated by reference in this annual report on Form 20-F may be deemed to be “forward-
looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Forward-looking
statements are often characterized by the use of forward-looking terminology such as “may,” “will,” “expect,” “anticipate,” “estimate,”
“continue,” “believe,” “should,” “intend,” “project” or other similar words, but are not the only way these statements are identified.
These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies,
statements that contain projections of results of operations or of financial condition, expected capital needs and expenses, statements
relating to the research, development, completion and use of our products, and all statements (other than statements of historical facts) that
address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future.
Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. We have based
these forward-looking statements on assumptions and assessments made by our management in light of their experience and their
perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate.
iii
Table of Contents
Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated
in these forward-looking statements include, among other things:
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
our history of significant losses and our need to raise additional capital and our inability to obtain additional capital on
acceptable terms, or at all;
our expectations regarding the timing and cost of commencing clinical trials with respect to tissues and organs which are
based on our rhCollagen based Bioink, VergenixSTR, and VergenixFG;
our ability to obtain favorable pre-clinical and clinical trial results;
regulatory action with respect to rhCollagen based BioInk, VergenixSTR, and VergenixFG including but not limited to
acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the
scope of the approved indication and labeling;
commercial success and market acceptance of our rhCollagen based BioInk, VergenixSTR, and VergenixFG;
our ability to establish sales and marketing capabilities or enter into agreements with third parties and our reliance on third
party distributors and resellers;
our ability to establish and maintain strategic partnerships and other corporate collaborations;
our reliance on third parties to conduct some or all aspects of our product manufacturing;
the scope of protection we are able to establish and maintain for intellectual property rights and our ability to operate our
business without infringing the intellectual property rights of others;
the overall global economic environment;
the impact of competition and new technologies;
general market, political, and economic conditions in the countries in which we operate;
projected capital expenditures and liquidity;
changes in our strategy;
litigation and regulatory proceedings; and
those factors referred to in “Item 3.D. Risk Factors,” “Item 4. Information on the Company,” and “Item 5. Operating and
Financial Review and Prospects”, as well as in this annual report on Form 20-F generally.
Readers are urged to carefully review and consider the various disclosures made throughout this annual report on Form 20-F
which are designed to advise interested parties of the risks and factors that may affect our business, financial condition, results of
operations and prospects.
You should not put undue reliance on any forward-looking statements. Any forward-looking statements in this annual report on
Form 20-F are made as of the date hereof and are expressly qualified in their entirety by the cautionary statements included in this annual
report. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
In addition, the section of this annual report on Form 20-F entitled “Item 4. Information on the Company” contains information
obtained from independent industry sources and other sources that we have not independently verified.
iv
Table of Contents
EXPLANATORY NOTE
Market data and certain industry data and forecasts used throughout this annual report were obtained from internal company
surveys, market research, consultant surveys commissioned by the Company, publicly available information, reports of governmental
agencies and industry publications and surveys. Industry surveys, publications, consultant surveys commissioned by the Company and
forecasts generally state that the information contained therein has been obtained from sources believed to be reliable. However, this
information may prove to be inaccurate because of the method by which some of the data for the estimates is obtained or because this
information cannot always be verified with complete certainty due to the limits on the availability and reliability of raw data, the voluntary
nature of the data gathering process and other limitations and uncertainties. As a result, the market and industry data and forecasts included
or incorporated by reference in this annual report, and estimates and beliefs based on that data, may not be reliable. We have relied on
certain data from third-party sources, including internal surveys, industry forecasts and market research, which we believe to be reliable
based on our management’s knowledge of the industry. However, we have not ascertained the underlying economic assumptions relied
upon therein. Forecasts are particularly likely to be inaccurate, especially over long periods of time. In addition, we do not necessarily know
what assumptions regarding general economic growth were used in preparing the forecasts we cite. Statements as to our market position are
based to the best of our knowledge on the most currently available data. While we are not aware of any misstatements regarding the
industry data presented in this annual report, our estimates involve risks and uncertainties and are subject to change based on various
factors, including those discussed under the heading “Risk Factors” in this annual report.
v
Table of Contents
PART I
ITEM 1.
IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS
Not applicable.
ITEM 2.
OFFER STATISTICS AND EXPECTED TIMETABLE
Not applicable.
ITEM 3.
KEY INFORMATION
A. Selected Financial Data
The following table sets forth our selected consolidated financial data for the periods ended and as of the dates indicated. The
following selected consolidated financial data should be read in conjunction with the financial information, “Item 5. Operational and
Financial Review and Prospects” and other information provided elsewhere in this annual report on Form 20-F and our consolidated
financial statements and related notes. The selected consolidated financial data in this section is not intended to replace the consolidated
financial statements and is qualified in its entirety thereby.
The selected consolidated financial data for the fiscal years set forth in the table below have been derived from our consolidated
financial statements and notes thereto. The selected consolidated statement of comprehensive loss data for the years ended December 31,
2017, 2016 and 2015, and the selected consolidated statement of financial position data as of December 31, 2017 and December 31, 2016,
have been derived from our audited consolidated financial statements and notes thereto set forth elsewhere in this annual report on Form
20-F. The selected consolidated statement of financial position data as of December 31, 2015 have been derived from our audited
consolidated financial statements not included in this annual report.
1
Table of Contents
Statement of comprehensive loss data
Revenues
Cost of revenue
Gross Profit
Research and development expenses
Participation in research and development expenses
Research and development expenses, net
General, administrative and marketing expenses
Operating loss
Financial income
Financial expenses
Financial expenses (income), net
Comprehensive loss
Loss per ordinary share, basic and diluted
Weighted average ordinary shares outstanding, basic and diluted
Year ended December 31,
2015
2016
2017
(NIS in thousands except per share data)
2017
(Convenience
translation
into USD
in thousands
except per
share data(1))
—
—
—
22,919
(11,055)
11,864
6,950
18,814
(215)
51
(164)
18,650
0.22
1,668
52
1,616
16,921
(2,855)
14,066
8,303
20,753
(253)
380
127
20,880
0.16
84,672,767 100,624,945 133,187,048
292
—
—
29,200
(12,411)
16,789
11,048
27,545
(93)
441
348
27,893
0.28
481
15
466
4,881
(823)
4,058
2,394
5,986
(74)
110
36
6,022
0.05
(1)
Calculated using the exchange rate reported by the Bank of Israel for December 31, 2017, at the rate of one U.S. dollar per NIS
3.467.
Statement of financial position
Cash and cash equivalents
Total assets
Total liabilities
Total equity
2015
2016
2017
December 31,
(NIS in thousands)
2017
(Convenience
translation
into USD in
thousands(1))
5,317
13,529
3,750
9,779
3,797
14,433
9,273
5,160
17,817
28,045
18,962
9,083
5,139
8,089
5,468
2,621
(1)
Calculated using the exchange rate reported by the Bank of Israel for December 31, 2017 at the rate of one U.S. dollar per NIS
3.467.
2
Table of Contents
The following table sets forth information regarding the exchange rates of NIS per U.S. dollar for the periods indicated. Average
rates are calculated by using the daily representative rates as reported by the Bank of Israel on the last day of each month during the
periods presented.
Annual
2017
2016
2015
2014
2013
Monthly
March 2018 (through March 15, 2018)
February 2018
January 2018
December 2017
November 2017
October 2017
September 2017
High
NIS per U.S. dollars
Low
Average
3.860
3.983
4.053
3.994
3.791
3.469
3.535
3.460
3.550
3.544
3.542
3.584
3.576
3.746
3.761
3.402
3.471
3.431
3.427
3.388
3.467
3.499
3.491
3.504
Period End
3.467
3.845
3.902
3.889
3.471
3.567
3.832
3.888
3.592
3.600
3.450
3.494
3.423
3.503
3.517
3.512
3.537
3.434
3.485
3.405
3.467
3.499
3.521
3.529
On March 15, 2018, the daily representative rate was $1.00 to NIS 3.434, as reported by the Bank of Israel.
B. Capitalization and Indebtedness
Not applicable.
C. Reasons for the Offer and Use of Proceeds
Not applicable.
D. Risk Factors
You should carefully consider the risks described below, together with all of the other information in this annual report on Form
20-F. The risks and uncertainties described below are those significant risk factors, currently known and specific to us, that we believe are
relevant to an investment in our securities. Additional risks and uncertainties not currently known to us or that we now deem immaterial
may also harm us. If any of these risks materialize, our business, results of operations or financial condition could suffer, and the price of
the ADSs could decline substantially.
Risks Related to Our Financial Position and Capital Requirements
We have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the
foreseeable future.
We are a regenerative medicine company. Although we commenced commercial sales of certain products, we have not generated
significant revenue from product sales to date. We have incurred losses in each year since our inception in 2004, including total
comprehensive loss of NIS 20.9 million ($6.0 million), NIS 27.9 million ($7.3 million) and 19.7 million ($4.8 million) for the years ended
December 31, 2017, December 31, 2016 and December 31, 2015, respectively. As of December 31, 2017, we had an accumulated deficit of
$50.3 million.
We have devoted most of our financial resources to research and development, including our clinical and preclinical development
activities. To date, we have financed our operations primarily through the sale of equity securities, grants from government authorities and
proceeds from strategic collaborators. The amount of our future net losses will depend, in part, on the rate of our future expenditures. If
and when we obtain regulatory approval to market any of our products, our future revenues will depend upon the size of any markets in
which our products have received approval, and our ability to achieve sufficient market acceptance, reimbursement from third-party payors
and adequate market share for our products in those markets.
3
Table of Contents
We expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate that our
expenses will increase substantially if and as we:
● continue our research and preclinical and clinical development of our products;
● initiate additional preclinical, clinical, or other studies for our products;
● seek marketing approvals for any of our products that successfully complete clinical trials;
● further develop and expand the manufacturing process for our products;
● establish a sales, marketing, and distribution infrastructure to commercialize our products for which we may obtain marketing
approval;
● seek to identify and validate additional products;
● maintain, protect, and expand our intellectual property portfolio;
● attract and retain skilled personnel;
● create additional infrastructure to support our operations as a public company; and
● experience any delays or encounter issues with any of the above.
The net losses we incur may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period
comparison of our results of operations may not be a good indication of our future performance. In any particular quarter or quarters, our
operating results could be below the expectations of securities analysts or investors, which could cause our share price to decline.
We will need to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain additional capital
when needed may force us to delay, limit, or terminate our product development efforts or other operations.
We are conducting clinical and preclinical development of our products and we intend to continue advancing their development.
Developing medical products is expensive, and we expect our research and development expenses to continue to be a material part of our
expenses, and may increase substantially in connection with our ongoing activities, particularly as we advance our products in clinical trials.
As of December 31, 2017, our cash and cash equivalents were $5.1 million. On September 6, 2017, we entered into a securities
purchase agreement, or the Alpha Purchase Agreement, with Alpha Capital Anstalt, or Alpha. On November 8, 2017, we entered into a
securities purchase agreement, or the Meitav Purchase Agreement, with Meitav Dash Provident Funds and Pension Ltd., or Meitav Dash.
On November 9, 2017, we entered into a securities purchase agreement, or the Sagi Purchase Agreement, with Ami Sagi. See “Item 10.C.
Material Contracts” below for additional information. We believe that our existing cash and cash equivalents, together with the net
proceeds of our 2018 Security Purchase Agreements will enable us to fund our operating expenses and capital expenditure requirements for
at least the next 12 months. However, our operating plan may change as a result of many factors currently unknown to us, and we may
need to seek additional funds sooner than planned, through public or private equity or debt financings, government or other third-party
funding, marketing and distribution arrangements, and other collaborations, strategic alliances, and licensing arrangements, or a
combination of these approaches. We will require additional capital to obtain U.S. Food and Drug Administration, or FDA, approval and
commercialize any product that receives regulatory approval. Even if we believe we have sufficient funds for our current or future
operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic considerations.
4
Table of Contents
Any additional fundraising efforts may divert our management from their day-to-day activities, which may compromise our ability
to develop and commercialize our products. In addition, we cannot guarantee that future financing will be available in sufficient amounts or
on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our shareholders,
and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of
our ordinary shares or ADSs to decline. The sale of additional equity or convertible securities would dilute all of our shareholders. The
incurrence of indebtedness would result in increased fixed payment obligations, and we may be required to agree to certain restrictive
covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell, or license intellectual
property rights, and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required
to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable, and we
may be required to relinquish rights to some of our technologies or products or otherwise agree to terms unfavorable to us.
If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay, or discontinue one or more
of our research or development programs or the commercialization of any products, and we may be unable to expand our operations or
otherwise capitalize on our business opportunities, as desired.
We have received and may continue to receive Israeli governmental grants to assist in the funding of our research and development
activities. If we lose our funding from these research and development grants, we may encounter difficulties in the funding of future
research and development projects and implementing technological improvements, which would harm our operating results.
Through December 31, 2017 we had received an aggregate of $9.4 million in the form of grants from the Israel Innovation
Authority, or the IIA (formerly known as the Office of the Chief Scientist of the Ministry of Economy and Industry, or the OCS). The
requirements and restrictions for such grants are found in the Encouragement of Research, Development and Technological Innovation in
the Industry Law 5744 1984 (formerly known as the Law for the Encouragement of Research and Development in Industry 5744 1984), or
the Innovation Law, and the IIA’s rules and guidelines. Under the IIA’s rules and guidelines, royalties of 3% to 6% on the income generated
from sales of products and related services developed in whole or in part under IIA programs are payable to the IIA (depending on the type
of the Recipient Company—i.e., whether it is a “Small Company”, a “Large Company” or a “Traditional Industrial Company” as such
terms are defined in the IIA’s rules and guidelines), up to the total amount of grants received, including annual interest, all as detailed in the
IIA’s rules and guidelines.
We developed our platform technologies, at least in part, with funds from these grants, and accordingly we are obligated to pay
these royalties on sales of any of our current products that achieve regulatory approval. In addition, the Government of Israel may from
time to time audit sales of products which it claims incorporate technology funded via the IIA programs and this may lead to additional
royalties being payable on additional products. As of December 31, 2017, the maximum royalty amount that would be payable by us,
excluding interest, is $9.1 million. As of December 31, 2017, we paid non-material amounts in royalties to the IIA, relating mainly to the
participation of strategic collaborators in product development. For the year ended December 31, 2017, we received grants totaling
$160,000 from the IIA. The grants represented 3% of our gross research and development expenditures for the year ended December 31,
2017. Following the full payment of such royalties and interest, there is generally no further liability for royalty payments; however, other
restrictions under the IIA’s rules and guidelines, described below under “The IIA grants we have received for research and development
expenditures restrict our ability to manufacture products and transfer know-how outside of Israel and require us to satisfy specified
conditions”, will continue to apply even after we have repaid the full amount of royalties on the grants.
On June 1, 2017, we received a notice from the IIA that our request for a research and development grant for the year 2017 was
rejected. We submitted an appeal for reconsideration of our request for 2017. On October 29, 2017, IIA notified us that for the year 2017
we were approved for a follow-up grant approval of NIS 3.5 million ($1 million), with 40% participation in research and development
costs.
5
Table of Contents
These grants have funded some of our personnel, development activities with subcontractors, and other research and development
costs and expenses. However, if these grants are not funded in their entirety or if new grants are not awarded in the future, due to, for
example, IIA budget constraints or governmental policy decisions, our ability to fund future research and development and implement
technological improvements would be impaired, which would negatively impact our ability to develop our products.
There are uncertainties and risks relating to the Alpha, Meitav Dash and Ami Sagi transactions.
We recently entered into securities purchase agreements with Alpha, Meitav Dash and Ami Sagi providing for up to $7.4 million
of financing. As of the date hereof, all closings under the Meitav Purchase Agreement and Sagi Purchase Agreement and the first and
second closing under the Alpha Purchase Agreement have occurred resulting in gross proceeds of approximately $6.4 million, however the
third closing of the Alpha Purchase Agreement has not occurred. There is no assurance that the remaining Alpha closing will be completed
on the contemplated terms, when anticipated, or at all, or that, if completed, that it will have a positive impact on us or our business,
operating results or financial condition. The foregoing purchase agreements also contain certain covenants that may impact our ability to
raise funds in the future, including without limitation, restrictions on future issuances of securities, pre-emption rights and full-ratchet anti-
dilution protection.
In addition, the staff of the Israel Securities Authority, or ISA, has informed us that the financings of Meitav Dash and Ami Sagi
should be viewed as constituting a single transaction under the provisions of section 270(5)(b)(3) of the Israeli Companies Law, 5759-
1999, or the Companies Law. This position is based on several arguments, including the identical price in these financings, their proximity
in timing, the similar structure of the financings, including their dates of completion as well as the conditioning of the second closing of
Meitav Dash upon the raising of NIS 3.7 million by us, which is an identical amount to the consideration paid by Ami Sagi, and the
disclosure with respect to which was published one business day following the disclosure of the Meitav Dash financing. In addition, the
Israel Securities Authority, or the ISA, informed us that the Meitav Dash and Ami Sagi financings should be submitted for approval at a
general meeting of shareholders as required by Section 270(5) of the Companies Law, since it cannot be determined that the terms of these
financings have been set at market terms, considering, among other things, the discount rate embedded in these financings, which was set
at 27%-33%. Their position is based on the fact that in our case, there is difficulty in determining market terms which derives, according to
the ISA’s position, from the differences in the prevalent discount rates of companies with similar characteristics as us. The differences
include the terms of issuance and certain adjustments, including protection for decrease in share price (full ratchet anti-dilution) and the
calculation of the fair market value of the warrants. The ISA’s position is that such differences may have implications on the calculation of
the discount rates in the Meitav Dash and Ami Sagi financings. Nevertheless, our board of directors believes that in the first place, the said
financings should not be considered as a single transaction, and that even if they were viewed as a single transaction, they were entered into
on market terms. Accordingly, we have proceeded to complete all closings under the Meitav Purchase Agreement and the Sagi Purchase
Agreement without seeking shareholder approval. As a result of the position adopted by the ISA, there is a possibility of derivative claims
and class action litigation being brought against us. Such litigation, if instituted, could result in the voiding of the transactions, incurrence
of damages, substantial costs and diversion of management attention and resources. In addition, plaintiffs may seek to obtain an injunction
prohibiting us from completing the remaining closings on the agreed upon terms, which could prevent the remaining closings from taking
place, or from taking place within the expected timeframe. Any conclusion of these matters in a manner adverse to us could have a material
adverse effect on our liquidity, financial condition and results of operations.
The IIA grants we have received for research and development expenditures restrict our ability to manufacture products and transfer
IIA funded know-how outside of Israel and require us to satisfy specified conditions.
Our research and development efforts have been financed, in part, through the grants that we have received from the IIA. We,
therefore, must comply with the requirements of the Innovation Law and the IIA’s rules and guidelines.
Under the Innovation Law and the IIA’s rules and guidelines, we are generally prohibited from manufacturing products developed
under the IIA’s funding outside of the State of Israel without the prior approval of the IIA (such approval is not required for the transfer of
less than 10% of the manufacturing capacity in the aggregate, but a mere notification). We may not receive the required approvals for any
proposed transfer of manufacturing activities. In general, in addition to the requirement of obtaining approval to manufacture products
developed with IIA grants outside of Israel, the royalty repayment rate would increase and we would be required to pay increased royalties,
between 120% and 300% of the grants plus annual interest, depending on the manufacturing volume that is performed outside of Israel.
This restriction may impair our ability to outsource manufacturing rights abroad.
6
Table of Contents
A company also has the option of declaring in its IIA grant application its intent to exercise a portion of the manufacturing
capacity abroad, thus avoiding the need to obtain additional approval following the receipt of the grant.
Additionally, under the Innovation Law and the IIA’s rules and guidelines, we are prohibited from transferring the IIA’s funded
know-how and related intellectual property rights outside of the State of Israel, except under limited circumstances and only with the
approval of the IIA’s committee. We may not receive the required approvals for any proposed transfer, and even if we receive the required
approvals, we may be required to pay the IIA a redemption fee up to a maximum of 600% of the grant amounts plus interest, depending
upon the value of the transferred know-how, our research and development expenses, the amount of the IIA’s support, the time of
completion of the IIA supported research project and other factors.
A transfer of IIA’s funded know-how to an Israeli company also requires the approval of the IIA’s committee, but will not subject
the Company to a payment of a redemption fee (we note that there will be an obligation to pay royalties to the IIA from the income of such
sale transaction as part of the royalty payment obligation), and approval may only be granted if the recipient abides by the provisions of
applicable laws, including the restrictions on the transfer of know-how and the manufacturing rights outside of Israel and the obligation to
pay royalties. No assurance can be given that approval to any such transfer, if requested, will be granted.
Recently, the IIA has published new rules and guidelines with respect to the grant of the right to use know-how that was
developed using the IIA’s grants to a foreign entity. According to these rules, the grant of a right to a foreign entity to use the IIA’s funded
know-how (without entirely expropriating from the IIA-funded company the possibility of using the IIA’s funded know-how) is subject to
receipt of the IIA’s prior approval. This approval is subject to payment to the IIA in accordance with the formulas stipulated in these rules.
These restrictions may impair our ability to sell our technology assets or to perform or outsource manufacturing outside of Israel,
or otherwise transfer our know-how outside of Israel. These restrictions may also require us to obtain the approval of the IIA for certain
actions and transactions and pay additional royalties and other amounts to the IIA. Furthermore, the consideration available to our
shareholders in a transaction involving the transfer outside of Israel of know-how developed with IIA funding (such as a merger or similar
transaction) may be reduced by any amounts that we are required to pay to the IIA.
If we fail to comply with the requirements of the Innovation Law, we may be required to refund certain grants previously received
along with interest and penalties, and we may become subject to criminal proceedings.
In August 2015, a new amendment to the Innovation Law was enacted, or Amendment No. 7, which came into effect on January 1,
2016. Under Amendment No. 7, the IIA has assumed oversight of activity previously subject to OCS’ responsibility. The IIA was granted
wide freedom of action, and among other things, the IIA has the authority to amend the requirements and restrictions which were specified
in the Innovation Law before Amendment No. 7 came into effect with respect to the ownership of IIA’s funded know-how (including with
respect to the restrictions on transfer of the IIA’s funded know-how and manufacturing activities outside of Israel), as well as with respect
to royalty payment obligations which apply to companies that receive grants from the IIA. Amendment No. 7 also includes new provisions
with respect to sanctions imposed for violations of the Innovation Law. Although the IIA recently published rules which for the most part
adopted the principal provisions and restrictions specified in the Innovation Law prior to the effectiveness of Amendment No. 7, as of the
date of this annual report on Form 20-F, we are unable to assess the effect of any future rules which may be published by the IIA on our
business.
7
Table of Contents
We may not be able to correctly estimate or control our future operating expenses, which could lead to cash shortfalls.
Our operating expenses may fluctuate significantly in the future for various reasons, many of which are outside of our control.
These reasons may include:
● the time, resources, and expenses required to conduct clinical trials of, seek regulatory approvals for, manufacture, market, and
sell our current products and any additional products we may develop;
● the time, resources, and expenses required to research and develop, conduct clinical trials of, and seek regulatory approvals for
additional indications of our current products;
● the costs of preparing, filing, prosecuting, defending, and enforcing patent claims and other patent-related costs, including
litigation costs or the results of such litigation;
● any product liability or other lawsuits related to our products and the costs associated with defending them or the results of such
lawsuits;
● the costs to attract and retain personnel with the skills required for effective operations; and
● the costs associated with being a public company in the United States.
It is difficult to forecast our future performance, which may cause our financial results to fluctuate unpredictably.
Because we do not yet have an established commercial operating history, and because the market for our products may rapidly
evolve, it is hard for us to predict our future performance. A number of factors, many of which are outside of our control, may contribute to
fluctuations in our financial results assuming that we receive marketing authorizations and begin selling our products. These factors may
include variations in:
● market demand for, and acceptance of, our products;
● our ability to obtain or maintain regulatory approvals;
● our sales and marketing operations, or the effectiveness of these operations;
● performance of our third-party contractors;
● the availability of procedures or products that compete with our products;
● media coverage of our technologies, the procedures or products of our competitors or our industry; and
● general economic and political conditions, including changes in general consumer confidence.
If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our
financial results or prevent fraud. As a result, our shareholders could lose confidence in our financial and other public reporting,
which would harm our business and the trading price of the ADSs.
Effective internal controls over financial reporting are necessary for us to provide reliable financial reports. Together with
adequate disclosure controls and procedures, effective internal controls are designed to prevent fraud. Any failure to implement required
new or improved controls or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In
addition, any testing by us conducted in connection with Section 404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, may
reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses, may require prospective or
retroactive changes to our financial statements, or may identify other areas for further attention or improvement. Inferior internal controls
could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price
of the ADSs.
8
Table of Contents
We are required to disclose changes made in our internal controls and procedures on an annual basis and our management is
required to assess the effectiveness of these controls annually. However, for as long as we are an “emerging growth company” under the
Jumpstart Our Business Startups Act, or the JOBS Act, our independent registered public accounting firm will not be required to attest to
the effectiveness of our internal controls over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act. We could be an
emerging growth company for up to five years. An independent assessment of the effectiveness of our internal controls could detect
problems that our management’s assessment might not. Undetected material weaknesses in our internal controls could lead to financial
statement restatements and require us to incur the expense of remediation.
Risks Related to Commercialization of Our Products
The commercial success of any current or future product, if approved, will depend upon the degree of market acceptance by physicians,
patients, third-party payors, pharma companies and others in the medical community.
Even if we obtain the requisite regulatory approvals, the commercial success of our products will depend in part on physicians,
patients, third party payors, pharma companies and others in the medical community accepting our products as medically useful, cost-
effective, and safe. Any product that we bring to the market may not gain market acceptance by physicians, patients, third-party payors, and
others in the medical community. If these products do not achieve an adequate level of acceptance, we may not generate significant product
revenue and may not become profitable. The degree of market acceptance of these products, if approved for commercial sale, will depend
on a number of factors, including:
● the cost, safety, efficacy, and convenience of our products in relation to alternative treatments and products;
● the ability of third parties to enter into relationships with us without violating their existing agreements;
● the effectiveness of our sales and marketing efforts;
● the prevalence and severity of any side effects, including any limitations or warnings contained in a product’s approved
labeling;
● the prevalence and severity of any side effects resulting from the procedure by which our products are administered;
● the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;
● the strength of marketing and distribution support for, and timing of market introduction of, competing products;
● publicity concerning our products or competing products and treatments; and
● sufficient third-party insurance coverage or reimbursement.
Even if a potential product displays a favorable safety and efficacy profile in clinical trials, market acceptance of the product will
not be known until after it is launched. Our efforts to educate the medical community and third-party payors on the benefits of the products
may require significant resources and may never be successful. Such efforts to educate the marketplace may require more resources than
are required by conventional technologies.
9
Table of Contents
We have only limited clinical data to support VergenixFG and VergenixSTR, which may make physicians, patients, third-party payors,
and others in the medical community reluctant to accept or purchase our products.
Physicians, patients, third party payors, and others in the medical community will only accept or purchase our products if they
believe them to be safe and effective, with advantages over competing products or procedures. To date, we have collected only limited
clinical data with which to assess the clinical and economic value of VergenixFG and VergenixSTR. The collection of clinical and
economic data and the process of generating peer review publications in support of our product and procedure is an ongoing focus for us. If
future publications of clinical studies indicate that procedures using the VergenixFG and VergenixSTR are less safe or less effective than
competing products or procedures, patients may choose not to undergo our procedure, and physicians or others in the medical community
may choose not to use our products. Furthermore, unsatisfactory patient outcomes or patient injury could cause negative publicity for our
products, particularly in the early phases of product introduction.
We have limited experience in producing our core components and products, and if we are unable to manufacture our core components
and products in high-quality commercial quantities successfully and consistently to meet demand, our growth will be limited.
We have experience manufacturing only limited quantities of rhCollagen, the recombinant human type I collagen used in our
products. Our manufacturing capabilities will need to be further improved to meet the standard requirements for future clinical studies and
for commercialization of our products. To manufacture our rhCollagen in quantities that we believe will be sufficient to produce our end
products and meet anticipated market demand, we will need to increase manufacturing capacity, which will involve significant challenges.
In addition, the development of commercial-scale, regulation-compliant manufacturing capabilities will require us to invest substantial
additional funds and hire and retain the technical personnel who have the necessary manufacturing experience. We may not successfully
complete any required increase to existing manufacturing processes in a timely manner, or at all. Our costs will be higher, and our
challenges greater, if we decide to develop internal manufacturing capabilities to produce our end products.
If there is a disruption to our internal manufacturing operations, we will have no other means of production for the components
and products from such operations until we restore the affected facilities or develop alternative manufacturing facilities, which would delay
our clinical trials or cause us to be unable to meet commercial demand for our products. In such case, we may need to arrange for third-
party manufacturing of our components and products, which would be expensive and time consuming, assuming we can identify an
appropriate third party manufacturer. Additionally, any damage to or destruction of our facilities or equipment may significantly impair our
ability to manufacture our components and products on a timely basis.
If we are unable to produce our products in sufficient quantities to meet anticipated customer demand, our revenues, business, and
financial prospects would be harmed. The lack of experience we have in producing commercial quantities of our components and products
may also result in quality issues and product recalls. Any product recall could be expensive and generate negative publicity, which could
impair our ability to market our products and further affect our results of operations. Manufacturing delays related to quality control could
negatively impact our ability to bring our technologies to market, harm our reputation, and decrease our revenues.
If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell any of our
products that obtain regulatory approval, we may be unable to generate any revenue.
We have limited experience in selling and marketing our products or any other products. To successfully commercialize our
products we will need to develop these capabilities, either on our own or with others. We are seeking to enter into commercial alliances
with third-party collaborators and distributors to utilize their marketing and distribution capabilities, but we may be unable to do so on
favorable terms, if at all. If any future collaboration or distribution partners do not commit sufficient resources to commercialize our future
products, and if we are unable to develop the necessary marketing capabilities on our own, we will be unable to generate sufficient product
revenue to sustain our business. We will be competing with many companies that currently have extensive and well-funded marketing and
sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to
compete successfully against these more established companies or successfully commercialize any of our products.
10
Table of Contents
We face competition and rapid technological change and the possibility that our competitors may develop therapies or products that are
more advanced or effective than ours, which could impair our ability to successfully commercialize our products.
We operate in the regenerative medicine field, which is rapidly changing. We have competitors both in the United States and
internationally, including major multinational pharmaceutical companies, biotechnology companies, medical technology companies, and
universities and other research institutions.
Many of our potential competitors have substantially greater financial, technical and other resources, such as larger research and
development staff and experienced marketing and manufacturing organizations. Competition may increase further as a result of advances in
the commercial applicability of technologies and greater availability of capital for investment in these industries. Our potential competitors
may succeed in developing, acquiring, or licensing on an exclusive basis, products that are more effective or less costly than any products
that we may develop, or achieve earlier patent protection, regulatory approval, product commercialization, and market penetration than us.
Additionally, technologies developed by others may render our potential products uneconomical or obsolete, and we may not be successful
in marketing our products against competitors.
We are not aware of any competitors that produce collagen from plants or that produce recombinant type I human collagen.
However, our collagen-based products will compete with alternative solutions; for example, our VergenixSTR product will compete with
companies that sell platelet-rich plasma, or PRP, kits. Our VergenixFG product will compete with companies that produce and market
animal collagen-based products and collagen products produced from skin donations.
A variety of risks associated with international operations could harm our business.
If any of our products are approved for commercialization, it is our current intention to market them on a regional or worldwide
basis in the jurisdictions where they may be approved, either alone or in collaboration with third parties. In addition, we may conduct
development activities in various jurisdictions throughout the world. We expect that we will be subject to additional risks related to
engaging in international operations, including:
● different regulatory requirements for product approval in foreign countries;
● reduced protection for intellectual property rights;
● unexpected changes in tariffs, trade barriers, and regulatory requirements;
● economic weakness, including inflation, or political instability in particular foreign economies and markets;
● compliance with tax, employment, immigration, and labor laws for employees living or traveling abroad;
● foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations
incident to doing business in another country;
● workforce uncertainty in countries where labor unrest is more common than in the United States and Israel;
● production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and
● business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including
earthquakes, typhoons, floods, and fires.
11
Table of Contents
The insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate
coverage and reimbursement for any of our products that are approved could limit our ability to market those products and compromise
our ability to generate revenue.
The availability of reimbursement by governmental and private payors is essential for most patients to be able to afford expensive
treatments. Sales of our products will depend substantially, both in Europe and in the United States, on the extent to which the costs of our
products will be paid by health maintenance, managed care, pharmacy benefit, and similar healthcare management organizations, or
reimbursed by government health administration authorities, private health coverage insurers, and other third-party payors. If
reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our products. Even
if we obtain coverage for our products, third-party payors may not establish adequate reimbursement amounts, which may reduce the
demand for, or the price of, our products. If reimbursement is not available or is available only to limited levels, we may not be able to
commercialize certain of our products.
Furthermore, publication of discounts by third-party payors or authorities may lead to further pressure on the prices or
reimbursement levels within the country of publication and other countries. If reimbursement of our products is unavailable or limited in
scope or amount, or if pricing is set at unacceptable levels, we or our partner may elect not to commercialize our products in such countries,
and our business and financial condition could be adversely affected.
Promotion of off-label uses of our products by physicians could adversely affect our business.
Any regulatory approval of our products is limited to those specific indications for which our products have been deemed safe and
effective by the regulatory authorities. In addition, any new indication for an approved product also requires regulatory approval. If we
produce an approved product, we will rely on physicians to use and administer it as we have directed and for the indications described on
the labeling. It is not, however, uncommon for physicians to use in unapproved, or “off-label,” uses or in a manner that is inconsistent with
the manufacturer’s directions. To the extent such off-label uses and departures from our administration directions become pervasive and
produce results such as reduced efficacy or other adverse effects, the reputation of our products in the marketplace may suffer. In addition,
off-label uses may cause a decline in our revenue or potential revenue, to the extent that there is a difference between the prices of our
product for different indications.
Furthermore, while physicians may choose to use our products for off-label uses, our ability to promote the products is limited to
those indications that are specifically approved by the regulators. Although regulatory authorities generally do not regulate the behavior of
physicians, they do restrict communications by companies with respect to off-label use. If our promotional activities fail to comply with
these regulations or guidelines, we may be subject to warnings from, or enforcement action by, these authorities. In addition, failure to
follow regulation authorities’ rules and guidelines relating to promotion and advertising can result in the regulation authorities’ refusal to
approve a product, the suspension or withdrawal of an approved product from the market, product recalls, fines, disgorgement of money,
operating restrictions, injunctions, or criminal prosecution.
Risks Related to the Clinical Development and Regulatory Approval of Our Products
We currently depend heavily on the future success of our rhCollagen-based biological ink, or BioInk , VergenixSTR, and VergenixFG.
Any failure to successfully develop, obtain regulatory approval for, and commercialize these products, independently or in cooperation
with a third party collaborator, or the experience of significant delays in doing so, would compromise our ability to generate revenue
and become profitable.
We have invested a significant portion of our efforts and financial resources in the development of BioInk, VergenixSTR, and
VergenixFG. Our ability to generate product revenue from our products depends heavily on the successful development, approval, and
commercialization of our products, which, in turn, depend on several factors, including the following:
● our ability to continue and support our rhCollagen platform technology and programs;
● successfully completing our ongoing and future clinical trials and other studies required for our products;
12
Table of Contents
● demonstrating and maintaining the safety and efficacy of our products at a sufficient level of statistical or clinical significance
and otherwise obtaining marketing approvals from regulatory authorities;
● establishing successful sales and marketing arrangements for our products VergenixSTR and VergenixFG in the jurisdictions
where they may be approved;
● the availability of coverage and reimbursement by healthcare payors for our products in the jurisdictions where they may be
approved;
● establishing successful manufacturing arrangements with third-party manufacturers that are compliant with current good
manufacturing practices, or cGMP, and which will ensure the development of a large scale manufacturing process and adequate
facilities or being able to conduct such manufacturing ourselves;
● establishing a large scale facility as a second source for the manufacture of commercial quantities of our products, if approved;
and
● other risks described in this “Risk Factors” section.
Our products are based on novel technology, which makes it difficult to predict the time and cost of product development and potential
regulatory approval.
We have concentrated our product research and development efforts on our novel rhCollagen technology. The FDA has approved
very few plant-expressed products, and has not yet approved a medical device which incorporates plant-produced materials. We may
experience development challenges in the future related to our technology, which could cause significant delays or unanticipated costs, and
we may not be able to solve such development challenges. We may also experience delays in developing a sustainable, reproducible, and
scalable manufacturing process or transferring that process to commercial partners, if we decide to do so, which may prevent us from
completing our clinical trials or commercializing our products on a timely or profitable basis, if at all.
In addition, the clinical trial requirements of European regulatory authorities, the FDA, and other regulatory authorities and the
criteria these regulators use to determine the safety and efficacy of a product vary substantially according to the type, complexity, novelty,
and intended use and market of the potential products. The regulatory approval process for novel products such as ours can be more
expensive and take longer than for other, better known or extensively studied medical devices or other products. Our products may also be
designated by the FDA or other regulatory authorities as Combination Products, which are products composed of two or more regulated
components, such as a drug and a medical device, and then may be regulated as drug or biologic product, resulting in a longer regulatory
approval process than the regulatory approval process for a medical device. Approvals by any regulatory authorities may not be indicative
of what the FDA or other regulatory agencies may require for approval, and vice versa.
Regulatory requirements governing medical devices and other products for medical use have changed frequently and may continue
to change in the future. Also, before a clinical trial can begin, an institutional review board, or IRB, at each institution at which a clinical
trial will be performed must review the proposed clinical trial to assess the safety of the trial. In addition, adverse developments in clinical
trials of medical devices and products conducted by others may cause European regulatory authorities, the FDA, or other regulatory
authorities to change the requirements for approval of any of our products.
These regulatory agencies and additional or new requirements may lengthen the regulatory review process, require us to perform
additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and
commercialization of our products, or lead to significant approval and post-approval limitations or restrictions. As we advance our products,
we will be required to consult with these regulatory authorities, and comply with applicable requirements. If we fail to do so, we may be
required to delay or discontinue development of our products. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory
approval necessary to bring a potential product to market could impair our ability to generate product revenue and to become profitable.
13
Table of Contents
We may find it difficult to enroll patients in our clinical trials, and patients could discontinue their participation in our clinical trials,
which could delay or prevent clinical trials of our products.
Identifying and qualifying patients to participate in clinical trials of our products is critical to our success. The timing of our
clinical trials depends on our ability to recruit patients to participate in our clinical trials. We may experience delays in patient enrollment in
the future. If patients are unwilling to participate in our clinical trials because of negative publicity from adverse events in the
biotechnology, pharmaceutical or medical technology industries, or for other reasons, including competitive clinical trials for similar
patient populations, the timeline for recruiting patients, conducting trials, and obtaining regulatory approval of potential products may be
delayed. These delays could result in increased costs, delays in advancing our product development, delays in testing the effectiveness of
our technology, or termination of the clinical trials altogether.
We may not be able to identify, recruit, and enroll a sufficient number of patients, or those with required or desired characteristics
to achieve diversity in a trial, to complete our clinical trials in a timely manner. Patient enrollment is affected by factors including:
● design of the trial protocol;
● size of the patient population;
● eligibility criteria for the trial in question;
● severity of the disease/wounds under investigation;
● perceived risks and benefits of the product under study;
● proximity and availability of clinical trial sites for prospective patients;
● availability of competing therapies, products, and clinical trials;
● efforts to facilitate timely enrollment in clinical trials;
● patient referral practices of physicians; and
● ability to monitor patients adequately during and after treatment.
We are currently conducting clinical trials in Israel and intend to seek marketing approval in Europe, China and the United States.
We may not be able to initiate or continue clinical trials if we cannot enroll a sufficient number of eligible patients to participate in the
clinical trials required by European regulatory authorities, the FDA, or other regulatory authorities.
In addition, patients enrolled in our clinical trials may discontinue their participation at any time during the trial as a result of a
number of factors, including withdrawing their consent or experiencing adverse clinical events, which may or may not be related to our
products under evaluation. The discontinuation of patients in any one of our trials may cause us to delay or abandon such clinical trial, or
cause the results from that trial not to be positive or sufficient to support a filing for regulatory approval of the applicable product.
14
Table of Contents
Our clinical trials may not be successful or may be delayed.
Before obtaining marketing approval from regulatory authorities for the sale of our products or any future product, we must
conduct clinical trials to demonstrate the safety in humans for European CE marking certification, and the safety and efficacy of our
products in humans for other regulatory authorities such as China and the United States. From time to time, we work with contract research
organizations, or CROs, which assist us in overseeing and implementing our clinical trials. Clinical trials are expensive, time consuming,
and uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all.
We may not receive FDA regulatory approval for the conduct of any particular clinical trial in the United States or regulatory approval for
conduct of such clinical trial in other countries. A failure of one or more clinical trials can occur at any stage of testing. Events that may
prevent successful or timely completion of clinical development include:
● delays in reaching a consensus with regulatory agencies on trial design;
● delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites;
● delays in obtaining required IRB approval at each clinical trial site;
● delays in recruiting suitable patients to participate in our clinical trials;
● imposition of a clinical hold by regulatory agencies, including after an inspection of our clinical trial operations or trial sites;
● failure by our CROs, other third parties or us to perform in accordance with clinical trial requirements or the FDA’s good
clinical practices, or GCP, or applicable regulatory requirements in other countries;
● delays in the testing, validation, manufacturing, and delivery of our products to the clinical sites;
● delays in having patients complete participation in a trial or return for post-treatment follow-up;
● clinical trial sites or patients dropping out of a trial;
● occurrence of serious adverse events associated with the products that are viewed to outweigh their potential benefits; or
● changes in regulatory requirements and guidance that require amending or submitting new clinical trial protocols.
Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our
ability to generate revenue from product sales. In addition, if we make manufacturing or design changes to our products, we may need to
conduct additional studies to bridge our modified products to earlier versions. Clinical trial delays could also shorten any periods during
which we may have the exclusive right to commercialize our products or allow our competitors to bring products to market before we do,
which could impair our ability to successfully commercialize our products.
If the results of our clinical trials are inconclusive or if there are safety concerns or adverse events associated with our products,
we may:
● fail to obtain, or be delayed in obtaining, marketing approval for our products;
● obtain approval for indications or patient populations that are not as broad as intended or desired;
● obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;
15
Table of Contents
● b e required to perform additional clinical trials to support approval or be subject to additional post-marketing testing
requirements;
● have regulatory authorities withdraw their approval of the product or impose restrictions on its distribution;
● be subject to the addition of labeling statements, such as warnings or contraindications;
● be sued; or
● experience damage to our reputation.
Any of these events could prevent us from achieving or maintaining market acceptance of our products and impair our ability to
commercialize our products.
Success in early clinical trials may not be indicative of results obtained in later trials.
There is a high failure rate for medical devices, drugs, and biologics proceeding through clinical trials. A number of companies in
the pharmaceutical, biotechnology, and medical technology industries have suffered significant setbacks in later stage clinical trials even
after achieving promising results in earlier stage clinical trials. Data obtained from preclinical and clinical activities are subject to varying
interpretations, which may delay, limit, or prevent regulatory approval. In addition, regulatory delays or rejections may be encountered as a
result of many factors, including the novelty of the product and changes in regulatory policy during the period of product development.
Even if we complete the necessary preclinical studies and clinical trials, we cannot predict when or if we will obtain regulatory approval
to commercialize a product, or the approval may be for a more narrow indication than we expect.
We cannot commercialize a product until the appropriate regulatory authorities have reviewed and approved the product. Even if
our products demonstrate safety and efficacy in clinical trials, the regulatory agencies may not complete their review processes in a timely
manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA Advisory Committee or other
regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections based upon
additional government regulation from future legislation or administrative action, or changes in regulatory agency policy during the period
of product development, clinical trials, and the review process. Regulatory agencies also may approve a treatment for fewer or more limited
indications than requested or may grant approval subject to the performance of post-marketing studies. In addition, regulatory agencies
may not approve the labeling claims that are necessary or desirable for the successful commercialization of our treatment.
Side effects may occur following treatment with our products which could make it more difficult for our products to receive regulatory
approval.
Treatment with our products may cause side effects or other adverse events. In addition, since our products may in the future be
administered in combination with other therapies, patients, or clinical trial participants may experience side effects or other adverse events
that are unrelated to our product, but may still impact the success of our clinical trials. Additionally, our products could potentially cause
other adverse events that have not yet been predicted. The experience of side effects and adverse events in our clinical trials could make it
more difficult to achieve regulatory approval of our products or, if approved, could negatively impact the market acceptance of such
products.
16
Table of Contents
Even if we obtain regulatory approval for a product, our products will remain subject to regulatory scrutiny.
Even if we obtain regulatory approval in a jurisdiction, the regulatory authority may still impose significant restrictions on the
indicated uses or marketing of our products, or impose ongoing requirements for potentially costly post-approval studies or post-market
surveillance. Advertising and promotional materials must comply with FDA, Federal Trade Commission, or FTC, and European and other
countries’ regulatory requirements and are subject to review by the FDA, FTC or other governmental authorities, in addition to other
potentially applicable federal and state laws.
The laws that may affect our operations in the United States include:
● the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting,
receiving, offering, or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation
of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs;
● federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or
entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-
party payors that are false or fraudulent;
● the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes
that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare
matters;
● HIPAA, as amended by the Health Information Technology and Clinical Health Act, or HITECH, and its implementing
regulations, which imposes certain requirements relating to the privacy, security, and transmission of individually identifiable
health information;
● t h e federal physician sunshine requirements under the Patient Protection and Affordable Care Act, which requires
manufacturers of drugs, devices, biologics, and medical supplies to report annually to the Centers for Medicare and Medicaid
Services, or CMS, information related to payments and other transfers of value to physicians, other healthcare providers, and
teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their
immediate family members; and
● foreign and state law equivalents of each of the above federal laws, such as the U.S. Foreign Corrupt Practices Act, or the
FCPA, and anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payor,
including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s
voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government, or otherwise
restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require
manufacturers to report information related to payments and other transfers of value to physicians and other healthcare
providers or marketing expenditures; and state laws governing the privacy and security of health information in certain
circumstances, many of which differ from each other in significant ways, thus complicating compliance efforts.
The scope of these laws and our lack of experience in establishing the compliance programs necessary to comply with this
complex and evolving regulatory environment increase the risks that we may violate the applicable laws and regulations.
In addition, product manufacturers and their facilities are subject to continual review and periodic inspections by the European
regulatory authorities, the FDA, and other regulatory authorities for compliance with cGMP or any applicable European or other
governmental regulations. If we or a regulatory agency discover previously unknown problems with a product such as adverse events of
unanticipated severity or frequency or problems with the facility where the product is manufactured, a regulatory agency may impose
restrictions relative to that product or the manufacturing facility, including requiring recall or withdrawal of the product from the market or
suspension of manufacturing.
17
Table of Contents
If we fail to comply with applicable regulatory requirements following approval of any of our products, one or more regulatory
authorities could:
● issue a warning letter asserting that we are in violation of the law;
● seek an injunction or impose civil or criminal penalties or monetary fines;
● suspend or withdraw regulatory approval;
● suspend any ongoing clinical trials;
● seize our product; or
● refuse to allow us to enter into supply contracts, including government contracts.
Any government investigation of alleged violations of law could require us to expend significant time and resources in response
and could generate negative publicity and potentially lead to private litigation. The occurrence of any event or penalty described above may
inhibit our ability to commercialize our products and generate revenues.
We have only limited experience in regulatory affairs and intend to rely on consultants and other third parties for regulatory matters,
which may affect our ability or the time we require to obtain necessary regulatory approvals.
Between 2010 and 2012, we had limited interactions with the FDA for a predecessor wound healing product and have not had any
discussions with the FDA regarding our current products. We have limited experience in preparing and filing the applications necessary to
gain regulatory approvals for our products. Moreover, the products that are likely to result from our development programs are based on
new technologies that have not been extensively used in humans. The regulatory requirements governing these types of product may be
less well defined or more rigorous than for conventional products. As a result, we may experience a longer regulatory review process in
connection with obtaining regulatory approvals, if any, of products that we develop. We intend to rely on independent consultants for
regulatory services and compliance and product development and filings in Europe, the United States and elsewhere. Any failure by our
consultants to properly advise us regarding, or properly perform tasks related to, regulatory submission and other requirements could
compromise our ability to develop and obtain regulatory approval of our products.
We are subject to stringent regulation and any adverse regulatory action may materially adversely affect our financial condition and
business operations.
Our products, development activities, and manufacturing processes are subject to extensive and rigorous regulation by numerous
government agencies, including European regulatory authorities, the FDA, and other regulatory authorities. To varying degrees, each of
these agencies monitors and enforces our compliance with laws and regulations governing the development, testing, manufacturing,
labeling, marketing, and distribution of our products. The process of obtaining marketing approval or clearance in Europe, the United
States, and other countries for new products or enhancements or modifications to existing products, could
● take a significant amount of time;
● require the expenditure of substantial resources;
● involve rigorous and expensive preclinical and clinical testing, as well as increased post-market surveillance;
● involve modifications, repairs, or replacements of our products; and
● result in limitations on the indicated uses of our products.
18
Table of Contents
We cannot be certain that we will receive required approval or clearance from European regulatory authorities, the FDA, or other
regulatory authorities for new products or modifications to existing products on a timely basis. The failure to receive approval or clearance
for significant new products or modifications to existing products on a timely basis could have a material adverse effect on our financial
condition and results of operations.
Both before and after a product is commercially released, we have ongoing responsibilities under FDA regulations. For example,
we are required to comply with the FDA’s Quality System Regulation, or QSR, which are the good manufacturing requirements that the
FDA applies to medical devices, and which mandates that manufacturers of medical devices adhere to certain requirements pertaining to,
among other things, development of our products, validation of manufacturing processes, controls for purchasing product components, and
documentation practices. As another example, FDA regulations require us to provide information to the FDA whenever there is evidence
that reasonably suggests that a product may have caused or contributed to a death or serious injury, or that a malfunction occurred which
would be likely to cause or contribute to a death or serious injury upon recurrence. Compliance with applicable regulatory requirements is
subject to continual review and is monitored rigorously through, among other things, periodic inspections by the FDA, which may result in
observations on Form 483 that require corrective action, and in some cases warning letters. If the FDA were to conclude that we are not in
compliance with applicable laws or regulations, or that any of our medical devices are ineffective or pose an unreasonable health risk, the
FDA could ban such medical devices, detain or seize such medical devices, order a recall, repair, replacement, or refund of such devices, or
require us to notify health professionals and others that the devices present unreasonable risks of substantial harm to the public health.
The FDA has been increasing its scrutiny of the medical device, drugs, and biologics industries, and regulatory agencies are
expected to continue to scrutinize the industry closely with inspections, with possible enforcement actions by the FDA or other agencies.
Additionally, the FDA may restrict manufacturing and impose other operating restrictions, enjoin and restrain certain violations of
applicable law pertaining to medical devices, and assess civil or criminal penalties against our officers, employees, or us. The FDA may
also recommend prosecution to the Department of Justice. Any adverse regulatory action, depending on its magnitude, may restrict us from
effectively manufacturing, marketing, and selling our products. In addition, negative publicity and product liability claims resulting from
any adverse regulatory action could have a material adverse effect on our financial condition and results of operations.
Finally, the FDA issued regulations regarding “Current Good Manufacturing Practice Requirements for Combination Products” on
January 22, 2013. These regulations may apply to some of our products if they are designated by the FDA as Combination Products, which
are products composed of two or more regulated components, such as a drug and a medical device. There have been and will be additional
costs associated with compliance with the FDA Good Manufacturing Practice Requirements regulations for Combination Products.
Governmental regulations have become increasingly stringent and more common, and we may become subject to even more
rigorous regulation by governmental authorities in various countries in the future. Penalties for a company’s non-compliance with
governmental regulation could be severe, including revocation or suspension of a company’s business license and criminal sanctions.
The impact of healthcare reform and other changes in the healthcare industry and in healthcare spending is currently unknown, and
may adversely affect our business model.
The commercial potential for our approved products, if any, could be affected by changes in healthcare spending and policy in
Europe, in the United States, and in other countries. We operate in a highly regulated industry and new laws, regulations, or judicial
decisions, or new interpretations of existing laws, regulations, or decisions, related to healthcare availability, the method of delivery, or
payment for healthcare products and services could negatively impact our business, operations, and financial condition.
19
Table of Contents
In addition to the level of commercial success of our products, if approved, our future prospects are also dependent on our ability to
successfully develop a pipeline of additional products, and we may not be successful in our efforts in using our platform technologies to
identify or discover additional products.
The success of our business depends primarily upon our ability to identify, develop, and commercialize products based on our
platform technology. Although we have three products at various stages of development, our research programs may fail to identify other
potential products for clinical development for a number of reasons. Our research methodology may be unsuccessful in identifying potential
products or our potential products may be shown to have harmful side effects or may have other characteristics that may make the products
unmarketable or unlikely to receive marketing approval.
If any of these events occur, we may be forced to abandon our development efforts for a program or programs. Research programs
to identify new products require substantial technical, financial, and human resources. We may focus our efforts and resources on potential
programs or products that ultimately prove to be unsuccessful.
Risks Related to Our Reliance on Third Parties
We expect to depend upon third-party distributors and resellers for a significant portion of our sales.
We expect to rely primarily upon sales through independent distributors and resellers. While we are highly dependent upon
acceptance of our products and solutions by such third parties and their active marketing and sales efforts relating to our products, most of
our distributors and resellers will not be obligated to deal with us exclusively and are not contractually subject to minimum purchase
requirements. In addition, some of our distributors and resellers may sell competing products or solutions. As a result, our distributors and
resellers may give higher priority to products or services of our competitors, thereby reducing their efforts in selling our products and
services.
There can be no assurance that such distributors and resellers will act as effective sales agents for us, that they will remain our
partners, or that, if we terminate or lose any of them, we will be successful in replacing them. In May 2017, we terminated an agreement for
the distribution of VergenixFG in Turkey due to a breach of the agreement by the distributor. Subsequently, in the same month, we entered
into a new agreement for the distribution of VergenixFG in Turkey. Any disruption in our distribution channels could adversely affect our
business, operating results, and financial condition.
We expect to rely on third parties to conduct some or all aspects of our product manufacturing, protocol development, research, and
preclinical and clinical testing, and these third parties may not perform satisfactorily.
We do not expect to independently conduct all aspects of our product manufacturing, protocol development, research, and
preclinical and clinical testing. We currently rely, and expect to continue to rely, on third parties with respect to parts of these items.
Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements,
it could delay our product development activities. Our reliance on these third parties for research and development activities will reduce
our control over these activities but will not relieve us of our responsibility to ensure compliance with all required regulations and study
protocols.
If these third parties do not successfully carry out their contractual duties, meet expected deadlines, or conduct our studies in
accordance with regulatory requirements or our stated study plans and protocols, we will not be able to complete, or may be delayed in
completing, the preclinical studies and clinical trials required to support future FDA, European, or other approvals of our products.
20
Table of Contents
Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured the products ourselves,
including:
● the inability to negotiate manufacturing agreements with third parties under commercially reasonable terms;
● reduced control as a result of using third-party manufacturers for all aspects of manufacturing activities;
● termination or non-renewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to
us; and
● disruptions to the operations of our third-party manufacturers or suppliers caused by conditions unrelated to our business or
operations, including the bankruptcy of the manufacturer or supplier.
Any of these events could lead to clinical trial delays or failure to obtain regulatory approval, or impact our ability to successfully
commercialize future products. Some of these events could be the basis of action from European regulatory authorities, the FDA, or other
regulatory authorities, including injunction, recall, seizure, or total or partial suspension of production.
If we or our third-party manufacturers on which we rely cannot manufacture our products at sufficient yields, we may experience
delays in development, regulatory approval, and commercialization.
Completion of our clinical trials and commercialization of our products require access to, or development of, facilities to
manufacture our products at sufficient yields and at commercial scale. We have limited experience in large scale manufacturing, or
managing third parties in manufacturing any of our products in the volumes that are expected to be necessary to support large-scale clinical
trials and sales. Our efforts to establish these capabilities may not meet our requirements as to scale-up, yield, cost, potency, or quality in
compliance with cGMP. Our clinical trials should be conducted with product produced under applicable cGMP regulations. Failure to
comply with these regulations would delay the regulatory approval process. Even an experienced third-party manufacturer may encounter
difficulties in production, including:
● costs and challenges associated with scale-up and attaining sufficient manufacturing yields;
● supply chain issues, including the timely availability and shelf life requirements of raw materials and supplies;
● quality control and assurance;
● shortages of qualified personnel and capital required to manufacture large quantities of product;
● compliance with regulatory requirements that vary in each country where a product might be sold;
● capacity limitations and scheduling availability in contracted facilities; and
● natural disasters that affect facilities and possibly limit production.
Any delay or interruption in the supply of our products could have a material adverse effect on our business and operations.
The regulatory authorities also may, at any time following approval of a product for sale, audit our manufacturing facilities or
those of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or our product
specifications or if a violation of applicable regulations, including a failure to comply with the product specifications, occurs independent of
such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly or time consuming
for us or a third party to implement and that may include the temporary or permanent suspension of a clinical trial or commercial sales or
the temporary or permanent closure of a facility.
21
Table of Contents
If we or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA or the European authorities can
impose regulatory sanctions including, among other things, refusal to approve a pending application for a new product or revocation of a
pre-existing approval.
Additionally, if supply from one approved manufacturer is interrupted, there could be a significant disruption in commercial
supply. Switching manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial
timelines.
These factors could cause the delay of clinical trials, regulatory submissions, required approvals, or commercialization of our
products; cause us to incur higher costs; and prevent us from commercializing our products successfully. Furthermore, if our suppliers fail
to meet contractual requirements, and we are unable to secure one or more replacement suppliers capable of production at a substantially
equivalent cost, our clinical trials may be delayed or we could lose potential revenue.
We expect to rely on third parties to conduct, supervise, and monitor our clinical trials, and if these third parties perform in an
unsatisfactory manner, it may harm our business.
We rely heavily on hospitals, clinic centers, and other institutions and third parties, including the principal investigators and their
staff, to carry out our clinical trials in accordance with our clinical protocols and designs. We also rely on a number of CROs to assist in
undertaking, managing, monitoring, and executing our ongoing clinical trials. We expect to continue to rely on CROs, clinical data
management organizations, medical institutions, and clinical investigators to conduct our development efforts in the future. We compete
with many other companies for the resources of these third parties, and large pharmaceutical and medical device companies often have
significantly more extensive agreements and relationships with such third-party providers, and such third-party providers may prioritize the
requirements of such large pharmaceutical and medical device companies over ours. The third parties on whom we rely may terminate their
engagements with us at any time, which may cause delay in the development and commercialization of our products. If any such third party
terminates its engagement with us or fails to perform as agreed, we may be required to enter into alternative arrangements, which would
result in significant cost and delay to our product development program. Moreover, our agreements with such third parties generally do not
provide assurances regarding employee turnover and availability, which may cause interruptions in the research on our products by such
third parties.
Moreover, while our reliance on these third parties for certain development and management activities will reduce our control over
these activities, it will not relieve us of our responsibilities. For example, European regulatory authorities, the FDA, and other regulatory
authorities require compliance with regulations and standards, including GCP requirements, for designing, conducting, monitoring,
recording, analyzing, and reporting the results of clinical trials to ensure that the data and results from trials are credible and accurate and
that the rights, integrity, and confidentiality of trial participants are protected. Although we rely on third parties to conduct our clinical
trials, we are responsible for ensuring that each of these clinical trials is conducted in accordance with its general investigational plan and
protocol under legal and regulatory requirements. Regulatory authorities enforce these GCP requirements through periodic inspections of
trial sponsors, principal investigators, and trial sites. If we or any of our CROs fail to comply with applicable GCP requirements, the clinical
data generated in our clinical trials may be deemed unreliable, and European regulatory authorities, the FDA, or other regulatory authorities
may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection
by a regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP requirements.
If CROs and other third parties do not successfully carry out their duties under their agreements with us, if the quality or accuracy
of the data they obtain is compromised due to their failure to adhere to trial protocols or to regulatory requirements, or if they otherwise fail
to comply with regulations and trial protocols or meet expected standards or deadlines, the trials of our products may not meet regulatory
requirements. If trials do not meet regulatory requirements or if these third parties need to be replaced, the development of our products
may be delayed, suspended, or terminated, or the results may not be acceptable. If any of these events occur, we may not be able to obtain
regulatory approval of our products on a timely basis, at a reasonable cost, or at all.
22
Table of Contents
Our reliance on third parties may require us to share our trade secrets, which increases the possibility that a competitor will discover
them or that our trade secrets will be misappropriated or disclosed.
Because we rely on third parties to manufacture our products, and because we collaborate with various organizations and academic
institutions on the advancement of our technology, we must, at times, share trade secrets with them. We seek to protect our proprietary
technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research
agreements, consulting agreements, or other similar agreements with our collaborators, advisors, employees, and consultants prior to
beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose
our confidential information, such as trade secrets. Despite these contractual provisions, the need to share trade secrets and other
confidential information increases the risk that such trade secrets become known by potential competitors, are inadvertently incorporated
into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part,
on our know-how and trade secrets, discovery by a third party of our trade secrets or other unauthorized use or disclosure would impair our
intellectual property rights and protections in our products.
In addition, these agreements typically restrict the ability of our collaborators, advisors, employees, and consultants to publish data
potentially relating to our trade secrets. Our academic collaborators typically have rights to publish data, provided that we are notified in
advance and may delay publication for a specified time in order to secure our intellectual property rights arising from the collaboration. In
other cases, publication rights are controlled exclusively by us, although in some cases we may share these rights with other parties.
Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of these agreements,
independent development, or publication of information including our trade secrets in cases where we do not have proprietary or otherwise
protected rights at the time of publication.
It could be difficult to replace some of our suppliers and equipment vendors.
Outside vendors provide key components, raw materials, and equipment used in the manufacture of our products. An uncorrected
defect or supplier’s variation in a component or raw material, either unknown to us or incompatible with our manufacturing process, could
harm our ability to manufacture products. We may not be able to find a sufficient alternative supplier in a reasonable time period, or on
commercially reasonable terms, if at all, and our ability to produce and supply our products could be impaired.
If we were suddenly unable to purchase from one or more of these companies, we would need a significant period of time to
qualify a replacement, and the production of any affected products could be disrupted. While it is our policy to maintain sufficient
inventory of components so that our production will not be significantly disrupted even if a particular component or material is not
available for a period of time, we remain at risk that we will not be able to qualify new components or materials quickly enough to prevent a
disruption if one or more of our suppliers ceases production of important components or materials, or if we are unable to quickly procure
replacement equipment.
If we fail to identify or enter into economically viable collaboration agreements for certain of our products, we may be unable to
commercialize them effectively or at all. However, there are risks associated with entering into any collaboration agreement.
To successfully develop and commercialize our products, we will need substantial financial resources as well as expertise and
physical resources and systems. We may elect to develop some or all of these physical resources and systems and expertise ourselves, or we
may seek to collaborate with another company that can provide some or all of such physical resources and systems as well as financial
resources and expertise.
The risks in a collaboration agreement include the following:
● the collaborator may not apply the expected financial resources, efforts, or required expertise in developing the physical
resources and systems necessary to successfully develop and commercialize a product;
● the collaborator may not invest in the development of a sales and marketing force and the related infrastructure at levels that
ensure that sales of the products reach their full potential;
23
Table of Contents
● we may be required to undertake the expenditure of substantial operational, financial, and management resources;
● we may be required to issue equity securities that would dilute our existing shareholders’ percentage ownership;
● we may be required to assume substantial actual or contingent liabilities;
● we may not receive requisite regulatory approvals;
● strategic partners could decide to move forward with a competing product developed either independently or in collaboration
with others, including our competitors;
● disputes may arise between us and a collaborator that delay the development or commercialization or adversely affect the sales
or profitability of the product; or
● the collaborator may independently develop, or develop with third parties, products that could compete with our products.
In addition, a collaborator for one or more of our products may have the right to terminate the collaboration at its discretion. Any
termination may require us to seek a new collaborator, which we may not be able to do on a timely basis, if at all, or require us to delay or
scale back our development and commercialization efforts. The occurrence of any of these events could adversely affect the development
and commercialization of our products and materially harm our business and stock price by delaying the development of our products, and
the sale of any products that may be approved by the FDA or other regulatory agencies, by slowing the growth of such sales, by reducing
the profitability of the product and/or by adversely affecting the reputation of the product.
Risks Related to Our Business Operations
Our future success depends on our ability to retain key employees, consultants, and advisors and to attract, retain, and motivate
qualified personnel.
We are dependent on principal members of our executive team listed under “Management” in this annual report on Form 20-F, the
loss of whose services may adversely impact the achievement of our objectives. While we have entered into employment agreements with
each member of our senior management, any of them could leave our employment at any time, as all of our employees are “at will”
employees. Recruiting and retaining other qualified employees, consultants, and advisors for our business, including scientific and technical
personnel, will also be critical to our success. There is currently a shortage of skilled executives in our industry, which is likely to continue.
As a result, competition for skilled personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel
on acceptable terms given the competition among numerous medical device companies for individuals with similar skill sets. In addition,
failure to succeed in clinical trials may make it more challenging to recruit and retain qualified personnel. The inability to recruit or loss of
the services of any executive, key employee, consultant, or advisor may impede the progress of our research, development, and
commercialization objectives.
Our collaborations with outside scientists and consultants may be subject to restriction and change.
We work with medical experts, chemists, biologists, and other scientists at academic and other institutions, and consultants who
assist us in our research, development, and regulatory efforts, including the members of our scientific advisory board. In addition, these
scientists and consultants have provided, and we expect that they will continue to provide, valuable advice regarding our programs and
regulatory approval processes. These scientists and consultants are not our employees and may have other commitments that would limit
their future availability to us. If a conflict of interest arises between their work for us and their work for another entity, we may lose their
services. In addition, we are limited in our ability to prevent them from establishing competing businesses or developing competing
products. For example, if a key scientist acting as a principal investigator in any of our clinical trials identifies a potential product that is
more scientifically interesting to his or her professional interests, his or her availability to remain involved fin our clinical trials could be
restricted or eliminated.
24
Table of Contents
We will need to expand our organization and we may experience difficulties in managing this growth, which could disrupt our
operations.
As of March 15, 2018, we had 39 employees. As we mature and undertake the activities required to advance our products into later
stage clinical development and to operate as a public company in the United States, we expect to expand our full-time employee base and to
hire more consultants and contractors. Our management may need to divert a disproportionate amount of its attention away from our day-
to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the
expansion of our operations, which may result in weaknesses in our infrastructure, operational setbacks, loss of business opportunities, loss
of employees, and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures
and may divert financial resources from other projects, such as the development of additional products. If our management is unable to
effectively manage our growth, our expenses may increase more than expected, our ability to generate or grow revenue could be
compromised, and we may not be able to implement our business strategy. Our future financial performance and our ability to
commercialize products and compete effectively will depend, in part, on our ability to effectively manage any future growth.
Our employees, principal investigators, consultants, and commercial partners may engage in misconduct or other improper activities,
including non-compliance with regulatory standards and requirements and insider trading.
We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants, and commercial
partners. Misconduct by these parties could include intentional failures to comply with regulations, provide accurate information to
European regulatory authorities, the FDA and other regulatory authorities, comply with healthcare fraud and abuse laws and regulations,
report financial information or data accurately, or disclose unauthorized activities to us. In particular, sales, marketing, and business
arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-
dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing
and promotion, sales commission, customer incentive programs, and other business arrangements. Such misconduct could also involve the
improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to
our reputation. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter
employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or
unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to
comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or
asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other
sanctions.
We face potential product liability, and, if successful claims are brought against us, we may incur substantial liability and costs. If the
use of our products harms patients, or is perceived to harm patients even when such harm is unrelated to our products, our regulatory
approvals could be revoked or otherwise negatively impacted and we could be subject to costly and damaging product liability claims.
The use of our products in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the
risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, medical device
companies, or others that sell or otherwise come into contact with our products. There is a risk that our products may induce adverse
events. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition,
regardless of merit or eventual outcome, product liability claims may result in:
● impairment of our business reputation;
● withdrawal of clinical trial participants;
25
Table of Contents
● costs due to related litigation;
● distraction of management’s attention from our primary business;
● substantial monetary awards to patients or other claimants;
● the inability to commercialize our products;
● decreased demand for our products, if approved for commercial sale; and
● impairment of our ability to obtain product liability insurance coverage.
We currently carry product liability insurance of $5.0 million for sales in Europe of VergenixFG and VergenixSTR. We intend to
acquire product liability insurance before commercializing any of our other products. We believe our clinical trials liability insurance
coverage is sufficient in light of our current clinical programs; however, we may not be able to obtain insurance coverage at a reasonable
cost or in sufficient amounts to protect us against losses due to product liability. If we obtain marketing approval for any of our products,
we intend to obtain insurance coverage to include the sale of commercial products, but we may not be able to obtain product liability
insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action
lawsuits based on medical treatments that had unanticipated adverse effects. A product liability claim or series of claims brought against us
could cause our ADS or ordinary share price to decline and, if judgments exceed our insurance coverage, could materially and adversely
affect our financial position.
Our development of rhCollagen relies upon the continued availability of tobacco plants, and any interruption in availability or supply of
tobacco plants may delay production and adversely affect commercial utilization of our rhCollagen-based products, if any such
products are approved and marketed in the future.
Our products are all based on our recombinant human collagen extracted from tobacco plants. Any disruption to the supply of
tobacco plants or any change in its availability for use would delay our production of collagen and adversely affect commercial utilization
of our products, if any such products are approved and marketed in the future.
The occurrence of severe adverse weather conditions or crop diseases may have a potentially devastating impact upon our tobacco
production. The effect of severe adverse weather conditions or the occurrence and effect of crop disease may reduce yields in our plants or
require higher levels of investment to maintain yields, even when only a portion of the crop is damaged. We cannot assure you that severe
future adverse weather conditions will not adversely impact our operating results and financial condition. Although some crop diseases are
treatable, the cost of treatment is high, and we cannot assure that such events in the future will not adversely affect our operating results and
financial condition.
26
Table of Contents
If our existing rhCollagen production site is damaged or destroyed, or production at this facility is otherwise interrupted, our business
and prospects would be negatively affected.
We currently have a single, small-scale production site in Israel where we manufacture rhCollagen. If our existing production
facility, or the equipment in it, is damaged or destroyed, we likely would not be able to quickly or inexpensively replace our production
capacity. Any new facility needed to replace our existing production facility would need to comply with the necessary regulatory
requirements and be tailored to our production requirements and processes. We would need regulatory approval before using any products
manufactured at a new facility in clinical trials or selling any products that are ultimately approved. Such an event could delay our clinical
trials or, if any of our products are approved by the regulator, reduce or eliminate our product sales.
If we fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur
costs that could have a material adverse impact on the success of our business.
We are subject to numerous environmental, health, and safety laws and regulations, including those governing laboratory
procedures and the handling, use, storage, treatment, and disposal of hazardous materials and wastes. Our operations involve the use of
hazardous materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally
contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from
these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any
resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines
and penalties.
Although we maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our
employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage
against potential liabilities. In addition, we may incur substantial costs in order to comply with current or future environmental, health, and
safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts.
Failure to comply with these laws and regulations also may result in substantial fines, penalties, or other sanctions.
We may use our financial and human resources to pursue a particular research program or product and fail to capitalize on programs
or products that may be more profitable or for which there is a greater likelihood of success.
Because we have limited resources, we may forego or delay pursuit of opportunities with certain programs or products or for
indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on
viable commercial products or profitable market opportunities. Our spending on current and future research and development programs for
products may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a
particular product, we may relinquish valuable rights to that product through strategic collaboration, licensing, or other royalty
arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to
such product, or we may allocate internal resources to a product in a therapeutic area in which it would have been more advantageous to
enter into a collaboration arrangement.
We are subject to foreign currency exchange risk, and fluctuations between the U.S. dollar and the NIS, the Euro, and other non-U.S.
currencies may adversely affect our earnings and results of operations.
We currently operate in two different currencies. While the NIS is our functional and reporting currency and certain investments in
our share capital have been denominated in NIS, our financial results may be adversely affected by fluctuations in currency exchange rates
as a significant portion of our operating expenses, including development and manufacturing expenses, are denominated in U.S. dollars.
We are exposed to the risks that the U.S. dollar may appreciate relative to the NIS, In such event, the dollar-denominated results of
operations would be adversely affected. We cannot predict any future trends in the rate of inflation in Israel or the rate of devaluation (if
any) of the NIS against the dollar. For example, the average exchange rate of the dollar against the NIS decreased in 2017, 2016 and
increased in 2015. Market volatility and currency fluctuations may limit our ability to cost-effectively hedge against our foreign currency
exposure. Hedging strategies may not eliminate our exposure to foreign exchange rate fluctuations and may involve costs and risks of their
own, such as devotion of management time, external costs to implement the strategies, and potential accounting implications. Foreign
currency fluctuations, independent of the performance of our underlying business, could lead to materially adverse results or could lead to
positive results that are not repeated in future periods.
27
Table of Contents
Risks Related to Our Intellectual Property
We have an extensive worldwide patent portfolio. The cost of maintaining our patent protection is high and maintaining our patent
protection requires continuous review and compliance in order to maintain worldwide patent protection. We may not be able to
effectively maintain our intellectual property position throughout the major markets of the world.
The U.S. Patent and Trademark Office, or U.S. PTO, and foreign patent authorities require maintenance fees and payments as well
as continued compliance with a number of procedural and documentary requirements. Non-compliance may result in abandonment or lapse
of the subject patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance
may result in reduced royalty payments for lack of patent coverage in a particular jurisdiction from our collaboration partners or may result
in competition, either of which could have a material adverse effect on our business.
We have made, and will continue to make, certain strategic decisions in balancing costs and the potential protection afforded by
the patent laws of certain countries. As a result, we may not be able to prevent third parties from practicing our inventions in all countries
throughout the world, or from selling or importing products made using our inventions in and into the United States or other countries.
Third parties may use our technologies in territories in which we have not obtained patent protection to develop their own products and,
further, may infringe our patents in territories which provide inadequate enforcement mechanisms, even if we have patent protection. Such
third-party products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient
to prevent them from competing.
If we are unable to obtain or protect intellectual property rights related to our products, we may not be able to obtain exclusivity for our
products or prevent others from developing similar competitive products.
We rely upon a combination of granted patents, pending patent applications, trade secret protection, and confidentiality
agreements to protect the intellectual property related to our products. The strength of patents in the field of regenerative medicine involves
complex legal and scientific questions and can be uncertain. The patent applications that we own may fail to result in issued patents with
claims that cover our products in the United States or in other countries. There is no assurance that all of the potentially relevant prior art
relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending
patent application. Even if patents do successfully issue and even if such patents cover our products, third parties may challenge their
validity, enforceability, or scope, which may result in the patent claims being narrowed or invalidated. Furthermore, even if they are
unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our products,
or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competition from third
parties.
Our ability to attract third parties to collaborate with us to develop products and our ability to commercialize future products may
be adversely affected if the patent applications we hold with respect to our techniques or products fail to issue, if the breadth or strength of
our patent protection is threatened, or if our patent portfolio fails to provide meaningful exclusivity for our products. Third parties may
challenge their validity or enforceability of our patents or patents that issue in the future from our patent applications, which may result in
such patents being narrowed, invalidated, or held unenforceable. Even if our patents and patent applications are not challenged by third
parties, they may not prevent others from designing around our claims and may not otherwise adequately protect our products. If the
breadth or strength of protection provided by the patents and patent applications we hold with respect to our products is threatened, our
ability to commercialize our products may be adversely effected.
Discoveries are generally published in the scientific literature well after their actual development, and patent applications in the
United States and other countries are typically not published until 18 months after filing and in some cases are never published. Therefore,
we cannot be certain that we were the first to make the inventions claimed in our owned granted patents or patent applications, or that we
were the first to file for patent protection covering such inventions. Subject to meeting other requirements for patentability, for United
States patent applications filed prior to March 16, 2013, the first to invent the claimed invention is entitled to receive patent protection for
that invention while, outside the United States, the first to file a patent application encompassing the invention is entitled to patent
protection for the invention. In addition, patents have a limited lifespan. In the United States, the expiration of a patent is generally 20 years
from the earliest non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is
limited. Once the patent life has expired for a product, we may be open to competition from third party products, including products that are
copies of our products. This risk is material in light of the length of the development process of our products and lifespan of our current
patent portfolio.
28
Table of Contents
In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect our
proprietary know-how and other proprietary information that is not patentable or that we elect not to patent. For example, many of our
discovery, development, and manufacturing processes involve proprietary know-how, information, or technology that is not covered by
patents. We seek to protect our trade secrets and proprietary technology and processes, in part, by entering into confidentiality agreements
with our employees, consultants, scientific advisors, and contractors. We also seek to preserve the integrity and confidentiality of our data
and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology
systems. Security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may
otherwise become known or be independently discovered by competitors. Although we expect all of our employees and consultants to
assign their inventions to us, and all of our employees, consultants, advisors, and any third parties who have access to our proprietary
know-how, information, or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements
have been duly executed, that our trade secrets and other confidential proprietary information will not be disclosed, or that competitors will
not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques.
Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may have a material adverse
effect on our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient
recourse against third parties for misappropriating the trade secret. In addition, others may independently discover our trade secrets and
proprietary information. For example, the FDA, as part of its Transparency Initiative, is currently considering whether to make additional
information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary
information, and it is not clear at the present time how the FDA’s disclosure policies may change in the future, if at all.
Further, the laws of some countries do not protect proprietary rights to the same extent or in the same manner as the laws of the
United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United
States and in other countries. If we are unable to prevent material disclosure of the non-patented intellectual property related to our
technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to
establish or maintain a competitive advantage in our market.
Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.
Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There
is a substantial amount of litigation, both within and outside the United States, involving patents and other intellectual property rights in the
biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, and inter partes review
proceedings before the U.S. PTO, and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent
applications, which are owned by third parties, exist in the fields in which we are pursuing development technologies. As the
biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our products may be subject to
claims of infringement of the patent rights of third parties.
Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party
patents or patent applications with claims to materials, formulations, methods of manufacture, or methods for treatment related to the use or
manufacture of our products. Because patent applications can take many years to issue, there may be currently pending patent applications
which may later result in issued patents that our products may be accused of infringing. In addition, third parties may obtain patents in the
future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent
jurisdiction to cover the manufacturing process of any of our products or any final product itself, the holders of any such patents may be
able to block our ability to commercialize such product unless we obtained a license under the applicable patents, or until such patents
expire. Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, processes
for manufacture, or methods of use, the holders of any such patents may be able to block our ability to develop and commercialize the
applicable product unless we obtained a license or until such patent expires. In either case, such a license may not be available on
commercially reasonable terms or at all.
29
Table of Contents
The patent landscape in competitive product areas is highly complex and there may be patents of third parties of which we are
unaware that may result in claims of infringement. Accordingly, there can be no assurance that our products do not infringe proprietary
rights of third parties. Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our
ability to further develop and commercialize one or more of our products. Defense of such claims, regardless of their merit, would involve
substantial litigation expense and would be a substantial diversion of financial and employee resources from our business. In the event of a
successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for
willful infringement, pay royalties, redesign our infringing products, or obtain one or more licenses from third parties, which may be
impossible or require substantial time and monetary expenditure.
We intend, if necessary, to vigorously enforce our intellectual property in order to protect the proprietary position of our products.
Active efforts to enforce our patents may include litigation, post-grant patent challenges, administrative proceedings, or all of the
foregoing, depending on the potential benefits that might be available from those actions and the costs associated with undertaking those
efforts against third parties. We review and monitor publicly available information regarding products that may be competitive with our
products and intend to assert our intellectual property rights where appropriate.
We may enter into license agreements with third parties, and if we fail to comply with our obligations in such agreements under which
we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our
licensors, we could lose license rights that are important to our business.
We may need to obtain licenses from third parties to advance our research or allow commercialization of our products. We may
fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend
significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or
commercialize the affected products.
We may be involved in lawsuits or administrative proceedings to obtain, protect or enforce our patents, which could be expensive, time
consuming, and unsuccessful.
Competitors may infringe our patents. To counter infringement or unauthorized use, we may be required to file an infringement
suit, which can be expensive and time consuming. In addition, in an infringement proceeding, the defendant may file a countersuit,
challenging the validity or enforceability of our patent. In that case, a court may decide that a patent of ours is not valid, is unenforceable,
or is not infringed, or it may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover
the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being
invalidated or interpreted narrowly and could put our patent applications at risk of not issuing.
We may not be able to prevent misappropriation of our intellectual property rights, particularly in countries where the laws may
not protect those rights.
We may be involved in interference proceedings in the U.S. PTO that are provoked by third parties or provoked by us when there
appears to be the same subject matter claimed in our patents or patent applications and the third parties’ patents or patent applications, in
order to determine the priority of inventions. An unfavorable outcome could require us to cease using the related technology, to lose our
patent claims partially or in entirety, or to attempt to license rights to it from the prevailing party. Our business could be harmed if the
prevailing party does not offer us a license on commercially reasonable terms. Our defense of interference proceedings may fail and, even
if successful, may result in substantial costs and distract our management and other employees.
30
Table of Contents
Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a
risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public
announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors
perceive these results to be negative, it could have a material adverse effect on the trading price of our ordinary shares or ADSs.
Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and
the enforcement or defense of our issued patents.
On September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith
Act includes a number of significant changes to U.S. patent law, including provisions that affect the way patent applications are prosecuted
and also affect patent litigation. The U.S. PTO has developed regulations and procedures to govern administration of the Leahy-Smith Act,
and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions which
were enacted March 16, 2013. However, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business.
The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent
applications and the enforcement or defense of our issued patents. We may become involved in post-grant proceedings challenging our
patents or the patents of others, and the outcome of any such proceedings are highly uncertain. An unfavorable outcome in any such
proceedings could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology and compete
directly with us, or result in our inability to manufacture, develop, or commercialize our products without infringing the patent rights of
others.
We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential
information of third parties or, that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.
Certain of our employees and personnel were previously employed at universities, medical institutions, or other biotechnology or
pharmaceutical companies. Although we try to ensure that our employees, consultants, and independent contractors do not use the
proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants, or
independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary
information, of any of our employee’s former employer or other third parties. Litigation may be necessary to defend against these claims. If
we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or
personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to
management and other employees. Furthermore, universities or medical institutions who employ some of our key employees and personnel
in parallel to their engagement by us may claim that intellectual property developed by such person is owned by the respective academic or
medical institution under the respective institution intellectual property policy or applicable law.
We may become subject to claims for remuneration or royalties for assigned service invention rights by our employees, which could
result in litigation and adversely affect our business.
A significant portion of our intellectual property has been developed by our employees in the course of their employment for us.
Section 134 of the Israeli Patents Law, 5727-1967, or the Patents Law, grants employees the right to receive consideration for service
inventions unless otherwise provided in an agreement between the parties. According to a decision by the special Committee for
Compensations and Royalties formed under the Patents Law, or the Committee, an employee’s right to receive consideration for service
inventions is a personal right and is entirely separate from the proprietary rights in such invention. A decision in May 2014 by the
Committee clarifies that the right to receive consideration under Section 134 can be waived and that such waiver does not necessarily have
to be explicit. However, the Committee has the authority to examine, on a case by case basis, the general contractual framework between
the parties, using interpretation rules of the general Israeli contract laws. Although such decision seems to alleviate the requirement to
obtain an explicit waiver for royalties for service inventions under Section 134 of the Patents Law, to the extent that there is no explicit
waiver in an employment agreement, the existence of such waiver will be subject to the interpretation of the Committee. Further, the
Committee has not yet determined one specific formula for calculating this remuneration (but rather uses the criteria specified in the Patents
Law) nor the criteria or circumstances under which an employee’s waiver of his right to remuneration will be disregarded. We generally
enter into assignment-of-invention agreements with our employees pursuant to which such individuals assign to us all rights to any
inventions created in the scope of their employment or engagement with us. Although our employees have agreed to assign to us service
invention rights, we may face claims demanding remuneration in consideration for assigned inventions. As a consequence of such claims,
we could be required to pay additional remuneration or royalties to our current or former employees, or be forced to litigate such claims,
which could negatively affect our business.
31
Table of Contents
We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
We may be subject to claims that former employees, collaborators, or other third parties have an ownership interest in our patents
or other intellectual property. Ownership disputes may arise in the future, for example, from conflicting obligations of consultants or others
who are involved in developing our products. Litigation may be necessary to defend against these and other claims challenging
inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable
intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a
material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial
costs and be a distraction to management and other employees.
Obtaining and maintaining our patent protection require compliance with various procedural, document submissions, fee payment, and
other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-
compliance with these requirements.
Periodic maintenance fees, renewal fees, annuity fees, and various other governmental fees on patents and applications are and will
be due to be paid to the U.S. PTO and various governmental patent agencies outside of the United States in several stages over the lifetime
of the patents and applications. The U.S. PTO and various non-U.S. governmental patent agencies require compliance with a number of
procedural, documentary, fee payment, and other similar provisions during the patent application process. There are situations in which
non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights
in the relevant jurisdiction.
Issued patents covering our products could be found invalid or unenforceable if challenged in court or in administrative proceedings.
If we initiate legal proceedings against a third party to enforce a patent covering one of our products, the defendant may contend
that the patent covering our product is invalid, unenforceable, or fails to cover the product or the infringing product. In patent litigation in
the United States, defendants commonly allege that asserted patent claims are invalid and unenforceable. Grounds for a validity challenge
could be an alleged failure to meet one or more of several statutory requirements, including lack of novelty, obviousness, lack of written
description, indefiniteness, and non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected
with prosecution of the patent withheld relevant information from the U.S. PTO, or made a misleading statement, during prosecution. Third
parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation.
Such mechanisms include re-examination, post grant review, and equivalent proceedings in foreign jurisdictions, such as opposition
proceedings. Such proceedings could result in revocation, amendments to our patent claims, or statements being made on the record such
that our claims may no longer be construed to cover our products. The outcome following legal assertions of invalidity and unenforceability
is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we
and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity, unenforceability,
or non-infringement, we would lose at least part, and perhaps all, of the patent protection on our products. For example, as further
described below, in July 2017, Fibrogen, Inc., or Fibrogen, prevailed in an administrative challenge to one of our patents in Europe,
resulting in the revocation of the patent and the abandonment of another patent. Even if resolved in our favor, litigation, or other legal
proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and
management personnel from their normal responsibilities. Moreover, third parties may continue to initiate new proceedings in the United
States and foreign jurisdictions to challenge our patents from time to time.
32
Table of Contents
In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or
developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the
market price of our ordinary shares or ADSs. Such litigation or proceedings could substantially increase our operating losses and reduce the
resources available for development activities or any future sales, marketing, or distribution activities.
Three issued patents in Europe covering our product were administratively challenged by Fibrogen.
Our European Patent No. 1 809 751 entitled “Collagen Producing Plants and Methods of Generating and Using Same,” was
granted by the European Patent Office, or the EPO, on September 1, 2010. On June 1, 2011, Fibrogen initiated an opposition proceeding
with the EPO, seeking revocation of the patent in its entirety on the grounds that the claims were not supported by the contents of the
patent, were not novel, and were not inventive. On January 22, 2013, the EPO issued its decision to maintain the patent in amended form
with claims that cover genetically modified plants that produce collagen.
On June 3, 2013, Fibrogen, Inc. appealed the decision. On August 1, 2013, we filed an appeal, seeking to expand the scope of the
patent. In July 2017, the EPO revoked the patent.
Our European Patent No. 2 357 241 entitled “Collagen Producing Plants and Methods of Generating and Using Same,” a
divisional of European Patent No. 1 809 751, was granted by the EPO, on March 4, 2015. On December 10, 2015, Fibrogen initiated an
opposition proceeding with the EPO, seeking revocation of the patent in its entirety on the grounds that the claims were not supported by
the contents of the patent, were not novel, and were not inventive. On August 16, 2016, we filed a response thereto. In September 2017, we
abandoned the patent and consequently the patent was revoked by the EPO in February 2018.
Our European Patent No. EP2816117 entitled “Collagen Producing Plants and Methods of Generating and Using Same,” a
divisional of European Patent No. 1 809 751, was granted by the EPO, on November 30, 2016. On August 30, 2017, Fibrogen initiated an
opposition proceeding with the EPO, seeking revocation of the patent in its entirety on the grounds that the claims were not supported by
the contents of the patent, and were not inventive. The ultimate outcome of this proceeding remains uncertain, and final resolution of the
proceeding may take a number of years and result in substantial costs to us.
Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.
As is the case with other companies in our industry, our success is heavily dependent on intellectual property, particularly patents.
Obtaining and enforcing patents in the biotechnology industry involve both technological and legal complexity, and is therefore is costly,
time consuming, and inherently uncertain. In addition, in recent years the United States enacted and implemented wide-ranging patent
reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and
weakened the rights of patent owners in some situations. In addition to increasing uncertainty with regard to our ability to obtain patents in
the future, this combination of events has created uncertainty with respect to the value of patents that had already been granted. The patent
laws and regulations may changes in unpredictable ways through actions of the U.S. Congress, the federal courts, and the U.S. PTO, in the
future, and any changes may adversely affect our ability to obtain new patents or to enforce our existing patents and patents that we might
obtain in the future.
We may not be able to protect our intellectual property rights throughout the world.
Filing, prosecuting, and defending patents on products in all countries throughout the world would be prohibitively expensive, and
our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition,
the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United
States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States,
or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Potential competitors
may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may export
otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as in the United States. These
products may compete with our products, if approved, and our patents or other intellectual property rights may not be effective or sufficient
to prevent them from competing.
33
Table of Contents
Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign
jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade
secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us
to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to
enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of
our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and
could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other
remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around
the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.
Intellectual property rights do not address all potential threats to any competitive advantage we may have.
The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have
limitations, and intellectual property rights may not adequately protect our business or permit us to maintain our competitive advantage.
The following examples are illustrative:
● Others may be able to make products that are the same as or similar to our current or future products but that are not covered by
the claims of the patents that we own or have exclusively licensed.
● We or any of our licensors or strategic partners might not have been the first to make the inventions covered by the issued
patent or pending patent application that we own or have exclusively licensed.
● We or any of our licensors or strategic partners might not have been the first to file patent applications covering certain of our
inventions.
● Others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing
our intellectual property rights.
● The prosecution of our pending patent applications may not result in granted patents.
● Granted patents that we own or have exclusively licensed may not provide us with any competitive advantages, or may be held
invalid or unenforceable, as a result of legal challenges by our competitors.
● Patent protection on our products may expire before we are able to develop and commercialize the product, or before we are
able to recover our investment in the product.
● Our competitors might conduct research and development activities in the United States and other countries that provide a safe
harbor from patent infringement claims for such activities, as well as in countries in which we do not have patent rights, and
may then use the information learned from such activities to develop competitive products for sale in markets where we intend
to market our products.
34
Table of Contents
Risks Related to the Offering and Ownership of the ADSs
The market price of the ADSs may be highly volatile.
Since our listing of the ADSs on The Nasdaq Capital Market on January 31, 2018 and which were previously quoted on the OTC
from March 2015 to January 30, 2018, an active market has not developed. You may not be able to sell your ADSs quickly or at the market
price if trading in the ADSs is not active.
The market price of the ADSs is likely to be volatile. Our ADS price could be subject to wide fluctuations in response to a variety
of factors, including the following:
● adverse results or delays in preclinical studies or clinical trials;
● reports of adverse events in other similar products or clinical trials of such products;
● inability to obtain additional funding;
● any delay in filing a regulatory submission for any of our products and any adverse development or perceived adverse
development with respect to the FDA’s review or European authorities’ review of that regulatory submission;
● failure to develop successfully and commercialize our products and future products;
● failure to enter into strategic collaborations;
● failure by us or strategic collaboration partners to prosecute, maintain, or enforce our intellectual property rights;
● changes in laws or regulations applicable to future products;
● inability to scale up our manufacturing capabilities (including in Israel), inability to obtain adequate product supply for our
products, or the inability to do so at acceptable prices;
● adverse regulatory decisions, including by the IIA under the Innovation Law;
● introduction of new products, services, or technologies by our competitors;
● failure to meet or exceed financial projections we may provide to the public;
● failure to meet or exceed the financial expectations of the investment community;
● the perception of the biotechnology industry by the public, legislatures, regulators, and the investment community;
● announcements of significant acquisitions, strategic partnerships, joint ventures, or capital commitments by us or our
competitors;
● disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain
patent protection for our technologies;
● additions or departures of key scientific or management personnel;
● significant lawsuits, including patent or shareholder litigation;
● changes in the market valuations of similar companies;
● sales of our ordinary shares or ADSs by us or our shareholders in the future; and
● trading volumes of our ordinary shares and ADSs.
35
Table of Contents
In addition, companies trading in the stock market in general, and medical device companies in particular, have experienced
extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies.
Broad market and industry factors may negatively affect the market price of our ordinary shares, regardless of our actual operating
performance.
We will incur significant additional costs as a result of the listing of the ADSs for trading on The Nasdaq Capital Market and thereby
becoming a public company subject to SEC reporting requirements in the United States, and our management will be required to devote
substantial additional time to new compliance initiatives as well as to compliance with ongoing United States and Israeli reporting
requirements.
In addition to the costs associated with being an Israeli public company, as a U.S. public reporting company, we are incurring and
will incur additional significant accounting, legal, and other expenses that we did not incur before the offering. We also anticipate that we
will incur costs associated with corporate governance requirements of the U.S. Securities and Exchange Commission, or the SEC, and The
Nasdaq Capital Market. We expect these rules and regulations to increase our legal and financial compliance costs, introduce new costs
such as investor relations, stock exchange listing fees and shareholder reporting, and to make some activities more time consuming and
costly. Our management and other personnel will need to devote substantial time to these compliance requirements; in addition, the
implementation of such compliance processes and systems may require us to hire outside consultants and incur other significant costs. Any
future changes in the laws and regulations affecting public companies in the United States and the rules and regulations adopted by the SEC
and The Nasdaq Capital Market, for so long as they apply to us, will result in increased costs to us as we respond to such changes. These
laws, rules, and regulations could make it more difficult or more costly for us to obtain certain types of insurance, including director and
officer liability insurance, and we may be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain
the same or similar coverage. The impact of these requirements could also make it more difficult for us to attract and retain qualified
persons to serve on our board of directors, on our board committees, if any, or as senior management.
Our securities will be traded on more than one market or exchange and this may result in price variations.
Our ordinary shares have been trading on the TASE since May 2010. The ADSs were quoted on the OTCQX from March 2015 to
May 25, 2017, and quoted on OTCQB from May 26, 2017 to January 30, 2018. The ADSs have been listed on The Nasdaq Capital Market
since January 31, 2018. Trading in ordinary shares and ADSs, as applicable, on these markets will take place in different currencies (U.S.
dollars on The Nasdaq Capital Market and NIS on the TASE), and at different times (resulting from different time zones, trading days, and
public holidays in the United States and Israel). The trading prices of our shares on these two markets may differ due to these and other
factors. Any decrease in the price of our ordinary shares on the TASE could cause a decrease in the trading price of the ADSs on The
Nasdaq Capital Market.
We may delist our ordinary shares from the TASE which may result in holders of our ordinary shares having difficulty disposing of
their shares.
We may delist our ordinary shares that currently trade on the TASE, subject to various approvals, including shareholder approval.
If we are successful in delisting our ordinary shares from the TASE, holders of our ordinary shares may have difficulty disposing of their
ordinary shares represented by ADSs in the absence of an active trading market and may incur additional costs as a result of holding
ordinary shares represented by ADSs.
Our principal shareholders, management and directors beneficially own a significant percentage of our ordinary shares and will be
able to exert significantly influence over matters subject to shareholder approval.
As of March 15, 2018, our senior management, directors, and five percent or more shareholders and their affiliates beneficially
owned approximately 48% of our ordinary shares. These shareholders will be able to significantly influence all matters requiring
shareholder approval, except for decisions that require a special majority at a shareholders’ meeting. For example, these shareholders, if
they were to act together, may be able to significantly influence elections of directors (other than our external directors, within the meaning
of Israeli law, as described under “Management—External Directors”), amendments of our organizational documents, or approval of any
merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for
our ordinary shares that you may believe are in your best interest as one of our shareholders.
36
Table of Contents
In addition, but for the application of blocker provisions in certain security instruments that subject the conversion or exercise of
such instruments, as applicable, to 4.99% beneficial ownership limitations and the need to conduct a special tender offer if Alpha wishes to
hold 25% or more of the voting rights in the Company, Alpha would beneficially own approximately 23% of our outstanding ordinary
shares as of March 15, 2018. Further, assuming the consummation of the third closing under the Alpha Purchase Agreement as well as all
closings under the Meitav Purchase Agreement, Sagi Purchase Agreement and that no further issuances of our ordinary shares take place,
then, but for the aforementioned blocker provisions and special tender offer requirement, Alpha would beneficially own approximately 40%
of our ordinary shares. If Alpha were to convert or exercise such instruments to the maximum extent possible, absent such blocker
provisions and special tender offer requirement, Alpha would have the ability to also obtain a substantial interest in our Company. This
concentration and potential further concentration of ownership could have the effect of delaying a change in our control or otherwise
discouraging a potential acquirer from attempting to obtain control of us, which could in turn have an adverse effect on the market price of
our ordinary shares or ADSs or prevent our shareholders from realizing a premium over the then-prevailing market price for their ordinary
shares or ADSs. Furthermore, because of the large number of shares that may be issued from time to time under security instruments issued
to Alpha, Meitav Dash and Ami Sagi, there may be an adverse effect on the market because of the quantity and regularity of conversion
and/or exercise and sale of those shares, or even the potential of those shares being sold. Therefore, there may be limited demand and
excessive price and volume volatility.
We are an “emerging growth company” and a “foreign private issuer,” and we cannot be certain if the reduced reporting requirements
applicable to emerging growth companies and foreign private issuers will make the ADSs less attractive to investors.
We are an “emerging growth company,” as defined in the JOBS Act. For as long as we continue to be an emerging growth
company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are
not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section 404 of the
Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in this annual report on Form 20-F and other
periodic reports and proxy statements, extended transition periods for adopting new or revised accounting standards, and exemptions from
the requirements of holding a non-binding advisory vote on executive compensation and shareholder approval of any golden parachute
payments not previously approved. We will be an emerging growth company until the earliest of: (i) the last day of the fiscal year during
which we had total annual gross revenues of $1.07 billion or more, (ii) the last day of the fiscal year following the fifth anniversary of the
date of the first sale of the ADSs pursuant to an effective registration statement, (iii) the date on which we have, during the previous three-
year period, issued more than $1 billion in non-convertible debt or (iv) the date on which we are deemed a “large accelerated filer” as
defined in Regulation S-K under the Securities Act, which means the market value of our ordinary shares that is held by non-affiliates
exceeds $700 million as of the prior June 30th.Furthermore, as a foreign private issuer, we are not subject to the same requirements that are
imposed upon U.S. domestic issuers by the SEC. Under the Exchange Act, we will be subject to reporting obligations that, in certain
respects, are less detailed and less frequent than those of U.S. domestic reporting companies. For example, we will not be required to issue
proxy statements that comply with the requirements applicable to U.S. domestic reporting companies. We will also have four months after
the end of each fiscal year to file our annual reports with the SEC and will not be required to file current reports as frequently or promptly
as U.S. domestic reporting companies. Furthermore, our officers, directors, and principal shareholders will be exempt from the
requirements to report transactions in our equity securities and from the short-swing profit liability provisions contained in Section 16 of
the Exchange Act. These exemptions and leniencies, along with other corporate governance exemptions resulting from our ability to rely on
home country rules, will reduce the frequency and scope of information and protections to which you may otherwise have been eligible in
relation to a U.S. domestic reporting companies. See “Item 16G. Corporate Governance Practices” for more information.
We cannot predict if investors will find the ADSs less attractive because we may rely on these reduced requirements. If some
investors find the ADSs less attractive as a result, there may be a less active trading market for the ADSs and our share price may be more
volatile.
37
Table of Contents
Sales of a substantial number of our ordinary shares or ADSs in the public market could cause our share price to fall.
If our existing shareholders sell, indicate an intention to sell, or the market perceives that they intend to sell, substantial amounts
of our securities, either on the TASE or on The Nasdaq Capital Market after the date of this annual report on Form 20-F, the market price
of our securities could decline significantly. As of March 15, 2018, we had 171,160,668 ordinary shares outstanding. Of those shares,
138,336,328 were freely tradable, without restriction. In addition, we have registered for resale up to 46,602,742 ordinary shares
represented by 932,054 ADSs which may be sold from time to time in the public markets.
In addition, as of March 15, 2018, an aggregate of 89,059,949 ordinary shares that are issuable pursuant to exercise of either
outstanding options or outstanding warrants will become eligible for sale in the public market to the extent permitted by the provisions of
various vesting schedules, and Rule 144 and Rule 701 under the Securities Act of 1933, as amended, or the Securities Act. If these
additional ordinary shares are sold, or if it is perceived that they will be sold, in the public market, the market price of our ordinary shares
could decline.
Future sales and issuances of our securities or rights to purchase securities, including pursuant to our equity incentive plans, could
result in additional dilution of the percentage ownership of our shareholders and could cause the prices of our securities to fall.
Additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by
issuing equity securities, our shareholders may experience substantial dilution. We may sell ordinary shares, ADSs, convertible securities,
or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell ordinary shares,
ADSs, convertible securities, or other equity securities in one or more transactions, existing investors may be materially diluted by
subsequent sales, and new investors could gain rights superior to our existing shareholders.
Pursuant to our Share Ownership and Option Plan (2010), or the 2010 Plan, our management is authorized to grant share options
and other equity-based awards to our employees, directors, and consultants. As of March 15, 2018, our officers, directors, employees and
consultants hold 47,544,792 options to purchase 26,838,931 ordinary shares under the 2010 Plan. If our board of directors elects to increase
the number of shares available for future grant by the maximum amount each year, our shareholders may experience additional dilution,
which could cause our share price to fall.
We do not intend to pay dividends on our securities, so any returns will be limited to the value of our shares.
We have never declared or paid any cash dividends on our share capital. We currently anticipate that we will retain future
earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the
foreseeable future. Any return to shareholders will therefore be limited to the appreciation of their shares. In addition, Israeli law limits our
ability to declare and pay dividends, and may subject our dividends to Israeli withholding taxes; see “Item 10.B. Memorandum and Articles
of Association——Dividend and Liquidation Rights” for additional information. As a result, investors in the ADSs or ordinary shares will
not be able to benefit from owning these securities unless their market price becomes greater than the price paid by such investors and they
are able to sell such securities. We cannot assure you that you will ever be able to resell our securities at a price in excess of the price paid.
38
Table of Contents
In the event we make distributions or dividends, you may not receive the same distributions or dividends as those we make to the holders
of our ordinary shares, and, in some limited circumstances, you may not receive dividends or other distributions, or receive any value
for them, if it is illegal or impractical to make them available to you.
The depositary for the ADSs has agreed to pay to you the cash dividends or other distributions it or the custodian receives on
ordinary shares or other deposited securities underlying the ADSs, after deducting its fees and expenses. You will receive these
distributions in proportion to the number of ordinary shares your ADSs represent. However, the depositary is not responsible if it decides
that it is unlawful or impractical to make a distribution available to any holders of ADSs. For example, it would be unlawful to make a
distribution to a holder of ADSs if it consists of securities that require registration under the Securities Act, but that are not properly
registered or distributed under an applicable exemption from registration. In addition, conversion into U.S. dollars from foreign currency
that was part of a dividend made with respect to deposited ordinary shares may require the approval or license of, or a filing with, any
government or agency thereof, which may be unobtainable. In these cases, the depositary may determine not to distribute such property and
hold it as “deposited securities” or may seek to effect a substitute dividend or distribution, including net cash proceeds from the sale of the
dividends that the depositary deems an equitable and practicable substitute. We have no obligation to register under U.S. securities laws
any ordinary shares, rights, or other securities made available through such distributions. We also have no obligation to take any other
action to permit the distribution of ADSs, ordinary shares, rights, or anything else to holders of ADSs. In addition, the depositary may
withhold from such dividends or distributions its fees and an amount on account of taxes or other governmental charges to the extent the
depositary believes it is required to make such withholding. This means that you may not receive the same distributions or dividends as
those we make to the holders of our ordinary shares, and, in some limited circumstances, you may not receive any value for such
distributions or dividends if it is illegal or impractical for us to make them available to you. These restrictions may cause a material decline
in the value of the ADSs.
Holders of ADSs must act through the depositary to exercise their rights.
Holders of the ADSs do not have the same rights of our shareholders and may only exercise the voting rights with respect to the
underlying ordinary shares in accordance with the provisions of the deposit agreement for the ADSs. In general, under Israeli law, the
minimum notice period required to convene a shareholders’ meeting is no less than 35 or 21 calendar days, depending on the proposals on
the agenda for the shareholders’ meeting. When a shareholders’ meeting is convened, holders of the ADSs may not receive sufficient
notice of a shareholders’ meeting to permit them to withdraw their ordinary shares to allow them to cast their vote with respect to any
specific matter. In addition, the depositary and its agents may not be able to send voting materials to holders of the ADSs or carry out their
voting instructions in a timely manner. We will make all reasonable efforts to cause the depositary to extend voting rights to holders of the
ADSs in a timely manner, but we cannot assure holders that they will receive the voting materials in time to ensure that they can instruct
the depositary to vote their ADSs. Furthermore, the depositary and its agents will not be responsible for any failure to carry out any
instructions to vote, for the manner in which any vote is cast or for the effect of any such vote. As a result, holders of the ADSs may not be
able to exercise their right to vote, and they may lack recourse if their ADSs are not voted as they requested. In addition, in the capacity as
a holder of ADSs, they will not be able to call a shareholders’ meeting.
You may be subject to limitations on transfer of your ADSs.
Your ADSs are transferable on the books of the depositary. However, the depositary may close its transfer books at any time or
from time to time when it deems expedient in connection with the performance of its duties. In addition, the depositary may refuse to
deliver, transfer, or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we or
the depositary deems it advisable to do so because of any requirement of law or of any government or governmental body or for any other
reason in accordance with the terms of the deposit agreement.
Your percentage ownership in us may be diluted by future issuances of share capital, which could reduce your influence over matters
on which shareholders vote.
Our board of directors will have the authority, in most cases without action or vote of our shareholders, to issue all or any part of
our authorized but unissued shares, including ordinary shares issuable upon the exercise of outstanding options and warrants. Issuances of
additional shares would reduce your influence over matters on which our shareholders vote.
39
Table of Contents
If equity research analysts do not publish research reports about our business or if they issue unfavorable commentary or downgrade
the ADSs, the price of the ADSs could decline.
The trading market for the ADSs will rely in part on the research and reports that equity research analysts publish about us and our
business. The price of the ADSs could decline if we do not obtain research analyst coverage or if one or more securities analysts
downgrade the ADSs, issue other unfavorable commentary, or cease publishing reports about us or our business.
Risks Related to Our Operations in Israel
We are a “foreign private issuer” and intend to follow certain home country corporate governance practices, and our shareholders may
not have the same protections afforded to shareholders of companies that are subject to all corporate governance requirements under
the listing rules of The Nasdaq Stock Market LLC, or the Nasdaq Listing Rules.
As a foreign private issuer, we are permitted to follow certain home country corporate governance practices instead of those
otherwise required under the Nasdaq Stock Market for domestic U.S. issuers. For instance, we follow home country practice in Israel with
regard to the quorum requirement for shareholder meetings. As permitted under the Companies Law, our articles of association provide that
the quorum for any meeting of shareholders shall be the presence of at least two shareholders present in person, by proxy, or by a voting
instrument, who hold at least 20% of the voting power of our shares. In addition, we will follow home country practices in Israel (and
consequently avoid the requirements that would otherwise apply to a U.S. company listed on The Nasdaq Capital Market) with regard to
the requirement to obtain shareholder approval for certain dilutive events (such as for the establishment or amendment of certain equity-
based compensation plans, issuances that will result in a change of control of the company, certain transactions other than a public offering
involving issuances of a 20% or more interest in the company, and certain acquisitions of the stock or assets of another company). We may
in the future (or may be required to) elect to follow home country practices in Israel with regard to other matters, as well, such as the
formation of compensation, nominating, and governance committees, separate executive sessions of independent directors and non-
management directors, , amending our compensation policy from time to time, and the approval of certain interested-parties transactions.
Following our home country governance practices as opposed to the requirements that would otherwise apply to a U.S. company listed on
The Nasdaq Capital Market may provide less protection to you than what is accorded to investors under the Nasdaq Listing Rules
applicable to domestic U.S. issuers. See “Item 16G. Corporate Governance Practices” for more information.
In addition, as a foreign private issuer, we are exempt from the rules and regulations under the Exchange Act related to the
furnishing and content of proxy statements, including the requirement for an emerging growth company to disclose the compensation of the
chief executive officer and other two highest compensated executive officers on an individual, rather than aggregate, basis. As long as our
securities are traded on the TASE and to the extent that we will adopt U.S. reporting duties, we will be exempt from most of the Israeli
reporting requirements pursuant to the Israeli Securities Law and regulations. Under regulations promulgated under the Companies Law, we
will be required to disclose in the notice for our annual meetings of shareholders, the annual compensation of our five most highly
compensated officers on an individual basis, rather than aggregate. However, this disclosure will not be as extensive as the disclosure
required by a U.S. domestic issuer. We will also have four months after the end of each fiscal year to file our annual reports with the SEC
and will not be required to file current reports as frequently or promptly as U.S. domestic reporting companies. Furthermore as a foreign
private issuer, our officers, directors and principal shareholders will be exempt from the requirements to report short-swing profit recovery
contained in Section 16 of the Exchange Act. Also, as a foreign private issuer, we are not subject to the requirements of Regulation FD
(Fair Disclosure) promulgated under the Exchange Act. These exemptions and leniencies will reduce the frequency and scope of
information and protections available to you in comparison to those applicable to a U.S. domestic reporting companies.
40
Table of Contents
In order to maintain our current status as a foreign private issuer, more than 50% of our outstanding voting securities must not be
directly or indirectly owned by residents of the U.S., and we must not have any of the following: (i) a majority of our executive officers or
directors being U.S. citizens or residents, (ii) more than 50% of our assets being located in the U.S., or (iii) our business being principally
administered in the U.S. Although we have elected to comply with certain U.S. regulatory provisions, our loss of foreign private issuer
status would make such provisions mandatory. The regulatory and compliance costs to us under U.S. securities laws as a U.S. domestic
reporting company may be significantly higher. If we are not a foreign private issuer, we will be required to file periodic reports and
registration statements on U.S. domestic reporting company forms with the SEC, which are more detailed and extensive than the forms
available to a foreign private issuer. We may also be required to modify certain of our policies to comply with accepted governance
practices associated with U.S. domestic reporting companies. Such conversion and modifications will involve additional costs. In addition,
we may lose our ability to rely upon exemptions from certain corporate governance requirements on U.S. stock exchanges that are available
to foreign private issuers.
Potential political, economic, and military instability in the State of Israel, where the majority of our senior management and our
research and development facilities are located, may adversely impact our results of operations.
We are incorporated under Israeli law and our offices and operations are located in the State of Israel. In addition, our employees,
officers, and all but two of our directors are residents of Israel. Accordingly, political, economic, and military conditions in Israel directly
affect our business. Since the State of Israel was established in 1948, a number of armed conflicts have occurred between Israel and its
neighboring countries. Any hostilities involving Israel or the interruption or curtailment of trade between Israel and its present trading
partners, or a significant downturn in the economic or financial condition of Israel, could adversely impact our operations. Since October
2000, there have been increasing occurrences of terrorist violence. Ongoing and revived hostilities or other Israeli political or economic
factors could harm our operations, product development and results of operations.
Although Israel has entered into various agreements with Egypt, Jordan, and the Palestinian Authority, there has been an increase
in unrest and terrorist activity, which began in October 2000 and has continued with varying levels of severity. The establishment in 2006
of a government in the Gaza Strip by representatives of the Hamas militant group has created additional unrest and uncertainty in the
region. In 2006, a conflict between Israel and the Hezbollah in Lebanon resulted in thousands of rockets being fired from Lebanon up to 50
miles into Israel. Starting in December 2008, for approximately three weeks, Israel engaged in an armed conflict with Hamas in the Gaza
Strip, which involved missile strikes against civilian targets in various parts of Israel and negatively affected business conditions in Israel.
In November 2012, for approximately one week, Israel experienced a similar armed conflict, resulting in hundreds of rockets being fired
from the Gaza Strip and disrupting most day-to-day civilian activity in southern Israel. Most recently, in July 2014, Israel yet again
experienced rocket strikes against civilian targets in various parts of Israel, as part of an armed conflict commenced between Israel and
Hamas. If continued or resumed, these hostilities may negatively affect business conditions in Israel in general and our business in
particular. Our insurance policies do not cover us for the damages incurred in connection with these conflicts or for any resulting disruption
in our operations. The Israeli government, as a matter of law, provides coverage for the reinstatement value of direct damages that are
caused by terrorist attacks or acts of war; however, the government may cease providing such coverage or the coverage might not be
enough to cover potential damages. In the event that hostilities disrupt the ongoing operation of our facilities or the airports and seaports on
which we depend to import and export our supplies and products, our operations may be materially adversely affected.
In addition, since the end of 2010, numerous acts of protest and civil unrest have taken place in several countries in the Middle
East and North Africa, many of which involved significant violence. The civil unrest in Egypt, which borders Israel, resulted in the
resignation of its president Hosni Mubarak, and to significant changes to the country’s government. In Syria, also bordering Israel, a civil
war is continuing to take place. The ultimate effect of these developments on the political and security situation in the Middle East and on
Israel’s position within the region is not clear at this time. Such instability may lead to deterioration in the political and trade relationships
that exist between the State of Israel and certain other countries.
41
Table of Contents
Popular uprisings in various countries in the Middle East and North Africa are affecting the political stability of those countries.
Such instability may lead to deterioration in the political and trade relationships that exist between the State of Israel and these countries.
Several countries, principally in the Middle East, still restrict doing business with Israel and Israeli companies, and additional countries
may impose restrictions on doing business with Israel and Israeli companies if hostilities in Israel or political instability in the region
continues or increases. Any hostilities involving Israel, interruption or curtailment of trade between Israel and its present trading partners,
or significant downturns in the economic or financial condition of Israel could adversely affect our operations and product development
and adversely affect our share price. Similarly, Israeli companies are limited in conducting business with entities from several countries.
For instance, in 2008, the Israeli legislature passed a law forbidding any investments in entities that transact business with Iran.
In addition, Iran has threatened to attack Israel and is widely believed to be developing nuclear weapons. Iran is also believed to
have a strong influence among extremist groups in the region, such as Hamas in Gaza, Hezbollah in Lebanon, and various rebel militia
groups in Syria. Additionally, a violent jihadist group named Islamic State of Iraq and Levant, or ISIL, is involved in hostilities in Iraq and
Syria. Although ISIL’s activities have not directly affected the political and economic conditions in Israel, ISIL’s stated purpose is to take
control of the Middle East, including Israel. These situations may potentially escalate in the future to more violent events which may affect
Israel and us. Any armed conflicts, terrorist activities, or political instability in the region could adversely affect business conditions and
could harm our results of operations and could make it more difficult for us to raise capital. Parties with whom we do business may decline
to travel to Israel during periods of heightened unrest or tension, forcing us to make alternative arrangements when necessary in order to
meet our business partners face to face. In addition, the political and security situation in Israel may result in parties with whom we have
agreements involving performance in Israel claiming that they are not obligated to perform their commitments under those agreements
pursuant to force majeure provisions in such agreements. Further, in the past, the State of Israel and Israeli companies have been subjected
to economic boycotts. Several countries still restrict business with the State of Israel and with Israeli companies. These restrictive laws and
policies may have an adverse impact on our operating results, financial condition, or the expansion of our business.
Our operations may be disrupted by the obligations of personnel to perform military service.
As of March 15, 2018, we had 39 employees, all of whom were based in Israel. Some of our employees may be called upon to
perform up to 36 days (and in some cases more) of annual military reserve duty until they reach the age of 40 (and in some cases, up to 45
or older) and, in emergency circumstances, could be called to immediate and unlimited active duty. In the event of severe unrest or other
conflict, individuals could be required to serve in the military for extended periods of time. Since September 2000, in response to increased
tension and hostilities, there have been occasional call-ups of military reservists, including in connection with the 2006 conflict in Lebanon,
and the December 2008, November 2012 and July 2014 conflicts with Hamas, and it is possible that there will be additional call-ups in the
future. Our operations could be disrupted by the absence of a significant number of our employees related to military service or the absence
for extended periods of one or more of our key employees for military service. Such disruption could materially adversely affect our
business and results of operations. Additionally, the absence of a significant number of the employees of our Israeli suppliers and
contractors related to military service or the absence for extended periods of one or more of their key employees for military service may
disrupt their operations.
The tax benefits that are available to us if and when we generate taxable income require us to meet various conditions and may be
prevented or reduced in the future, which could increase our costs and taxes.
If and when we generate taxable income, we may be eligible for certain tax benefits provided to “Preferred Enterprises” under the
Israeli Law for the Encouragement of Capital Investments, 5719-1959, as amended, or the Investment Law. The benefits that may be
available to us under the Investment Law are subject to the fulfillment of conditions stipulated in the Investment Law. Further, in the future
these tax benefits may be reduced or discontinued. If these tax benefits are reduced, cancelled, or discontinued, our Israeli taxable income
would be subject to regular Israeli corporate tax rates. The standard corporate tax rate for Israeli companies is currently 25%. Additionally,
if we increase our activities outside of Israel through acquisitions, for example, our expanded activities might not be eligible for inclusion in
future Israeli tax benefit programs. See “Item 10.E. Taxation—Israeli Tax Considerations and Government Programs—Law for the
Encouragement of Capital Investments, 5719-1959.”
42
Table of Contents
It may be difficult to enforce a U.S. judgment against us, our officers and directors, and the Israeli experts named in this annual report
on Form 20-F in Israel or the United States, or to assert U.S. securities laws claims in Israel or serve process on our officers and
directors and these experts.
We were incorporated in Israel, and our corporate headquarters and substantially all of our operations are located in Israel. All of
our senior management and all but one of our directors are located in Israel. All of our assets are located outside the United States.
Therefore, it may be difficult for an investor, or any other person or entity, to enforce a U.S. court judgment based upon the civil liability
provisions of the U.S. federal securities laws against us or any of these persons in a U.S. or Israeli court, or to effect service of process upon
these persons in the United States. Additionally, it may be difficult for an investor, or any other person or entity, to assert U.S. securities
law claims in original actions instituted in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities
laws against us or our officers and directors on the grounds that Israel is not the most appropriate forum in which to bring such a claim.
Even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is
found to be applicable, the content of applicable U.S. law must be proved as a fact by expert witnesses, which can be a time-consuming and
costly process. Certain matters of procedure would be governed by Israeli law. There is little binding case law in Israel addressing the
matters described above.
Your rights and responsibilities as our shareholder will be governed by Israeli law, which may differ in some respects from the rights
and responsibilities of shareholders of U.S. corporations.
Because we are incorporated under Israeli law, the rights and responsibilities of our shareholders are governed by our articles of
association and Israeli law. These rights and responsibilities differ in some material respects from the rights and responsibilities of
shareholders of U.S. corporations. In particular, a shareholder of an Israeli company has a duty to act in good faith and in a customary
manner in exercising its rights and performing its obligations towards the company and other shareholders and to refrain from abusing its
power in the company, including, among other things, in voting at the general meeting of shareholders on certain matters, such as an
amendment to the company’s articles of association, an increase of the company’s authorized share capital, a merger of the company, and
approval of related party transactions that require shareholder approval. A shareholder also has a general duty to refrain from discriminating
against other shareholders. In addition, a controlling shareholder or a shareholder who knows that it possesses the power to determine the
outcome of a shareholder vote or to appoint or prevent the appointment of an officer of the company has a duty to act in fairness towards
the company with regard to such vote or appointment. However, Israeli law does not define the substance of this duty of fairness. There is
limited case law available to assist us in understanding the nature of this duty or the implications of these provisions. These provisions may
be interpreted to impose additional obligations and liabilities on our shareholders that are not typically imposed on shareholders of U.S.
corporations. See “Item 6.C. Board Practices—Approval of Related Party Transactions under Israeli Law—Shareholders’ Duties.”
Provisions of Israeli law and our amended and restated articles of association could make it more difficult for a third party to acquire us
or increase the cost of acquiring us, even if doing so would benefit our shareholders.
Israeli law regulates mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special
approvals for transactions involving directors, officers, or significant shareholders and regulates other matters that may be relevant to such
types of transactions. For example, a tender offer for all of a company’s issued and outstanding shares, or a Full Tender Offer, can only be
completed if the acquirer receives approval of the holders of at least 95% of the issued share capital. Completion of the Full Tender Offer
also requires approval of a majority of the offerees that do not have a personal interest in the tender offer, unless at least 98% of the
company’s outstanding shares are tendered. Furthermore, the shareholders, including those who indicated their acceptance of the Full
Tender Offer (unless the acquirer stipulated in its tender offer that a shareholder that accepts the offer may not seek appraisal rights), may,
at any time within six months following the completion of the tender offer, petition an Israeli court to alter the consideration for the
acquisition. In case the Full Tender Offer has not been accepted by the required threshold, the offeror is limited to acquire shares that will
confer on the offeror a holding of not more than 90% of the issued share capital of the company. See “Item 10.B. Memorandum and
Articles of Association—Acquisitions under Israeli Law” for additional information.
43
Table of Contents
Further, Israeli tax considerations may make potential transactions undesirable to us or to some of our shareholders whose country
of residence does not have a tax treaty with Israel granting tax relief to such shareholders from Israeli tax. For example, Israeli tax law does
not recognize tax-free share exchanges to the same extent as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral in
certain circumstances but makes the deferral contingent on the fulfillment of a number of conditions, including, in some cases, a holding
period of two years from the date of the transaction during which sales and dispositions of shares of the participating companies are subject
to certain restrictions. Moreover, with respect to certain share swap transactions, the tax deferral is limited in time, and when such time
expires, the tax becomes payable even if no disposition of the shares has occurred.
We have received grants from the IIA for certain research and development expenditures. The terms of these grants may require
us to satisfy specified conditions in order to manufacture products and transfer technologies outside of Israel. For more information, see “—
Risks Related to Our Financial Condition and Capital Requirements—The IIA grants we have received for research and development
expenditures restrict our ability to manufacture products and transfer know-how outside of Israel and require us to satisfy specified
conditions.”
We may be classified as a passive foreign investment company for U.S. federal income tax purposes, and our U.S. shareholders may
suffer adverse tax consequences as a result.
Generally, if, for any taxable year, either, at least 75% of our gross income is passive income (including our pro-rata share of the
gross income of our 25% or more-owned corporate subsidiaries), or at least 50% of the average value of our assets (including our pro-rata
share of the assets of our 25% or more-owned corporate subsidiaries) is attributable to assets that produce passive income or are held for
the production of passive income, we would be characterized as a passive foreign investment company, or PFIC, for U.S. federal income
tax purposes. Passive income generally includes dividends, interest, and gains from disposition of passive assets and rents and royalties.
If we are characterized as a PFIC for any taxable year (or portion thereof) that is included in the holding period of a U.S. holder
(as defined below) of our securities, such U.S. holder generally will be subject to certain adverse U.S. federal income tax consequences,
including increased tax liability on gains from dispositions of our securities and certain distributions and a requirement to file annual reports
with the Internal Revenue Service, or IRS. See “Item 10.E. Taxation—Material U.S. Federal Income Tax Consequences—Passive Foreign
Investment Company Consequences.”
Since PFIC status depends on the composition of our income and the composition and value of our assets (which may be
determined in large part by reference to the market value of our ordinary shares, which may be volatile) from time to time, there can be no
assurance that we will not be considered a PFIC for any taxable year. However, based on our non-passive revenue-producing operations for
the year ended December 31, 2017, we do not expect to be a PFIC for our 2017 taxable year. Because the PFIC determination is highly fact
intensive, there can be no assurance that we will not be a PFIC in 2018 or any other year.
U.S. investors are urged to consult their own tax advisors regarding the possible application of the PFIC rules. For more
information, see “Item 10.E. Taxation—Material U.S. Federal Income Tax Consequences—Passive Foreign Investment Company
Consequences.”
Our facilities in Israel are subject to local Business Licensing and Planning and Zoning regulations and we may be subject to fines if
not complied with.
Under the Israeli Licensing of Businesses Law, to which our production site and offices and laboratories are subject, operating a
business without a license or temporary permit is a criminal offense. We have a business license for our laboratories and offices, in effect
until December 31, 2019. We also have a business license for our plant growth and production site at Yessod Hama’ala, in effect until
November 3, 2019. In addition, our production sites and laboratories are subject to the Israeli Planning and Zoning Law, which sets
provisions and obligations, inter alia, regarding the licensing process for a new building, including building permits, non-conforming use
and easements, the supervision over its construction, and the required occupancy permits. According to the Planning and Zoning Law, work
or use of land without a permit, where such permit is required, a deviation from the permit granted, or use of agricultural land in violation
of the law constitute criminal offenses.
44
Table of Contents
ITEM 4.
INFORMATION ON THE COMPANY
A. History and Development of the Company
Our legal and commercial name is CollPlant Holdings Ltd. We were incorporated in Israel on November 9, 1981 as a private
company limited by shares. As of 1993, we are a public company, and all of our ordinary shares are listed on the TASE. On January 31,
2018, our ADSs commenced trading on The Nasdaq Capital Market under the symbol “CLGN”. The ADSs were quoted on the OTCQX
from March 2015 to May 25, 2017, and quoted on the OTCQB from May 26, 2017 to January 30, 2018. Our name has changed several
times, but has been CollPlant Holdings Ltd. since May 30, 2010, immediately after the consummation of the merger transaction with
CollPlant Ltd.
We hold all of the issued and outstanding shares of CollPlant Ltd. and have no holdings in other companies. CollPlant Ltd. was
incorporated in Israel on August 12, 2004 as a private company limited by shares and began its operations as a technology incubator
company under the IIA’s technology incubators program. CollPlant Ltd. owns all of our intellectual property.
Our principal offices are located at 3 Sapir Street, Weizmann Science Park, Ness Ziona 74140, Israel, and our telephone number is
+972-73-232-5600. Our primary internet address is http://www.collplant.com. None of the information on our website is incorporated by
reference herein. Puglisi & Associates serves as our agent for service of process in the United States, and its address is 850 Library Avenue,
Suite 204, Newark, Delaware 19711.
We use our website (http://www.collplant.com) as a channel of distribution of Company information. The information we post on
our website may be deemed material. Accordingly, investors should monitor our website, in addition to following our press releases, SEC
filings and public conference calls and webcasts. The contents of our website are not, however, a part of this annual report.
We are an emerging growth company, as defined in Section 2(a) of the Securities Act, as implemented under the JOBS Act. As
such, we are eligible to, and intend to, take advantage of certain exemptions from reporting requirements that generally apply to public
companies, including the auditor attestation requirements with respect to internal control over financial reporting under Section 404 of the
Sarbanes-Oxley Act, compliance with new standards adopted by the Public Company Accounting Oversight Board which may require
mandatory audit firm rotation or auditor discussion and analysis, exemption from say on pay, say on frequency, and say on golden
parachute voting requirements, and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy
statements. We will be an emerging growth company until the earliest of: (i) the last day of the fiscal year during which we had total annual
gross revenues of $1.07 billion or more, (ii) the last day of the fiscal year following the fifth anniversary of the date of the first sale of the
ADSs pursuant to an effective registration statement, (iii) the date on which we have, during the previous three-year period, issued more
than $1 billion in non-convertible debt, or (iv) the date on which we are deemed a “large accelerated filer” as defined in Regulation S-K
under the Securities Act, which means the market value of our ordinary shares that is held by non-affiliates exceeds $700 million as of the
prior June 30th.
As a foreign private issuer we are exempt from certain rules and regulations under the Exchange Act, that are applicable to other
public companies that are not foreign private issuers. For example, although we intend to report our financial results on a quarterly basis,
we will not be required to issue quarterly reports, proxy statements that comply with the requirements applicable to U.S. domestic reporting
companies, or individual executive compensation information that is as detailed as that required of U.S. domestic reporting companies. We
will also have four months after the end of each fiscal year to file our annual report with the SEC and will not be required to file current
reports as frequently or promptly as U.S. domestic reporting companies. We may also present financial statements pursuant to International
Financial Reporting Standards, or IFRS, instead of pursuant to U.S. generally accepted accounting principles, or U.S. GAAP. Our senior
management, directors, and principal shareholders will be exempt from the requirements to report transactions in our equity securities and
from the short-swing profit liability provisions contained in Section 16 of the Exchange Act. As a foreign private issuer, we will also not be
subject to the requirements of Regulation FD (Fair Disclosure) promulgated under the Exchange Act.
45
Table of Contents
Our capital expenditures for December 31, 2017, 2016 and 2015 amounted to NIS 447,000 (approximately $129,000), NIS
492,000 (approximately $128,000), and NIS 1.39 million (approximately $356,000), respectively. Our purchases of fixed assets primarily
include laboratory equipment and establishment of our production site in Rehovot. We financed these expenditures primarily from cash on
hand.
B. Business Overview
Overview
We are a regenerative medicine company focused on developing and commercializing tissue repair products, initially for three-
dimensional, or 3D, bioprinting of tissues and organs, orthobiologics and advanced wound care markets. Our products are based on our
rhCollagen, a form of human collagen produced with our proprietary plant-based genetic engineering technology. We believe our
technology is the only commercially viable technology available for the production of genetically engineered, or recombinant, human
collagen. We believe that our rhCollagen, which is identical to the type I collagen produced by the human body, has significant advantages
compared to currently marketed tissue-derived collagens, including improved biological function, superior homogeneity, and reduced risk
of immune response. We believe the attributes of our rhCollagen make it suitable for numerous tissue repair applications throughout the
human body. We believe that the annual market opportunity for two of our current products utilizing our rhCollagen within the
orthobiologics and advanced wound care markets exceeds $5 billion.
Our rhCollagen has superior biological function when compared to any tissue-derived collagens, whether from animal or human
tissues, according to data published in peer-reviewed scientific publications. Our rhCollagen can be fabricated in different forms and shapes
including gels, pastes, sponges, sheets, membranes, fibers, and thin coats, all of which have been tested in vitro and in animal models and
proven superior to tissue-derived products. We have demonstrated that, due to its homogeneity, rhCollagen can produce fibers and
membranes with high molecular order, meaning all the molecules are oriented in the same direction, which enables the formation of tissue
repair products with distinctive physical properties. We produce our rhCollagen in genetically engineered tobacco plants, assuring an
abundant supply of high quality raw materials.
Our three leading rhCollagen-based products are:
● CollPlant rhCollagen-based BioInk for use in the 3D printing of tissues and organs. CollPlant’s BioInk is being developed to
enable the printing of three-dimensional scaffolds combined with human cells and/or growth factors as a basis for tissue or
organ formation. In addition to collagen, CollPlant’s BioInk formulations can include other proteins and/or polymers as well.
Our BioInk is being developed to be compatible with numerous 3D bioprinting technologies and with printed organ
characteristics.
● VergenixSTR, a soft tissue repair matrix composed of our rhCollagen and PRP extracted from the patient’s blood.
VergenixSTR is intended to accelerate healing in the treatment of tendinopathy, such as in the elbow tendon (for treatment of
“tennis elbow”), rotator cuff, patellar tendon, Achilles tendon, and hand tendons. VergenixSTR forms a viscous gel matrix to
serve as a scaffold in the vicinity of a tendon injury site. Following the scaffold formation, our rhCollagen activates the
platelets in PRP to provide sustained release of growth factors, which promote healing and repair of tendon injuries. In August
2016, we completed an open label, single arm, multi-center clinical trial of VergenixSTR in Israel. In October 2016, we
received CE marking certification for VergenixSTR which is required for a product to be marketed in the European Union. In
November 2016, we entered into an exclusive distribution agreement with Arthrex GmbH in Munich, Germany, an affiliate of
Arthrex, Inc., for VergenixSTR covering Europe, the Middle East, India, and certain African countries and sales began in
Europe.
46
Table of Contents
● VergenixFG, a wound-filling flowable gel made from our rhCollagen. VergenixFG is intended to enhance the quality and
speed of closure of deep surgical incisions and wounds, including diabetic ulcers, burns, bedsores, and other chronic wounds.
The VergenixFG formulation provides a scaffold that fills the wound site and establishes intimate contact with the surrounding
tissue. VergenixFG provides complete coverage of the wound site, facilitates wound closure through an engineered
synchronization between scaffold degradation and growth of new tissue, and offers a non-allergenic and pathogen-free scaffold
for safe and efficacious wound care therapy. We completed an open label, single arm, multi-center clinical trial of VergenixFG
in Israel to support CE marking certification. In February 2016, we received CE marking certification for VergenixFG. Since
then we have entered into distribution agreements for the distribution of VergenixFG in Italy, Switzerland, Turkey, the
Netherlands, Greece and Cyprus, and we intend to enter into additional distribution agreements in Europe.
Collagen and Collagen-Based Products
Collagen is the main component of connective tissue and is the most abundant protein in mammals. In humans, it comprises
approximately 30% of the protein found in the body. Due to its unique characteristics and diverse profile in human body functions, collagen
is frequently selected from a variety of biocompatible materials for use in tissue repair to support structural integrity, induce cellular
infiltration and promote healing. We estimate the size of the market for human collagen-based tissue repair products for use in
orthobiologics and advanced wound care applications is approximately $20 billion.
Type I collagen is the most abundant form of collagen in the human body. It is the dominant constituent of connective tissue and
serves as the primary scaffold in tissue or organ repair processes, making it a logical choice for regenerative medicine products. It is found
in tendons, skin, artery walls, corneas, the endomysium surrounding muscle fibers, fibrocartilage, and the organic part of bones and teeth.
Type II collagen is primarily found in articular cartilage. Type III collagen, which is produced quickly by young fibroblasts before the
tougher type I collagen is synthesized, is found in granulation tissue such as artery walls, skin, intestines, and the uterus. While there may
be some niche applications in the future where type III or possibly type II collagen is appropriate, type I collagen is best suited for
applications associated with regenerative medicine because of its essential role in the healing process of bones, skin, and tendons. Type III
recombinant human collagen is currently available for the research market, and is not used in any products currently approved for medical
use.
Disadvantages of Current Collagen-Based Products
Currently, type I collagen for medical use is primarily derived from bovine (cow) and porcine (pig) sources, as well as from
human cadavers. It is extracted from the tissues using mechanical processes and chemical treatments. Tissue-derived collagens suffer from
a number of disadvantages:
● The harsh chemical conditions required to recycle collagen from mature tissue results in a collagen product with random defects
in its protein structure, leading to a compromised triple helix. Consequently, tissue-derived collagens have significant damage to
binding sites for progenitor cells, which are required for cell proliferation and differentiation into tissue.
● Tissue-derived collagens are non-homogenous and contains high proportions of cross-linked collagen species with high
molecular weight. The rate of degradation of collagen is based on the proportion of cross-linked collagen species within the
product. Excessive proportions of cross-linked collagen can impair the collagen’s ability to self-assemble homogenous
scaffolds with a high surface area and fully functional integrin-binding capacity, and can also impede its rate of degradation.
The inability to effectively control the level of cross-linked collagen species in tissue-derived collagens results in variability of
performance for a given product, and affects the rate of infiltration of cells into the scaffold, which can delay healing.
● The extraction of collagen from mature mammalian tissues leaves, in many cases, contaminant proteins, growth factors, and
cytokines. As a result, scaffolds made of tissue-derived collagens may provoke inflammation, as well as undesirable immune
and foreign body responses that may cause adverse effects and unpredictable biological outcomes.
47
Table of Contents
● Extraction from animals or humans is also associated with risk of disease transmission. Since 2007 the FDA has highlighted the
risks of transmissible diseases to humans in medical devices that contain materials derived from animal sources. In January
2014, the FDA released draft guidance suggesting precautionary procedures to be used in the production of medical devices
containing materials derived from animal sources.
● Although collagen molecules are similar among various animal species, slight differences in the protein sequence between
species may result in different biological behavior when applied to humans, and in some cases, invoke specific immune
responses; for example, bovine collagen is associated with hypersensitivity and allergic reactions in approximately 3% of
people.
Advantages of our rhCollagen and rhCollagen-based Products
All of our products are based on our proprietary recombinant type I human collagen, rhCollagen, which is identical to the type I
collagen produced by the human body. The graphic below illustrates the structural differences between rhCollagen produced with our
proprietary plant-based technology and currently marketed tissue-derived collagens.
[GRAPHIC]
The key advantages of products using our rhCollagen, as compared to those using collagen derived from animals or human
cadaveric tissue, include:
● Better biofunctionality in tissue regeneration. Our rhCollagen has superior biological function when compared to animal or
human tissue-derived collagen and has a number of useful physical characteristics, including thermal stability, or resistance to
decomposition at high temperatures, and a pristine triple helix, according to data published in peer-reviewed scientific
publications. The triple helix structure of collagen is formed when two α-1 protein chains and one α-2 protein chain wind
together along a common axis. In the formation of rhCollagen, this structure is achieved without modifications that can lead to
defects in the triple helix structure, thereby leading to a pristine triple helix identical to the form found in nature. A pristine
triple helix enables superior binding, which accelerates primary human cell proliferation. Collagen scaffolds of our rhCollagen
support endothelial, fibroblast, and keratinocyte cell attachment and proliferation. In all cell types tested, cell proliferation was
significantly better in scaffolds made of rhCollagen than in commercially available scaffolds made of bovine collagen. The
accelerated cell proliferation achieved with our rhCollagen results in faster wound healing, less scarring, and higher quality
tissue regeneration.
● Superior homogeneity. Because our rhCollagen is synthesized by five human genes in tobacco plants producing pure molecules
that are repeatable and identical to type I human collagen, it is more homogenous than collagen derived from animal or human
tissue sources. The high level of homogeneity of our rhCollagen allows the formulation of extremely high concentrations of
monomeric, or single-molecule, collagen, up to 150-200mg/ml, which is at least 10 to 100 times higher than the concentration
achieved with tissue-derived collagen. The high concentration of homogeneous monomeric collagen is of particular importance
where strong collagen fibers are needed for 3-D scaffolds. The homogeneity of our rhCollagen enables us to engineer consistent
and reproducible products with a controlled degradation rate which can be optimized to the targeted indication. Achieving the
same level of engineered performance would be difficult, if not impossible, with tissue-derived collagen that varies from batch
to batch.
48
Table of Contents
● Improved safety and greater purity. Our pure rhCollagen does not induce an immunogenic response, whereas impurities carried
over from the source of tissue-derived collagen can lead to immune system rejection. In vitro studies performed under an
academic collaboration have demonstrated that rhCollagen incubated with activated THP1-macrophages produces significantly
lower levels of inflammatory cytokines when compared with bovine collagen that is similarly incubated. This demonstrates that
animal-derived collagen can provoke a foreign body response not seen with rhCollagen, which delays healing and increases
scarring. Further, with our rhCollagen, there are no potential side effects in the growth of tissue because there are no residues of
growth factors. In addition, with tissue-derived collagen, there is a possibility that the animal or human from which the collagen
was produced was infected with a virus, prion, or other pathogen. With our rhCollagen there is no risk of transmitting diseases
and pathogens.
● Novel applications. Due to our ability to control the protein at the molecular level, it is possible to use our rhCollagen to
produce products with unique physical features, as well as high repeatability, which is not possible with tissue-derived collagen.
As compared to tissue-derived collagen, rhCollagen membranes have shown better thermal stability, improved tensile strength
due to alignment of the collagen fibers, and higher levels of transparency. In addition, rhCollagen can be used to produce high
concentration solutions of collagen at low viscosities. The unique properties of our rhCollagen make it an ideal building block
for many products that we believe cannot currently be produced using tissue-derived collagen, such as BioInks for 3-D printing,
artificial tendons, and transparent ophthalmic products.
We believe the clinical attributes of our rhCollagen will translate into benefits for patients, payors, and physicians, and will be
adopted rapidly by the market once our products receive regulatory approval. The improved biofunctionality of our products is intended to
lead to faster recovery, better clinical outcomes, and reduced hospitalization time. Our in vivo studies have shown faster tissue remodeling,
faster wound closure, and reduced scarring compared to competing products made from tissue-derived collagen.
The advantages of our rhCollagen outlined above have been demonstrated through in vitro testing and in preclinical animal
studies, and are based on the performance of rhCollagen alone. The performance demonstrated in these studies is not necessarily indicative
of the performance of our products which contain rhCollagen. We cannot assure you that the same advantages of rhCollagen will be seen in
clinical testing of our products containing rhCollagen.
We can produce our rhCollagen cost-effectively and have access to an abundant supply of raw materials. Tobacco is a relatively
easy plant to grow, and can be cultivated in a wide range of climates and soils. The tobacco plant is an extremely hardy plant, may be grown
in very large volumes and its growth time to reach desired maturity is relatively short (about eight weeks). Under our current production
technology, we are able to achieve a cost of goods that allows us to offer products at prices that are competitive with tissue-derived
collagen. We are advancing a new production process that will result in labor cost reductions and higher yields, assuring an abundant raw
material supply as demand for our rhCollagen increases.
Collagen-based products are already used extensively in the marketplace; therefore, we expect our products will be eligible for
reimbursement by third-party payors, including government agencies and insurance companies. We believe that the demand for tissue-
derived collagen will decrease as the market recognizes the significant advantages of our rhCollagen.
Our Market Opportunity
Our rhCollagen represents a platform for the development of products addressing significant opportunities in multiple therapeutic,
aesthetic, and other medical markets. We are initially focused on BioInk for use in the 3D printing of tissues and organs, orthobiologics and
advanced wound care markets.
We also see a significant opportunity to use our rhCollagen platform to develop products to address additional indications in these
markets as well as in new markets, including cardiovascular, aesthetics to develop next generation soft tissue fillers and ophthalmic
markets. We believe that the potential addressable market opportunity for products using our technology is even greater than the market
size served by currently available collagen-based products, mainly due to continued unmet medical needs and the shortcomings of tissue-
derived collagen.
49
Table of Contents
BioInk for 3D printing of tissues & organs
Regenerative medicine and tissue engineering have seen unprecedented growth in the past decade, driving the field of artificial
tissue models towards a revolution in future medicine. Progress has been achieved through the development of innovative
biomanufacturing strategies to pattern and assemble cells and extracellular matrix, or ECM, in three dimensions to create functional tissue
constructs. Bioprinting has emerged as a promising 3D biomanufacturing technology, enabling precise control over spatial and temporal
distribution of cells and ECM. Bioprinting technology can be used to engineer artificial tissues and organs by producing scaffolds with
controlled spatial heterogeneity of physical properties, cellular composition, and ECM organization. This innovative approach is
increasingly utilized in biomedicine, and has potential to create artificial functional constructs for drug screening and toxicology research,
as well as tissue and organ transplantation.
MarketandMarkets estimates that the global 3D bioprinting market will reach $1.3 billion by 2021 from $411.4 million in 2016, at
a CAGR of 26.5% during the forecast period. The growth of the global market is largely driven by increasing large demand of tissues and
organs for transplantation and the innovations and advancements in technology for 3D bioprinting. A large number of people across the
globe are waiting for organ or tissue transplant, due to the large gap in demand for organs transplant and donors. This has created traction in
the 3D bioprinting industry for developing live tissues and organs. Different companies along with academic institutes and laboratories are
investing capital for 3D bioprinting research and development. Some of the other factors driving the growth of the global market include
increasing research and development activities and increasing compliance for 3D bioprinting in drug discovery processes. Growing stem
cell research and increasing adoption of 3D bioprinting in cosmetic industry are expected to create ample growth opportunities for the
global market.
Orthobiologics Market
The established orthopedic market—estimated by QiG Group at more than $40 billion annual revenue worldwide in 2012—
continues to offer exceptional growth opportunities. An aging population, active demographics, innovative technology, and emerging
geographic areas are expected to continue to drive growth in the global orthopedic market. Top market segments within orthopedics include
reconstructive devices, such as joint replacements; spinal implants and instruments, used to treat joint pain; fracture repair, including the
use of plates and screws; and arthroscopy and soft tissue repair, primarily for sports and movement related injuries.
Chronic complex musculoskeletal injuries that are slow to heal pose challenges to physicians and patients alike. Orthobiologics
use cell-based therapies and biomaterials to help injuries heal more rapidly with a superior outcome. These products are made from
substances that are naturally found in the body, which dynamically interact with the musculoskeletal system to facilitate the healing of
bone, cartilage, meniscus, tendons, and ligaments affected by disease or injury. Orthobiologics products are spread across all segments of
the larger orthopedic market, generating much of the growth within orthopedics. MarketandMarkets recently estimated that in 2017 the
major segments of the orthobiologics market currently comprise an annual $4.7 billion worldwide market.
The orthobiologics market is segmented as follows:
● Cell-based therapies, such as PRP;
● Bone allografts;
● Bone graft substitutes;
● Viscosupplementation; and
● Growth factors, such as BMP.
50
Table of Contents
It is estimated that bone and joint disorders account for approximately half of all chronic conditions in individuals above 50 years
of age in developed countries, and they are the most common cause of severe, long-term pain and disability. Moreover, the U.S. population
aged 60 years and above is projected to increase by 33% this decade, which represents a key driver of this market as elderly patients are
slower to heal and more in need of products that enhance and speed recovery. A rise in the geriatric population along with lifestyle changes
such as increased obesity and growing participation in sports and outdoor activities among the older as well as younger generation all
contribute to the increase in musculoskeletal disorders. The overall increase in prevalence of musculoskeletal disorders combined with
technological advancements in the orthobiologics field are fueling the growth of this market, resulting in a CAGR of 7.7% in the North
American market from 2014 to 2019, as predicted by MicroMarket Monitor.
Advanced Wound Care Market
The global market for wound care encompasses traditional dressings and bandages, as well as advanced wound care products such
as bioengineered skin and skin substitutes and wound care growth factors. Over the past 30 years, there has been a shift from traditional
wound dressings towards advanced therapies that aim to optimize the wound healing environment. Advanced wound care is composed of
biocompatible products that are intended to actively promote wound healing by interacting either directly or indirectly with wound tissues.
Attempts to reduce the duration of hospital stays in order to limit healthcare costs and the goal of enhancing therapeutic outcomes are
driving the demand for advanced wound care and closure products. One of the primary market drivers for advanced wound care products is
the increasing incidence of chronic wounds, which are on the rise due to an aging population and a sharp rise in the incidence of diabetes
and obesity worldwide. Both advanced age and chronic medical conditions are associated with a slower healing process, and all phases of
wound healing are affected. The inflammatory response is decreased or delayed, as is the proliferative response.
Espicom estimates that the global market for advanced wound care in 2013 had reached $6.2 billion, representing a growth rate of
approximately 5% since 2012. The three major market segments are device-based wound care, comprised of negative-pressure wound
therapy and hydrosurgery systems; moist wound care, comprised of dressings that create and maintain a moist environment; and biologics,
comprised of bioactive technologies that provide new approaches to debridement and dermal repair and regeneration.
With a wide range of dressings to choose from, dressing selection is a significant challenge for wound care clinicians. The ideal
dressing should induce rapid healing at reasonable cost with minimal inconvenience to the patient. In a healing wound, a cascade of events
occurs that includes platelet accumulation, inflammation, fibroblast proliferation, cell contraction, angiogenesis, and re-epithelization,
ultimately leading to scar formation and wound remodeling. Collagen plays an important role in each of these phases of wound healing.
Native intact collagen provides a natural scaffold or substrate for new tissue growth. Dressings containing collagen are thought to provide
the wound with an alternative collagen source that is degraded over time, leaving the endogenous native collagen to continue normal wound
healing.
Biological wound dressings have the benefit of forming part of the natural tissue matrix and some of them play an important role
in natural wound healing and new tissue formation. These characteristics make them the most attractive and fastest growing segment of the
overall advanced wound care market with anticipated double digit growth in upcoming years. In certain instances, these bioactive matrices
are incorporated with compounds such as growth factors and antimicrobials for delivery to the wound site. There are a number of
biological wound care dressings available that incorporate tissue-derived collagen to enhance wound bed preparation.
Our Strategy
We plan to exploit the unique characteristics of our rhCollagen to develop and commercialize an extensive portfolio of
regenerative medicine products. The key elements of our strategy include the following:
● Position our rhCollagen as the “gold standard” platform technology for collagen-based products in a broad range of
markets. We believe that our rhCollagen represents a significant advance in collagen technology, demonstrated by its
improved biofunctionality, superior homogeneity, and reduced risk of immune response. Our rhCollagen is a platform
technology which can be utilized in a broad range of therapeutic, aesthetic, and other medical applications, as well as in
emerging industries such as 3D bioprinting which we believe cannot be adequately addressed with currently available collagen
technologies. We intend to expand the awareness of rhCollagen through partnerships and collaborations with leading
commercial and academic partners around the world and further clinical trials which we will seek to have published in peer-
reviewed journals, as well as through our participation in academic and industry conferences, to position rhCollagen as the
“gold standard” platform technology for collagen-based products. We believe our platform technology, and the knowledge and
expertise we have gained in its development, will enable the development, both independently and with collaborators, of
differentiated products in multiple industries with a short time to market.
51
Table of Contents
● Establish a regulatory process for rhCollagen-based end products using VergenixSTR and VergenixFG as precedent.
We have obtained marketing clearance for our initial products, VergenixSTR and VergenixFG, through CE marking in Europe.
The CE mark is a symbol that indicates that a product conforms with all applicable EU requirements and, once affixed, enables
a product to be sold within the European Union and other countries that recognize the CE mark, subject to compliance with
applicable submission and approval requirements in such other countries. Following adoption by key opinion leaders and
establishment of sales in Europe, we plan to hold a pre-Investigational Device Exemption, or IDE, meeting with the FDA. This
meeting will help us determine the regulatory pathway required for FDA approval for our rhCollagen-based products. We
believe that this strategy will allow us to gain earlier market access and thereby more rapid industry acceptance for our
rhCollagen-based end products, since the timeline to achieve CE marking is generally shorter than the FDA approval route.
Utilizing this strategy is expected to result in more physicians gaining exposure to rhCollagen-based products sooner. We are
conducting post-marketing surveillance studies of our products, resulting in physicians gaining more hands-on experience with
rhCollagen. Should these post-marketing surveillance studies successfully demonstrate the efficacy of our product, we will
endeavor to have these results published in peer-reviewed medical journals as a means of expanding the clinical credibility of
rhCollagen and rhCollagen-based end products.
● Utilize collaborative partners and distributors to develop and commercialize our technology and products. We believe
the market-leading characteristics of our rhCollagen will create attractive collaboration opportunities for our products, and we
intend to selectively establish collaborations and strategic partnerships with respect to our current and future products in order to
accelerate their development and commercialization. We intend to create a commercial organization, initially in Europe, with
well-established companies whose distribution networks are deeply entrenched. Our commercial organization will be
comprised of the distribution networks of our collaboration partners, particularly in the United States and China, as well as
local and regional distributors in certain markets.
● Expand our manufacturing capacity to support commercialization of rhCollagen-based end products. We cultivate the
tobacco plants used in the production of our rhCollagen in a network of farms in Israel, and we extract the raw materials used to
manufacture our rhCollagen from these tobacco plants. We intend to construct a manufacturing facility in Israel that will enable
us to manufacture commercial quantities of our rhCollagen and rhCollagen-based end products in a cost-competitive manner for
application in both premium and commodity markets.
● Expand our pipeline through ongoing development of new products. We intend to continue to develop additional products,
both independently and with strategic collaborators, initially in 3D bioprinting of tissues and organs, orthobiologics and
advanced wound care markets and subsequently in other high value markets, based on our rhCollagen. Our product pipeline and
our research and development program are expected to yield new products in the coming years. Some of these new products are
derivatives of current products, and therefore may benefit from an easier regulatory pathway and shorter time to market, should
our current products receive regulatory approval.
● Advance our leadership position in recombinant protein production through our plant-based technology. We continually
seek to expand our knowledge of plant-based protein production systems and introduce improvements into our process. We are
shifting production to an enhanced line of tobacco plants with higher collagen yield, along with improvements in the growing
and cultivation process as well as collagen extraction and purification. As tissue engineering and regenerative medicine
continue to evolve and expand, we expect that the demand for high-quality biomaterials will grow.
52
Table of Contents
Our Products
BioInk for 3D printing of tissues & organs
3D bioprinting is being applied to the field of regenerative medicine to address the need for complex scaffolds, tissues, and organs
that are suitable for transplantation. We have developed rhCollagen-based BioInks that are optimized for the three-dimensional bioprinting
of tissues and organs.
For that purpose, rhCollagen was modified chemically to adapt the biological molecules for printing such that BioInks keep a
controlled fluidity during printing and cure to form hydrogels when irradiated by certain light sources ranging from UV to visible light. The
unique viscosity and shear thinning properties of the modified rhCollagen enable the formulation of BioInks that are suitable for different
printing technologies including extrusion, ink-jet, Laser Induced Forward Transfer and Stereolithography. The control of chemical
modification in combination with illumination energy allows tight control of the physical properties of the resulting scaffolds to match
natural tissue properties, from stiff cartilage to soft adipose. BioInks formulated from rhCollagen were evaluated with all major printing
technologies exhibited the required physical properties and excellent support for cells including a series of primary and differentiated
human cells.
We believe our BioInk offers ideal characteristics for 3D bioprinting, including:
● Biocompatibility—supports cell viability and promotes proliferation
● Potential safety—has not shown to promote allergic and other tissue reactions
● Optimized viscosity and gelation kinetics—printability and compatibility with multiple printing technologies
● Curing with a range of light sources based on specific requirements
● Controlled degradation profile
● Customized physical properties of the printed constructs that are compatible with natural tissues
We have initiated several research collaborations with biotechnology and medical device companies, as well as academic and
research institutions. These collaborations include development of technology for 3D bioprinting of life-saving organs and different tissues
such as cornea, using our BioInk formulations. Our collaborations are generally structured such that our partners provide research funding
to cover the scope of work, in part or in full. This funding is typically reflected as collaboration revenues in our financial statements. Upon
entering into a collaboration, we disclose the financial details only to the extent that they are material to our business and not subject to
confidentiality agreements with our partners. Research collaborations with academic or research institutions typically involve both us and
the academic partner contributing resources directly to projects, but also may involve sponsored research agreements where we fund
specific research programs.
In May 2017, we created a division focused on development of our rhCollagen-based BioInk, following the expansion of our
research activities in the field of 3D biologic printing of organs and tissues.
In September 2017, we received an initial order for our rhCollagen-based BioInk. The order is from a leading biotechnology
company with which CollPlant is in discussions for the possible co-development of 3D bioprinting of life-saving organs. In November
2017, we received a repeat order from the same company.
In October 2017, we entered into a five-month work plan with one of the world’s leading medical device companies to develop a
prototype of 3D-printed orthopedic implant based on our rhCollagen-based BioInk.
VergenixSTR—Tendinopathy Treatment
VergenixSTR is a soft tissue repair matrix which combines cross-linked rhCollagen with PRP, a concentrated blood plasma that
contains high levels of platelets, a critical component of the healing process. Platelets contain growth factors that are responsible for
stimulating tissue generation and repair, including soft tissue repair, bone regeneration, development of new blood vessels, and stimulation
of the wound healing process. VergenixSTR serves as a scaffold to support cell proliferation and the release of growth factors. The product
is injected into the affected area, and forms a viscous gel matrix which serves as a temporary reservoir for PRP in the vicinity of a tendon
injury site, holding the platelet concentrate in place at the injured area. The matrix formed has the capabilities to activate the platelets in
PRP, thereby releasing growth factors in a controlled manner and controlled biodegradation time, enabling optimal healing.
53
Table of Contents
The following graphic illustrates the VergenixSTR kit and application:
[GRAPHIC]
Market for Tendinopathy Treatment
VergenixSTR is intended for the treatment of tendinopathy by promoting healing and repair of tendon injuries in a variety of
tendons including the elbow tendon (for treatment of “tennis elbow”), rotator cuffs, patellar tendons, Achilles tendon, and hand tendon.
[GRAPHIC]
Tendinopathy: Annual procedures per indication in the United States
Today, the main treatments offered for tendinopathy are local steroid injection, shock wave therapy, and PRP alone. PRP is an
orthobiologic that has recently gained popularity as an adjuvant treatment for musculoskeletal injuries. PRP has found application in diverse
surgical fields to enhance bone and soft-tissue healing by placing high concentrations of autologous platelets at the site of tissue damage.
The platelets contain alpha granules that are rich in several growth factors and play key roles in tissue repair mechanisms. The relative ease
of preparation, applicability in the clinical setting, favorable safety profile, and possible beneficial outcome make PRP a promising
therapeutic approach for regenerative treatments. One of the challenges in utilizing PRP for tissue repair is the localization of the platelets
in the vicinity of the injured tissue. PRP injected alone displays a tendency to migrate and is rapidly degraded. Without addressing the issue
of platelet localization, PRP’s efficacy will be limited, particularly in joints like the knee and shoulder which contain relatively large
volumes of synovial fluid. VergenixSTR was developed to overcome these inherent limitations associated with the current use of PRP.
We estimate the size of the target market for VergenixSTR for treating tendinopathy is three million procedures per year, or
approximately $2.0 billion. While our initial focus for VergenixSTR is in tendinopathy, VergenixSTR may be applicable to other soft tissue
indications such as tendon rupture, meniscus tear, and cartilage repair, as well as in the aesthetic market as a dermal filler. Transparency
Market Research valued the global orthopedic soft tissue market at $5.6 billion in 2013. Globally, the aging population is playing a major
role in increasing the incidence of sports injuries as the reduced flexibility and mobility associated with aging can make the body more
prone to injury. Consequently, Transparency Market Research forecasts that the orthopedic soft tissue market will grow to $8.5 billion in
2019, a CAGR of 7.2%. The difficulties associated with healing in an aging population highlight the need for advanced orthobiologics
products to serve this market.
VergenixSTR Product Development
As part of the VergenixSTR development, we conducted a number of preclinical studies to validate the treatment protocol and
confirm the enhanced healing potential of the treatment. We completed a preclinical study in August 2013 based on an established model of
tendinopathy induced in rats by injection of collagenase into the Achilles tendon. The purpose of this study was to demonstrate the healing
ability of VergenixSTR in the treatment of injured and inflamed tendons. The control group participating in the VergenixSTR testing was
treated with an injection of PRP only. The efficacy of the product was assessed by histology, measuring parameters of healing at different
stages. The preclinical study findings demonstrated that VergenixSTR resulted in lower initial inflammatory mononuclear cell levels, which
correlates with a reduction in pain. This effect, along with observations on the appearance of mature fibrosis and elimination of early
granulated tissue, suggests that VergenixSTR may accelerate the healing of tendons in comparison with the control treatment.
54
Table of Contents
In a follow-up preclinical study, the ability of VergenixSTR to form a scaffold which is retained to promote healing was assessed
through injection of the product into a subcutaneous pocket in rats. Animals treated with VergenixSTR demonstrated a slow degradation of
the clot over a period of four to eight weeks, whereas the control group demonstrated nearly immediate dispersion of the injected material.
[GRAPHIC]
Results of subcutaneous clot implantation in rats. Clot degradation profile is presented as % of weight at time 0.
Analysis of the injection sites showed significant levels of the growth factors PGDF and VEGF, which are both due to the healing
process, throughout the study period, suggesting that VergenixSTR is effective in retaining platelet-related growth factors at the site of
tendon injury. The preclinical study results confirm VergenixSTR’s ability to promote an improved healing process through the activity of
platelet-related growth factors.
We completed a 40 patient open label, single arm, multi-center clinical trial of VergenixSTR at hospitals in Israel which
demonstrated the safety and evaluated the performance of VergenixSTR in patients suffering from tennis elbow or lateral epicondylitis.
Tennis elbow is an inflammation of the tendons that join the forearm muscles on the outside of the elbow. The forearm muscles and
tendons become damaged from overuse, leading to pain and tenderness on the outside of the elbow. Tennis, racquet sports and other sports
and activities are a common cause of this condition. Tennis elbow affects 1% to 3% of population in the United States and Europe.
[GRAPHIC]
The trial, which commenced in January 2015, initially enrolled 20 patients and was expanded to enroll an additional 20 patients.
Patients enrolled in the trial received a one-time injection of VergenixSTR and are monitored for the level of pain, tendon healing, and
recovery of hand movement at three and six months after treatment.
In August 2016, we announced final results. At the three-month and six-month follow ups, patients treated with VergenixSTR
reported an average 51% and 59% reduction in pain and improvement in motion, respectively, as measured by score improvement over the
baseline on the Patient-Rated Tennis Elbow Evaluation, or PRTEE, questionnaire. The PRTEE questionnaire is designed to measure
reduction in pain and recovery of motion for patients with tennis elbow. Furthermore, at three-month and six-month follow ups, 74% and
86%, respectively, of patients treated with VergenixSTR showed at least a 25% reduction in pain and improvement in motion as measured
by PRTEE. In contrast, a study of standard-of-care tennis elbow therapies published in 2010 in the American Journal of Sports Medicine, or
AJSM, reported that, at three and six months, 48% and 36%, respectively, of steroid patients showed at least a 25% reduction in pain and
improvement in motion as measured by PRTEE. Also at the three-month and six-month follow ups, 62% and 64%, respectively, of patients
treated with VergenixSTR showed at least a 50% reduction in pain and improvement in motion as measured by PRTEE, whereas the 2010
AJSM study showed 33% and 17% reductions at three and six months, respectively, for this same measurement.
In October 2016, we received CE marking certification for VergenixSTR. Following adoption by key opinion leaders and
establishment of sales in Europe, we intend to pursue regulatory approval for VergenixSTR in the United States under the premarket
approval application, or PMA, regulatory pathway. In November 2016, we entered into an exclusive distribution agreement with
Arthrex GmbH in Munich, Germany, an affiliate of Arthrex, Inc, for VergenixSTR covering Europe, the Middle East, India, and certain
African countries. Sales in Europe commenced in the fourth quarter of 2016.
55
Table of Contents
In June 2017, we announced the first positive feedback from treatments as part of our product launch of VergenixSTR in Europe
through Arthrex for the treatment of tendinopathy. VergenixSTR was used in treating 45 patients suffering from various cases of
tendinopathy including tennis elbow, Achilles tendon, shoulder tendon and plantar fasciitis. Feedback from patient surveys indicated a
recovery characterized by a decrease in the level of pain and an improvement in range of motion.
In March 2018, Arthrex, announced results of ACP Tendo, a product for treatment of tendinopathy combining our Vergenix®STR
and Arthrex’s platelet reach plasma extraction kit, in a European case series. The safety and performance of ACP Tendo was evaluated for
the treatment of tendinopathy in 24 patients in 9 different European locations. The indications included injuries in rotator cuff, Achilles
tendon, perneal tendon, tibialis tendon and common extensor tendon. In all treatment groups, patient-recorded-pain decreased after 2 weeks
and continued along this trend up to the last follow-up at 6 months. Specifically for rotator cuff and common extensor tendon groups, the
functionality was increased over the study period, almost achieving pre-symptom levels after 6 months.
VergenixFG—Wound Filler
VergenixFG is an advanced wound care product based on our rhCollagen which received CE marking certification in February
2016. VergenixFG is intended for the treatment of deep surgical incisions and deep wounds, including diabetic ulcers, venous and
pressure ulcers, burns, bedsores, and other chronic wounds that are difficult to heal. VergenixFG is designed to be easy to use and to be
administrated through a cannula by a doctor or nurse. The VergenixFG formulation provides a scaffold of pure human collagen, an
important characteristic in promoting the closure of wounds, that fills the wound bed and is engineered to create maximal contact with the
surrounding tissue, which is believed to enhance healing. VergenixFG provides complete coverage of the wound site, facilitates wound
closure through an engineered synchronization between scaffold degradation and growth of new tissue, and offers a non-allergenic and
pathogen-free scaffold for safe and efficacious wound care therapy. Other flowable gel products are available on the market, but they are
based on tissue-derived collagen.
Market for Chronic Wounds
VergenixFG is designed to meet the needs of the advanced wound care market, initially in the treatment of chronic wounds.
Chronic wounds are rarely seen in individuals who are otherwise healthy. Major chronic diseases such as peripheral vascular diseases,
cardiovascular diseases, diabetes, and other debilitating diseases have led to an increase in the incidence of chronic wounds. In wound
healing, a cascade of events occurs that includes platelet accumulation, inflammation, fibroblast proliferation, cell contraction,
angiogenesis, and re-epithelization, ultimately leading to scar formation. A chronic wound is stalled at one of these healing stages. This
usually occurs during the inflammatory phase and is linked to elevated levels of the matrix metalloproteinases, or MMPs, in the wound.
During normal wound healing, proteases such as MMPs are attracted to the wound during the inflammatory phase and have an important
role in breaking down unhealthy ECMs so that new tissue forms. However, when MMPs are present in a wound at elevated levels for a
prolonged period of time, this results in the destruction of healthy ECMs, which is associated with delayed wound healing and an increase in
wound size. When the excess of MMPs is not balanced by normal physiological processes, alternative methods are required to reduce
protease levels in the wound. This suggests a role for dressings containing collagen in the management of wounds where healing is stalled,
as dressings containing collagen are thought to provide the wound with an alternative collagen source that can be degraded by the high
levels of MMPs as a sacrificial substrate, leaving the body’s native collagen to continue normal wound healing.
We plan on selling VergenixFG at a competitive price to the other advanced healing products in the market. Our initial market for
VergenixFG in Europe is chronic wounds, which includes diabetic foot ulcers, venous ulcers, and pressure ulcers. Eucomed has reported
there are two million chronic wounds annually in the European Union. We also see the opportunity for expansion of VergenixFG beyond
chronic wounds into the treatment of deep surgical incisions. The National Center for Health Statistics reported a total of 51.4 million
inpatient surgical procedures took place in the United States in 2010, and we believe at least half of those resulted in a major surgical
wound that could benefit from an advanced wound closure product such as VergenixFG to facilitate healing. We estimate that the
addressable market for the VergenixFG product within the global advanced wound care market is approximately $3 billion.
56
Table of Contents
VergenixFG Product Development
As part of our product development of VergenixFG during the years 2011 to 2013, preclinical studies were conducted by an
external laboratory under Good Laboratory Practices, or GLPs. The purpose of the studies was to investigate the performance of
VergenixFG in the treatment of wounds in large animals in comparison to a competing product produced from bovine collagen. In a
cutaneous full-thickness wound pig model, a broadly accepted model for the human healing process, 95% wound closure was observed
with VergenixFG at day 21 compared to 68% closure in wounds treated with the benchmark product. Moreover, VergenixFG treatment
induced an early angiogenic response and induced a significantly lower inflammatory response than in the control group. The researchers
concluded that VergenixFG proved effective in animal wound models and is expected to be capable of reducing the healing time of human
wounds.
We have completed an open label, single arm, multi-center registration trial of VergenixFG of 20 patients in Israel to demonstrate
safety and to evaluate the performance of VergenixFG in patients with hard-to-heal chronic wounds of the lower limbs. Patients enrolled in
the trial, which commenced in November 2014, received a single treatment of VergenixFG followed by a four-week follow up. Product
performance was examined according to several measures, the main one being the percentage of wound closure achieved.
In November 2015, we announced final results of the trial, which indicated that VergenixFG is safe for use on human subjects. An
analysis of the final results found average wound closure rates of 80% within four weeks of treatment, with 9 of the 20 patients treated
(45%) achieving full wound closure in that time period. In contrast, according to a scientific study published in 2014 in the International
Wound Journal treatment with the current standard-of-care resulted in complete wound closure after 12 weeks of treatment in just 24% of
patients, for wounds comparable in their severity to the wounds treated in our VergenixFG trial.
In February 2016, we received CE marking certification for VergenixFG. In June 2016, we entered into our first distribution
agreement with an Italian company to distribute VergenixFG in Italy, and in July 2016, we supplied our first order. Subsequently, in 2016
and 2017, we entered into three additional European territories, under distribution agreements. In June 2017 we received an approval from
the Israeli Ministry of Health, or the Ministry of Health, in Israel for marketing the VergenixFG, and we began treating patients in Israel.
We intend to enter into additional distribution agreements in Europe, and following adoption by key opinion leaders and establishment of
sales in Europe, we intend to pursue regulatory approval for VergenixFG in the United States under the PMA regulatory pathway.
In April 2017, we announced positive results from post-marketing surveillance of 10 patients treated with VergenixFG, for the
treatment of patients with chronic, hard to heal wounds in Europe. An analysis of the results found average wound closure rates of 80%
within five weeks of treatment.
In July 2017, we announced that we started treatments of acute and chronic wounds using VergenixFG for the first time in Israel,
by a large private wound-treatment center in the Tel Aviv metropolitan area.
Technology
Our rhCollagen is based upon research conducted by our founder and Chief Scientific Officer, Prof. Oded Shoseyov. We believe
our technology is the only viable technology available for the production of recombinant type I human collagen, the most abundant
collagen in the human body.
The production of our rhCollagen begins with the creation of genetically engineered cultures which are transferred to selected
greenhouses across Israel, and continues with the harvesting of tobacco leaves and the processing of such leaves to an extract which then
undergoes purification until the completion of the rhCollagen.
Five human genes encoding heterotrimeric type I collagen are introduced into tobacco plants. The three protein chains that make
up type I collagen—two α1 protein chains and one α2 protein chain—are encoded by two genes. The other three genes encode the human
prolyl-4-hydroxylase (P4Hα and P4Hβ) as well as lysyl hydroxylase 3 (LH3) enzymes. These enzymes are responsible for key post-
translational modifications of collagen, and plants co-expressing all five of these vacuole-targeted genes generate intact procollagen. The
plants are grown in a greenhouse under strict growing protocols and mature leaves are transported to a protein extraction facility. Upon
extraction, pro-collagen is enzymatically converted to atelocollagen using a plant-derived protease. The protein is purified to homogeneity
through a cost-effective industrial process taking advantage of collagen’s unique properties which make it soluble at a very low pH.
57
Table of Contents
rhCollagen forms thermally stable triple helix structures which readily fibrillate at natural pH and low sodium chloride
concentrations, making it ideal for use in the manufacture of products for tissue repair in the human body. Binding of integrins
(transmembrane receptors) presented by the cells to a specific 3D structure on type I collagen fibrils requires a perfect triple helix. This
binding is essential for binding and proliferation of cells on tissue repair scaffolds. In a recent study published in the Journal of Biomedical
Materials Research Part B: Applied Biomaterials, rhCollagen was compared with acid-solubilized collagen from bovine dermis and
pepsin-solubilized collagen from human fibroblast cell culture. Tested samples of the tissue-derived collagens had random fibrillar
organization, whereas rhCollagen membranes showed far greater regional fibril alignment and transparency. RhCollagen membranes also
showed better thermal stability compared with the tissue-derived collagens. The authors concluded that cross-linked rhCollagen membranes
had a superior combination of desirable properties, namely higher transparency, higher thermal and tensile strengths, and adequate
hydration.
We have selected tobacco as the medium for production of rhCollagen due to certain attributes of the tobacco plant that provide us
with a number of advantages:
● The genetic structure of tobacco is well understood and therefore can be effectively manipulated.
● We can monitor the effect of weather conditions on the accumulation of proteins in the plants, which allows us to make optimal
use of the growing area. We control the growing process in order to maximize yields.
● Because tobacco is not part of the food chain, there are no concerns about cross-contamination of the food supply that could
result from genetically modified plants, which eases the regulatory burden.
● Tobacco plants may be grown in very large volumes and its growth time until reaching the desired maturity is relatively short
(about eight weeks).
We have developed a large portfolio of configurations and composites based on our rhCollagen that are used to create high-quality
products, including our three products, as follows:
[GRAPHIC]
Our Development Activities
Development History
Our rhCollagen was first developed as a collaboration among several commercial partners and the Hebrew University of
Jerusalem, a major academic institution in Israel, under the direction of our founder, Professor Oded Shoseyov. Prof. Shoseyov is a faculty
member at the Robert Smith Institute of Plant Science and Genetics at the Hebrew University of Jerusalem. The intellectual property was
transferred to our wholly owned subsidiary, CollPlant Ltd.
As part of our regulatory strategy, we first developed and achieved a CE marking for a collagen-based non-invasive dressing,
VergenixWD. We believe that VergenixWD is the first medical device in the world based on rhCollagen to be authorized for marketing.
VergenixWD is a sterile, biodegradable advanced wound care sheet supplied in various sizes, composed of rhCollagen that provides a moist
wound healing environment. Currently, we are not promoting a marketing strategy for VergenixWD, which is considered a commodity
product, and it is not part of the advanced wound care market that is our target market. We pursued a CE mark for this product as a
predicate product for achieving our intended CE marking for our VergenixSTR and VergenixFG product in the European Union.
58
Table of Contents
Between 2013 and 2017 we developed a surgical matrix, a novel resorbable carrier designed to help accelerate bone healing and
formation. The surgical matrix is a novel resorbable carrier composed of rhCollagen and synthetic minerals which is intended to be charged
with a bone morphogenetic protein developed by Bioventus for use as a bone graft substitute in bone repair indications such as spinal fusion
and trauma. The surgical matrix was developed in collaboration with Bioventus. The collaboration ended in March 2017 and we are not
currently continuing development of this surgical matrix.
In May 2017, we created a division focused on development of collagen-based biological ink, or BioInk, following the expansion
of our research activities in the field of 3D biologic printing of organs and tissues.
Future Development
To facilitate efficient development, our management holds annual research and development meetings where they prioritize
development projects and determine future products. The prioritization process is based on several factors, including our business plan,
commercial potential of the products, time to market, cost of development, feasibility of the project, and our established strategic
objectives. We have several development projects which are in different stages of development.
Future Products
We periodically examine the continued development of other collagen-based products that we have conceived. Each one of our
current products offers a platform to product derivatives that can address other indications and contribute to our pipeline and revenues.
These derivative products include, for example, the use of VergenixSTR for cartilage repair and ACL reconstruction applications, and the
use of VergenixFG for the treatment of deep surgical incisions. Through ongoing research we are also pursuing other platforms for our
rhCollagen, such as biomaterial coatings in order to reduce foreign body response and tissue adhesion. We are also in discussions with
companies in the field, to develop next generation soft tissue fillers.
Other Recombinant Proteins
As tissue engineering and regenerative medicine continue to evolve and expand, we expect that the demand for high-quality
biomaterials will grow. There are a number of other extracellular proteins such as elastin, fibronectin, and different types of collagen which
may be produced through our plant production system. Another protein, Resilin, has been produced using another proprietary technology
for the production of recombinant proteins. Resilin is a polymeric rubber-like protein secreted by insects to specialized cuticle regions, in
areas where high resilience and low stiffness are required. Combining collagen at the nano-scale with Resilin to produce fibers resulted in
super-performing fibers with greater tensile strength and elasticity exceeding that of natural collagen fibers. This composite biomaterial can
be used in indications where elasticity, strength, and memory shape properties are required, such as tendons, meniscus, and nucleus
polyposis.
Manufacturing, Supply, and Production
The majority of our product research and development work is carried out at our offices and research laboratories in Weizmann
Science Park in Ness-Ziona, Israel. The agricultural research and development and extraction activities for our rhCollagen are carried out at
our site in the north of Israel.
We work with subcontractors with greenhouses for growing the tobacco plant containing human collagen in several locations in
Israel. This tobacco growth occurs year-round and is optimized to the climate conditions in order to achieve the maximum amount of the
protein in the leaves. The growers use our protocols and are monitored by our agronomists to ensure their compliance with these protocols.
Each grower has the infrastructure that can be scaled-up to accommodate future demand without additional capital expenditures.
59
Table of Contents
We perform the extraction process by which rhCollagen is extracted from the tobacco plants at our manufacturing facility in the
north of Israel. The collagen purification process which produces rhCollagen is carried out by dedicated subcontractors spread across Israel.
Our rhCollagen-based products are currently manufactured in the United States by a subcontractor using rhCollagen we supply to them
under our production protocols.
We currently have the ability to produce sufficient quantities of quality recombinant type I human collagen to support our product
development activities and the sales of VergenixFG and VergenixSTR and BioInk in Europe in 2018. We are undertaking development and
optimization of the production process, which will enable us to increase production capacity in 2018 and reduce production costs. Our
activities are focused on yield improvement, scale-up, and cost reduction.
While our upstream and downstream processes are quite robust and efficient, we continuously invest in further yield improvement
and scalability, in order to reduce costs. In order to increase yield, we plan to increase biomass per growing area by using new genetic
derivatives, improvement and optimization of growing techniques, and introduction of online controls. Our next-generation tobacco plants
have been created through improved genetics and cross-breeding, and produce three times the amount of collagen as our first-generation
plants. Shifting our growing process from tissue culture techniques to cultivation of plants from seed, which we implemented, is also
streamlining the production process and reduce costs. In addition, increased growing areas will reduce overall cost per harvest. We also
plan further process optimization of our extraction process to increase yields.
We are currently developing a full in-house purification capability. Following the purification process development, and in order to
accommodate upcoming commercialization requirements, we plan to increase our overall production capacity through the establishment of
a new facility which will be equipped with the production equipment and infrastructure to support the larger scale (i.e., clean rooms, water
and air systems). We intend to construct this manufacturing facility in Israel, which will enable us to produce large commercial quantities
of our rhCollagen and rhCollagen-based end products.
Under our current production techniques, we achieve a cost of goods that allow us to offer competitive pricing in the
orthobiologics, advanced wound care, and other premium collagen-based products markets. We anticipate that the above-mentioned
production enhancements will reduce the production cost of our rhCollagen to a level that will enable us to be competitive in both premium
and commodity markets for collagen-based products.
Sales, Marketing, and Distribution
We are marketing and distributing VergenixSTR and VergenixFG in the European market with business partners. In November
2016, we entered into an exclusive distribution agreement with Arthrex GmbH in Munich, Germany, an affiliate of Arthrex, Inc. for
VergenixSTR covering Europe, the Middle East, India, and certain African countries. In December 2016, we supplied our first order to
Arthrex and since then we are supplying Arthrex shipments upon purchase orders, to support sales in Europe.
In June 2016, we entered into distribution agreement with an Italian company to distribute VergenixFG in Italy, and in July 2016,
we supplied our first order. Subsequently since then we signed distribution agreements to distribute VergenixFG in Switzerland, Turkey,
the Netherlands, Greece and Cyprus. We are currently in discussions with additional distributors in Europe for the commencement of sales
of VergenixFG in additional European countries. These potential distributors are active in the wound healing markets and have the existing
sales infrastructure in place.
We have commenced post marketing surveillance studies for both VergenixSTR and VergenixFG with our European key opinion
leaders and physicians in order to generate additional clinical data that demonstrates the efficacy and superiority of our products. The study
is intended to facilitate market adoption of our products in Europe, as well as provide additional support for the submission package to
other regulatory agencies, such as the FDA.
We anticipate that any products we develop in collaboration with a strategic partner or collaborator, such as organs based on our
BioInk for 3D bioprinting, will be marketed by the partner’s sales force.
60
Table of Contents
Our proprietary end products will be marketed to physicians, hospitals, and clinics. We plan to expand the awareness of
rhCollagen and our rhCollagen-based products to the end users through the publication of clinical trial data as well as marketing studies we
may conduct, along with participation in academic and industry conferences. We will also market our rhCollagen to companies developing
products using collagen which do not compete with our primary end products. We anticipate entering into collaborations or partnerships
with these companies where we would supply them with rhCollagen for use in their products in return for royalties.
Until middle of 2016, our only sales of rhCollagen were to different consumers in the research market. We sell our rhCollagen in
the research market under the brand name Collage. Sigma-Aldrich Company distributes Collage in the global research market, which
includes, among others, academic institutions and hospitals worldwide. The Collage that we sell to Sigma-Aldrich under this framework is
intended only for research laboratories (in vitro) and not for preclinical or clinical (in vivo) uses. To date, sales to Sigma-Aldrich were
immaterial in scope and amount.
Competition
We are not aware of any competitors that produce human collagen from plants or that produce recombinant type I human
collagen. However, our industry is characterized by rapidly evolving technology and intense competition, and our rhCollagen-based
products will compete with several alternative tissue-derived or synthetic products. Adequate protection of intellectual property, successful
product development, adequate funding, and retention of skilled, experienced, and professional personnel are among the many factors
critical to success in the pharmaceutical industry.
Generally, our competitors currently include large fully integrated companies, as well as academic research institutes and
companies in various developmental stages that develop alternative sources and forms of collagen and tissue-derived products.
The primary competitors to our BioInk are potential bio-material inks for 3D biological printing, based on tissue-derived
collagens. Manufacturers of these products include, among others Collagen Solutions and Advanced BioMatrix.
Our VergenixSTR product will compete with companies that sell steroid injections and PRP kits, including Biomet Inc., Harvest
Technologies Corporation, MTF Sports Medicine, and Arteriocyte Medical Systems Inc.
The primary competitors to our VergenixFG product are products based on tissue-derived collagens. Manufacturers of these
products include, among others, Integra Lifesciences Corporation, Wright Medical Technology Inc., Smith & Nephew, Molnlycke,
Convatec, Coloplast, and Urgo.
Intellectual Property
Our success depends, in part, on our ability to protect our proprietary technology and intellectual property. We rely on a
combination of patent, trade secret, and trademark laws in the United States and other jurisdictions to protect our intellectual property
rights. In addition, we rely on proprietary processes and know-how, intellectual property licenses, and other contractual rights, including
confidentiality and invention assignment agreements, to protect our intellectual property rights and develop and maintain our competitive
position.
Patents
We have a global patent portfolio that is comprised of ten patent families. Almost three dozen of our patent applications have
issued as patents or will issue soon, having been allowed by the relevant patent office. We have exclusive ownership of 17 issued patents in
our patent family that cover methods of creating collagen-producing plants and two issued patents in our patent family that cover methods
of processing recombinant collagen. These issued patents and others that may issue in the future in these patent families, assuming timely
payment of annual fees, are expected to expire beginning in 2025. Our patent portfolio also includes patent families that cover production
and use of collagen.
61
Table of Contents
In addition, our patent portfolio includes pending applications, some of which are jointly owned with Yissum Research
Development Company of the Hebrew University of Jerusalem Ltd., or Yissum, as well as issued patents that are jointly owned with
Yissum, which cover production of other biomaterials. Our more recently filed patent applications, if granted, could provide patent
protection for our rhCollagen through 2034.
We are not aware of any impediments to the patent applications being granted in the United States or other jurisdictions. However,
our patent applications may never issue as patents, and our issued patents and any that may issue in the future may be challenged,
invalidated or circumvented.
Trade Secrets and Confidential Information
In addition to patented technology, we rely on our trade secrets and continuing technological innovations to develop and maintain
our competitive position. In an effort to protect our trade secrets, we rely on, among other safeguards, confidentiality and invention
assignment agreements to protect our proprietary technology, know-how and other intellectual property that may not be patentable or that
we believe is best protected by means that do not require public disclosure. For example, we require our employees, consultants and
advisors to execute confidentiality agreements in connection with their employment or consulting relationships with us, and to disclose and
assign to us inventions conceived in connection with their services to us. These agreements also provide that all confidential information
developed or made known to the individual during the course of their relationship with us must be kept confidential, except in specified
circumstances.
Trademarks
We rely on trade names, trademarks and service marks to protect our name brands. Our registered trademarks in several countries
include the following: “collage” and “Vergenix.”
Materials Transfer Agreements
We periodically enter into materials transfer agreements with commercial organizations, medical institutions and research and
development institutions to transfer materials and products developed by us. These agreements include provisions that are customary for
such agreements concerning the permitted use of the transferred material and any results obtained using the material, confidentiality, the
rights in the transferred materials and in the results of the research and/or development in which the materials are used, and instructions
concerning care and usage of the materials. These agreements may be used as a basis for further cooperation between us and the
counterparties.
We may be unable to obtain, maintain, and protect the intellectual property rights necessary to conduct our business, and may be
subject to claims that we infringe or otherwise violate the intellectual property rights of others, which could materially harm our business.
For a more comprehensive summary of the risks related to our intellectual property, see “Item 3.D. Risk Factors.”
Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. with respect to our rhCollagen
Under an agreement dated July 13, 2004 among Meytav—Technological Innovation Center Ltd., Yehuda Zafrir Fagin, Yissum,
and Prof. Oded Shoseyov (our chief scientific officer and a director), we carried out a research and development project to develop a
process for the production of quality human collagen in plants and further developed the resulting products created by us, Professor
Shoseyov and Zafrir, for commercial applications. Yissum and Professor Shoseyov have assigned all intellectual property rights developed
by Professor Shoseyov and owned by them to us, including the intellectual property rights in connection with the development of the
method for production of quality human collagen in plants.
62
Table of Contents
Government Regulation
We are a developer of tissue products which are subject to extensive regulation as medical devices in the United States, the
European Union and other jurisdictions. These regulations govern, among other things, the introduction of new medical devices, the
observance of certain standards with respect to the design, manufacture, testing, promotion and sales of the devices, the maintenance of
certain records, the ability to track devices, the reporting of potential product defects, the import and export of devices, and other matters.
As a medical device company that wishes to obtain marketing authorization in the United States, we are subject to extensive
regulation by the FDA and other federal, state, and local regulatory agencies. The Federal Food, Drug, and Cosmetic Act, or FD&C Act,
the Public Health Service Act, or the PHS Act, and their implementing regulations set forth, among others, requirements for the research,
testing, development, manufacture, quality control, safety, effectiveness, approval, labeling, storage, record keeping, reporting, distribution,
import, export, advertising, and promotion of our products. A failure to comply with relevant requirements may lead to administrative,
civil, or criminal sanctions. These sanctions could include the imposition by the FDA of a clinical hold or other suspension on clinical
trials, refusal to approve pending marketing applications or supplements, withdrawal of approval, warning letters, product recalls, product
seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, or criminal prosecution.
Although the discussion below focuses on regulation in the United States, we anticipate seeking approval for the marketing of our
products in other countries which have their own regulatory requirements. Generally, our activities in other countries will be subject to
regulations that are similar in nature and scope as that imposed in the United States such as medical device approval, quality system
requirements, product data and certifications, although there can be important differences and the number and scope of these regulatory
requirements are generally increasing.
We must obtain approval by comparable regulatory authorities of foreign countries outside of the European Union and the United
States before we can commence clinical trials or marketing of our products in those countries. The approval process varies from country to
country and the process may be longer or shorter than that required for FDA approval. In addition, the requirements governing the conduct
of clinical trials, product licensing, pricing, and reimbursement vary greatly from country to country. In all cases, clinical trials must be
conducted in accordance with the FDA’s regulations, commonly referred to as good clinical practices, or GCPs, and the applicable
regulatory requirements and ethical principles that have their origin in the Declaration of Helsinki.
Government regulation may delay or prevent testing or marketing of our products and impose costly procedures upon our
activities. The testing and approval process, and the subsequent compliance with appropriate statutes and regulations, require substantial
time, effort, and financial resources, and we cannot be certain that the FDA or any other regulatory agency will grant approvals for our
products or any future product candidates on a timely basis, or at all. The policies of the FDA or any other regulatory agency may change
and additional governmental regulations may be enacted that could prevent or delay regulatory approval of our products or any future
product candidates or approval of new indications or label changes. We cannot predict the likelihood, nature or extent of adverse
governmental regulation that might arise from future legislative, judicial, or administrative action, either in the United States or abroad.
63
Table of Contents
Approval by Health Authorities
The following is a summary review of the laws and regulations governing our operations. Our products are medical products, and
their marketing, once development is complete, is contingent upon approval of the health authorities in every country in which the products
will be marketed:
Israel
Our operations are subject to permits from the Ministry of Health on two levels:
● First, the registration of medical devices, importing and marketing the medical devices and accessories, and issuing the
documentation necessary for the export of medical devices from Israel are all supervised by the medical accessories and
devices unit, or AMR, of the Ministry of Health.
● Second, pertaining to research and development, clinical trials in humans are subject to the approval of the Helsinki Committee
of the institution conducting the trial, which is governed by the Public Health Regulations (Trials in Human Beings), 1980,
including all amendments until 1999, or the Trials in Human Subjects Regulations, and are conducted in accordance with the
Guidelines for Clinical Trials in Human Subjects issued by the Ministry of Health, or the Guidelines, and the guidelines of the
Declaration of Helsinki, or any other approval required by the Ministry of Health. According to the Trials in Human Subjects
Regulations and the Guidelines, the Helsinki Committee must plan and approve every experimental process that involves
human beings. The Helsinki Committee is an institutional committee that acts in the medical institution where the trial is
performed and is the body that approves and supervises the entire trial process. In practice, the physician, who is the principal
investigator, submits a trial protocol to the committee on behalf of the requesting party. The committee forwards its decisions
regarding the requests for clinical trials that were approved by the committee to the manager of the medical institute and the
manager has the authority to approve the requests, and in some cases the additional approval of the Ministry of Health will be
required. According to the procedure for medical trials in human beings set forth by the Ministry of Health, the Helsinki
Committee will not approve performance of a clinical trial, unless it is absolutely convinced that the following conditions,
among others, are fulfilled: (i) the expected benefits for the participant in the clinical trial and to the requesting party to justify
the risk and the inconvenience involved in the clinical trial to its participant; (ii) the available medical and scientific information
justifies the performance to the requested clinical trial; (iii) the clinical trial is planned in a scientific manner that enables a
solution to the tested question and is described in a clear, detailed, and precise manner in the protocol of the clinical trial,
conforming with the Declaration of Helsinki; (iv) the risk to the participant in the clinical trial is as minimal as possible;
(v) optimal monitoring and follow-up of the participant in the clinical trial; (vi) the initiator, the principal investigator and the
medical institute are capable and undertake to allocate the resources required for adequate execution of the clinical trial,
including qualified personnel and required equipment; and (vii) the nature of the commercial agreement with the principal
investigator and the medical institute does not impair the adequate performance of the clinical trial.
All phases of clinical trials conducted in Israel must be conducted in accordance with the Trials in Human Subjects Regulations,
including amendments and addenda thereto, the Guidelines, and the International Conference for Harmonized Tripartite Guideline for Good
Clinical Practice. The Trials in Human Subjects Regulations and the Guidelines stipulate that a medical study on humans will only be
approved after the Helsinki Committee at the hospital intending to perform the study has approved the medical study and notified the
relevant hospital director in writing. In addition, certain clinical studies require the approval of the Ministry of Health. The relevant hospital
director, and the Ministry of Health, if applicable, also must be satisfied that the study is not contrary to the Declaration of Helsinki or to
other regulations.
Additionally the Israeli penal code prohibits bribing a foreign public employee in exchange for any action related to such
employee’s role, in order to achieve, guarantee, or promote business activities or other business advantage.
In June 2017, we received AMR approval for VergenixFG, and started treating patients in Israel.
United States
The regulatory process of obtaining product approvals and clearances can be onerous and costly. Foreign companies
manufacturing medical devices intended for sale in the United States are required to meet the FDA’s regulatory requirements. The FDA
does not recognize the regulatory certification provided by governmental authorities of other countries.
64
Table of Contents
Pre-Marketing Regulation
In the United States, medical devices are regulated by the FDA. Unless an exemption applies, a new medical device will require
either prior 510(k) clearance or approval of a PMA before it can be marketed in the United States. The information that must be submitted
to the FDA in order to obtain clearance or approval to market a new medical device varies depending on how the medical device is
classified by the FDA. Medical devices are classified into one of three classes on the basis of the controls deemed by the FDA to be
necessary to reasonably ensure their safety and effectiveness. Class I devices, which are those that have the lowest level or risk associated
with them, are subject to general controls, including labeling, premarket notification, and adherence to the QSR. Class II devices are subject
to general controls and special controls, including performance standards. Class III devices, which have the highest level of risk associated
with them, are subject to most of the previously identified requirements as well as to premarket approval. Most Class I devices and some
Class II devices are exempt from the 510(k) requirement, although manufacturers of these devices are still subject to registration, listing,
labeling and QSR requirements.
A 510(k) premarket notification must demonstrate that the device in question is substantially equivalent to another legally
marketed device, or predicate device, that did not require premarket approval. In evaluating the 510(k), the FDA will determine whether
the device has the same intended use as the predicate device, and: (i)(a) has the same technological characteristics as the predicate device,
or (b) has different technological characteristics; and (ii)(a) the data supporting the substantial equivalence contains information, including
appropriate clinical or scientific data, if deemed necessary by the FDA, that demonstrates that the device is as safe and as effective as a
legally marketed device, and (b) does not raise different questions of safety and effectiveness than the predicate device. Most 510(k)s do
not require clinical data for clearance, but the FDA may request such data. If the FDA does not agree that the new device is substantially
equivalent to the predicate device, the new device will be classified in Class III, and the manufacturer must submit a PMA.
The PMA process is more complex, costly, and time consuming than the 510(k) clearance procedure. A PMA must be supported
by extensive data including, but not limited to, technical, preclinical, clinical, manufacturing, control, and labeling information to
demonstrate to the FDA’s satisfaction the safety and effectiveness of the device for its intended use. After a PMA is submitted, the FDA
has 45 days to determine whether it is sufficiently complete to permit a substantive review. If the PMA is complete, the FDA will file the
PMA. The FDA is subject to performance goal review times for PMAs and may issue a decision letter as a first action on a PMA within
180 days of filing, but if it has questions, it will likely issue a first major deficiency letter within 150 days of filing. It may also refer the
PMA to an FDA advisory panel for additional review, and will conduct a preapproval inspection of the manufacturing facility to ensure
compliance with the QSR, either of which could extend the 180-day response target. A PMA can take several years to complete, and there
is no assurance that any submitted PMA will ever be approved. Even when approved, the FDA may limit the indication for which the
medical device may be marketed. Changes to the device, including changes to its manufacturing process, may require the approval of a
supplemental PMA.
If a medical device is determined to present a “significant risk,” the manufacturer may not begin a clinical trial until it submits an
investigational device exemption, or IDE, to the FDA and obtains approval of the IDE from the FDA. The IDE must be supported by
appropriate data, such as animal and laboratory testing results, and include a proposed clinical protocol. The clinical trials must be
conducted in accordance with applicable regulations, including but not limited to the FDA’s IDE regulations and current good clinical
practices. A clinical trial may be suspended by the FDA or the sponsor at any time for various reasons, including a belief that the risks to
the study participants outweigh the benefits of participation in the trial. Even if a clinical trial is completed, the results may not demonstrate
the safety and efficacy of a device, or may be equivocal or otherwise not be sufficient to obtain approval.
In August 2010, we submitted a 510(k) notification to the FDA for VergenixWD, a collagen-based non-invasive dressing. In
October 2010, we received notice that the Center for Devices and Radiological Health, or CDRH, which is the FDA center with jurisdiction
over medical devices, determined that the product required a submission of a PMA for regulatory approval and not a 510(k). We filed an
appeal of this decision which was denied, and in April 2012, the FDA confirmed its previous determination that our product would require
PMA approval prior to its marketing in the United States. We believe that most, if not all, of our products will be subject to the PMA
process.
65
Table of Contents
We expect, based on our prior limited interaction with the FDA in connection with our predecessor wound healing product, that
our current products will be regulated as medical devices through a PMA process; however, no assurance can be given that the FDA will
not impose additional, more stringent, regulatory requirements with respect to one or more of our current or future product candidates.
Conducting clinical trials for our pipeline product candidates that are required to undergo the PMA process may take one to three years,
depending on the composition of the product candidate under development and its designation.
We are not presently conducting any discussions with the FDA with respect to any of our products.
European Union
Under the European Union Medical Device Directive, or EU MDD, medical devices must meet the EU MDD requirements and
receive a CE marking certification prior to marketing in the European Union, or EU. CE marking is the uniform labeling system of products
designed to facilitate the supervision and control of the EU concerning manufacturers’ compliance with the various regulations and
directives of the EU and to clarify the obligations imposed in the various legislative provisions in the EU. Use of a uniform product
labeling indicates compliance with all of the directives and regulations required for the application of such labeling, and it is effective as a
manufacturer’s declaration that the product meets the required criteria and technical specifications of the relevant authorities such as health,
safety, and environmental protection. CE marking ensures free trade between the EU and European Free Trade Association countries
(Switzerland, Iceland, Liechtenstein, and Norway) and permits the enforcement and customs authorities in European countries not to allow
the marketing of similar products that do not bear the CE marking sign. Such certification allows, among other things, marking the products
(according to various categories) with the CE marking and their sale and marketing in the EU.
CE marking certification requires a comprehensive quality system program, comprehensive technical documentation and data on
the product, which are then reviewed by a Notified Body, or NB. An NB is an organization designated by the national governments of the
EU member states to make independent judgments about whether a product complies with the EU MDD requirements and to grant the CE
marking if we, and our product, comply with specified terms. After receiving the CE marking, we must pass a review carried out by the
competent NB annually, under which it audits our facilities to verify our compliance with the ISO 13485 quality system standard.
Compliance with the ISO 13485 standard, for medical device quality management systems, is required for regulatory purposes.
ISO standards are recognized international quality standards that are designed to ensure that we develop and manufacture quality medical
devices. Other countries are also instituting regulations regarding medical devices. Compliance with these regulations requires extensive
documentation and clinical reports for all of our products, revisions to labeling, and other requirements such as facility inspections to
comply with the registration requirements.
In February 2016, we received CE marking certification for VergenixFG and in October 2016, we received CE marking for
VergenixSTR. In December 2012, we received CE marking permitting the sale and marketing of VergenixWD in Europe. VergenixWD
was our first medical product based on collagen protein derived from plants that is authorized for sale and marketing in Europe, but we are
not currently promoting a marketing strategy for VergenixWD, which is considered a commodity product and is not targeted towards the
advanced wound care market, which is our target market.
66
Table of Contents
China
China’s medical device market, currently in a rapid state of expansion, is overseen by the China Food and Drug Administration, or
CFDA (formerly the State Food and Drug Administration). The CFDA issues registration certificates required for all medical devices sold
in China. The CFDA uses a risk-based system, and its approval process requires mandatory testing for Class II and III devices. Class II
devices are moderate-risk devices and Class III devices are high-risk medical devices. Third-party reviews of devices are currently not
allowed in China; only the CFDA is authorized to approve devices. The registration process requires the submission of a registration
standard along with device samples for testing. Manufacturers of Class II and Class III medical devices are also required to demonstrate
that the device has been approved by the country of origin with documents like a CE certificate, 510(k) letter and PMA approval and
compliance with ISO 13485, and they may also be required to submit clinical data in support of their application. In addition to these
requirements, all medical device manufacturers must also include product information in Chinese on all packaging and labeling.
Manufacturers exporting medical devices to China must appoint several China-based agents to act on their behalf. These include a
registration agent to coordinate the CFDA registration process, a legal agent to handle any adverse events reported with a registered device,
including a product recall, and an after-sales agent to provide technical service and maintenance support.
Other U.S. Federal Healthcare Laws and Regulations
Healthcare providers, physicians, and third-party payors play a primary role in the recommendation and medical devices that are
granted marketing approval. In the United States, we are subject to laws and regulations pertaining to healthcare fraud and abuse, including
anti-kickback laws and physician self-referral laws that regulate the means by which companies in the healthcare industry may market their
products to hospitals and healthcare providers and may compete by discounting the prices of their products. The delivery of our products is
subject to regulation regarding reimbursement, and federal healthcare laws apply when a customer submits a claim for a product that is
reimbursed under a federally funded healthcare program. These rules require that we exercise care in structuring our sales and marketing
practices and customer discount arrangements.
Arrangements with healthcare providers, third-party payors, and other customers are subject to broadly applicable fraud and abuse
and other healthcare laws and regulations, including the following:
● the federal healthcare Anti-Kickback Law prohibits, among other things, persons from knowingly and willfully soliciting,
offering, receiving, or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of
an individual for, or the purchase, order, or recommendation of, any good or service for which payment may be made, in whole
or in part, under a federal healthcare program such as Medicare and Medicaid;
● the U.S. False Claims Act imposes civil penalties, and provides for civil whistleblower or qui tam actions, against individuals or
entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or
fraudulent or making a false statement to avoid, decrease, or conceal an obligation to pay money to the federal government;
● the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for
executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;
● HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing
regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security,
and transmission of individually identifiable health information;
● the federal false statements statute prohibits knowingly and willfully falsifying, concealing, or covering up a material fact or
making any materially false statement in connection with the delivery of or payment for healthcare benefits, items, or services;
● the federal transparency requirements under the Health Care Reform Law require manufacturers of drugs, devices, and medical
supplies to report to the U.S. Department of Health and Human Services information related to payments and other transfers of
value to physicians and teaching hospitals and physician ownership and investment interests; and
● analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or
marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payers,
including private insurers.
67
Table of Contents
Healthcare providers that purchase medical devices generally rely on third-party payors, including, in the United States, the
Medicare and Medicaid programs and private payors, such as indemnity insurers, employer group health insurance programs, and managed
care plans, to reimburse all or part of the cost of the products. As a result, demand for our products is and will continue to be dependent in
part on the coverage and reimbursement policies of these payors. The manner in which reimbursement is sought and obtained varies based
upon the type of payor involved and the setting in which the product is furnished and utilized. Reimbursement from Medicare, Medicaid,
and other third-party payors may be subject to periodic adjustments as a result of legislative, regulatory, and policy changes as well as
budgetary pressures. Possible reductions in, or eliminations of, coverage or reimbursement by third-party payors, or denial of, or provision
of uneconomical reimbursement for new products, may affect our customers’ revenue and ability to purchase our products. Any changes in
the healthcare regulatory, payment, or enforcement landscape relative to our customers’ healthcare services has the potential to significantly
affect our operations and revenue.
Other Approvals
Our international operations as well as being an Israeli company subject us to laws regarding sanctioned countries, entities, and
persons; customs, import-export, and laws regarding transactions in foreign countries; and the U.S. Foreign Corrupt Practices Act and local
anti-bribery and other laws regarding interactions with healthcare providers. Among other things, these laws restrict, and in some cases can
prevent, United States companies from directly or indirectly selling goods, technology, or services to people or entities in certain countries.
In addition, these laws require that we exercise care in structuring our sales and marketing practices in foreign countries.
In addition to the above regulations, we are and may be subject to regulation under country-specific federal and state laws,
including, but not limited to, requirements regarding record keeping, and the maintenance of personal information, including personal
health information. As a public company whose securities will be registered pursuant to the Securities Act, we will be subject to U.S.
securities laws and regulations, including the Sarbanes-Oxley Act. We also are subject to other present, and could be subject to possible
future, local, state, federal, and non-U.S. regulations in countries in which we will distribute our products.
Israeli Ministry of Agriculture
The process of growth of transgenic plants and the treatment thereof is subject to the regulations published by the Israeli Ministry
of Agriculture and the approval of the Ministry of Agriculture to engage in the cultivation of recombinant plants. Although the Ministry of
Agriculture requirements do not necessarily apply to our operations, we hold a valid permit from the Plant Protection and Inspection
Services Administration, or PPIS, for growing tobacco plants in greenhouses in the north of Israel, as well as in all of our subcontractors’
facilities.
Business Licensing
Under the Israeli Licensing of Businesses Law, to which our production site and laboratories are subject, operating a business
without a license or temporary permit is a criminal offense. We have a business license for our laboratories and offices, in effect until
December 31, 2019. We have a business license for our production site at Yessod Hama’ala, in effect until November 3, 2019.
Planning and Zoning
Our production sites and laboratories are subject to the Israeli Planning and Zoning Law, which sets provisions and obligations,
inter alia, regarding the licensing process for a new building, including building permits, non-conforming use and easements, the
supervision over its construction, and the required occupancy permits. According to the Planning and Zoning Law, work or use of land
without a permit where such permit is required, a deviation from the permit granted, or use of agricultural land in violation of the law,
constitutes a criminal offense.
68
Table of Contents
Employees
As of December 31, 2017, we had 29 full-time employees, including eight in research and development, thirteen in manufacturing
and eight in general and administrative positions. Five of our employees have either MDs or PhDs. All of our employees are located in
Israel. We believe our employee relations are good.
In addition, we employ a limited number of part-time employees on a temporary basis, as well as consultants and service
providers.
Israeli labor laws govern the length of the workday, minimum wages for employees, procedures for hiring and dismissing
employees, determination of the scope of severance pay, annual leave, sick days, advance notice of termination of employment, equal
opportunity and anti-discrimination laws, and other conditions of employment. Subject to specified exceptions, Israeli law generally
requires severance pay upon the retirement, death, or dismissal of an employee. We fund our ongoing severance obligations by making
monthly payments to insurance policies that comply with the applicable Israeli legal requirements. All of our current employees have
agreed that upon termination of their employment, they will be entitled to receive only the amounts accrued in the insurance policies with
respect to severance pay. Furthermore, Israeli employers and employees are required to make payments to the National Insurance Institute,
which is similar to the U.S. Social Security Administration.
None of our employees currently work under any collective bargaining agreements.
Environmental, Health, and Safety Matters
Our research, development, and manufacturing processes involve the controlled use of certain hazardous materials. Therefore, we
are subject to extensive environmental, health, and safety laws and regulations in a number of jurisdictions, in Israel, governing, among
other things: the use, storage, registration, handling, emission, and disposal of chemicals, waste materials, and sewage; chemicals, air,
water, and ground contamination; air emissions, and the cleanup of contaminated sites, including any contamination that results from spills
due to our failure to properly dispose of chemicals, waste materials, and sewage. Our operations at our Ness-Ziona manufacturing facility
use chemicals and produce waste materials and sewage. Our activities require permits from various governmental authorities including local
municipal authorities, the Ministry of Environmental Protection, and the Ministry of Health. The Ministry of Environmental Protection, the
Ministry of Health, local authorities, and the municipal water and sewage company conduct periodic inspections in order to review and
ensure our compliance with various regulations.
These laws, regulations, and permits could potentially require the expenditure by us of significant amounts for compliance or
remediation. We believe that our environmental, health, and safety procedures for handling and disposing of these materials comply with
the standards prescribed by the controlling laws and regulations. If we fail to comply with such laws, regulations, or permits, we may be
subject to fines and other civil, administrative, or criminal sanctions, including the revocation of permits and licenses necessary to continue
our business activities. In addition, we may be required to pay damages or civil judgments with respect to third-party claims, including
those relating to personal injury (including exposure to hazardous substances we use, store, handle, transport, manufacture, or dispose of),
property damage, or contribution claims. These risks are managed to minimize or eliminate associated business impacts. Some
environmental, health, and safety laws allow for strict joint and several liability for remediation costs, regardless of comparative fault. We
may be identified as a responsible party under such laws. Such developments could have a material adverse effect on our business,
financial condition, and results of operations as these kinds of liabilities could exceed our resources. We could be subject to a regulatory
shutdown of a facility that could prevent the distribution and sale of products manufactured in such facility for a significant period of time
and we could suffer a casualty loss that could require a shutdown of the facility in order to repair it, any of which could have a material,
adverse effect on our business. Although we continuously strive to maintain full compliance with respect to all applicable global
environmental, health, and safety laws and regulations, we could incur substantial costs to fully comply with future laws and regulations,
and our operations, business, or assets may be negatively affected.
69
Table of Contents
In addition, compliance with laws and regulations relating to environmental, health, and safety matters is an ongoing process and
are often subject to change. In the event of any changes or new laws or regulations, we could be subject to new compliance measures or to
penalties for activities which were previously permitted. For instance, Israeli regulations were promulgated in 2012 relating to the discharge
of industrial sewage into the sewer system. These regulations establish new and potentially significant fines for discharging forbidden or
irregular sewage into the sewage system. We have compliance procedures in place for employee health and safety programs, driven by a
centrally led organizational structure that ensures proper implementation, which is essential to our overall business objectives.
We invest resources in creating a green production environment, and in the treatment and disposal of waste using environmentally
friendly processes. We have received all the necessary permits from the Ministry of Environmental Protection regarding our operations in
Yessod Hama’ala and Ness-Ziona. We consult with environmental consultants for direction on environmental issues.
Legal Proceedings
From time to time we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our
business. We are currently not a party to any material legal or administrative proceedings and except as set forth below, are not aware of
any pending or threatened material legal or administrative proceedings against us. To date, we are a party to the following legal
proceedings:
Opposition Proceedings to European Patent No. 0 951 537 B1
On August 2, 2006, we initiated opposition proceedings at the EPO to European Patent No. 0 951 537 B1, published in the name
of Meristem Therapeutics SA, or Meristem, relating to the production of recombinant collagen in plants. To the best of our knowledge,
patent opposition proceedings were also initiated by Fibrogen. In addition, to the best of our knowledge, Meristem’s patent rights in Europe
and Canada expired as a result of failure to make payment of the annual renewal fees. The patent application filed by Meristem in the
United States matured into a patent (U.S. 6,617,431) which, to the best of our knowledge, does not limit our business. To the best of our
knowledge, the opposition proceedings in Europe continued at the request of the second entity opposing these proceedings (which we
believe to be Fibrogen), and in the absence of a defense on the part of Meristem, on October 4, 2010, notice was received from the EPO
that the patent was revoked. To the best of our knowledge, on January 30, 2011, Meristem’s window for appealing the cancellation of the
patent expired.
Opposition Proceedings to European Patent No. 1 809 751 B1
Our European Patent No. 1 809 751 entitled “Collagen Producing Plants and Methods of Generating and Using Same,” was
granted by the EPO on September 1, 2010. On June 1, 2011, Fibrogen initiated an opposition proceeding with the EPO, seeking revocation
of the patent in its entirety on the grounds that the claims were not supported by the contents of the patent, were not novel, and were not
inventive. On January 22, 2013, the EPO issued its decision to maintain the patent in amended form with claims that cover genetically
modified plants that produce collagen.
On June 3, 2013, Fibrogen appealed the decision. On August 1, 2013, we filed an appeal, seeking to expand the scope of the
patent. Oral hearings on these appeals were held in July 2017 which resulted in the EPO revoking the patent in Europe.
Opposition Proceedings to European Patent No. 2 357 241
Our European Patent No. 2 357 241 entitled “Collagen Producing Plants and Methods of Generating and Using Same,” a
divisional of the above 1 809 751, was granted by the EPO, on March 4, 2015. On December 10, 2015, Fibrogen initiated an opposition
proceeding with the EPO, seeking revocation of the patent in its entirety on the grounds that the claims were not supported by the contents
of the patent, were not novel, and were not inventive. On August 16, 2016, we filed a response. In September, 2017, we determined to
abandon the patent and consequently the patent was revoked by the EPO in February 2018.
70
Table of Contents
Opposition Proceedings to European Patent No. EP2816117
Our European Patent No. EP2816117 entitled “Collagen Producing Plants and Methods of Generating and Using Same,” a
divisional of European Patent No. 1 809 751, was granted by the EPO, on November 30, 2016. On August 30, 2017, Fibrogen initiated an
opposition proceeding with the EPO, seeking revocation of the patent in its entirety on the grounds that the claims were not supported by
the contents of the patent, and were not inventive. The ultimate outcome of this proceeding remains uncertain, and final resolution of the
proceeding may take a number of years and result in substantial costs to us.
C. Organizational Structure
We currently have one wholly owned subsidiary: CollPlant Ltd., which is incorporated in the State of Israel.
D. Property, Plant and Equipment
Our corporate headquarters and research facilities are located in Weizmann Science Park in Ness-Ziona, Israel, where we lease an
aggregate of approximately 7,653 square feet of office and laboratory space, pursuant to lease agreements that expire on August 17, 2018.
We rent additional areas in Yessod Hama’ala, Israel, of approximately 64,583 square feet of greenhouse and manufacturing facility
pursuant to a lease agreement that expires on April 20, 2021. In addition, on July 28, 2016, we leased additional space in Rehovot, Israel, of
approximately 6,329 square feet for development and production activities pursuant to a lease agreement that expires on July 28, 2019, with
an option to extend for four additional years.
The majority of our research and development work is carried out at our offices and research laboratories in Weizmann Science
Park in Ness-Ziona, Israel. The plant research process and production of our rhCollagen are carried out at our site in the north Israel, while
the tobacco plant cultivation and collagen purification are carried out in various areas in Israel. Our greenhouses for tobacco growing are
located in several areas in Israel, where we are using subcontractors under several agreements. The greenhouses are used by us for growing
tobacco plants and other development services.
We believe that our existing facilities are adequate for our near-term needs. When our leases expire, we may look for additional or
alternate space for our operations. We believe that suitable additional or alternative space and area would be available if required in the
future on commercially reasonable terms.
ITEM 4A. UNRESOLVED STAFF COMMENTS
Not applicable.
ITEM 5.
OPERATING AND FINANCIAL REVIEW AND PROSPECTS
You should read the following discussion and analysis of our financial condition and results of operations together with the section
titled “Item 3.A.—Selected Financial Data” and our consolidated financial statements and related notes included elsewhere in this annual
report on Form 20-F. This discussion and other parts of this annual report on Form 20-F contain forward-looking statements based upon
current expectations that involve risks and uncertainties. This discussion and other parts of this annual report on Form 20-F contain
forward-looking statements that involve risk and uncertainties, such as statements of our plans, objectives, expectations, and intentions. Our
actual results could differ materially from those discussed in these forward looking statements. Factors that could cause or contribute to
such differences include, but are not limited to, those discussed in the section titled “Item 3.D.—Risk Factors” and elsewhere in this annual
report in Form 20-F.
The share and per share numbers in the following discussion reflect a 1-for-3 reverse share split that we effected on November 20,
2016. We report financial information under IFRS as issued by the International Accounting Standards Board and none of the financial
statements were prepared in accordance with generally accepted accounting principles in the United States.
71
Table of Contents
Overview
We are a regenerative medicine company focused on developing and commercializing tissue repair products, initially for 3D
bioprinting of tissues and organs, orthobiologics, and advanced wound care markets. Our products are based on our rhCollagen, a form of
human collagen produced with our proprietary plant-based genetic engineering technology. We believe our technology is the only
commercially viable technology available for the production of genetically engineered, or recombinant, human collagen. We believe that
our rhCollagen, which is identical to the type I collagen produced by the human body, has significant advantages compared to currently
available tissue-derived collagens, including improved biofunctionality, superior homogeneity, and reduced risk of immune response. We
believe the attributes of our rhCollagen make it suitable for numerous tissue repair applications throughout the human body. We believe
that the annual market opportunity for our current products utilizing our rhCollagen within the orthobiologics and advanced wound care
markets exceeds $5 billion. Although we commenced commercial sales of our products, we have not generated significant revenue from
product sales to date.
Our rhCollagen-based BioInk for use in the 3D printing of tissues and organs is being developed to enable the printing of three-
dimensional scaffolds combined with human cells and/or growth factors as a basis for tissue or organ formation. In addition to collagen, our
BioInk formulations can include other proteins and/or polymers as well. Our BioInk is being developed to be compatible with numerous 3D
bioprinting technologies and with printed organ characteristics.
Our VergenixSTR product is a soft tissue repair matrix which combines cross-linked rhCollagen with platelet-rich plasma, or PRP,
a concentrated blood plasma that contains high levels of platelets, and is intended for the treatment of tendinopathy. We commenced
commercial sales of VergenixSTR in December 2016. Prior to that, in August 2016, we completed an open label, single arm, multi-center
clinical trial of VergenixSTR of 40 patients in Israel to demonstrate safety and to evaluate the performance of VergenixSTR in patients
suffering from tennis elbow or lateral epicondylitis, an inflammation of the tendons that join the forearm muscles on the outside of the
elbow. In October 2016, we received CE marking for VergenixSTR, which is required for a product to be marketed in the European Union
and in November 2016, we entered into an exclusive distribution agreement with Arthrex for VergenixSTR covering Europe, the Middle
East, India, and certain African countries.
Our VergenixFG product is a wound-filling flowable gel made from our rhCollagen intended for treatment of deep surgical
incisions and wounds, including diabetic ulcers, burns, bedsores, and other chronic wounds. We completed an open label, single arm, multi-
center clinical trial of VergenixFG of 20 patients in Israel to demonstrate safety and to evaluate the performance of VergenixFG in patients
with hard-to-heal chronic wounds of the lower limbs. In February 2016, we received CE marking certification for VergenixFG, and in July
2016, we supplied our first order in Europe. To bring our initial two products to market, we first commercialized the products in Europe and
then pursue U.S. FDA approval under the PMA regulatory pathway for our rhCollagen-based products.
Since incorporation of our wholly owned subsidiary CollPlant Ltd. in 2004, which merged with and into CollPlant Holdings Ltd.
in 2010, we have achieved a number of significant milestones:
● From 2005 to 2011, we developed our plant-based technology, which we believe is the only commercially viable technology
available for the production of rhCollagen.
● In December 2011, we entered into a joint development agreement with Pfizer for the development of a product for the
orthopedic market, comprised of a growth factor and our rhCollagen, along with other components. This agreement expired in
2013. From 2013 to 2017, this co-development continued with Bioventus Inc., or Bioventus, which acquired the rights for
commercialization of the BMP from Pfizer and to whom Pfizer assigned certain of its rights and obligations under the 2011
joint development agreement. In March 2017, the co-development with Bioventus terminated.
72
Table of Contents
● In December 2012, following a successful clinical trial, we received a CE mark for a predecessor wound healing product. This
is the first medical device in the world to receive a CE marking that is based on rhCollagen. The product is a sterile,
biodegradable advanced wound care sheet supplied in various sizes, composed of rhCollagen that provides a moist wound
healing environment. Currently, we are not marketing this product, as we perceive it as a commodity product, and it is not part
of the advanced wound care market that is our target market.
● In 2014, we completed the preclinical studies required to launch clinical trials in Israel for two of our products, VergenixSTR
and VergenixFG, and we launched clinical trials for VergenixSTR in January 2015 and VergenixFG in November 2014.
● In November 2015, we announced final results of our clinical trial of VergenixFG, showing full wound closure at four weeks in
45% of the 20 patients treated.
● In December 2015, we announced interim results for our clinical trial of patients suffering from tennis elbow who were treated
with VergenixSTR, showing an average PRTEE questionnaire score improvement of 51.3% at three months for the first 23
patients enrolled in the trial. Also in December 2015, we applied for CE marking certification for VergenixSTR.
● In February 2016, we received CE marking certification for VergenixFG, and we announced final results with respect to the
first 20 patients enrolled in our VergenixSTR trial, with 90% of patients showing at least a 25% reduction in pain and
improvement in motion at six months post treatment, as measured by PRTEE.
● In June 2016, we entered into our first distribution agreement an Italian company to distribute VergenixFG in Italy, and in
July 2016, we supplied our first order. We have since entered into distribution agreements with distributors to distribute
VergenixFG in Switzerland, Turkey, the Netherlands, Greece and Cyprus.
● In August 2016, we announced final results of our VergenixSTR trial. Results of the trial indicated that VergenixSTR was
found to be safe for use on human subjects. At the three-month and six-month follow ups, patients reported an average 51% and
59% reduction in pain and improvement in motion, respectively, as measured by the PRTEE questionnaire.
● In October 2016, we received CE marking certification for VergenixSTR.
● In November 2016, we entered into an exclusive distribution agreement with Arthrex for VergenixSTR covering Europe, the
Middle East, India, and certain African countries.
● In April 2017, we announced positive results from post-marketing surveillance of VergenixFG, for the treatment of patients
with chronic, hard to heal wounds in Europe.
● In May 2017, we created a division focused on development of BioInk following the expansion of our research activities in the
field of 3D biologic printing of organs and tissues. Subsequently in June 2017, we filed a patent application in the US for
BioInk based on our rhCollagen for 3D printing of tissues and organs.
● In June 2017, we announced the first positive feedback from treatments as part of our product launch of VergenixSTR in
Europe through Arthrex for the treatment of tendinopathy.
● In July 2017, we announced that we started treatments of acute and chronic wounds using VergenixFG for the first time in
Israel, by a large private wound-treatment center in the Tel Aviv metropolitan area.
● In September 2017, we received an initial order for our rhCollagen-based BioInk from a leading biotechnology company with
which CollPlant is in discussions for the possible co-development of 3D bioprinting of life-saving organs. In November 2017,
we received a repeat order from the same company.
73
Table of Contents
● In October 2017, we entered into a work plan with one of the world’s leading medical device companies to develop a prototype
of 3D-printed orthopedic implant based on our rhCollagen-based BioInk.
To date, we have financed our operations primarily with the net proceeds from private placements and from public offerings of our
securities on the TASE, participation in product development collaborations, and government grants from the IIA.
Since our inception, we have incurred significant losses. Our total comprehensive loss was NIS 20.9 million for the year ended
December 31, 2017 and NIS 27.9 million and NIS 18.6 million for the years ended December 31, 2016 and 2015, respectively. As of
December 31, 2017, we had an accumulated deficit of NIS 174.4 million. We have not generated significant revenue to date from sales of
our products.
We expect to continue to incur expenses and operating losses for the foreseeable future. The net losses we incur may fluctuate
significantly from quarter to quarter. We anticipate that our expenses will increase substantially if and as we:
● continue our research and preclinical and clinical development of our pipeline products;
● seek marketing approvals for VergenixSTR and VergenixFG and any other products in the United States and other new
territories;
● maintain, expand, and protect our intellectual property portfolio;
● hire additional operational, clinical, quality control, and scientific personnel;
● establish plant infrastructure to accommodate product capacity increase;
● add operational, financial, and management information systems and personnel, including personnel to support our product
development, any future commercialization efforts, and our transition to a public reporting company in the United States; and
● identify additional product candidates.
Financial Operations Overview
Revenue
To date, we have not generated significant revenues from sales of our products. Our ability to generate significant revenues will
depend on the successful commercialization of our rhCollagen-based BioInk, VergenixSTR and VergenixFG. In the year ended December
31, 2017, we reported revenues of NIS 1.7 million from the sale of VergenixSTR and VergenixFG in Europe and the sales of rhCollagen-
based BioInk in the United States.
Our revenues are measured at fair value of the consideration received or receivable for the sale of goods in the ordinary course of
business. Revenues are recognized to the extent that it is probable that the economic benefits will flow to us and the revenues can be
reliably measured. Revenues from the sale of products are recognized when all the significant risks and rewards of ownership of the
products have passed to the buyer.
Operating Expenses
Research and Development Expenses
Research and development expenses consist of costs incurred for the development of both of our rhCollagen and our products.
Those expenses include:
● employee-related expenses, including salaries and share-based compensation expenses for employees in research and
development functions;
74
Table of Contents
● expenses incurred in operating our laboratories and small-scale manufacturing facility;
● expenses incurred under agreements with CROs and investigative sites that conduct our clinical trials;
● expenses relating to outsourced and contracted services, such as external laboratories, consulting, and advisory services;
● supply, development, and manufacturing costs relating to clinical trial materials;
● maintenance of facilities, depreciation, and other expenses, which include direct and allocated expenses for rent and insurance;
and
● costs associated with preclinical and clinical activities.
Research and development activities are the primary focus of our business. Products in later stages of clinical development
generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and
duration of later-stage clinical trials. We expect that our research and development expenses will increase in absolute dollars in future
periods as we continue to invest in research and development activities related to the development of our products.
Our total research and development expenses for the years ended December 31, 2017, December 31, 2016 and December 31, 2015
were NIS 16.9 million, NIS 29.2 million and NIS 22.9 million, respectively. The research and development expenditures on our rhCollagen
technology and our products for the years ended December 31, 2017, December 31, 2016 and December 31, 2015 were partly funded in the
amounts of NIS 2.9 million, NIS 12.4 million and NIS 11.0 million, respectively, by Bioventus and government grants. We charge all
research and development expenses to operations as they are incurred.
There are numerous factors associated with the successful commercialization of any of our products, including future trial design
and various regulatory requirements, many of which cannot be determined with accuracy at this time. Additionally, future commercial and
regulatory factors beyond our control will affect our clinical development programs and plans.
Participation in Research and Development Expenses
Our research and development expenses are net of the following participations by third parties.
Participation by the Israel Innovation Authority. We have received grants from IIA part of the research and development
programs for our rhCollagen technology and our products. The requirements and restrictions for such grants are found in the Innovation
Law and the regulations promulgated thereunder. These grants are subject to repayment through future royalty payments on any products
resulting from these research and development programs, including VergenixSTR and VergenixFG. Under the Innovation Law and related
regulations, royalties of 3% - 6% on the income generated from sales of products and from related services developed in whole or in part
under IIA programs are payable to the IIA, up to the total amount of grants received, linked to the U.S. dollar and bearing interest at an
annual rate of LIBOR applicable to U.S. dollar deposits, as published on the first business day of each calendar year. The total gross
amount of grants actually received by us from the IIA as of December 31, 2017, totaled approximately NIS 32.4 million. As of December
31, 2017, we paid non-material royalty amounts to the IIA.
In addition to paying any royalty due, we must abide by other restrictions associated with receiving such grants under the
Innovation Law that continue to apply following repayment to the IIA. These restrictions may impair our ability to outsource
manufacturing or otherwise transfer our know-how outside of Israel and may require us to obtain the approval of the IIA for certain actions
and transactions and pay additional royalties and other amounts to the IIA. For more information, see “Item 3.D. Risk Factors—Risks
Related to Our Financial Condition and Capital Requirements—The IIA grants we have received for research and development
expenditures restrict our ability to manufacture products and transfer know-how outside of Israel and require us to satisfy specified
conditions.” If we fail to comply with the Innovation Law, we may be subject to civil claims and criminal charges.
75
Table of Contents
Research and development grants received from the IIA are recognized upon receipt as a liability if future economic benefits are
expected from the project that will result in royalty-bearing sales. The amount of the liability for the loan is first measured at fair value
using a discount rate that reflects a market rate of interest that reflects the appropriate degree of risks inherent in our business. The change
in the fair value of the liability associated with grants from the IIA is reflected as an increase or decrease in our research and development
expenses for the relevant quarter.
Under applicable accounting rules, the grants from the IIA have been accounted for as an off-set against the related research and
development expenses in our financial statements. Our balance sheet liabilities include obligations regarding royalties that we are obligated
to pay to the IIA based on future sales of our products. As a result, our research and development expenses are shown on our financial
statements net of the IIA grants, and the participation in research and development expenses are shown on our financial statements net of
the provision for IIA royalties. See Note 2G in our consolidated financial statements for the year ended December 31, 2017 for more
information.
Participation by collaborators. In 2011, we entered into a joint development agreement with Pfizer for the development of a
product for the orthopedic market, the Surgical Matrix Carrier, comprised of a growth factor and our rhCollagen, along with other
components. This agreement expired in 2013. From 2013 to 2017, this co-development continued with Bioventus, which acquired the rights
for commercialization of the growth factor from Pfizer and to whom Pfizer assigned certain of its rights and obligations under the 2011
joint development agreement. In March 2017, the co-development with Bioventus terminated.
General, Administrative, and Marketing Expenses
Our general and administrative expenses consist principally of:
● employee-related expenses, including salaries, benefits, and related expenses, including equity-based compensation expenses;
● legal and professional fees for auditors and other consulting expenses not related to research and development activities;
● cost of offices, communication, and office expenses;
● information technology expenses; and
● business development and marketing activities.
We expect that our general, administrative, and marketing expenses will increase in the future as our business expands and we
incur additional general and administrative costs associated with being a public company in the United States, including compliance under
the Sarbanes-Oxley Act and rules promulgated by the SEC. These public company-related increases will likely include costs of additional
personnel, additional legal fees, audit fees, directors’ liability insurance premiums, and costs related to investor relations. We also expect
that our marketing expenses will increase, as we will incur additional marketing costs associated with the commencement of sales, when
and if our products are approved.
Financial Income/Financial Expense
Financial income includes interest income regarding short term deposits and exchange rate differences. Financial expense consists
primarily of exchange rate differences and bank commissions.
76
Table of Contents
Taxes on Income
We do not generate taxable income in Israel, as we have historically incurred operating losses resulting in carry forward tax
losses. As of December 31, 2017, we have incurred operating losses of approximately NIS 10.9 million for CollPlant Holdings Ltd. and
NIS 149 million for CollPlant Ltd. We anticipate that we will be able to carry forward these tax losses indefinitely to future tax years
assuming that we utilize them at the first opportunity. Accordingly, we do not expect to pay taxes in Israel until we have taxable income
after the full utilization of our carry forward tax losses.
The standard corporate tax rate in Israel is 25%. Under the Investment Law, and other Israeli laws, we may be entitled to certain
additional tax benefits, including reduced tax rates, accelerated depreciation, and amortization rates for tax purposes on certain assets and
amortization of other intangible property rights for tax purposes.
A. Operating Results
The table below provides our results of operations for the years ended December 31, 2017, 2016 and 2015.
Year ended December 31,
2015
2016
2017
Statement of comprehensive loss data:
Revenue
Cost of revenue
Gross Profit
Research and development expenses
Participation in research and development expenses
Research and development expenses, net
General, administrative, and marketing expenses
Operating loss
Financial income
Financial expenses
Financial expenses (income), net
Comprehensive loss
(NIS in thousands)
—
—
—
22,919
(11,055)
11,864
6,950
18,814
(215)
51
(164)
18,650
292
—
—
29,200
(12,411)
16,789
11,048
27,545
(93)
441
348
27,893
2017
(Convenience
translation
into
USD in
thousands(1))
1,668
52
1,616
16,921
(2,855)
14,066
8,303
20,753
(253)
380
127
20,880
481
15
466
4,881
(823)
4,058
2,394
5,986
(74)
110
36
6,022
(1)
Calculated using the exchange rate reported by the Bank of Israel for December 31, 2017 at the rate of one U.S. dollar per NIS
3.467.
Revenues
We generated revenues from sale of VergenixFG, VergenixSTR, and our Bioink in the year ended December 31, 2017 of
approximately NIS 1.7 million, compared to NIS 292,000 in the year ended December 31, 2016. During 2015, we did not generate any
revenue. The increase in sales in 2017 is due to initial sales of Bioink in the amount of NIS 689,000 and an increase in the volume of
VergenixFG and VergenixSTR sales activity which is due to a number of factors including the following: (i) sales for the year ended
December 31, 2017 included twelve months of sales activity of VergenixFG and VergenixSTR while the comparable period only included
less than six months for VergenixFG as the first commercial sales commenced in July 2016, and less than one month for VergenixSTR as
the first commercial sales commenced in December 2016 (ii) the number of European territories has expanded from two territories for
Vergenix FG and Vergenix STR combined in the year ended December 31, 2016 to more than ten territories for VergenixFG and
VergenixSTR combined in the year ended December 31, 2017. As the demand for our products has increased, there was no material change
in the average product’s sale prices.
77
Table of Contents
Research and Development Expenses
We incurred research and development expenses of NIS 16.9 million in the year ended December 31, 2017, compared to NIS
29.2 million in the year ended December 31, 2016. The expenses primarily related to the development of our BioInk, VergenixSTR and
VergenixFG, and other development projects. In addition, expenses include development costs related to the Surgical Matrix Carrier
incurred through the end of March 2017. The total decrease in expenses amounting to NIS 12.3 million is primarily due to (i)a decrease in
subcontractors and consumables expenses attributable to a reduction in the amount of NIS 8.0 million in production and product
development cost, and expenses in the amount of NIS 1.8 million related to the Surgical Matrix Carrier, a project that ended in March 2017,
and (ii) a reduction in salaries and amortization of equity-based compensation in the amount of NIS 2.0 million related to a reduction of
development staff costs.
The participation by parties not affiliated with the Company in the research and development expenses was NIS 2.9 million in
2017, compared to NIS 12.4 million in 2016. The decrease in the amount of NIS 9.5 million is mainly due to termination of the
development of the Surgical Matrix Carrier in March 2017, a project that was fully funded by Bioventus.
Research and development expenses increased from NIS 22.9 million in the year ended December 31, 2015 to NIS 29.2 million in
the year ended December 31, 2016. The expenses primarily related to the development of VergenixSTR, VergenixFG and the Surgical
Matrix Carrier. The total increase in expenses amounting to NIS 6.3 million, is primarily due to our product development costs and related
to the production of collagen in the amount of NIS 4.5 million, NIS 1.0 million in salary costs for additional development staff and NIS
400,000 relating to rent of a new production facility.
The participation in the research and development expenses increased from NIS 11.0 million in 2015 to NIS 12.4 million in 2016.
The increase in the amount of NIS 1.4 million is mainly due to the funding of Bioventus of the Surgical Matrix Carrier development.
General, Administrative, and Marketing Expenses
We incurred general, administrative, and marketing expenses of NIS 8.3 million in the year ended December 31, 2017, compared
to NIS 11.0 million in the year ended December 31, 2016. The decrease is primarily attributable to a decrease of NIS 2.7 million related to
costs of our fundraising efforts in the U.S. in 2016.
General, administrative, and marketing expenses increased from NIS 6.9 million in the year ended December 31, 2015, to NIS
11.0 million in the year ended December 31, 2016. The increase is primarily attributable to an increase of NIS 3.0 million related to costs in
relation to our attempted IPO in the U.S. in 2016.
Financial Expenses (Income), Net
Financial expenses, net, totaled NIS 127,000 in the year ended December 31, 2017, compared to financial expense, net of
NIS 348,000 in the year ended December 31, 2016. The decrease in 2017 as compared to the same period in 2016 was due to exchange rate
differences in the U.S. dollar exchange rate against the NIS, where the U.S. dollar exchange rate decreased compared to the NIS, and
affected our U.S. dollar currency cash and cash equivalents and affected our liability for remaining obligations to the IIA.
Financial income, net, totaled NIS 164,000 in the year ended December 31, 2015, compared to financial expense, net of NIS
348,000 in the year ended December 31, 2016. The increase in 2016 as compared to the same period in 2015 was due to exchange rate
differences in the U.S. dollar exchange rate against the NIS, where the U.S. dollar exchange rate decreased compared to the NIS, and
affected our U.S. dollar currency cash and cash equivalents, and the exchange rate differences in the NIS against the Euro, where the NIS
exchange rate decreased against the Euro, and affected our liability for remaining obligations to the IIA.
78
Table of Contents
Significant Accounting Estimates and Judgments
Estimates and judgments are reviewed on an ongoing basis and are based on past experience and other factors, including
expectations of future events, which are considered reasonable in view of current circumstances.
Significant Accounting Estimates
We make estimates and assumptions with respect to the future. By nature, the accounting estimates are rarely identical to actual
results. The estimate that has a significant risk of resulting in a material adjustment to carrying amounts of assets and liabilities in the next
financial year is listed below.
Impairment of In Process Research and Development
We annually review the need to record impairment of in process research and development, or IPR&D. To test for impairment, we
as a whole have been identified as the smallest cash-generating unit to which the intangible asset can be attributed. Accordingly, we
measure our recoverable amount as a whole. The recoverable amount is the higher of value in use and fair value less costs of disposal. In
accordance with IFRS 13, the quoted market price in an active market provides the most reliable evidence of fair value. Since fair value
less costs of disposal, which is based on our market price, is significantly higher than the carrying amount of the cash-generating unit, we
determined that no impairment exists.
Fair value measurement of debentures
We measured the fair value of the debentures based on accepted valuation models and assumptions regarding unobservable inputs
used in the valuation models. See also Note 12 to the financial statements.
Significant Judgments Made When Applying our Accounting Policies
Grants from the IIA
In accordance with the accounting treatment prescribed in Note 2G to our financial statements appearing elsewhere in this annual
report on Form 20-F, our management is required to examine whether there is reasonable assurance that the IIA grant that was received
will be repaid. In addition, if, at the date of initial recognition, the grant is recognized in the statement of comprehensive income (loss),
then in subsequent periods our management is required to evaluate whether it is no longer reasonably assured that royalties will not be paid
to the IIA. In such a case, a liability would be recognized based on our best estimate of the amount required to settle our royalty obligation
to the IIA.
As of December 31, 2017, grants received were recorded against the related research and development expenses in the statement
of comprehensive loss.
As of December 31, 2017, two of our products for the orthobiologics and advanced wound care markets received marketing
clearance in Europe. Following the signing of four distribution agreements and the supply of orders for VergenixFG, and the distribution
agreement signed with Arthrex for VergenixSTR, we believe that, as of December 31, 2017, there is reasonable assurance that NIS 1.2
million of royalties will be paid to the IIA and a liability is included in our financial statements as of December 31, 2017.
Development Costs
Development costs are capitalized in accordance with the accounting policy described in Note 2E(3) to our financial statements
appearing elsewhere in this annual report on Form 20-F. Capitalization of costs is based on management’s judgment about technological
and economic feasibility.
Our management believes that as of December 31, 2017, the above conditions were not met; therefore development costs were not
capitalized.
79
Table of Contents
Recent Accounting Pronouncements
IFRS 9 Financial Instruments
The complete version of IFRS 9 replaces most of the guidance in IAS 39. IFRS 9 retains but simplifies the mixed measurement
model and establishes three primary measurement categories or financial assets: amortized cost, fair value through other comprehensive
income, or OCI, and fair value through profit and loss. The basis of classification depends on the entity’s business model and the
contractual cash flow characteristics of the financial asset. Investments in equity instruments are required to be measured at fair value
through profit or loss with the irrevocable option at inception to present changes in fair value in OCI. There is now a new expected credit
losses model that replaces the incurred loss impairment model used in IAS 39.
For financial liabilities there were no changes to classification and measurement except for the recognition in other comprehensive
income of changes resulting from own credit risk, in liabilities designated at fair value, through profit or loss.
The standard is effective for accounting periods beginning on or after January 1, 2018. Early adoption is permitted. We concluded
that the adoption of the new standard as of its initial application will not have a material effect on our consolidated financial statement.
IFRS 16 Leases
IFRS 16 will replace upon first-time implementation the existing guidance in IAS 17—Leases, or IAS 17. The standard sets out
the principles for the recognition, measurement, presentation, and disclosure of leases, and is expected to have a material impact mainly on
the accounting treatment applied by the lessee in a lease transaction.
IFRS 16 changes the existing guidance in IAS 17 and requires lessees to recognize a lease liability that reflects future lease
payments and a “right-of-use asset” in all lease contracts (except for the following exemption), with no distinction between financing and
capital leases. IFRS 16 exempts lessees in short-term leases or the when underlying asset has a low value.
IFRS 16 changes the definition of a “lease” and the manner of assessing whether a contract contains a lease.
IFRS 16 will be effective retrospectively for annual periods beginning on or after January 1, 2019, taking into account the relief
specified in the transitional provisions of IFRS 16. Under the provisions of IFRS 16, early adoption is permitted only if IFRS 15 has also
been applied. We are assessing the expected impact of IFRS 16 on our financial statements.
IFRS 15 Revenues from Contracts with Customers
IFRS 15 will replace, on its first implementation, the directives on the subject of recognizing revenues existing today under
International Financial Reporting Standards.
The core principle of IFRS 15 is that revenues from contracts with customers must be recognized in a way that reflects the transfer
of control of goods or services supplied to customers in the framework of the contracts by amounts which reflect the proceeds that the
entity expects that it will be entitled to receive for those goods or services.
IFRS 15 sets forth a single model for recognizing revenues, according to which the entity will recognize revenues according to the
said core principle by implementing five stages:
(1) Identifying the contract(s) with the customer.
(2) Identifying the separate performance obligations in the contract.
80
Table of Contents
(3) Determining the transaction price.
(4) Allocating the transaction price to separate performance obligations in the contract.
(5) Recognizing revenue when (or as) each of the performance obligations is satisfied.
We examined the expected effects of the application of IFRS 15 on its consolidated financial statements. We intends to apply
IFRS 15 on the date it becomes effective as from the first quarter of 2018, in accordance with the transitional directive, which allows
recognition of the cumulative effect of the initial application as an adjustment to the opening balance of equity of initial application.
Based on such examination, management concluded that the implementation of IFRS 15 will not have a material effect on its
consolidated financial statements.
JOBS Act
With less than $1.07 billion in revenues during our last fiscal year, we qualify as an emerging growth company under the JOBS
Act. An emerging growth company may take advantage of specified provisions in the JOBS Act that provide exemptions or reductions of
its regulatory burdens related to reporting and other requirements that are otherwise applicable generally to public companies. These
provisions include an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting
pursuant to the Sarbanes-Oxley Act. We may take advantage of some, but not necessarily all, of these provisions to reduce our burdens or
exempt ourselves from regulatory requirements for up to five years or such earlier time that we are no longer deemed an emerging growth
company. We have elected not to avail ourselves of an exemption that allows emerging growth companies to extend the transition period
for complying with new or revised financial accounting standards. This election is irrevocable. We will be an emerging growth company
until the earliest of: (i) the last day of the fiscal year during which we had total annual gross revenues of $1.07 billion or more, (ii) the last
day of the fiscal year following the fifth anniversary of the date of the first sale of the ADSs pursuant to an effective registration statement,
(iii) the date on which we have, during the previous three-year period, issued more than $1 billion in non-convertible debt, or (iv) the date
on which we are deemed a “large accelerated filer” as defined in Regulation S-K under the Securities Act.
B. Liquidity and Capital Resources
To date, we have financed our operations primarily with the net proceeds from private placements and from public offerings of our
securities on the TASE, participation from product development collaborations, and government grants from the IIA.
We believe that based on our current business plan, our existing cash, cash equivalents, together with the net proceeds of our 2018
Security Purchase Agreements and the Alpha Purchase Agreement will be able to maintain our current planned development,
manufacturing and marketing activities and the corresponding level of expenditures for at least the next 12 months, although no assurance
can be given that we will not need additional funds prior to such time. If there are unexpected increases in general, administrative and
marketing expenses or research and development expenses, we may need to seek additional financing.
81
Table of Contents
Cash Flows
The following table summarizes our consolidated statement of cash flows for the years ended December 31, 2015, 2016 and 2017.
Net cash provided by (used in):
Operating activities
Investing activities
Financing activities
Year ended December 31,
2015
2016
2017
(NIS in thousands)
2017
(Convenience
translation
into USD
in
thousands(1))
(14,497)
(1,389)
10,037
(19,357)
(492)
18,486
(17,884)
(447)
32,395
(5,158)
(129)
9,345
(1)
Calculated using the exchange rate reported by the Bank of Israel for December 31, 2017, at the rate of one U.S. dollar per
NIS 3.467.
Net Cash Used in Operating Activities
The use of cash in all periods resulted primarily from our net losses adjusted for non-cash charges and measurements and changes
in components of working capital. Adjustments to net income for non-cash items include depreciation and amortization and share-based
compensation.
Net cash used in operating activities resulted primarily from our net losses adjusted for non-cash charges and measurements and
changes in components of working capital. Adjustments to net loss for non-cash items include depreciation and amortization, equity-based
compensation and exchange differences on cash and cash equivalents. This cash flow mainly reflects the cash needed for funding the
products and pipeline products development and management costs of the Company during the applicable periods.
Net cash used in operating activities in the year ended December 31, 2017 totaled NIS 17.9 million and consisted primarily of (i) a
net loss of NIS 20.9 million, adjusted for non-cash items, including depreciation and amortization of NIS 1.0 million and share based
compensation of NIS 5.0 million, and (ii) a net increase in operating assets and liabilities of NIS 3.1 million, which are mainly attributable
to a decrease in royalties to the IIA liability of NIS 1.0 million, and a decrease in trade payables and long term payable of NIS 2.2 million as
a result of the decrease in our development activity with the Surgical Matrix Carrier.
Net cash used in operating activities in the year ended December 31, 2016 totaled NIS 19.3 million and consisted primarily of a
net loss of NIS 27.9 million, adjusted for non-cash items including depreciation and amortization of NIS 864,000 and share based
compensation of NIS 3.6 million, and a net decrease in operating assets and liabilities of NIS 3.9 million, mainly attributable to an increase
in royalties to the IIA liability of NIS 2.2 million, an increase in trade payables and long term payable of NIS 2.5 million, all as a result of
an increase of our development activity with VergenixSTR and the Surgical Matrix Carrier and an increase in inventory of NIS 487,000.
Net cash used in operating activities in the year ended December 31 2015 totaled NIS 14.5 million and consisted primarily of net
loss of NIS 18.6 million, adjusted for non-cash items including depreciation and amortization of NIS 788,000 and shared-based
compensation of NIS 4.1 million, and a net increase in operating assets and liabilities of NIS 611,000, mainly attributable to an increase in
other receivables of NIS 1.7 million and an increase in trade payables of NIS 854,000 and other payable of NIS 249,000, all as a result of an
increase of our development activity with VergenixSTR and the Surgical Matrix Carrier.
Net Cash Used in Investing Activities
Net cash used in investing activities was NIS 447,000 and NIS 492,000 for the year ended December 31, 2017 and 2016,
respectively, and related primarily to the purchases of property and equipment.
Net cash used in investing activities was NIS 492,000 during the year ended December 31, 2016 and NIS 1.4 million during the
year ended December 31, 2015. The decrease in the amount of approximately NIS 897,000 relates mainly to our investment in equipment
for scaling up our capacity during 2015.
82
Table of Contents
Net Cash Provided by Financing Activities
Net cash provided by financing activities was NIS 32.4 million for the year ended December 31, 2017, compared to NIS 18.5
million in the year ended December 31, 2016. Proceeds generated by 2017 financing includes NIS 6.8 million in return for the issuance of
our ordinary shares and warrants in an equity raise in Israel, NIS 3.6 million for exercise of warrants, and NIS 22.2 million of proceeds
from the issuances of securities under the Alpha Purchase Agreement, the Meitav Purchase Agreement, and the Sagi Purchase Agreement,
and net of NIS 253,000 of payment made for equipment on financing terms. Cash flow from financing activities in the year ended
December 31, 2016 amounted to NIS 18.5 million in return for the issuance of our ordinary shares and warrants in an equity raise in Israel.
Net cash provided by financing activities amounted to approximately NIS 18.5 million for 2016 and NIS 10.0 million in 2015. In
2016, we consummated an equity raise in Israel and raised a net NIS 18.5 million in return for the issuance of our shares and warrants.
Cash flow from financing activities in 2015 amounted to NIS 10.0 million in return for the issuance of our shares and warrants.
Cash and Funding Sources
The table below summarizes our sources of funding for the years ended December 31, 2015, 2016 and 2017:
Issuance of
Ordinary
Shares and
Warrants
Government
Grants and
Strategic
Collaboration
Total
Total
(Convenience
translation
into USD
in
thousands(1))
10,006
9,262
6,083
Year ended December 31, 2017
Year ended December 31, 2016
Year ended December 31, 2015
(NIS in thousands)
2,044
12,411
11,055
32,648
19,702
10,037
34,692
32,113
21,092
(1)
Calculated using the exchange rate reported by the Bank of Israel for December 31, 2017 at the rate of one U.S. dollar per NIS
3.467.
Funding Requirements
We believe that our existing cash and cash equivalents, together with the net proceeds of our 2018 Security Purchase Agreements
will enable us to fund our operating expenses and capital expenditures for at least the next 12 months. We have based this estimate on
assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect.
Our present and future funding requirements will depend on many factors, including, among other things:
● the progress, timing, and completion of preclinical testing and clinical trials in the U.S. for tissues and organs which are based
on our BioInk, VergenixSTR and VergenixFG or any future pipeline product;
● selling and marketing activities undertaken in connection with the commercialization of VergenixSTR and VergenixFG and any
other products;
● the costs of upscaling our manufacturing capabilities;
● costs involved in the development of distribution channels, and for an effective sales and marketing organization, for the
commercialization of our products in Europe;
● the time and costs involved in obtaining regulatory approvals and any delays we may encounter as a result of evolving
regulatory requirements or adverse results with respect to any of these products;
83
Table of Contents
● the number of potential new products we identify and decide to develop; and
● the costs involved in filing patent applications and maintaining and enforcing patents or defending against claims or
infringements raised by third parties.
For more information as to the risks associated with our future funding needs, see “Item 3.D. Risk Factors—We will need to raise
additional funding, which may not be available on acceptable terms, or at all. Failure to obtain additional capital when needed may force us
to delay, limit, or terminate our product development efforts or other operations.”
C. Research and Development, Patents and Licenses
See above, under Item 5A – “Operating Results”.
D. Trend Information
We are in a development stage with regard to different 3D Bioinks and are in early stages of commercialization for VergenixFG
and VergenixSTR in Europe, and our Bioinks for customers that develop technologies for 3D bio-printing of tissues and organs. It is not
possible for us to predict with any degree of accuracy the outcome of our research, development or commercialization efforts. As such, it is
not possible for us to predict with any degree of accuracy any known trends, uncertainties, demands, commitments or events that are
reasonably likely to have a material effect on our net sales or revenues, income from continuing operations, profitability, liquidity or capital
resources, or that would cause reported financial information to not necessarily be indicative of future operating results or financial
condition. However, to the extent possible, certain trends, uncertainties, demands, commitments and events are in this “Operating and
Financial Review and Prospects.”
E. Off-Balance Sheet Arrangements
As of December 31, 2017, we do not have any, and during the periods presented we did not have any, off-balance sheet
arrangements.
F. Contractual Obligations
Our significant contractual obligations as of December 31, 2017 are summarized in the following table.
Payments due by period
Less than
1 year
1 to 2 years 2 to 5 years
(NIS in thousands)
More than
5 years
Total
Operating lease obligations(1)
1,328
639
1,361
296
3,624
(1)
Operating lease obligations consist of payments pursuant to lease agreements for office and laboratory facilities, as well as lease
agreements for five vehicles, which generally run for a period of three years.
Our balance sheet liabilities do not include all of the obligations regarding royalties that we are obligated to pay to the IIA based
on future sales of our products. As of December 31, 2017, our balance sheet liability in amount of NIS 1.2 million includes the liability for
future royalties payable to the IIA where the maximum royalty amount that would be payable by us, before interest, is approximately
NIS 31.7 million (assuming 100% of the royalties are payable). This liability is contingent upon sales of our rhCollagen-based products.
84
Table of Contents
ITEM 6.
DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES
A. Directors and Senior Management
The following table sets forth certain information relating to our directors and senior management. Unless otherwise stated, the
address for our directors and senior management is at the Company’s registered address c/o 3 Sapir Street, Weizmann Science Park,
P.O. Box 4132, Ness-Ziona 74140, Israel.
Name
Age
Position
Senior Management
Yehiel Tal
Prof. Oded Shoseyov
Eran Rotem, CPA
Dr. Ilana Belzer
Dr. Nadav Orr
Dr. Philippe Bensimon
Shomrat Shurtz(1)
Non-Employee Director
David Tsur(8)
Adi Goldin
Dr. Abraham Havron(2)(3)(4)(6)(7)(8)
Dr. Gili Hart(2)(3)(4)(5)(6)(7)(8)
Scott R. Burell(3)(4)(6)(8)
Dr. Elan Penn(2)(3)(4)(5)(6)(7)(8)
65
61
50
58
60
52
51
68
43
70
43
53
66
Chief Executive Officer
Founder, Chief Scientific Officer
Deputy CEO and Chief Financial Officer
Chief Operating Officer
Vice President, Research and Development
Vice President, Regulatory Affairs and Quality Assurance
Vice President, Commercialization
Chairman of the Board and Director
Director
Director
Director
Director
Director
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
Ms. Shurtz’s employment with us ends on March 29, 2018.
Member of the Compensation Committee
Member of the Audit Committee
Member of Financial Statements Committee
External Director under Israeli Law
Independent Director under Israeli Law
Member of the Nominating and Corporate Governance Committee
Independent Director under the Nasdaq Listing Rules
Senior Management
Yehiel Tal has served as our chief executive officer since January 2010. Mr. Tal possesses over 23 years of management
experience in the Israeli and American high-tech and biotechnology industries. Prior to joining us, Mr. Tal was the chief executive officer
and co-founder of Regentis Biomaterials Ltd. Prior to that Mr. Tal served as vice-president of business development at ProChon
BioTech Ltd. He has also served as vice president of marketing and business development at OrthoScan Technologies Ltd. and director of
business development and business unit manager at Kulicke and Soffa Industries, Inc. Mr. Tal holds a Bachelor’s and a Master’s degree in
mechanical engineering from the Technion, Israel Institute of Technology.
Prof. Oded Shoseyov founded our subsidiary CollPlant Ltd. in 2004 and has served as our chief scientific officer since August
2008 and was a member of our board of directors from May 2010 until October 2016. Prof. Shoseyov is a faculty member of the Hebrew
University of Jerusalem. He has extensive experience with plant transformation systems and protein engineering. Prof. Shoseyov has
authored or co-authored over 160 scientific publications and is the inventor or co-inventor of 45 patents. Prof. Shoseyov holds a Ph.D. from
The Hebrew University of Jerusalem, Israel. Prof. Shoseyov received the Outstanding Scientist Polak Award for 2002, the 1999 and 2010
Kay Awards for Innovative and Applied Research, and The 2012 Israel Prime Minister Citation for Entrepreneurship and Innovation. He is
the scientific founder of nine companies, including: SP-Nano Ltd., a nano-biotech company which manufactures SP1-Carbon Nano Tube
coated fabrics for the composite industry; CBD-Technologies/FuturaGene, a forestry agro-biotech company that develops and
commercializes transgenic trees for the pulp and paper and the bio-fuel industry; Melodea Ltd., a nano-biotech company that develops and
manufactures Nano Crystaline Cellulose from sludge for structural foam additives for the paint, printing and packaging industries; and
Valentis Nanotech Ltd., a nanotechnology company that develops and manufactures nano-bio-based transparent films for food packaging
and agriculture.
85
Table of Contents
Eran Rotem has served as our chief financial officer since January 2012 and since November 2017, also as our deputy CEO.
Mr. Rotem possesses more than 20 years of broad financial and operational experience, primarily with biotechnology and industrial
companies. Prior to joining us, Mr. Rotem served as the chief financial officer of Tefron Ltd., an industrial global company traded on both
the Tel Aviv Stock Exchange (TASE:TFRN) and on the OTCBB (OTC:TFRFF) in the United States. Before Tefron, Mr. Rotem served as
chief financial officer of Healthcare Technologies, Ltd. (NASDAQ:HCTL) and Gamida Ltd., a group of companies that specialize in the
development, manufacturing, and marketing of clinical diagnostic test kits, as well as medical equipment and services to the biotechnology
and high-tech industries. Prior to joining Healthcare Technologies, Ltd., Mr. Rotem served as a senior manager at Ernst & Young.
Mr. Rotem holds a Bachelor’s degree in Accounting and Business Administration from the Tel Aviv College of Management and is a
Certified Public Accountant in Israel.
Dr. Ilana Belzer has served as our chief operating officer since October 2015. Prior to joining us, Dr. Belzer served as the chief
operating officer of BioHarvest, an innovative biotechnology company, from October 2012 to September 2015, and prior to that as vice
president of research and development and operations at Procognia Ltd. Prior to that, Dr. Belzer held executive positions in Omrix
Biopharmaceuticals Inc., now part of the Johnson & Johnson family of companies, and InterPharm Laboratories Ltd., now a subsidiary of
Merck-Serono. Dr. Belzer holds an M.Sc., a B.Sc. and a Ph.D. in Microbiology and Cell Biology from Tel Aviv University, Israel.
Dr. Nadav Orr has served as our vice president of research and development since September 2014. Dr. Orr has over 15 years of
experience in research and development, including 12 years in the development of biosurgery products. Prior joining us, Dr. Orr served as
the associate director of research and development at Omrix Biopharmaceuticals Ltd., a subsidiary of Ethicon US LLC, part of the
Johnson & Johnson family of companies. As part of his role at Omrix, Dr. Orr led an international team in the development of hemostatic
combination products and led base business support for production processes and products. Dr. Orr holds a Ph.D. from the Weizmann
Institute of Science, Israel.
Dr. Philippe Bensimon has served as our vice president of quality assurance and clinical affairs since February 2011.
Dr. Bensimon has 25 years of experience in regulatory affairs, quality assurance and clinical affairs in international medical device
companies. Prior to joining us Dr. Bensimon served for 14 years at InterVascular Datascope (now Maquet-Getinge Group), a manufacturer
of long-term cardiovascular implants, as director of regulatory affairs, quality assurance, and clinical affairs. Dr. Bensimon also served for
five years at 3M Medical as manager of regulatory affairs. Dr. Bensimon holds a PharmD degree from the University of Pharmacy,
Marseille, France.
Shomrat Shurtz has served as our Vice President for Commercialization since September 2016. Before that, Ms. Shurtz has
served as Senior Director of Business Development from September 2015. Ms. Shurtz has over 20 years of diverse experience in sales,
marketing, regulatory, and strategy management. Prior to joining us, Ms. Shurtz served as a senior director at Protalix Biotherapeutics Inc.
where she oversaw the company’s lead product through its clinical development, approval, and commercialization. Prior to that, Ms. Shurtz
held executive positions in BBDO Data Pro-Proximity Worldwide, Bank Hapoalim Switzerland Ltd., and Clal Insurance Enterprises
Holdings Ltd. Ms. Shurtz holds an M.Sc. and B.Sc. degree in Biology from Tel Aviv University, Israel.
Non-Employee Directors
David Tsur has served on our board of directors since March 2017 and became chairman in January 2018. Mr. Tsur has served as
Active Deputy Chairman of the board of directors of Kamada Ltd since July 2015 on a part-time basis. Prior to that, Mr. Tsur served as
Kamada Ltd.’s Chief Executive Officer and as a director since its inception in 1990. Prior to co-founding Kamada in 1990, Mr. Tsur served
as Chief Executive Officer of Arad Systems and RAD Chemicals Inc. Mr. Tsur has also held various positions in the Israeli Ministry of
Economy and Industry (formerly named the Ministry of Industry and Trade), including Chief Economist and Commercial Attache in
Argentina and Iran. Mr. Tsur holds a Bachelor of Art degree in Economics and International Relations and an MBA in Business
Management from the Hebrew University in Jerusalem
86
Table of Contents
Adi Goldin has served on our board of directors since May 2010, and from May 2016 to January 2018 acted as our chairman.
Mr. Goldin has over 15 years of experience in the life science, industrial, and technology industries in the areas of investments, business
strategy, deal structure, and company management. For the last 13 years, Mr. Goldin has served as a vice president at Docor
International BV, and has played a key role in investing, managing, and nurturing technology-driven companies and startups in the
information technology, industrial, and life science industries. Mr. Goldin also serves on the board of several portfolio companies of Docor.
Until 2010, Mr. Goldin was the chief executive officer of Softlib Ltd., an information technology company. Previously, Mr. Goldin was VP
of investments and analysis at Inventech Investment Company Ltd. (TASE: IVTC), where he took an active role in building startup
companies and was involved in public offerings, M&A, and various aspects of the capital markets. In addition, Mr. Goldin was part of the
teaching staff of the Executive MBA program run by Tel Aviv University. Mr. Goldin participated in the International Marketing and
Global Consulting Program, a joint project of the University of Pennsylvania’s Wharton Business School and Tel Aviv University’s
Business School. Mr. Goldin is a member of the Israel Bar Association. Mr. Goldin holds Bachelor’s and Master’s degrees in economics,
summa cum laude, and an LL.B. in law from Tel Aviv University, Israel.
Dr. Abraham Havron has served on our board of directors since May 2016. Dr. Havron is a 37-year veteran of the biotechnology
industry. Since 2011, Dr. Havron has been serving a director at Kamada (NASDAQ: KMDA) where he was initially elected as an external
director (within the meaning of the Companies Law) and served in such capacity until January 30, 2017, since which time he has served as
an ordinary (non-external) director. From 2005 to 2013, Dr. Havron has served as the Chief Executive Officer and a director of PROLOR
Biotech Ltd., which in 2013 merged with OPKO Health Inc. Dr. Havron was a member of the founding team and Director of Research and
Development of Interpharm Laboratories Ltd. (a subsidiary of Merck Serono S.A.) from 1980 to 1987. Dr. Havron served as Vice-President
Manufacturing and Process—Development of BioTechnology General Ltd., based in Rehovot, Israel (now, a subsidiary of Ferring
Pharmaceuticals) from 1987 to 1999; and Vice President and Chief Technology Officer of Clal Biotechnology Industries Ltd. from 1999 to
2003. Since 2014, Dr. Havron has also served on the board of directors of MediWound Ltd. (NASDAQ: MDWD) until June 2017 and
Enlivex Theraputics Ltd., a private company. Dr. Havron earned his PhD in Bio-Organic Chemistry from the Weizmann Institute of
Science, and served as a Research Fellow at the Harvard Medical School, Department of Radiology.
Dr. Gili Hart has served on our board of directors since July 2017. Dr. Hart served as the Chief Executive Officer of OPKO
Biologics from 2014 and until 2017. From 2011 to 2014, Dr. Hart served as Vice President of Prolor Biotech Ltd. Dr. Hart serves as a
director in Enlivex Therapeutics and. Dr. Hart holds a B.Sc degree in Biological engineering and an M.Sc degree from the Weizmann
Institute of Science as well as a Ph.D. from the Weizmann Institute of Science.
Scott R. Burell has served on our board of directors since October 2017. From November 2006 until November 2017, Mr. Burell
served as Chief Financial Officer, Secretary and Treasurer of CombiMatrix Corporation (NASDAQ: CBMX). Prior to this, Mr. Burell had
served as CombiMatrix’s Vice President of Finance since November 2001 and as its Controller from February 2001 to November 2001.
From May 1999 to first joining CombiMatrix in February 2001, Mr. Burell was the Controller for Network Commerce, Inc., a publicly
traded technology and information infrastructure company located in Seattle. Prior to this, Mr. Burell spent nine years with Arthur
Andersen’s Audit and Business Advisory practice in Seattle. During his tenure in public accounting, Mr. Burell worked with many clients,
both public and private, in the high-tech and healthcare markets, and was involved in numerous public offerings, spin-offs, mergers and
acquisitions. Mr. Burell is also a member of the Board of Directors of Microbot Medical (NASDAQ: MBOT), an Israeli-based medical
device company specializing in the researching, designing, developing and commercializing of transformational micro-robotics medical
technologies. Mr. Burell obtained his Washington state CPA license in 1992 and is a certified public accountant (currently inactive). He
holds Bachelor of Science degrees in Accounting and Business Finance from Central Washington University.
87
Table of Contents
Dr. Elan Penn has served on our board of directors since January 2018. Dr. Penn has served as chief executive officer and
chairman of Penn Publishing Ltd., a private company based in Tel Aviv, Israel since 2001. From 2000 to 2001, Dr. Penn served as vice
president of finance and administration of A.I. Research and Development Ltd. Dr. Penn served as chief executive officer of Sivan
Computer Training Company Ltd. during the years 1998 through 2000. From 1992 to 2000, Dr. Penn served as vice president of finance
and administration of Mashov Computers Ltd. From 1987 to 1991 and again from 1992 to 1997, Dr. Penn served as vice president of
finance and administration of Magic Software Enterprises Ltd. (NASDAQ: MGIC) and from 2005 to 2014 served as an external director of
Magic Software. Dr. Penn previously served as a director of Telkoor Power Supplies Ltd. (TASE: TLCR) and Nexgen Biofuels Ltd.
(formerly Healthcare Technologies Ltd) (OTC: NXGN). Dr. Penn holds a B.A. degree in Economics from the Hebrew University of
Jerusalem and a Ph.D. in Management Science from the University of London.
Adi Goldin and Dr. Havron are also board members of CollPlant Ltd., our wholly owned subsidiary.
Advisory Boards
We have established a scientific advisory board and a clinical advisory board. The members of our advisory boards are appointed
by our chief executive officer after consultation with our board of directors. Once nominated, the members of our advisory boards sign a
standard letter of engagement. Most of the members of our advisory boards are not appointed for a specific term and their position may be
terminated by either us or the member of the advisory board according to standard notice periods. With the exception of Prof. Hershko,
who is our employee, the members of our advisory boards are all paid either daily or hourly fees for their services and are entitled to the
reimbursement of their expenses. Furthermore, several of the members of our advisory boards have been granted options due to their
strategic role and years of service. The members of our advisory boards are as follows:
Scientific Advisory Board
Prof. Avraham Hershko
Prof. Vicki Rosen
Prof. Abhay Pandit
Prof. Ofer Levy, MD, MCh (Orth)
Joseph M. Lane, MD
Clinical Advisory Board
Prof. Ofer Levy, MD, MCh (Orth)
Joseph M. Lane, MD
Scott Rodeo, MD
Thomas Serena, MD
Gabi Agar, MD
B. Compensation
Compensation of Senior Management and Directors
The following table presents in the aggregate all compensation we paid to all of our senior management and directors as a group
for the year ended December 31, 2017. The table does not include any amounts we paid to reimburse any of such persons for costs incurred
in providing us with services during this period.
Salaries, fees,
commissions, and
bonuses(1)(2)
(thousand NIS)
Salaries, fees,
commissions, and
bonuses(1)(2)(4)
(thousand USD)
Value of
Options
Granted(3)
(thousand NIS)
Value of
Options
Granted(3)(4)
(thousand USD)
All senior management and directors as a group, consisting
of 16 persons
5,532
1,595
1,785
515
(1)
Salary includes cost of salary to the Company and ancillary benefits such as payments to the National Insurance Institute, advanced
education funds, managers’ insurance and pension funds; vacation pay; recuperations pay as mandated by Israeli law.
88
Table of Contents
(2)
(3)
(4)
Consists of bonus for the year ended December 31, 2017 that was paid in 2018.
Consists of amounts recognized as share-based compensation expense for the year ended December 31, 2017. Assumptions and key
variables used in the calculation of such amounts are discussed in Note 14 of our financial statements.
Calculated using the exchange rate reported by the Bank of Israel for December 31, 2017, at the rate of one U.S. dollar per NIS
3.467.
In accordance with the Companies Law, the following table presents information regarding compensation of our five most highly
paid office holders, namely our chief executive officer, chief financial officer, vice president regulatory affairs and quality assurance, vice
president research and development and chief scientific officer, during the year ended December 31, 2017.
Name and Position
Yehiel Tal, CEO
Eran Rotem, Deputy CEO and CFO
Philippe Bensimon, VP Reg. Affairs &
QA
Nadav Orr, VP R&D
Oded Shoseyov, CSO
Salary(1)
(thousand
NIS)
Bonus(2)
(thousand
NIS)
Consulting
Fees
(thousand
NIS)
Value of
Options
Granted(3)
(thousand
NIS)
Total
(thousand
NIS)
858
776
709
708
—
220
182
88
—
—
—
—
—
—
384
455
109
52
43
780
Total
(thousand
US dollar)(4)
442
308
1,533
1,067
849
751
1,164
245
216
336
(1)
(2)
(3)
(4)
Salary includes cost of salary to the Company and ancillary benefits such as payments to the National Insurance Institute, advanced
education funds, managers’ insurance and pension funds; vacation pay; recuperations pay as mandated by Israeli law.
Consists of bonus for the year ended December 31, 2017 that was paid in 2018.
Consists of amounts recognized as share-based compensation expense for the year ended December 31, 2017. Assumptions and key
variables used in the calculation of such amounts are discussed in Note 14 of our financial statements.
Calculated using the exchange rate reported by the Bank of Israel for December 31, 2017, at the rate of one U.S. dollar per NIS
3.467.
Compensation of Directors
Under the Companies Law and the rules and regulations promulgated thereunder, external directors are generally entitled to fixed
annual compensation and an additional payment for each meeting attended. We currently pay our directors an annual fee of NIS 29,000 and
a per meeting fee of NIS 1,800.
During 2017, we granted David Tsur 486,000 options to purchase 486,000 ordinary shares in two tranches. 221,000 options were
granted without an exercise price and vested immediately on the grant date and 265,000 options at an exercise price per option of NIS 0.33
($0.09). The options vest subject to a vesting period of four years, with a quarter of the options vesting on the first anniversary of the grant
date, and the remaining options vesting in equal parts at the end of every quarter thereafter.
In January 2018, we granted David Tsur, Dr. Elan Penn, Dr. Gili Hart, Dr. Abraham Havron and Scott Burell 500,000 options to
purchase 500,000 ordinary shares each and Adi Goldin 650,000 options to purchase 650,000 ordinary shares, each at an exercise price per
option of NIS 0.58 ($0.16). The options vest subject to a vesting period of four years, with a quarter of the options vesting on the first
anniversary of the grant date, and the remaining options vesting in equal parts at the end of every quarter thereafter.
89
Table of Contents
Employment and Services Agreements with Senior Management
Yehiel Tal
Mr. Tal has been our chief executive officer since January 2010. Mr. Tal’s current gross monthly salary is NIS 65,000. In addition,
Mr. Tal is entitled to social benefits, such as paid annual vacation days, severance pay, annual recreation allowance, manager’s insurance,
sick leave, education fund and expenses reimbursement. In addition, we provide Mr. Tal with a leased company car and a mobile phone.
Mr. Tal’s employment agreement is terminable by either us or Mr. Tal upon 90 days’ prior written notice other than in the case of a
termination for cause. Mr. Tal’s employment agreement contains a non-compete obligation for a period of 12 months following termination
of his employment, and customary provisions regarding confidentiality of information, and assignment of inventions. The agreement does
not provide for benefits upon the termination of employment, other than payment of salary and benefits during the required notice period.
Mr. Tal’s agreement also provides for annual bonus payments based upon criteria determined by the board of directors, as well as special
bonuses which may be payable upon the achievement of specified milestones, such as the execution of an income-generating commercial
agreement or consummation of an initial public offering (subject to the satisfaction of certain conditions). Mr. Tal’s bonus for the year
2017 was based on Mr. Tal’s achievement of objectives which includes business development and positioning of 3D BioInk as the
Company's growth engine, the development of potential cooperative ventures with international pharma and medical equipment companies,
and the planning and execution the Company’s reorganization plan. As of March 15, 2018, Mr. Tal held 1,505,875 ordinary shares and
9,573,041 options to purchase 5,691,014 ordinary shares at a weighted average exercise price of NIS 0.45, of which 4,051,166 options are
fully vested and 1,771,875 options will vest over a period of three years from May 19, 2016, in equal parts at the end of every quarter
thereafter and 3,750,000 options will vest over a period of four years, with a quarter of the options vesting on January 14, 2019, and the
remaining options vesting in equal parts at the end of every quarter thereafter.
Eran Rotem
Mr. Rotem has served as our chief financial officer since January 2012 and since November 2017, also as our deputy chief
executive officer. Mr. Rotem’s current gross monthly salary is NIS 54,000. In addition, Mr. Rotem is entitled to social benefits, such as
paid annual vacation days, severance pay, annual recreation allowance, manager’s insurance, sick leave, education fund and expenses
reimbursement. In addition, we provide Mr. Rotem with a leased company car and a mobile phone. Mr. Rotem’s employment agreement is
terminable by either us or Mr. Rotem upon 90 days’ prior written notice. Mr. Rotem’s employment agreement contains a non-compete
obligation for a period of 12 months following termination of his employment and customary provisions regarding confidentiality of
information and assignment of inventions. Mr. Rotem’s employment agreement also provides for a grant of options to purchase up to
150,000 ordinary shares under the 2010 Plan, which will vest subject to certain conditions. The agreement does not provide for benefits
upon the termination of employment, other than payment of salary and benefits during the required notice period. Mr. Rotem’s agreement
also provides for annual bonus equal to up to two months’ salary based upon successful achievement of objectives determined by our chief
executive officer and in accordance with our compensation policy, within three months from the beginning of each calendar year and
approval of our board of directors. Mr. Rotem’s bonus for the year 2017 was based on Mr. Rotem’s achievement of objectives which
includes planning and execution of 2017 fundraising rounds, and the planning and execution the Company’s reorganization plan. As of
March 20, 2018, Mr. Rotem held 5,826,607 options to purchase 3,442,202 ordinary shares at a weighted average exercise price of NIS 0.59,
of which 2,639,107 options are fully vested, and 937,500 options will vest over a period of three years from May 19, 2016, in equal parts at
the end of every quarter thereafter and 2,250,000 options will vest over a period of four years, with a quarter of the options vesting on
December 26, 2018, and the remaining options vesting in equal parts at the end of every quarter thereafter.
90
Table of Contents
Prof. Oded Shoseyov
Prof. Shoseyov founded our subsidiary CollPlant Ltd. in 2004 and has been our chief scientific officer since August 2008. We
entered into written consulting and option agreements with Prof. Shoseyov and is currently paid a monthly service fee of NIS 32,000
including VAT. Prof. Shoseyov’s consulting agreement creates an independent contractor relationship between us and therefore does not
provide for severance or other employment related benefits. Prof. Shoseyov’s agreement is terminable by either us or Prof. Shoseyov upon
90 days’ prior written notice other than in the case of a termination for cause. Under the provisions of the services agreement we have
complete ownership in any invention which is derived from our operations and businesses as well as first rights (for the development and
commercialization) in any invention that is not our invention and that may be a result of Prof. Shoseyov’s activity in the course of providing
the services with the exceptions of specific inventions defined in the agreement. The services agreement sets a non-compete obligation for
a period of two years following the later of the termination of the services agreement, disposal of all of our securities held by Prof.
Shoseyov, the termination of Prof. Shoseyov’s membership in our board of directors or termination of any other of Prof. Shoseyov’s
engagement with us, and further provisions regarding confidentiality. As of March 15, 2018, Prof. Shoseyov held 2,737,573 ordinary
shares and 13,373,722 options to purchase 5,124,574 ordinary shares at a weighted average exercise price of NIS 0.61, of which 7,873,722
options are fully vested and 4,500,000 options will vest over a period of five years from September 22, 2016, in equal parts at the end of
every quarter thereafter and 1,000,000 options will vest over a period of four years, with a quarter of the options vesting on December 26,
2018, and the remaining options vesting in equal parts at the end of every quarter thereafter.
Dr. Philippe Bensimon
Dr. Bensimon has served as our vice president of regulatory affairs quality assurance and clinical affairs since February 2011.
Dr. Bensimon is entitled to a monthly gross salary of NIS 44,000, and to social benefits, such as paid annual vacation days, severance pay,
annual recreation allowance, manager’s insurance, sick leave, education fund and expenses reimbursement. In addition, we provide
Dr. Bensimon with a leased company car and a mobile phone. Dr. Bensimon’s employment agreement is terminable by either us or
Dr. Bensimon upon 60 days’ prior written notice other than in the case of a termination for cause. Dr. Bensimon’s employment agreement
contains a non-compete obligation for a period of 12 months following termination of his employment and customary provisions regarding
confidentiality of information and assignment of inventions. Dr. Bensimon’s employment agreement also provides for a grant of options to
purchase up to 66,667 ordinary shares under the 2010 Plan, which will vest subject to certain conditions. The agreement does not provide
for benefits upon the termination of employment, other than payment of salary and benefits during the required notice period.
Dr. Bensimon’s agreement also provides for annual bonus payments based upon successful achievement of objectives determined each year
by our chief executive officer and in accordance with our compensation policy and approval of our board of directors. Dr. Bensimon’s
bonus for the year 2017 was based on Dr. Bensimon’s achievement of objectives which includes product regulation process, and planning
and execution of the post marketing surveillance studies in Europe, with regards to the Company’s products. As of March 15, 2018,
Dr. Bensimon held 2,600,000 options to purchase 1,366,667 ordinary shares at a weighted exercise price of NIS 0.64, of which 1,428,125
options are fully vested, and 421,875 options will vest over a period of three years from May 19, 2016, in equal parts at the end of every
quarter thereafter and 750,000 options will vest over a period of four years, with a quarter of the options vesting on December 26, 2018, and
the remaining options vesting in equal parts at the end of every quarter thereafter.
Dr. Ilana Belzer
Dr. Belzer has served as our chief operating officer since October 2015. Dr. Belzer is entitled to a monthly gross salary of NIS
43,000, and to social benefits, such as paid annual vacation days, severance pay, annual recreation allowance, manager’s insurance, sick
leave, education fund and expenses reimbursement. In addition, we provide Dr. Belzer with a leased company car and a mobile phone.
Dr. Belzer’s employment agreement is terminable by either us or Dr. Belzer upon 60 days’ prior written notice. Dr. Belzer’s employment
agreement contains a non-compete obligation for a period of six months following termination of her employment and customary
provisions regarding confidentiality of information and assignment of inventions. The agreement does not provide for benefits upon the
termination of employment, other than payment of salary and benefits during the required notice period. Dr. Belzer’s agreement also
provides for an annual bonus, payable within three months from the beginning of each calendar year, equal to up to two months’ salary
based upon the successful achievement of objectives determined by our chief executive officer and in accordance with our compensation
policy, subject to approval of our board of directors. As of March 15, 2018, Dr. Belzer held 1,450,000 options to purchase 983,333 ordinary
shares at a weighted exercise price of NIS 0.59, of which 437,500 options are fully vested and 262,500 options will vest over a period of
three years from August 31, 2016, in equal parts at the end of every quarter thereafter and 750,000 options will vest over a period of four
years, with a quarter of the options vesting on December 26, 2018, and the remaining options vesting in equal parts at the end of every
quarter thereafter.
91
Table of Contents
Dr. Nadav Orr
Dr. Orr has served as our vice president of research and development since September 2014. Dr. Orr is entitled to a monthly gross
salary of NIS 40,000, and to social benefits, such as paid annual vacation days, severance pay, annual recreation allowance, manager’s
insurance, sick leave, education fund and expenses reimbursement. In addition, we provide Dr. Orr with a leased company car and a mobile
phone. Dr. Orr’s employment agreement is terminable by either us or Dr. Orr upon 90 days’ prior written notice. Dr. Orr’s employment
agreement contains a non-compete obligation for a period of six months following termination of his employment and customary
provisions regarding confidentiality of information and assignment of inventions. Dr. Orr’s employment agreement also provides for a
grant of options to purchase up to 133,333 ordinary shares under the 2010 Plan, which will vest subject to certain conditions. The
agreement does not provide for benefits upon the termination of employment, other than payment of salary and benefits during the required
notice period. Dr. Orr’s agreement also provides for annual bonus equal to up to two months’ salary based upon successful achievement of
objectives determined by our chief executive officer and in accordance with our compensation policy, within three months from the
beginning of each calendar year and approval of our board of directors. As of March 15, 2018, Dr. Orr held 2,150,000 options to purchase
1,216,667 ordinary shares at a weighted average exercise price of NIS 0.53, of which 1,037,500 options are fully vested, 50,000 options
will vest subject to a vesting period that ends in September 2018, and 312,500 options will vest over a period of the next three years from
May 19, 2016, in equal parts at the end of every quarter thereafter and 750,000 options will vest over a period of four years, with a quarter
of the options vesting on December 26, 2018, and the remaining options vesting in equal parts at the end of every quarter thereafter.
Shomrat Shurtz
Ms. Shurtz has served as our vice president for commercialization since September 2016 and her employment with us ends on
March 29, 2018. Prior to her current position, Ms. Shurtz was senior director of business development from September 2015. Ms. Shurtz is
entitled to a monthly gross salary of NIS 38,000, and to social benefits, such as paid annual vacation days, severance pay, annual recreation
allowance, manager’s insurance, sick leave, education fund and expenses reimbursement. In addition, we provide Ms. Shurtz with a leased
company car and a mobile phone. Ms. Shurtz’s employment agreement is terminable by either us or Ms. Shurtz upon 60 days’ prior written
notice. Ms. Shurtz’s employment agreement contains a non-compete obligation for a period of six months following termination of her
employment and customary provisions regarding confidentiality of information and assignment of inventions. The agreement does not
provide for benefits upon the termination of employment, other than payment of salary and benefits during the required notice period.
Ms. Shurtz’s agreement also provides for an annual bonus, payable within three months from the beginning of each calendar year, equal to
up to two months’ salary based upon the successful achievement of objectives determined by our chief executive officer and in accordance
with our compensation policy, subject to approval of our board of directors. As of March 15, 2018, Ms. Shurtz held 600,000 options to
purchase 200,000 ordinary shares at a weighted average exercise price of NIS 0.6, of which 375,000 options are fully vested, and 225,000
options will vest over a period of three years from August 31, 2016, in equal parts at the end of every quarter thereafter.
The term “cause” in all of our employment and services agreements means a breach by the employee/consultant of any of the
material terms or conditions of his employment agreement, or any other agreement between him and us, employee/consultant’s willful
misconduct, or action of personal dishonesty, bad faith, or breach of trust towards us or any of our subsidiaries and/or affiliates, the
commission by the employee/consultant of a criminal offense, or fraud against us and/or any of our subsidiaries and/or affiliates or in cases
of employees only, circumstances that would otherwise deny the employee of the severance payments due to him under applicable law.
In addition, we have entered into compensation agreements with certain of our directors. The amounts payable pursuant to these
arrangements have been approved by our board of directors and shareholders.
The Companies Law generally requires directors’ compensation to be approved by the compensation committee, then by the
board of directors, and finally by the shareholders. Under our Compensation Policy, the compensation of our directors may be fixed, as an
annual all-inclusive payment or as payment for participation in meetings, or as a combination thereof, and may also include equity-based
compensation. Compensation to directors may include, subject to approvals required by the Companies Law: (i) in the case of a director
who is also an officer or a service provider, a salary or other compensation with respect to his or her work as an officer or services as a
service provider, as may be agreed upon by the director and us; and (ii) reimbursement of expenses, including travel expenses, expended in
connection with his or her duties as a member of the board of directors. To date, our external directors and independent directors have
received annual participation fees, and all of our directors (except for external directors) have been granted options as part of our 2010
Plan.
92
Table of Contents
C. Board Practices
Board of Directors
Under the Companies Law, the overseeing of the management of our business is vested in our board of directors. Our board of
directors may exercise all powers and may take all actions that are not specifically granted to our shareholders or to management. Our
officers are responsible for our day-to-day management and have individual responsibilities established by our board of directors and
specified in their specific employment agreements. Our chief executive officer is appointed by, and serves at the discretion of, our board of
directors, subject to the employment agreement that we have entered into with him. All other officers are appointed by our chief executive
officer with the prior review of our board of directors and compensation committee, and are subject to the terms of any applicable
employment agreements that we may enter into with them.
Under our articles of association, our board of directors must consist of at least three and not more than twelve directors, including
at least two external directors. Currently our board of directors consists of six directors, including two external directors. Other than
external directors, for whom special election requirements apply under the Companies Law, as detailed below, our articles of association
provide that directors (other than external directors) are elected annually at the general meeting of our shareholders by a vote of the holders
of a majority of the voting power present and voting, in person or by proxy, at that meeting.
We have three types of directors: independent directors, external directors (who are also independent in nature), and “regular”
directors. For purposes of complying with the Nasdaq Listing Rules to list the Company’s ADSs on The Nasdaq Capital Market, our board
of directors will be comprised of five independent directors (of which two are external directors).
Our board of directors has determined that with the exception of Adi Goldin, all of our directors are independent under such rules.
The definition of “independent director” under the Nasdaq Listing Rules and “external director” under the Companies Law overlap to a
significant degree such that we would generally expect the two directors serving as external directors to satisfy the requirements to be
independent under the Nasdaq Listing Rules. The definition of external director under the Companies Law includes a set of statutory
criteria that must be satisfied, including criteria whose aim is to ensure that there is no factor that would impair the ability of the external
director to exercise independent judgment. The definition of independent director under Nasdaq Listing Rules specifies similar, if slightly
less stringent, requirements in addition to the requirement that the board of directors consider any factor which would impair the ability of
the independent director to exercise independent judgment. See “—External Directors” below for a description of the requirements under
the Companies Law for a director to serve as an external director.
Under the Companies Law any shareholder holding at least 1% of our outstanding voting power may propose to nominate one or
more persons for election as directors at a general meeting by delivering a written notice of such shareholder’s intent to make such
nomination or nominations to our registered office. Each such notice must set forth all of the details and information as required to be
provided by our amended and restated articles of association and regulations promulgated under the Companies law.
In addition, our articles of association allow our board of directors to appoint additional director or directors who shall remain in
office until the next annual shareholders’ meeting, provided that the board of directors must consist of no more than 12 directors. In
addition, our articles of association allow our board of directors to appoint alternate directors to fill vacancies on our board of directors, for
a term of office equal to the remaining period of the term of office of the director(s) whose office(s) have been vacated.
93
Table of Contents
Under the Companies Law, our board of directors must determine the minimum number of directors who are required to have
accounting and financial expertise. See “—External Directors” below. In determining the number of directors required to have such
expertise, our board of directors must consider, among other things, the type and size of the company and the scope and complexity of its
operations. Our board of directors has determined that the minimum number of directors who are required to have accounting and financial
expertise is one.
External Directors
Under the Companies Law, a public company is required to have at least two directors who qualify as external directors.
Regulations promulgated under the Companies Law further provide relief for Israeli companies whose shares are listed on certain stock
exchanges outside of Israel (including The Nasdaq Capital Market) with no controlling shareholder, such as ourselves, exempting such
companies from being required to appoint external directors so long as such companies satisfy the requirements of the foreign laws in the
listing jurisdiction outside of Israel which apply to companies incorporated in such jurisdiction, in respect of the appointment of
independent directors and the composition of the audit committee and compensation committee. We presently have two external directors
on our board of directors, but we may elect in the future to rely on such exemption available to such dual-listed and foreign listed
companies with no controlling shareholder. The appointment of our external directors was made by a resolution of the general meeting of
our shareholders, and our external directors are Dr. Gili Hart and Dr. Elan Penn.
The Companies Law provides that external directors must be elected by a majority vote of the shares present and voting at a
shareholders’ meeting, provided that either:
● such majority includes at least a majority of the shares held by all shareholders who are not controlling shareholders and do not
have a personal interest in the election of the external director (other than a personal interest not deriving from a relationship
with a controlling shareholder) that are voted at the meeting, excluding abstentions, to which we refer as a disinterested
majority; or
● the total number of shares voted against the election of the external director by non-controlling shareholders and by
shareholders who do not have a personal interest in the election of the external director (other than a personal interest not
deriving from a relationship with a controlling shareholder) does not exceed 2% of the aggregate voting rights in the company.
Under the Companies Law, the term “controlling shareholder” means a shareholder with the ability to direct the activities of the
company, other than by virtue of serving as an office holder. A shareholder is presumed to be a controlling shareholder if the shareholder
holds 50% or more of the voting rights in a company or has the right to appoint the more than half of the directors of the company or its
general manager. For the purpose of approving transactions with controlling shareholders, a controlling shareholder is deemed to include
any shareholder that holds 25% or more of the voting rights in a public company if no other shareholder holds more than 50% of the voting
rights in the company. For purposes of determining the holding percentage stated above, two or more shareholders who have a personal
interest in a transaction that is brought for the company’s approval are deemed as joint holders.
Under the Companies Law, the initial term of an external director is three years. Thereafter, an external director may be reelected
to serve in that capacity for no more than two additional three-year terms, provided that either (i) his or her service for each such additional
term is recommended by one or more shareholders holding at least 1% of the company’s voting rights and is approved at a shareholders’
meeting by a disinterested majority, where the total number of shares held by non-controlling, disinterested shareholders voting for such
reelection exceeds 2% of the aggregate voting rights in the company, provided that the nominating shareholder, the external director, and
certain of their related parties meet additional independence requirements; (ii) his or her service for each such additional term is
recommended by the board of directors and is approved at a shareholders’ meeting by the same majority required for the initial election of
an external director (as described above); or (iii) the external director has recommended that he or she be nominated for each such
additional term and such nomination is approved at a shareholders’ meeting by the same majority and under the same criteria required as if
he had been recommended by a shareholder.
94
Table of Contents
The term of office for external directors for companies traded on certain foreign stock exchanges, including The Nasdaq Capital
Market, may be further extended, in increments of additional three-year terms provided that, in addition to reelection in such manner
described above, (i) the audit committee and subsequently the board of directors of the company confirm that, in light of the external
director’s expertise and special contribution to the work of the board of directors and its committees, the reelection for such additional
period is beneficial to the company, and provided that (ii) the external director is reelected subject to the same shareholder vote
requirements as if elected for the first time (as described above). Prior to the approval of the reelection of the external director at a general
shareholders’ meeting, the company’s shareholders must be informed of the term previously served by him or her and of the reasons why
the board of directors and audit committee recommended the extension of his or her term.
External directors may be removed from office by an extraordinary general meeting of shareholders called by the board of
directors, which approves such dismissal by the same shareholder vote percentage required for their election or by a court, in each case,
only under limited circumstances, including ceasing to meet the statutory qualifications for appointment, or violating their duty of loyalty to
the company. If an external directorship becomes vacant and there are fewer than two external directors on the board of directors at the
time, then the board of directors is required under the Companies Law to call a shareholders’ meeting as soon as possible to appoint a
replacement external director.
Each committee of the board of directors that exercises the powers of the board of directors must include at least one external
director. The audit committee and the compensation committee must include all external directors then serving on the board of directors
and should be comprised of a majority of independent directors, the external directors must be the majority of the members of the
compensation committee, and the audit and compensation committee’s chairman must be an external director. See “—Committees of the
Board of Directors” below. Under the Companies Law, external directors of a company and all members of the compensation committee
are prohibited from receiving, directly or indirectly, any compensation for their services, other than for their services as external directors
pursuant to the Companies Law and the regulations promulgated thereunder. Compensation of an external director is determined prior to his
or her appointment and may not be changed during his or her term subject to certain exceptions. Under the regulations pursuant to the
Companies Law, certain exemptions and reliefs are granted to companies which securities are traded outside of Israel. We may use those
exemptions and reliefs in the future.
The Companies Law provides that a person is not qualified to serve as an external director if (i) the person is a relative of a
controlling shareholder of the company or (ii) if that person or his or her relative, partner, employer, another person to whom he or she was
directly or indirectly subject, or any entity under the person’s control, has or had, during the two years preceding the date of appointment as
an external director: (a) any affiliation or other disqualifying relationship with the company, with any person or entity controlling the
company or a relative of such person, or with any entity controlled by or under common control with the company; or (b) in the case of a
company with no shareholder holding 25% or more of its voting rights, had at the date of appointment as external director, any affiliation or
other disqualifying relationship with a person then serving as chairman of the board or chief executive officer, a holder of 5% or more of
the issued share capital or voting power in the company, or the most senior financial officer.
The term “relative” is defined under the Companies Law as a spouse, sibling, parent, grandparent, or descendant; spouse’s sibling,
parent, or descendant; and the spouse of each of the foregoing persons. Under the Companies Law, the term “affiliation” and the similar
types of prohibited relationships include (subject to certain exceptions):
● an employment relationship;
● a business or professional relationship even if not maintained on a regular basis (excluding insignificant relationships);
● control; and
95
Table of Contents
● service as an office holder, excluding service as a director in a private company prior to the initial public offering of its shares if
such director were appointed as a director of the private company in order to serve as an external director following the initial
public offering.
The term office holder is defined under the Companies Law as the general manager, chief executive officer, chief business
manager, deputy general manager, vice general manager, any other person assuming the responsibilities of any of these positions regardless
of that person’s title, and a director, or a manager directly subordinate to the general manager.
In general, the external directors must be of Israeli residency (unless the company on which he or she serves, had offered shares
(or bonds) to the public outside of Israel or are registered on a stock exchange outside of Israel) and must possess the minimal criteria
required for the directorship of a “regular” director. In addition, no person may serve as an external director if that person’s position or
professional or other activities create, or may create, a conflict of interest with that person’s responsibilities as a director or otherwise
interfere with that person’s ability to serve as an external director or if the person is an employee of the ISA or of an Israeli stock exchange.
A person may furthermore not continue to serve as an external director if he or she received direct or indirect compensation from the
company including amounts paid pursuant to indemnification or exculpation contracts or commitments and insurance coverage for his or
her service as an external director, other than as permitted by the Companies Law and the regulations promulgated thereunder.
For a period of two years from the date that an external director of a company ceases to act in such capacity, the company in which
such external director served, and its controlling shareholder or any entity under control of such controlling shareholder may not, directly or
indirectly, grant such former external director, or his or her spouse or child, any benefit, including via (i) the appointment of such former
director or his or her spouse or his child as an officer in the company or in an entity controlled by the company’s controlling shareholder,
(ii) the employment of such former external director and (iii) the engagement, directly or indirectly, of such former external director as a
provider of professional services for compensation, including via an entity under his or her control. With respect to a relative who is not a
spouse or a child, such limitations shall only apply for one year from the date such external director ceased to be engaged in such capacity.
If, at the time at which an external director is appointed, all members of the board of directors, who are not controlling
shareholders or relatives of controlling shareholders of the company are of the same gender, the external director to be appointed must be
of the other gender. A director of one company may not be appointed as an external director of another company if a director of the other
company is acting as an external director of the first company at such time.
According to the Companies Law, a person may be appointed as an external director only if he or she has professional
qualifications or if he or she has accounting and financial expertise (each, as defined below). In addition, at least one of the external
directors must be determined by our board of directors to have accounting and financial expertise.
According to regulations promulgated under the Companies Law a director with accounting and financial expertise is a director
who, due to his or her education, experience, and skills, possesses an expertise in, and an understanding of, financial and accounting matters
and financial statements, such that he or she is able to understand the financial statements of the company and initiate a discussion about
the presentation of financial data. A director is deemed to have professional qualifications if he or she has: (i) an academic degree in
economics, business management, accounting, law, or public administration; (ii) an academic degree or has completed other higher
education, in the primary field of business of the company or a field which is relevant to his or her position in the company; or (iii) at least
five years of experience serving in one of the following capacities, or at least five years cumulative experience serving in two or more of
the following capacities: (a) a senior business management position in a company with a significant volume of business; (b) a senior
position in a company’s primary field of business; or (c) a senior position in public administration or service. The board of directors is
charged with determining whether a director possesses financial and accounting expertise or professional qualifications.
96
Table of Contents
Role of Board of Directors in Risk Oversight Process
Risk assessment and oversight are an integral part of our governance and management processes. Our board of directors
encourages management to promote a culture that incorporates risk management into our corporate strategy and day-to-day business
operations. Management discusses strategic and operational risks at regular management meetings, and conducts specific strategic planning
and review sessions during the year that include a focused discussion and analysis of the risks facing us. Throughout the year, senior
management reviews these risks with the board of directors at regular board meetings as part of management presentations that focus on
particular business functions, operations or strategies, and presents the steps taken by management to mitigate or eliminate such risks.
Leadership Structure of the Board of Directors
In accordance with the Companies Law and our articles of association, our board of directors is required to appoint one of its
members to serve as chairman of the board of directors. Our board of directors has appointed David Tsur to serve as chairman of the board
of directors.
Committees of the Board of Directors
Currently, our board of directors has three permanent committees: an audit committee, a compensation committee, and a financial
statements committee. The first two committees are mandatory and regulated under the Companies Law provisions. A nominating and
corporate governance committee has been constituted.
Audit Committee
Under the Companies Law, we are required to appoint an audit committee. The audit committee of a public company must be
comprised of at least three directors, including all of the external directors, one of whom must serve as chairman of the committee. The
audit committee may not include the chairman of the board, any director employed by or otherwise providing services on a regular basis to
the company, to a controlling shareholder or to any entity controlled by a controlling shareholder, any director who derives most of his or
her income from a controlling shareholder, nor a controlling shareholder or a relative thereof.
In addition, under the Companies Law, the audit committee of a publicly traded company must consist of a majority of
independent directors. In general, an “independent director” under the Companies Law is defined as either an external director or as a
director who meets the following criteria:
● he or she meets the qualifications for being appointed as an external director and the audit committee has approved that he or
she meets such qualifications, except for the requirement (i) that the director be an Israeli resident (which does not apply to
companies such as ours whose securities have been offered outside of Israel to date or are listed outside of Israel) and (ii) for
accounting and financial expertise or professional qualifications; and
● he or she has not served as a director of the company for a period exceeding nine consecutive years. For this purpose, a break of
less than two years in the service shall not be deemed to interrupt the continuation of the service.
Under the Nasdaq Listing Rules, we are required to maintain an audit committee consisting of at least three independent directors,
all of whom are financially literate and at least one of whom has accounting or related financial management expertise.
Recent amendments to regulations promulgated under the Companies Law exempt Israeli companies whose shares are listed on
certain stock exchanges outside of Israel (including The Nasdaq Capital Market) with no controlling shareholder, such as ourselves, from
certain Companies Law provisions with respect to the composition of the audit committee and the quorum and majority requirements at its
meetings, so long as such companies satisfy the requirements of the foreign laws in the listing jurisdiction outside of Israel which apply to
companies incorporated in such jurisdiction in respect of the appointment of independent directors and the composition of the audit
committee and compensation committee. Presently, we have an audit committee in place which composition complies with the listing
requirements of the Companies Law, although we may elect in the future to rely on such exemption available to dual-listed companies with
no controlling shareholder.
97
Table of Contents
Our audit committee consists of Dr. Gili Hart, Dr. Abraham Havron, Dr. Elan Penn and Scott Burell. Dr. Penn and Mr. Burell
possess accounting and financial expertise and are both audit committee financial experts as defined by the SEC rules, and all of the
members of our audit committee have the requisite financial literacy as defined by the Nasdaq Listing Rules. All audit committee members
are “independent” as such term is defined in Rule 10A-3(b)(1) under the Exchange Act and under the Nasdaq Listing Rules.
Our board of directors has adopted an audit committee charter setting forth the responsibilities of the audit committee consistent
with the rules of the SEC and the Nasdaq Listing Rules as well as the requirements for such committee under the Companies Law,
including the following:
● oversight of our independent registered public accounting firm and recommending the engagement, compensation or
termination of engagement of our independent registered public accounting firm to the board of directors in accordance with
Israeli law;
● recommending the engagement or termination of the person filling the office of our internal auditor; and
● recommending the terms of audit and non-audit services provided by the independent registered public accounting firm for pre-
approval by our board of directors.
Our audit committee provides assistance to our board of directors in fulfilling its legal and fiduciary obligations in matters
involving our accounting, auditing, financial reporting, internal control, and legal compliance functions by pre-approving the services
performed by our independent accountants and reviewing their reports regarding our accounting practices and systems of internal control
over financial reporting. Our audit committee also oversees the audit efforts of our independent accountants and takes those actions that it
deems necessary to satisfy itself that the accountants are independent of management.
Under the Companies Law, our audit committee is mainly responsible for:
● determining whether there are deficiencies in our business management practices, including in consultation with our internal
auditor or the independent auditor, and making recommendations to the board of directors to improve such practices;
● determining whether certain acts of an office holder not in accordance with his or her fiduciary duty owed to the Company are
extraordinary or material and to approve such acts and certain related party transactions (including transactions in which an
office holder has a personal interest) and whether such transaction is extraordinary or material under the Companies Law (see
“—Approval of Related Party Transactions Under Israeli Law” below);
● determining procedures for a competitive process, or other procedures, before approving related party transactions with
controlling shareholders, even if such transactions are deemed by the audit committee not to be extraordinary transactions. This
process is to be supervised by the audit committee, or any person authorized for such supervision, or via any other method
approved by the audit committee;
● determining the approval process for transactions that are not negligible, as well as determine which types of transactions would
require the approval of the audit committee. Non-negligible transactions are defined as related party transactions with a
controlling shareholder, or in which the controlling shareholder has a personal interest, even if they are deemed by the audit
committee not to be extraordinary transactions but which have also been classified by the audit committee as non-negligible
transactions;
98
Table of Contents
● where the board of directors approves the work plan of the internal auditor, to examine such work plan before its submission to
the board and propose amendments thereto;
● examining our internal controls and internal auditor’s performance, including whether the internal auditor has sufficient
resources and tools to dispose of its responsibilities;
● examining the scope of our auditor’s work and compensation and submitting a recommendation with respect thereto to our
board of directors or shareholders, depending on which of them is considering the appointment of our auditor; and
● establishing procedures for the handling of employees’ complaints as to deficiencies in the management of our business and the
protection to be provided to such employees.
Our audit committee may not approve any actions requiring its approval (see “—Approval of Related Party Transactions Under
Israeli Law” below), unless at the time of approval a majority of the committee’s members are present, which majority consists of
independent directors including at least one external director.
Compensation Committee
Our compensation committee consists of Dr. Abraham Havron, Dr. Gili Hart and Dr. Elan Penn.
Under the Companies Law, the board of directors of a public company must appoint a compensation committee. Subject to certain
exceptions compensation committee must be comprised of at least three directors, including all of the external directors, which shall be a
majority of the members of the compensation committee and one of whom must serve as chairman of the committee.
Each compensation committee member who is not an external director must be a director whose compensation is equivalent to the
compensation that may be paid to an external director. The compensation committee is subject to the same Companies Law restrictions as
the audit committee as to who may not be a member of the committee. According to the Companies Law, our audit committee may also act
as compensation committee.
Recent amendments to regulations promulgated under the Companies Law exempt Israeli companies whose shares are listed on
certain stock exchanges outside of Israel (including The Nasdaq Capital Market) with no controlling shareholder, such as ourselves, from
the Companies Law requirements to appoint a compensation committee or of its composition, so long as such companies satisfy the
requirements of the foreign laws in the listing jurisdiction outside of Israel which apply to companies incorporated in such jurisdiction in
respect of the appointment of independent directors and the composition of the audit committee and compensation committee. Presently,
we have a compensation committee in place which composition complies with the requirements of the Companies Law, although we may
elect in the future to rely on such exemption available to dual-listed companies with no controlling shareholder.
The duties of the compensation committee include the recommendation to the company’s board of directors of a policy regarding
the terms of engagement of office holders, to which we refer as a compensation policy and to examine the necessity of updating the
compensation policy. That policy must be adopted by the company’s board of directors, after considering the recommendations of the
compensation committee, and must be approved by the company’s shareholders, which approval requires a special majority. For this
purpose, a “special majority” approval requires shareholder approval by a majority vote of the shares present and voting at a meeting of
shareholders called for such purpose, provided that either: (i) such majority includes at least a majority of the shares held by all
shareholders who are not controlling shareholders and do not have a personal interest in such compensation arrangement; or (ii) the total
number of shares of non-controlling shareholders and shareholders who do not have a personal interest in the compensation arrangement
and who vote against the arrangement does not exceed 2% of the company’s aggregate voting rights. Under special circumstances, the
board of directors may approve the compensation policy despite the objection of the shareholders on the condition that the compensation
committee (or the audit committee acting in lieu of a compensation committee pursuant to the Companies Law) and then the board of
directors decide, on the basis of detailed arguments and after discussing again the compensation policy, that approval of the compensation
policy, despite the objection of the meeting of shareholders, is for the benefit of the company. Our new compensation policy was approved
by our shareholders on March 1, 2018 and will be in effect for a period of three years from the date of approval. The compensation policy
does not, by nature, grant any rights to our directors or officers. The compensation policy includes both long-term and short-term
compensation elements and is to be reviewed from time to time by our compensation committee and our board of directors, according to the
requirements of the Companies Law.
99
Table of Contents
Our compensation policy serves as the basis for decisions concerning the financial terms of employment or engagement of office
holders, including exculpation, insurance, indemnification or any monetary payment or obligation of payment with respect to employment
or engagement. According to the Companies Law, the compensation policy must be approved (or reapproved) not longer than every three
years and relate to certain factors, including advancement of the company’s objectives, the company’s business plan and its long-term
strategy, and creation of appropriate incentives for office holders. It must also consider, among other things, the company’s risk
management, size, and nature of its operations. The compensation policy must furthermore consider the following additional factors:
● the knowledge, skills, expertise, and accomplishments of the relevant office holder;
● the office holder’s roles and responsibilities and prior compensation agreements with him or her;
● the ratio between the terms offered and the average compensation of the other employees of the company, including those
employed through manpower companies, and in particular the ratio between the average wage and the median salary of such
employees;
● the impact of disparities in salary upon work relationships in the company;
● the possibility of reducing variable compensation at the discretion of the board of directors;
● the possibility of setting a limit on the exercise value of non-cash variable equity-based compensation; and
● as to severance compensation, the period of service of the office holder, the terms of his or her compensation during such
service period, the company’s performance during that period of service, the person’s contributions towards the company’s
achievement of its goals and the maximization of its profits, and the circumstances under which the person is leaving the
company.
The compensation policy must also include the following principles:
● the linkage between variable compensation and long-term performance and measurable criteria; however, in certain
circumstances, we may grant up to three monthly salaries per year of unmeasurable criteria for an office holder who is not our
chief executive officer.
● the ratio between variable and fixed compensation, and the ceiling for the value of variable compensation at the time of the
payment (or with respect to variable equity compensation that is not paid for in cash, a ceiling for their value on the grant date);
● the conditions under which an office holder would be required to repay compensation paid to him or her if it was later shown
that the data upon which such compensation was based was inaccurate and was required to be restated in the company’s
financial statements;
● the minimum holding or vesting period for variable, equity-based compensation with a view to long-term incentives; and
● maximum limits for severance compensation.
100
Table of Contents
Our board of directors has adopted a compensation committee charter setting forth the responsibilities of the committee, which
include:
● the responsibilities set forth in the compensation policy;
● reviewing and approving the granting of options and other incentive awards to the extent such authority is delegated by our
board of directors; and
● reviewing, evaluating, and making recommendations regarding the compensation and benefits for our non-employee directors.
Financial Statements Committee
Our financial statements committee, which complies with the Israeli Companies Regulations (Provisions and Conditions
Regarding the Financial Statements’ Authorization Process), 2010, is responsible for considering and making recommendations to the
board of directors on our financial statements. Prior to the approval of our financial statements by our board of directors, the financial
statements committee reviews and discusses the financial statements and presents its recommendations with respect to the financial
statements to the board of directors. Our financial statements committee currently consists of the members of our audit committee:
Dr. Abraham Havron, Dr. Gili Hart, Mr. Scott R. Burell and Dr. Elan Penn.
Nominating and Corporate Governance Committee
Our nominating and corporate governance committee consists of Dr. Gili Hart, Dr. Abraham Havron, and Dr. Elan Penn. Each of
the members of our nominating and corporate governance committee is independent under the listing requirements of The Nasdaq Capital
Market.
Our board of directors has adopted a nominating and governance committee charter setting forth the responsibilities of the
nominating and governance committee which include:
● overseeing and assisting our board in reviewing and recommending nominees for election as directors;
● assessing the performance of the members of our board; and
● establishing and maintaining effective corporate governance policies and practices, including, but not limited to, developing and
recommending to our board a set of corporate governance guidelines applicable to our company.
Internal Auditor
Under the Companies Law, the board of directors of a public company must appoint an internal auditor based on the
recommendation of the audit committee. The role of the internal auditor is to examine, among other things, our compliance with applicable
law and orderly business procedures. The audit committee is required to oversee the activities and to assess the performance of the internal
auditor as well as to review the internal auditor’s work plan.
An internal auditor may not be:
● a person (or a relative of a person) who holds more than 5% of the company’s outstanding shares or voting rights;
● a person (or a relative of a person) who has the power to appoint a director or the general manager of the company;
● an office holder or director (or a relative of an officer or director) of the company; or
101
Table of Contents
● a member of the company’s independent accounting firm, or anyone on its behalf.
Ms. Dana Gottesman Erlich, has been serving as our Internal Auditor since November 2013. Ms. Gottesman is a CPA, CIA, MA,
Partner in the Risk Advisory Services (RAS) Group at the accounting firm of BDO Ziv Haft. Ms. Gottesman has more than 10 years of
experience in the provision of internal audit and risk management consulting services to public and private companies, government
agencies, municipalities, non-profit organizations, and more. Ms. Gottesman specializes in the analysis and specification of work
procedures and their assimilation in the organization, the internal audit of work procedures in different organizations, including the
performance of risk surveys and fraud and embezzlement surveys. Ms. Gottesman holds a BA in Accounting and Business Administration
and an MA in Internal Audit and Public Administration. Ms. Gottesman’s nomination satisfies the requirements of the Companies Law.
Approval of Related Party Transactions under Israeli Law
Fiduciary Duties of Directors and Officers
The Companies Law imposes a duty of care and a fiduciary duty on all office holders of a company. Each person listed in the table
under “Management—Senior Management and Directors” is an office holder under the Companies Law.
The duty of care requires an office holder to act with the degree of proficiency with which a reasonable office holder in the same
position would have acted under the same circumstances. The fiduciary duty requires that an office holder act in good faith and in the best
interests of the company.
The duty of care includes a duty to use reasonable means to obtain:
● information on the advisability of a given action brought for his or her approval or performed by virtue of his or her position;
and
● all other important information pertaining to these actions.
The fiduciary duty includes a duty to:
● refrain from any act involving a conflict of interest between the performance of his or her duties to the company and his or her
other duties or personal affairs;
● refrain from any activity that is competitive with the company;
● refrain from exploiting any business opportunity of the company to receive a personal gain for himself or herself or others; and
● disclose to the company any information or documents relating to the company’s affairs which the office holder received as a
result of his or her position as an office holder.
Disclosure of Personal Interests of an Office Holder and Approval of Certain Transactions
The Companies Law requires that an office holder promptly disclose to the company any personal interest that he or she may be
aware of and all related material information or documents concerning any existing or proposed transaction by the company. An interested
office holder’s disclosure must be made promptly and in any event no later than the first meeting of the board of directors at which the
transaction is considered. An office holder is not obliged to disclose a personal interest if it derives solely from the personal interest of his
or her relative in a transaction that is not considered as an extraordinary transaction.
102
Table of Contents
A “personal interest” is defined under the Companies Law to include a personal interest of any person in an act or transaction of a
company, including the personal interest of such person’s relative or of a corporate body in which such person or a relative of such person
is a 5% or greater shareholder, director, or general manager or in which he or she has the right to appoint at least one director or the general
manager, but excluding a personal interest solely stemming from one’s ownership of shares in the company.
A personal interest furthermore includes the personal interest of a person for whom the office holder holds a voting proxy or the
personal interest of the office holder with respect to his or her vote on behalf of a person for whom he or she holds a proxy even if such
shareholder has no personal interest in the matter. An office holder is not, however, obliged to disclose a personal interest if it derives
solely from the personal interest of his or her relative in a transaction that is not considered an extraordinary transaction.
Under the Companies Law, an extraordinary transaction is defined as any of the following:
● a transaction other than in the ordinary course of business;
● a transaction that is not on market terms; or
● a transaction that may have a material impact on the company’s profitability, assets, or liabilities.
If it is determined that an office holder has a personal interest in a transaction which is not an extraordinary transaction, approval
by the board of directors is required for such transaction, unless the company’s articles of association provide for a different method of
approval. An extraordinary transaction in which an office holder has a personal interest requires approval first by the company’s audit
committee and subsequently by the board of directors. In general, the compensation of, or an undertaking to indemnify or insure, an office
holder who is not a director requires approval first by the company’s compensation committee, then by the company’s board of directors,
and, if such compensation arrangement or an undertaking to indemnify or insure is inconsistent with the company’s stated compensation
policy or if the office holder is the chief executive officer (apart from a number of specific exceptions), then such arrangement is subject to
a special majority approval. Arrangements regarding the compensation, exculpation, indemnification, or insurance of a director require the
approval of the compensation committee, board of directors, and shareholders by ordinary majority, in that order, and under certain
circumstances, a special majority approval.
Generally, a person who has a personal interest in a matter which is considered at a meeting of the board of directors or the audit
committee may not be present at such a meeting or vote on that matter unless the chairman of the relevant committee or board of directors
(as applicable) determines that he or she should be present in order to present the transaction that is subject to approval. If a majority of the
members of the audit committee or the board of directors (as applicable) has a personal interest in the approval of a transaction, then all
directors may participate in discussions of the audit committee or the board of directors (as applicable) on such transaction and the voting
on approval thereof, but shareholder approval is also required for such transaction.
Disclosure of Personal Interests of Controlling Shareholders and Approval of Certain Transactions
Under Israeli Law, the term “controlling shareholder” means a shareholder with the ability to direct the activities of our company,
other than by virtue of being an executive officer or director. A shareholder is presumed to be a controlling shareholder if the shareholder
holds 50% or more of the voting rights in a company or has the right to appoint at least half of the directors of the company or its general
manager. For the purpose of approving transactions with controlling shareholders, a controlling shareholder is deemed to include any
shareholder that holds 25% or more of the voting rights in a public company if no other shareholder holds more than 50% of the voting
rights in the company. For purposes of determining the holding percentage stated above, two or more shareholders who have a personal
interest in a transaction that is brought for the company’s approval are deemed as joint holders.
103
Table of Contents
Pursuant to Israeli law, the disclosure requirements regarding personal interests that apply to directors and executive officers also
apply to a controlling shareholder of a public company. See “—External Directors” above for a definition of controlling shareholder. In the
context of a transaction involving a shareholder of the company, a controlling shareholder also includes a shareholder who holds 25% or
more of the voting rights in the company if no other shareholder holds more than 50% of the voting rights in the company. For this
purpose, the holdings of all shareholders who have a personal interest in the same transaction will be aggregated. The approval of the audit
committee or compensation committee, the board of directors, and a special majority, in that order, is required for: (i) extraordinary
transactions with a controlling shareholder or in which a controlling shareholder has a personal interest; (ii) the engagement with a
controlling shareholder or his or her relative, directly or indirectly, for the provision of services to the company; (iii) the terms of
engagement and compensation of a controlling shareholder or his or her relative who is not an office holder; or (iv) the employment of a
controlling shareholder or his or her relative by the company, other than as an office holder. For this purpose, a “special majority” approval
requires shareholder approval by a majority vote of the shares present and voting at a meeting of shareholders called for such purpose,
provided that either: (a) such majority includes at least a majority of the shares held by all shareholders who do not have a personal interest
in such compensation arrangement; or (b) the total number of shares of non-controlling shareholders and shareholders who do not have a
personal interest in the compensation arrangement and who vote against the arrangement does not exceed 2% of the company’s aggregate
voting rights.
To the extent that any such transaction with a controlling shareholder is for a period extending beyond three years, approval is
required once every three years, unless, with respect to certain transactions, the audit committee determines that the duration of the
transaction is reasonable given the circumstances related thereto.
Arrangements regarding the compensation, exculpation, indemnification, or insurance of a controlling shareholder in his or her
capacity as an office holder require the approval of the compensation committee and board of directors, and, in general, approval by a
special majority of shareholders.
Pursuant to regulations promulgated under the Companies Law, certain transactions with a controlling shareholder or his or her
relative, or with directors, that would otherwise require approval of a company’s shareholders may be exempt from shareholder approval
upon certain determinations of the audit committee or compensation committee and board of directors.
Shareholders’ Duties
Under the Companies Law, a shareholder has a duty to act in good faith and in a customary manner toward the company and other
shareholders and to refrain from abusing his or her power in the company, including, among other things, in voting at general meetings of
shareholders and class meetings of shareholders with respect the following matters:
● an amendment of the articles of association or memorandum of association of the company;
● an increase in the company’s authorized share capital;
● a merger; or
● the approval of related party transactions and acts of office holders that require shareholder approval.
A shareholder also has a general duty to refrain from discriminating against other shareholders. In addition, certain shareholders
have a duty of fairness toward the company. These shareholders include any controlling shareholder, any shareholder who knows that he or
she has the power to determine the outcome of a shareholder vote and any shareholder who has the power to appoint or to prevent the
appointment of an office holder of the company or other power. The Companies Law does not define the substance of the duty of fairness,
except to state that the remedies generally available upon a breach of contract will also apply in the event of a breach of the duty to act with
fairness.
Exculpation, Insurance and Indemnification of Directors and Officers
Under the Companies Law, a company may not exculpate an office holder from liability for a breach of the duty of loyalty. An
Israeli company may exculpate an office holder in advance from liability to the company, in whole or in part, for damages caused to the
company as a result of a breach of duty of care but only if a provision authorizing such exculpation is included in its articles of association.
Our articles of association include such a provision. A company may not exculpate a director from liability arising out of a prohibited
dividend or distribution to shareholders.
104
Table of Contents
Under the Companies Law and the Israeli Securities Law, an Israeli company may indemnify an office holder with respect to the
following liabilities and expenses incurred for acts performed as an office holder, either in advance of an event or following an event,
provided a provision authorizing such indemnification is contained in its articles of association:
● financial liability imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator’s
award approved by a court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in
advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen
based on the company’s activities when the undertaking to indemnify is given, and to an amount or according to criteria
determined by the board of directors as reasonable under the circumstances, and such undertaking must detail the
abovementioned foreseen events and amount or criteria;
● reasonable litigation expenses, including attorneys’ fees, incurred by the office holder: (i) as a result of an investigation or
proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that
(a) no indictment was filed against such office holder as a result of such investigation or proceeding and (b) no financial
liability was imposed upon him or her as a substitute for the criminal proceeding as a result of such investigation or proceeding
or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal
intent; and (ii) in connection with a monetary sanction;
● expenses associated with an administrative procedure, as defined in the Israeli Securities Law, conducted regarding an office
holder, including reasonable litigation expenses and reasonable attorneys’ fees; and
● reasonable litigation expenses, including attorneys’ fees, incurred by the office holder or imposed by a court in proceedings
instituted against him or her by the company, on its behalf or by a third party or in connection with criminal proceedings in
which the office holder was acquitted or as a result of a conviction for an offense that does not require proof of criminal intent.
Under the Companies Law and the Israeli Securities Law, a company may insure an office holder against the following liabilities
incurred for acts performed as an office holder if and to the extent provided in the company’s articles of association:
● a breach of duty of care to the company or to a third party, including a breach arising out of the negligent conduct of the office
holder;
● a breach of fiduciary duty to the company, to the extent that the office holder acted in good faith and had a reasonable basis to
believe that the act would not prejudice the company;
● a monetary liability imposed on the office holder in favor of a third party; and
● expenses incurred by an office holder in connection with an administrative procedure, including reasonable litigation expenses
and reasonable attorneys’ fees.
Under the Companies Law, a company may not indemnify or insure an office holder against any of the following:
● a breach of fiduciary duty, except for indemnification and insurance for a breach of the fiduciary duty to the company and to the
extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the
company;
105
Table of Contents
● a breach of duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the
office holder;
● an act or omission committed with intent to derive illegal personal benefit; or
● a fine or forfeit levied against the office holder.
Under the Companies Law, exculpation, indemnification, and insurance of office holders in a public company must be approved
by the compensation committee and the board of directors and, with respect to certain office holders or under certain circumstances, by the
shareholders.
Our articles of association and compensation policy allow us to exculpate, indemnify, and insure our office holders according to
applicable law.
As of the date of this annual report on Form 20-F, no claims for directors’ and officers’ liability insurance have been filed under
this policy and we are not aware of any pending or threatened litigation or proceeding involving any of our directors or officers in which
indemnification is sought.
We have obtained directors’ and officers’ liability insurance for the benefit of our office holders and intend to continue to maintain
such coverage and pay all premiums thereunder to the fullest extent permitted by the Companies Law. In addition we have entered into
agreements with each of our current office holders undertaking to indemnify them to the fullest extent permitted by the Companies Law and
our articles of association, to the extent that these liabilities are not covered by insurance.
In the opinion of the Securities and Exchange Commission, indemnification of directors and office holders for liabilities arising
under the Securities Act, however, is against public policy and therefore unenforceable.
There is no pending litigation or proceeding against any of our directors or officers as to which indemnification is being sought,
nor are we aware of any pending or threatened litigation that may result in claims for indemnification by any director or officer.
D. Employees.
See “Item 4.B. Business Overview―Employees”.
E. Share Ownership.
See “Item 7.A. Major Shareholders” below.
106
Table of Contents
Share Incentive Plan
In May 2010, we adopted the 2010 Plan, an option plan for employees and senior officers, and as part of the acquisition of
CollPlant Ltd., all of the options under the Employee Share Ownership and Option Plan (2004) of CollPlant Ltd. were substituted with and
assumed by options under our 2010 Plan, while any restriction periods under Sections 102(b)(2) and 102(b)(3) of the Israeli Income Tax
Ordinance, or the Ordinance were calculated as of their original grant date. The 2010 Plan allows us to grant options to purchase our
ordinary shares to our officers, employees, and consultants. The 2010 Plan is intended to enhance our ability to attract and retain desirable
individuals by increasing their ownership interests in us. As of March 15, 2018, our employees, officers, and consultants hold an aggregate
of 47,544,792 options to purchase 26,838,931 ordinary shares under the 2010 Plan. As of March 15, 2018, 7,464,183 options to purchase an
aggregate of 2,488,061 ordinary shares had been exercised and transferred to the beneficial holders. The 2010 Plan is designed to reflect the
provisions of the Israeli Income Tax Ordinance, or the Ordinance, mainly Sections 102 and 3(i), which affords certain tax advantages to
Israeli employees, officers, and directors that are granted options in accordance with its terms. Section 102 of the Ordinance allows
employees, directors, and officers, who are not controlling shareholders and who are Israeli residents, to receive favorable tax treatment for
compensation in the form of shares or options. Section 102 of the Ordinance includes two alternatives for tax treatment involving the
issuance of options or shares to a trustee for the benefit of the grantees and also includes an additional alternative for the issuance of options
or shares directly to the grantee. Sections 102(b)(2) and 102(b)(3) of the Ordinance, which provide the most favorable tax treatment for
grantees, permit the issuance to a trustee under the “capital gains track.” In order to comply with the terms of the capital gains track, all
options granted under a specific plan and subject to the provisions of Section 102 of the Ordinance, as well as the shares issued upon
exercise of such options and other shares received following any realization of rights with respect to such options, such as share dividends
and share splits, must be registered in the name of a trustee selected by the board of directors and held in trust for the benefit of the relevant
employee, director, or officer. The trustee may not release these options or shares to the relevant grantee before the second anniversary of
the registration of the options in the name of the trustee. However, under this track, our ability to deduct an expense with respect to the
issuance of the options or shares might be limited. Section 3(i) of the Ordinance does not provide for similar tax benefits.
The plans may be administered by our board of directors either directly or upon the recommendation of a committee appointed by
our board of directors.
The compensation committee recommends to the board of directors, and the board of directors determines or approves the eligible
individuals who receive options under the plan, the number of ordinary shares covered by those options, the terms under which such
options may be exercised, and other terms and conditions of the options, all in accordance with the provisions of the plans. Option holders
may not transfer their options except in the event of death or transfer to an Administrator in accordance with law in the event of the absence
of legal competency. Our compensation committee or board of directors may at any time amend or terminate each of the plans; however,
any amendment or termination may not adversely affect any options or shares granted under such plan prior to such action.
The option exercise price is determined by the compensation committee, following the approval of the board of directors, and
specified in each option award agreement. In general, and according to our compensation policy, the option exercise price is the market
value of the shares on the date of grant as traded on the TASE.
Awards under the 2010 Plan may be granted until 2020, 10 years from the date on which the 2010 Plan was approved by our board
of directors.
Options granted under the 2010 Plan generally vest over four years commencing on the date of grant such that 25% vest on the
first anniversary of the date of grant and an additional 6.25% vest at the end of each subsequent three-month period thereafter for
36 months and some every calendar year, unless otherwise provided in a specific allocation agreement.
Options, other than certain incentive share options, that are not exercised within 10 years from the grant date expire, unless
otherwise determined by our board of directors. Except as otherwise determined by the board of directors or as set forth in an individual’s
award agreement, in the event of termination of employment or services for reasons of disability, death, or retirement, the grantee, or in the
case of death, his or her legal successor, may exercise options that have vested prior to termination within a period of one year from the
date of disability, death, or retirement. If we terminate a grantee’s employment or service for cause, all of the grantee’s unvested options
will expire on the date of termination, yet options which by that date the offeree’s eligibility to exercise has already been formed shall
remain exercisable. If a grantee’s employment or service is terminated for any other reason, the grantee may exercise his or her vested
options within 90 days of the date of termination. Any expired or unvested options return to the pool for reissuance.
107
Table of Contents
In the event of (i) a sale of all or substantially all of our assets or (ii) our consolidation or merger in which we are not the ongoing
or surviving corporation, then, and unless otherwise determined in the agreement or by the board, we shall be entitled to determine that all
of the outstanding unexercised options held by or for the benefit of any grantee shall be assumed or substituted for an appropriate number
of options of the successor company, provided that the aggregate amount of the exercise price for such options shall be equal to the
aggregate amount of the exercise price of our unexercised options held by each grantee at such time. With respect to the grants that were
made since October 2017, the above acceleration provision was amended in a manner that the options’ vesting is fully accelerated upon the
occurrence of a M&A Transaction or Reorganization : (1) “M&A Transaction” shall mean a “merger” as such term or term of similar
nature is defined in the Israeli Companies Law of 1999, as well as (i) a sale of 50% or more of the assets of the Company and its
subsidiaries taken as a whole, or the sale or disposition (whether by merger or otherwise) of one or more subsidiaries of the Company if
more than 50% of the assets of the Company and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries; or (ii) a sale
of all or more than 50% of the shares of the share capital of the Company whether by a single transaction or a series of related transactions
which occur either over a period of 12 months or within the scope of the same acquisition agreement; (iii) an issuance of shares of the
Company, whether by a single transaction or a series of related transactions which occur either over a period of 12 months or within the
scope of the same acquisition agreement, that results in the offeree holding more than 50% of the share capital of the Company; or (iv) a
merger, consolidation or like transaction of the Company with or into another corporation including a reverse triangular merger, but
excluding a merger which falls within the definition of Reorganization; and/or (2) “Reorganization” shall mean any re-domestication of the
Company, share flip, creation of a holding Company for the Company which will hold all, or 50% or more, of the shares of the Company
or any other transaction involving the Company in which the ordinary shares of the Company outstanding immediately prior to such
transaction continue to represent, or are converted into or exchanged for shares that represent, immediately following such transaction, at
least a majority, by voting power, of the share capital of the surviving, acquiring or resulting corporation and in which there is no material
change to the interests held by the shareholders of the Company prior to such transaction and thereafter.
In the event of termination of the employment or the director or service-provider relationship by us or by a related company
within 12 months after a significant event in which the options were assumed, then the unvested portion of the options shall become fully
vested, and shall remain exercisable for a period of three months following the termination or notice of termination. For such purposes, a
“Significant Event” would include our consolidation or merger with or into another corporation in which we are the ongoing or surviving
corporation or in which, the ongoing or surviving corporation (or, if such transaction is effected through a subsidiary, the parent of such
ongoing or surviving corporation) assumes the option or substitutes it with an appropriate option in the surviving corporation (or in the
parent as aforesaid) in the manner set forth above.
ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS
A. Major Shareholders
The following table sets forth information with respect to the beneficial ownership of our ordinary shares as of March 15, 2018 by:
● each of our directors and senior management;
● all of our directors and senior management as a group; and
● each person (or group of affiliated persons) known by us to be the beneficial owner of 5% or more of the outstanding ordinary
shares.
Beneficial ownership is determined in accordance with the rules of the SEC. These rules generally attribute beneficial ownership
of securities to persons who possess sole or shared voting or investment power with respect to those securities, and include shares subject to
options and warrants that are exercisable within 60 days after March 15, 2018. Such shares are also deemed outstanding for purposes of
computing the percentage ownership of the person holding the option, but not the percentage ownership of any other person.
Unless otherwise indicated below, to our knowledge, all persons named in the table have sole voting and investment power with
respect to their shares, except to the extent that authority is shared by spouses under community property laws. None of our shareholders
has informed us that he, she, or it is affiliated with a registered broker-dealer or is in the business of underwriting securities. None of our
shareholders has different voting rights from other shareholders.
108
Table of Contents
Unless otherwise indicated, the address of each beneficial owner is c/o 3 Sapir Street, Weizmann Science Park, P.O. Box 4132,
Ness-Ziona 74140, Israel.
Senior Management and Directors
Adi Goldin(1)
Oded Shoseyov(2)
Abraham Havron(3)
Scott Burell(3)
David Tsur(4)
Dr. Gili Hart(3)
Dr. Elan Penn(3)
Yehiel Tal(5)
Eran Rotem(6)
Philippe Bensimon(7)
Nadav Orr(8)
Shomrat Shurtz(9)
Ilana Belzer(10)
All senior management and directors as a group (13 persons)
More than 5% Shareholders
Meitav Dash Investment Ltd.(11)
Docor Levi Lassen BV(12)
Ami Sagi(13)
Alpha Capital Anstalt(14)
Ordinary
Shares
Beneficially
Owned
Percentage
Owned**
280,847
5,528,814
0
0
221,000
0
0
2,856,264
879,702
476,042
345,833
125,000
145,833
10,859,335
47,558,277
10,609,639
28,688,439
8,555,340
*
3.2%
0
0
*
0
0
1.7%
*
*
*
*
*
6.11%
25.6%
6.2%
15.9%
4.9%
*
**
(1)
(2)
(3)
(4)
(5)
(6)
Less than 1%
Based on 171,160,668 ordinary shares outstanding
Consists of: (i) 118,000 ordinary shares, and (ii) 488,542 options to purchase 162,847 ordinary shares at an exercise price of NIS
1.80 per share and expiring on July 7, 2025. Does not include 650,000 options to purchase 650,000 ordinary shares at an exercise
price of NIS 0.58 per share and expiring on January 14, 2025 that vest in more than 60 days of March 15, 2018.
Consists of (i) 2,737,573 ordinary shares, (ii) 2,258,813 options to purchase 752,938 ordinary shares at an exercise price of NIS
2.07 per share and expiring on February 16, 2021, (iii) 109,091 options to purchase 36,364 ordinary shares at an exercise price of
NIS 0.90 per share and expiring on May 3, 2020, (iv) 6,000,000 options to purchase 2,000,000 ordinary shares at an exercise price
of NIS 1.80 per share and expiring on July 31, 2025, and (v) 5,818 warrants to purchase 1,939 ordinary shares at an exercise price of
NIS 2.40 per share and expiring on January 31, 2019. Does not include 1,000,000 options to purchase 1,000,000 ordinary shares at
an exercise price of NIS 0.58 per share and expiring on December 26, 2024 that vest in more than 60 days of March 15, 2018.
Does not include 500,000 options to purchase 500,000 ordinary shares at an exercise price of NIS 0.58 per share and expiring on
January 14, 2025 that vest in more than 60 days of March 15, 2018.
Consists of 221,000 options to purchase 221,000 ordinary shares without an exercise price expiring on August 22, 2024. Does not
include (i) 265,000 options to purchase 265,000 ordinary shares at an exercise price of NIS 0.33 per share and expiring on August
22, 2024, and (ii) 500,000 options to purchase 500,000 ordinary shares at an exercise price of NIS 0.58 per share and expiring on
January 14, 2025, that in each case vest in more than 60 days of March 15, 2018.
Consists of (i) 1,505,875 ordinary shares, (ii) 153,041 options to purchase 51,014 ordinary shares exercisable at an exercise price of
NIS 0.90 per share and expiring on May 3, 2020, and (iii) 3,898,125 options to purchase 1,299,375 ordinary shares exercisable at an
exercise price of NIS 1.80 per share and expiring on July 31, 2025. Does not include 3,750,000 options to purchase 3,750,000
ordinary shares at an exercise price of NIS 0.58 per share and expiring on January 14, 2025 that vest in more than 60 days of March
15, 2018.
Consists of (i) 450,000 options to purchase 150,000 ordinary shares exercisable at an exercise price of NIS 1.90 per share and
expiring on October 20, 2021, (ii) 126,607 options to purchase 42,202 ordinary shares exercisable at an exercise price of NIS 0.90
per share and expiring on May 3, 2020, and (iii) 2,062,500 options to purchase 687,500 ordinary shares exercisable at an exercise
price of NIS 1.80 per share and expiring on May 15, 2025. Does not include 2,250,000 options to purchase 2,250,000 ordinary
shares at an exercise price of NIS 0.58 per share and expiring on December 26, 2024 that vest in more than 60 days of March 15,
2018.
109
Table of Contents
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
Consists of (i) 200,000 options to purchase 66,667 ordinary shares exercisable at an exercise price of NIS 4.17 per share and
expiring on October 20, 2021, (ii) 300,000 options to purchase 100,000 ordinary shares exercisable at an exercise price of NIS 1.32
per share and expiring on May 3, 2020, and (iii) 928,125 options to purchase 309,375 ordinary shares exercisable at an exercise
price of NIS 1.80 per share and expiring on May 18, 2025. Does not include 750,000 options to purchase 750,000 ordinary shares at
an exercise price of NIS 0.58 per share and expiring on December 26, 2024 that vest in more than 60 days of March 15, 2018.
Consists of (i) 350,000 options to purchase 116,667 ordinary shares exercisable at an exercise price of NIS 0.76 per share and
expiring on September 8, 2024, and (ii) 687,500 options to purchase 229,167 ordinary shares exercisable at an exercise price of NIS
1.80 per share and expiring on May 18, 2025. Does not include 750,000 options to purchase 750,000 ordinary shares at an exercise
price of NIS 0.58 per share and expiring on December 26, 2024 that vest in more than 60 days of March 15, 2018.
Consists of 375,000 options to purchase 125,000 ordinary shares exercisable at an exercise price of NIS 1.80 per share and expiring
on August 31, 2025.
Consists of 437,500 options to purchase 145,833 ordinary shares exercisable at an exercise price of NIS 1.80 per share and expiring
on August 31, 2025. Does not include 750,000 options to purchase 750,000 ordinary shares at an exercise price o of NIS 0.58 per
share and expiring on December 26, 2024 that vest in more than 60 days of March 15, 2018.
Consists of (i) 32,931,110 ordinary shares, (ii) 8,181,500 warrants to purchase 2,727,167 ordinary shares exercisable at an exercise
price of NIS 1.80 per share and expiring on May 31, 2019, and (iii) 11,900,000 warrants to purchase 11,900,000 ordinary shares
exercisable at an exercise price of NIS 0.80 per share and expiring on March 7, 2023. To the best of our knowledge, Meitav Dash
Investments Ltd. is a public company traded on the Tel Aviv Stock Exchange Ltd. According to its public reports, to date, the
natural person or persons who hold voting and dispositive control over the shares beneficially owned by Meitav Dash Investments
Ltd. are: Mr. Eli Barkat, Mr. Nir Barkat, Mr. Yuval Rechavi and Mr. Zvi Stepak.
Consists of (i) 9,847,639 ordinary shares, (ii) 2,286,000 warrants to purchase 762,000 ordinary shares exercisable at an exercise
price of NIS 1.80 per share and expiring on May 31, 2019. The ordinary shares are being held as follows: 5,543,305 by Docor Levi
Lassen BV and 4,304,334 by its parent company, Docor International BV. To the best of our knowledge, to date, the Van Leer
Foundation Group holds voting and dispositive control over the shares beneficially owned by Docor Levi Lassen BV and Docor
International BV.
Consists of (i) 19,304,045 ordinary shares, (ii) 26,181 warrants to purchase 8,727 ordinary shares exercisable at an exercise price of
NIS 2.40 per share and expiring on January 31, 2019, (iii) 227, warrants to purchase 75,667 ordinary shares exercisable at an
exercise price of NIS 1.8 per share and expiring on May 31, 2019, and (iv) 9,300,000 warrants to purchase 9,300,000 ordinary
shares exercisable at an exercise price of NIS 0.80 per share and expiring on March 7, 2023.
Consists of 8,555,340 ordinary shares. Pursuant to the terms of certain warrants, the holder cannot convert such warrants if it would
beneficially own, after any such conversion, more than 4.99% of the outstanding ordinary shares. The percentage in the table above
gives effect to the blocker. Excludes (i) the 786,455 ADSs representing approximately 39,322,742 ordinary shares issuable upon
exercise of a prepaid warrant within 60 days of March 15, 2018, and which are subject to the foregoing blocker, (ii) the number of
ADSs representing an aggregate of approximately 9,921,482 ordinary shares issuable upon exercise of a prepaid warrant to be
issued in the third closing under the Alpha Purchase Agreement, and (iii) 49,607,407 ordinary shares issuable upon exercise of
warrants to be issued in the third closing under the Alpha Purchase Agreement. Konrad Ackerman has voting and dispositive power
over the securities owned by Alpha.
Bank of New York Mellon, or BNY, is the holder of record for our ADR program, pursuant to which each ADS represents 50
ordinary shares. As of March 15, 2018, BNY held 474,483 ordinary shares representing 0.3% of the outstanding ordinary shares at that
date. Certain of these ordinary shares were held by brokers or other nominees. As a result, the number of holders of record or registered
holders in the United States is not representative of the number of beneficial holders or of the residence of beneficial holders.
To our knowledge, from March 31, 2015 to March 15, 2018, the ownership percentage of Meitav Dash increased by 7% from
18.6% to 25.6%, the ownership percentage of Docor Levi Lassen BV decreased by 2.4% from 8.6% to 6.2% during such period, the
ownership percentage of Ami Sagi increased by 9.1% from 6.8% to 15.9%. See “Item 7.B. Related Party Transactions” and “Item 10.C.
Material Contracts” below for additional information.
B. Related Party Transactions
The following is a description of the material terms of those transactions with related parties to which we are party and which were
in effect since January 1, 2017.
110
Table of Contents
U.S. dollar translations of NIS amounts are translated using the rate of NIS 3.467 to one U.S. dollar, the exchange rate reported by
the Bank of Israel for December 31, 2017. All share amounts have been adjusted to give effect to the 1 for 3 reverse share split effected on
November 20, 2016 while maintaining the exercise price of each option and warrant in effect prior to November 20, 2016, such that each
option or warrant will be exercised for one third of one ordinary share of the Company. The descriptions provided below are summaries of
the terms of such agreements and do not purport to be complete and are qualified in their entirety by the complete agreements.
We believe that we have executed all of our transactions with related parties on terms no less favorable to us than those we could
have obtained from unaffiliated third parties. See “Item 6.C. Board Practices—Approval of Related Party Transactions under Israeli Law.”
Issuances of Securities
● On February 12, 2017, we completed a public offering in which we sold 21,152,000 ordinary shares at a price per share of NIS
0.34, as well as 10,576,000 Series L warrants to purchase 10,576,000 ordinary shares at an exercise price of NIS 0.36 ($0.10)
per warrant, for gross proceeds of NIS 7,191,680 ($2,074,324). The warrants were exercisable at NIS 0.36 per warrant until
June 13, 2017. In addition, we issued 941,400 Series L warrants to purchase 941,400 ordinary shares to the underwriters in the
transaction under the same conditions set out above. The following owners of our ordinary shares participated in these
offerings: Meitav DS Investments Ltd, Docor International BV, Docor Levi Lassen BV, and Adi Goldin, the Chairman of the
Company’s board of directors. During the second quarter of 2017, 10,055,464 Series L warrants were exercised into 10,055,464
ordinary shares at an exercise price of NIS 0.36 for each warrant resulting in NIS 3,618,000 ($1,043,553) in gross proceeds.
1,461,936 Series L warrants that were not exercised expired on June 14, 2017.
● On August 22, 2017, we issued to David Tsur, a director, 221,000 options to purchase 221,000 ordinary shares without an
exercise price as well as an additional 265,000 options to purchase 265,000 ordinary shares with an exercise price of NIS 0.33
each.
● On September 6, 2017, we entered into the Alpha Purchase Agreement with Alpha, pursuant to which we agreed, upon the
terms and subject to the conditions of the Alpha Purchase Agreement, to issue and sell to Alpha in a private placement, certain
of our securities in three tranches, as follows: (i) at the first closing, ordinary shares and a Debenture, for a purchase price of
$2,000,000, (ii) at the second closing, ordinary shares and/or a Debenture for a purchase price of $2,000,000, and (iii) at the
third closing, ordinary shares and/or a pre-paid warrant, and a warrant to purchase 49,607,407 ordinary shares for a purchase
price of $1,000,000. The first closing occurred on October 26, 2017 and the second closing occurred on December 31, 2017.
● On November 8, 2017, we entered into the Meitav Purchase Agreement with Meitav Dash, pursuant to which we agreed, upon
the terms and subject to the conditions of the Meitav Purchase Agreement, to issue and sell to Meitav Dash in a private
placement, certain of our securities in three tranches, as follows: (i) at the first closing, 9,500,000 ordinary shares, for a
purchase price of NIS 3,800,000 ($1,096,048), (ii) at the second closing, 2,400,000 ordinary shares for a purchase price of NIS
960,000 ($276,896), provided that Meitav Dash shall not be obligated to buy or hold, immediately following the second
closing, 20% or more of our share capital, and (iii) at the third closing for no additional consideration, warrants exercisable into
9,500,000 ordinary shares, and if the second closing has occurred, additional warrants exercisable into 2,400,000 ordinary
shares. The first and second closings occurred on December 26, 2017 and the third closing occurred on March 7, 2018.
● On November 9, 2017, we entered into the Sagi Purchase Agreement with Ami Sagi pursuant to which we agreed, upon the
terms and subject to the conditions of the Sagi Purchase Agreement, to issue and sell to Ami Sagi in a private placement, certain
of our securities in two tranches, as follows: (i) at the first closing, 9,300,000 ordinary shares, for a purchase price of NIS
3,720,000 ($1,072,974),and (ii) at the second closing for no additional consideration, warrants exercisable into 9,300,000
ordinary shares, or the Sagi Warrants. The first closing occurred on December 26, 2017 and the second closing occurred on
March 7, 2018.
111
Table of Contents
● On December 7, 2017, our board of directors approved the grant of 16,050,000 options to purchase 16,050,000 ordinary shares
at an exercise price of NIS 0.58 ($0.17) per option to certain officers, directors and employees. On January 14, 2018, our
shareholders approved the grant to the directors and to our CEO.
● On January 18, 2018, we entered into Security Purchase Agreements for the purchase and sale, in a private placement, of an
aggregate of 4,344,340 ordinary shares for an aggregate of NIS 2,172,170 ($626,527) to the following three investors as
follows: (i) Alpha entered into a Security Purchase Agreement for the purchase and sale of 1,275,340 ordinary shares for
NIS 637,670 ($183,926); (ii) Ami Sagi entered into a Security Purchase Agreement for the purchase and sale of 2,046,000
ordinary shares for NIS 1,023,000 ($295,068); and (iii) Docor International BV entered into a Security Purchase Agreement for
the purchase and sale of 1,023,000 ordinary shares for NIS 511,500 ($147,533). Closing occurred on January 25, 2018.
Agreements with Yissum
We have entered into certain agreements with Yissum, in which Prof. Oded Shoseyov, our chief scientific officer, has or might
have a personal interest, including an agreement dated July 13, 2004 with respect to the intellectual property rights relating to our
rhCollagen. See “Item 4.B. Business Overview— Intellectual Property—Agreement with Yissum Research Development Company of the
Hebrew University of Jerusalem Ltd. with Respect to Our rhCollagen”, and see “Item 6.C. Board Practices—Approval of Related Party
Transactions Under Israeli Law.”
On July 29, 2010, we signed a joint development and cross license agreement with Yissum, which agreement was amended on
September 4, 2017. The agreement governs the relationship between the parties in connection with the invention protected by a patent
application for the Resilin protein and future results from development work related to Resilin conducted jointly by us and Yissum or solely
by us or Yissum. The Resilin protein and its patent are not related to our collagen protein and its related patents. The agreement stipulates
that the parties will be co-owners of the Resilin patent and its associated know-how developed prior to the date of execution of the
agreement. Developments results developed by the company together with Yissum, or independently by Yissum within the company’s field
shall be jointly owned by both parties. Developments results developed independently by the company, or independently by Yissum in
Yissum’s field, shall be owned by the developing party. Each party has granted the other an exclusive worldwide license, which can be sub-
licensed, to make use of the Resilin patent and its associated know-how, including the joint IP developed under this agreement, for the
purposes of research, development, production, marketing, distribution, license or sale of products limited to the licensee’s field of use.
Accordingly, per the agreement as amended, we have exclusive rights to the technology for all medical and cosmetic human uses
(including, without limitation therapeutic, aesthetic, skin care and diagnostic uses but not including hair straightening and nail coating uses)
and veterinary uses. Yissum has exclusivity in any other field. We were also granted first rights to develop and commercialize products in
Yissum’s field of exclusivity where a sub-license has not yet been given by Yissum to a third party.
On April 20, 2015, we entered into a consortium agreement with several international companies and academic institutions,
outlining the framework of a tissue research and development project using nanotechnology, our rhCollagen, and stem cell technology. The
project is expected to last approximately three years. The Hebrew University of Jerusalem together with Yissum and Prof. Oded Shoseyov,
our chief scientist and the project manager on behalf of Yissum, will also take part in the project.
As part of the project, we will supply an insignificant amount of our rhCollagen to the Hebrew University, and become a member
of the steering committee of the project. The agreement contains provisions protecting each consortium member’s rights including with
respect to the intellectual property to be developed as part of the project, and protecting us, our rhCollagen, and any intellectual property
developed as part of the project with respect to our rhCollagen whether by the Hebrew University or by other parties participating in the
consortium, as applicable.
112
Table of Contents
Rights of Appointment
Our current board of directors currently consists of six directors. See “Item 6.A.—Directors and Senior Management”. Currently
serving directors that were appointed (other than the external directors) will continue to serve pursuant to their appointment until the next
annual meeting of shareholders.
Under the Alpha Purchase Agreement on the first closing, we are required to appoint two directors selected by Alpha (out of a
seven-member board) and on the second closing, we are required to appoint one additional director selected by Alpha (out of an eight-
member board), each who shall serve as directors at least until the end of our 2018 annual general meeting. At the first closing, Alpha
selected Scott Burell to serve on the board and is yet to select an additional director.
Registration Rights
In connection with the first closing of the Alpha financing, we entered into a Registration Rights Agreement with Alpha. Pursuant
to the Registration Rights Agreement, we agreed to file a registration statement with the SEC within 45 days from the date of the
Registration Rights Agreement to register the resale of our ordinary shares held by Alpha that were issued in the private placement
including ordinary shares underlying the Debentures, Alpha Warrants and pre-funded Alpha Warrants and to maintain the effectiveness
thereunder. We also agreed to use best efforts to have the registration statement declared effective within 105 days from the date of the
Registration Rights Agreement and use best efforts to keep the registration statement continuously effective until the earlier of (i) the date
after which all of the securities to be registered thereunder have been sold, or (ii) the date on which all the securities to be registered
thereunder may be sold without volume or manner-of-sale restrictions and without current public information pursuant to Rule 144 under
the Securities Act.
Agreements with Directors and Senior Management
Insurance, Exculpation, and Indemnification Agreements
We have entered into indemnification agreements with each of our current directors and executive officers exculpating them from
a breach of their duty of care to us to the fullest extent permitted by law, subject to limited exceptions, and undertaking to indemnify them to
the fullest extent permitted by Israeli law, subject to limited exceptions, and including with respect to liabilities resulting from this offering
to the extent such liabilities are not covered by insurance. See “Item 6.C. Board Practices—Approval of Related Party Transactions Under
Israeli Law—Exculpation, Insurance and Indemnification of Directors and Officers.”
Employment and Services Agreements
We have entered into employment or services agreements with our senior management. See “Item 6.B. Compensation.”
Options
We have granted options to purchase our ordinary shares to certain of our officers and directors. See “Item 6.B. Compensation”
and “Item 7.A. Major Shareholders”. We describe our option plans under “Item 6.E. Share Ownership” and “Item 7.A. Major
Shareholders”.
C.
Interests of Experts and Counsel
Not applicable.
ITEM 8.
FINANCIAL INFORMATION.
A. Consolidated Statements and Other Financial Information.
See “Item 18. Financial Statements.”
113
Table of Contents
Legal Proceedings
See “Item 4.B. Business Overview―Legal Proceedings.”
Dividends
We have never declared or paid cash dividends to our shareholders. Currently, we do not intend to pay cash dividends. We intend
to reinvest any earnings in developing and expanding our business. Any future determination relating to our dividend policy will be at the
discretion of our board of directors and will depend on a number of factors, including future earnings, our financial condition, operating
results, contractual restrictions, capital requirements, business prospects, applicable Israeli law and other factors our board of directors may
deem relevant. In addition, the distribution of dividends is limited by Israeli law, which permits the distribution of dividends only out of
distributable profits.
If we pay any dividends, we will also pay such dividends to the ADS holders to the same extent as holders of our ordinary shares,
subject to the terms of the deposit agreement, including the fees and expenses payable thereunder. No dividends will accrue for any
unexercised warrants. Cash dividends on our ordinary shares, if any, will be paid to ADS holders in U.S. dollars.
B. Significant Changes
Other than as otherwise described in this annual report on Form 20-F and as set forth below, no significant change has occurred in
our operations since the date of our consolidated financial statements included in this annual report on Form 20-F.
On March 1, 2018, we convened extraordinary general meetings of our shareholders and the holders of its Series G, Series H,
Series I and Series K warrants.
The sole agenda item at the extraordinary general meeting of the holders of the Series G, Series H, Series I and Series K warrants
was to adopt the provisions of Chapter E3 of the Israeli Securities Law of 1968 which allow us to report in Israel in accordance with U.S.
reporting requirements. The sole agenda item at each of the meetings was approved in accordance with the majority required for such item.
At the extraordinary general meeting of the shareholders of the Company, the following items were on the agenda:
(i) adoption of the provisions of Chapter E3 of the Israeli Securities Law of 1968 which allow the Company to report in Israel
in accordance with U.S. reporting requirements;
(ii) approval of an increase in our authorized share capital by 250,000,000 ordinary shares, par value NIS 0.03 per share, to
750,000,000 ordinary shares, par value NIS 0.03 per share;
(iii) approval of a new compensation policy; and
(iv) approval of certain amendments to the terms of employment of Yehiel Tal, our Chief Executive Officer, including, among
others, (i) an increase of Mr. Tal’s monthly salary to 65,000 NIS, and (ii) a one-time bonus equal to four monthly salaries (i.e. 220,000 NIS)
for achievements in 2017.
Each of the foregoing agenda items was approved at the extraordinary general meeting of the shareholders in accordance with the
majority required for each item.
114
Table of Contents
ITEM 9.
THE OFFER AND LISTING
A. Offer and Listing Details
Our ordinary shares have traded on the TASE under the symbol "CLPT" from May 2010 to January 2018 and on February 1, 2018
began trading under the symbol “CLGN”. On November 20, 2016, we effected a 1-for-3 reverse share split of our ordinary shares. The
share prices below have been adjusted to give effect to the 1-for-3 reverse share split effected on November 20, 2016.
The following table shows the annual, quarterly, and monthly ranges of the high and low per share closing price for our ordinary
shares as reported by the TASE in NIS and U.S. dollars. U.S. dollar amounts per ordinary share are provided using the U.S. dollar
representative rate of exchange on the date to which the high or low market price is applicable, as reported by the Bank of Israel.
Annual:
2017
2016
2015
2014
2013
Quarterly:
First Quarter 2018 (through March 15, 2018)
Fourth Quarter 2017
Third Quarter 2017
Second Quarter 2017
First Quarter 2017
Fourth Quarter 2016
Third Quarter 2016
Second Quarter 2016
First Quarter 2016
Most Recent Six Months:
March 2018 (through March 15, 2018)
February 2018
January 2018
December 2017
November 2017
October 2017
NIS Price
Per Ordinary
Share
U.S. Dollar
Price Per
Ordinary
Share
High
Low
High
Low
0.62
1.55
2.54
0.89
1.22
0.60
0.61
0.62
0.52
0.43
0.97
1.05
1.35
1.55
0.50
0.55
0.60
0.59
0.59
0.61
0.25
0.34
0.66
0.46
0.61
0.47
0.44
0.28
0.37
0.25
0.34
0.91
0.94
1.20
0.47
0.50
0.54
0.49
0.44
0.52
0.17
0.39
0.67
0.25
0.35
0.17
0.17
0.17
0.14
0.12
0.26
0.27
0.36
0.39
0.14
0.16
0.17
0.17
0.17
0.17
0.07
0.09
0.17
0.12
0.17
0.16
0.13
0.08
0.11
0.07
0.09
0.23
0.24
0.31
0.14
0.14
0.16
0.14
0.13
0.15
On January 31, 2018, our ADSs commenced trading on The Nasdaq Capital Market under the symbol “CLGN”. The ADSs were
quoted on the OTCQX from March 2015 to May 25, 2017, and quoted on the OTCQB from May 26, 2017 to January 30, 2018.
115
Table of Contents
The following table sets forth, for the periods indicated, the reported high and low closing sale prices of the ADSs on The Nasdaq
Capital Market in U.S. dollars.
Annual:
2018 (through March 15, 2018)
2017
2016 (from June 8, 2016)*
Quarterly:
First Quarter 2018 (through March 15, 2018)
Fourth Quarter 2017
Third Quarter 2017
Second Quarter 2017
First Quarter 2017
Fourth Quarter 2016
Third Quarter 2016
Second Quarter 2016 (from June 8, 2016)*
Most Recent Six Months:
March 2018 (through March 15, 2018)
February 2018
January 2018
December 2017
November 2017
October 2017
September 2017
U.S.$
Price Per
ADS
High
Low
9.00
9.34
11.93
9.00
9.34
7.15
7.15
6.00
11.93
11.93
11.93
7.00
8.99
9.00
8.85
8.72
9.34
7.15
6.70
5.70
5.45
6.70
7.15
7.15
6.00
5.70
5.45
11.93
11.93
7.00
6.70
8.85
7.50
7.72
7.15
7.15
* To our knowledge, quoted sale prices of the ADSs are available from June 8, 2016.
On March 15, 2018, the last reported sales price of the ADSs on The Nasdaq Capital Market was $7.00 per ADS.
B. Plan of Distribution
Not applicable.
C. Markets
Our ADSs are listed on The Nasdaq Capital Market.
D. Selling Shareholders
Not applicable.
E. Dilution
Not applicable.
F. Expenses of the Issue
Not applicable.
ITEM 10. ADDITIONAL INFORMATION
A. Share Capital
Not applicable.
B. Memorandum and Articles of Association
Articles of Association
The following are summaries of material provisions of our articles of association and the Companies Law insofar as they relate to
the material terms of our ordinary shares.
116
Table of Contents
Purposes and Objects of the Company
Our purpose as set forth in our articles of association is to engage in any lawful activity.
Registration Number
Our registration number with the Israeli Registrar of Companies is 52-0039785.
Voting Rights and Conversion
All ordinary shares have identical voting and other rights in all respects.
Transfer of Shares
Our fully paid ordinary shares are issued in registered form and may be freely transferred under our articles of association, unless
the transfer is restricted or prohibited by another instrument, applicable law, or the rules of a stock exchange on which the shares are listed
for trade. The ownership or voting of our ordinary shares by non-residents of Israel is not restricted in any way by our articles of
association or the laws of the State of Israel, except for ownership by nationals of some countries that are, or have been, in a state of war
with Israel.
Election of Directors
Our ordinary shares do not have cumulative voting rights for the election of directors. As a result, the holders of a majority of the
voting power represented at a shareholders meeting have the power to elect all of our directors, subject to the special approval requirements
for external directors described under “Management—External Directors.”
Under our articles of association, our board of directors must consist of not less than three but no more than twelve directors,
including two external directors, as required by the Companies Law. Pursuant to our articles of association, other than the external
directors, for whom special election requirements apply under the Companies Law, the vote required to appoint a director is a simple
majority vote of holders of our voting shares, participating and voting at the relevant meeting. Each director will serve until his or her
successor is duly elected and qualified or until his or her earlier death, resignation, or removal by a vote of the majority voting power of our
shareholders at a general meeting of our shareholders or until his or her office expires by operation of law, in accordance with the
Companies Law. In addition, our articles of association allow our board of directors to appoint directors to fill vacancies on the board of
directors to serve for a term of office equal to the remaining period of the term of office of the directors(s) whose office(s) have been
vacated. External directors are elected for an initial term of three years, may be elected for additional terms of three years each under
certain circumstances, and may be removed from office pursuant to the terms of the Companies Law. See “Item 6.A. Directors and Senior
Management—External Directors.” for more information.
Dividend and Liquidation Rights
We may declare a dividend to be paid to the holders of our ordinary shares in proportion to their respective shareholdings. Under
the Companies Law, dividend distributions are determined by the board of directors and do not require the approval of the shareholders of a
company unless the company’s articles of association provide otherwise. Our articles of association do not require shareholder approval of
a dividend distribution and provide that dividend distributions may be determined by our board of directors.
Pursuant to the Companies Law, the distribution amount is limited to the greater of retained earnings or earnings generated over
the two most recent fiscal years, according to our then last reviewed or audited financial statements, provided that the date of the financial
statements is not more than six months prior to the date of the distribution, or we may otherwise only distribute dividends that do not meet
such criteria only with court approval. In each case, we are only permitted to distribute a dividend if our board of directors or the court, if
applicable, determines that there is no reasonable concern that payment of the dividend will prevent us from satisfying our existing and
foreseeable obligations as they become due.
117
Table of Contents
In the event of our liquidation, after satisfaction of liabilities to creditors, our assets will be distributed to the holders of our
ordinary shares in proportion to their shareholdings. This right, as well as the right to receive dividends, may be affected by the grant of
preferential dividend or distribution rights to the holders of a class of shares with preferential rights that may be authorized in the future.
With respect to non-exculpation of a director from liability arising out of a prohibited dividend or distribution to shareholders see
“Item 6.C. Board Practices—Approval of Related Party Transactions Under Israeli Law—Exculpation, Insurance and Indemnification of
Directors and Officers.”
Shareholder Meetings
Under Israeli law, we are required to hold an annual general meeting of our shareholders once every calendar year that must be
held no later than 15 months after the date of the previous annual general meeting. All meetings other than the annual general meeting of
shareholders are referred to in our articles of association as extraordinary general meetings. Our board of directors may call extraordinary
general meetings whenever it sees fit, at such time and place, within or outside of Israel, as it may determine. In addition, the Companies
Law provides that our board of directors is required to convene an extraordinary general meeting upon the written request of (i) any two of
our directors or one-fifth of the members of our board of directors or (ii) one or more shareholders holding, in the aggregate, either (a) 5%
or more of our outstanding issued shares and 1% of our outstanding voting power or (b) 5% or more of our outstanding voting power. One
or more shareholders, holding 1% or more of the outstanding voting power, may ask the board to add an item to the agenda of a prospective
meeting, if the proposal merits discussion at the general meeting.
Subject to the provisions of the Companies Law and the regulations promulgated thereunder, shareholders entitled to participate
and vote at general meetings are the shareholders of record on a date to be decided by the board of directors, which may be between four
and 40 days prior to the date of the meeting. Furthermore, the Companies Law requires that resolutions regarding the following matters
must be passed at a general meeting of our shareholders:
● amendments to our articles of association;
● appointment or termination of our auditors;
● appointment of external directors;
● approval of certain related party transactions;
● increases or reductions of our authorized share capital;
● a merger; and
● the exercise of our board of director’s powers by a general meeting, if our board of directors is unable to exercise its powers and
the exercise of any of its powers is required for our proper management.
The Companies Law and the regulations thereof require that a notice of any annual general meeting or extraordinary general
meeting be provided to shareholders at least 21 days or 14 days, as applicable, prior to the meeting and if the agenda of the meeting
includes, for example, the appointment or removal of directors, the approval of transactions with office holders or interested or related
parties, or an approval of a merger, notice must be provided at least 35 days prior to the meeting.
All shareholder decisions are to be taken by votes in a shareholders’ meeting. Under the Companies Law and our articles of
association, shareholders are not permitted to take action via written consent in lieu of a meeting.
118
Table of Contents
Voting Rights
Quorum Requirements
Pursuant to our articles of association, holders of our ordinary shares have one vote for each ordinary share held on all matters
submitted to a vote before the shareholders at a general meeting. As a foreign private issuer, the quorum required for our general meetings
of shareholders consists of at least two shareholders present in person, by proxy or written ballot who hold or represent between them at
least 20% of the total outstanding voting rights. A meeting adjourned for lack of a quorum is generally adjourned to the same day in the
following week at the same time and place or to a later time or date if so specified in the notice of the meeting. At the reconvened meeting,
any two or more shareholders present in person or by proxy shall constitute a lawful quorum. See “Item 16G.—Corporate Governance
Practices” for more information.
Vote Requirements
Our articles of association provide that all resolutions of our shareholders require a simple majority vote, unless otherwise
required by the Companies Law or by our articles of association. Under the Companies Law, each of (i) the approval of an extraordinary
transaction with a controlling shareholder and (ii) the terms of employment or other engagement of the controlling shareholder of the
company or such controlling shareholder’s relative (even if not extraordinary) requires the approval described above under “Management
—Approval of Related Party Transactions Under Israeli Law—Disclosure of Personal Interests of Controlling Shareholders and Approval
of Certain Transactions.” Under our articles of association, the alteration of the rights, privileges, preferences, or obligations of any class of
our shares requires a simple majority vote of the class so affected (or such other percentage of the relevant class that may be set forth in the
governing documents relevant to such class), in addition to the ordinary majority vote of all classes of shares voting together as a single
class at a shareholder meeting. An exception to the simple majority vote requirement is a resolution for the voluntary winding up, or an
approval of a scheme of arrangement or reorganization, of the company pursuant to Section 350 of the Companies Law, which requires the
approval of holders of 75% of the voting rights represented at the meeting, in person, by proxy, or by voting deed and voting on the
resolution.
Access to Corporate Records
Under the Companies Law, shareholders are provided access to: minutes of our general meetings; our shareholders register and
principal shareholders register, articles of association and financial statements; and any document that we are required by law to file
publicly with the Israeli Companies Registrar or the ISA. In addition, shareholders may request to be provided with any document related to
an action or transaction requiring shareholder approval under the related party transaction provisions of the Companies Law. We may deny
this request if we believe it has not been made in good faith or if such denial is necessary to protect our interest or protect a trade secret or
patent.
Modification of Class Rights
Under the Companies Law and our articles of association, the rights attached to any class of share, such as voting, liquidation, and
dividend rights, may be amended by adoption of a resolution by the holders of a majority of the shares of that class present at a separate
class meeting, or otherwise in accordance with the rights attached to such class of shares, as set forth in our articles of association.
Pursuant to Israel’s securities laws, a company whose shares are registered for trade on the TASE may not have more than one
class of shares for a period of one year following initial registration of the company on the TASE, after which it is permitted to issue
preferred shares, if the preference of those shares is limited to a preference in the distribution of dividends and these preferred shares have
no voting rights.
119
Table of Contents
Registration Rights
In connection with the first closing of the Alpha financing, we entered into a Registration Rights Agreement with Alpha. Pursuant
to the Registration Rights Agreement, we agreed to file a registration statement with the SEC within 45 days from the date of the
Registration Rights Agreement to register the resale of our ordinary shares held by Alpha that were issued in the private placement
including ordinary shares underlying the Debentures, the Alpha Warrants and pre-funded warrants issuable upon conversion of the
Debentures, or the Pre-Funded Warrants, and to maintain the effectiveness thereunder. We also agreed to use best efforts to have the
registration statement declared effective within 105 days from the date of the Registration Rights Agreement and use best efforts to keep
the registration statement continuously effective until the earlier of (i) the date after which all of the securities to be registered thereunder
have been sold, or (ii) the date on which all the securities to be registered thereunder may be sold without volume or manner-of-sale
restrictions and without current public information pursuant to Rule 144 under the Securities Act.
Acquisitions under Israeli Law
Full Tender Offer
A person wishing to acquire shares of an Israeli public company and who would as a result hold over 90% of the target company’s
issued and outstanding share capital is required by the Companies Law to make a tender offer to all of the company’s shareholders for the
purchase of all of the issued and outstanding shares of the company. A person wishing to acquire shares of a public Israeli company and
who would as a result hold over 90% of the issued and outstanding share capital of a certain class of shares is required to make a tender
offer to all of the shareholders who hold shares of the relevant class for the purchase of all of the issued and outstanding shares of that
class. If the shareholders who do not accept the offer hold less than 5% of the issued and outstanding share capital of the company or of the
applicable class, and more than half of the shareholders who do not have a personal interest in the offer accept the offer, all of the shares
that the acquirer offered to purchase will be transferred to the acquirer by operation of law. However, a tender offer will also be accepted if
the shareholders who do not accept the offer hold less than 2% of the issued and outstanding share capital of the company or of the
applicable class of shares.
Upon a successful completion of such a full tender offer, any shareholder that was an offeree in such tender offer, whether such
shareholder accepted the tender offer or not, may, within six months from the date of acceptance of the tender offer, petition an Israeli court
to determine whether the tender offer was for less than fair value and that the fair value should be paid as determined by the court.
However, under certain conditions, the offeror may include in the terms of the tender offer that an offeree who accepted the offer will not
be entitled to petition the Israeli court as described above.
If (i) the shareholders who did not respond or accept the tender offer hold at least 5% of the issued and outstanding share capital of
the company or of the applicable class or the shareholders who accept the offer constitute less than a majority of the offerees that do not
have a personal interest in the acceptance of the tender offer, or (ii) the shareholders who did not accept the tender offer hold 2% or more of
the issued and outstanding share capital of the company (or of the applicable class), the acquirer may not acquire shares of the company
that will increase its holdings to more than 90% of the company’s issued and outstanding share capital or of the applicable class from
shareholders who accepted the tender offer.
Special Tender Offer
The Companies Law provides that an acquisition of shares of an Israeli public company must be made by means of a special tender
offer if as a result of the acquisition the purchaser would become a holder of 25% or more of the voting rights in the company. This
requirement does not apply if there is already another holder of at least 25% of the voting rights in the company. Similarly, the Companies
Law provides that an acquisition of shares in a public company must be made by means of a special tender offer if, as a result of the
acquisition, the purchaser would become a holder of more than 45% of the voting rights in the company, provided that there is no other
shareholder of the company who holds more than 45% of the voting rights in the company, subject to certain exceptions.
120
Table of Contents
A special tender offer must be extended to all shareholders of a company but the offeror is not required to purchase shares
representing more than 5% of the voting power attached to the company’s outstanding shares, regardless of how many shares are tendered
by shareholders. A special tender offer may be consummated only if (i) outstanding shares representing at least 5% of the voting power of
the company will be acquired by the offeror and (ii) the number of shares tendered in the offer exceeds the number of shares whose holders
objected to the offer (excluding the purchaser, controlling shareholders, holders of 25% or more of the voting rights in the company or any
person having a personal interest in the acceptance of the tender offer). If a special tender offer is accepted, then the purchaser or any
person or entity controlling it or under common control with the purchaser or such controlling person or entity may not make a subsequent
tender offer for the purchase of shares of the target company and may not enter into a merger with the target company for a period of one
year from the date of the offer, unless the purchaser or such person or entity undertook to effect such an offer or merger in the initial special
tender offer.
Under the Companies Regulations (Relief for Public Companies whose Shared are Traded on Exchanges outside of Israel), the
above requirements for a special tender offer do not apply in instances whereby according to the laws of the foreign jurisdiction there are
limitations regarding the acquisition of a controlling interest in the company of any specified portion or the acquisition of a controlling
interest of any specified portion necessitates an offer by the potential acquirer of a controlling interest to acquire shares from amongst the
publicly traded shares.
Merger
The Companies Law permits merger transactions if approved by each party’s board of directors and, unless certain requirements
described under the Companies Law are met, by a majority vote of each party’s shareholders, and, in the case of the target company, a
majority vote of each class of its shares, voted on the proposed merger at a shareholders meeting.
The board of directors of a merging company is required pursuant to the Companies Law to discuss and determine whether in its
opinion there exists a reasonable concern that, as a result of a proposed merger, the surviving company will not be able to satisfy its
obligations towards its creditors, taking into account the financial condition of the merging companies. If the board of directors has
determined that such a concern exists, it may not approve a proposed merger. Following the approval of the board of directors of each of
the merging companies, the boards of directors must jointly prepare a merger proposal for submission to the Israeli Registrar of Companies.
For purposes of the shareholder vote, unless a court rules otherwise, the merger will not be deemed approved if a majority of the
votes of shares represented at the shareholders meeting that are held by parties other than the other party to the merger, or by any person
(or group of persons acting in concert) who holds (or hold, as the case may be) 25% or more of the voting rights or the right to appoint 25%
or more of the directors of the other party, vote against the merger. If, however, the merger involves a merger with a company’s own
controlling shareholder or if the controlling shareholder has a personal interest in the merger, then the merger is instead subject to the same
special majority approval that governs all extraordinary transactions with controlling shareholders (as described under “Management—
Approval of Related Party Transactions Under Israeli Law—Disclosure of Personal Interests of Controlling Shareholders and Approval of
Certain Transactions”).
If the transaction would have been approved by the shareholders of a merging company but for the separate approval of each class
or the exclusion of the votes of certain shareholders as provided above, a court may still approve the merger upon the request of holders of
at least 25% of the voting rights of a company, if the court holds that the merger is fair and reasonable, taking into account the value of the
parties to the merger and the consideration offered to the shareholders of the target company.
Upon the request of a creditor of either party to the proposed merger, the court may delay or prevent the merger if it concludes
that there exists a reasonable concern that, as a result of the merger, the surviving company will be unable to satisfy the obligations of the
merging entities, and may further give instructions to secure the rights of creditors.
In addition, a merger may not be consummated unless at least 50 days have passed from the date on which a proposal for approval
of the merger was filed by each party with the Israeli Registrar of Companies and at least 30 days have passed from the date on which the
merger was approved by the shareholders of each party.
121
Table of Contents
Anti-Takeover Measures under Israeli Law
For as long as our securities are traded on the TASE, the Israeli Securities Law does not generally allow us, as a public company
traded on the TASE, to create and issue shares having rights different from those attached to our ordinary shares, other than preferred
shares with a dividend preference and without voting rights. For as long as our shares are traded on the TASE, no preferred shares will be
authorized under the Israeli Securities Law and our articles of association. The authorization and designation of a class of preferred shares
will require an amendment to our articles of association, which requires the prior approval of the holders of a majority of the voting power
attaching to our issued and outstanding shares at a general meeting. The convening of the meeting, the shareholders entitled to participate,
and the majority vote required to be obtained at such a meeting will be subject to the requirements set forth in the Companies Law as
described above in “—Voting Rights.”
Borrowing Powers
Pursuant to the Companies Law and our articles of association, our board of directors may exercise all powers and take all actions
that are not required under law or under our articles of association to be exercised or taken by our shareholders, including the power to
borrow money for company purposes.
Changes in Capital
Our articles of association enable us to increase or reduce our share capital. Any such changes are subject to the provisions of the
Companies Law and must be approved by a resolution duly passed by our shareholders at a general meeting by voting on such change in
the capital. In addition, certain transactions that have the effect of reducing capital, such as the declaration and payment of dividends in the
absence of sufficient retained earnings or profits, require the approval of both our board of directors and an Israeli court.
C. Material Contracts
Except as set forth below, we have not entered into any material contract within the two years prior to the date of this annual report
on Form 20-F, other than contracts entered into in the ordinary course of business, or as otherwise described herein in “Item 4.A. History
and Development of the Company”, “Item 4.B. Business Overview”, “Item 7A. Major Shareholders” or “Item 7B. Related Party
Transactions” above.
February 2017 Financing
On February 12, 2017, we completed a public offering in which we sold 21,152,000 ordinary shares at a price per share of NIS
0.34, as well as 10,576,000 Series L warrants to purchase 10,576,000 ordinary shares at an exercise price of NIS 0.36 ($0.10) per warrant,
for gross proceeds of NIS 7,191,680 ($2,074,324). The warrants were exercisable at NIS 0.36 per warrant until June 13, 2017. In addition,
we issued 941,400 Series L warrants to purchase 941,400 ordinary shares to the underwriters in the transaction under the same conditions
set out above. The following owners of our ordinary shares participated in these offerings: Meitav Investments Ltd, Docor
International BV, Docor Levi Lassen BV, and Adi Goldin, the Chairman of the Company’s board of directors.
During the second quarter of 2017, 10,055,464 Series L warrants were exercised into 10,055,464 ordinary shares at an exercise
price of NIS 0.36 for each warrant resulting in NIS 3,618,000 ($1,043,554) in gross proceeds. 1,461,936 Series L warrants that were not
exercised expired on June 14, 2017.
Alpha Financing
On September 6, 2017, we entered into the Alpha Purchase Agreement with Alpha, pursuant to which we agreed, upon the terms
and subject to the conditions of the Alpha Purchase Agreement, to issue and sell to Alpha in a private placement, certain of our securities in
three tranches, as follows: (i) at the first closing, ordinary shares and a Debenture, for a purchase price of $2,000,000, (ii) at the second
closing, ordinary shares and/or a Debenture for a purchase price of $2,000,000, and (iii) at the third closing, ordinary shares and/or a
Debenture, and a warrant to purchase 49,607,407 ordinary shares, or the Alpha Warrant, for a purchase price of $1,000,000.
122
Table of Contents
Alpha Purchase Agreement
At each closing, the number of ordinary shares issuable shall be calculated by dividing the applicable purchase price by NIS
0.36144, subject to adjustment for share splits, share dividends and the like, and with respect to each of the first and second closings, an
additional 3,458,408 ordinary shares are issuable for no cash consideration; provided that to the extent that the purchaser’s ownership of
ordinary shares, together with any of its affiliates, would exceed a beneficial ownership limitation of 4.99%, then Alpha may at its option,
elect to apply the applicable purchase price to the purchase of Debentures. Additionally, on March 20, 2018, our board of directors agreed
to issue to Alpha an additional 1,060,000 ordinary shares, subject to shareholder approval.
We completed the first closing on October 26, 2017, which resulted in the issuance to Alpha of an aggregate of 7,280,000 ordinary
shares and a Debenture in the principal amount of $1,375,144 for gross proceeds of $2,000,000. We completed the second closing on
December 31, 2017, which resulted in the issuance to Alpha of a Debenture in the principal amount of $2,000,000. Upon the listing of our
ADSs on The NASDAQ Capital Market, the Debentures automatically converted into pre-paid warrants to purchase 786,455 ADSs
representing approximately 39,322,742 ordinary shares. Assuming the third closing occurs under the currently contemplated terms, then we
will issue a prepaid warrant to purchase such number of ADSs representing approximately 9,921,482 ordinary shares and the Alpha
Warrant to purchase 49,607,407 ordinary shares.
Each of the closings was subject to certain closing conditions. The third closing was subject to the receipt of shareholder and
option holder approval to adopt the provisions of Chapter E3 of the Israeli Securities Law of 1968 (which allow us to report in Israel in
accordance with U.S. reporting requirements), or the Dual Reporting Security Holders’ Approval. On March 1, 2018, such shareholder and
option holder approval was obtained.
Under the Alpha Purchase Agreement, Alpha was granted a right of participation in certain future offerings until October 26,
2018. In addition, the Alpha Purchase Agreement contains full-ratchet anti-dilution protection until October 26, 2019 in the event of certain
subsequent equity issuances at a price that is lower than the then applicable per ordinary share purchase price.
The Alpha Purchase Agreement provides for the following restrictions on future issuances of securities (subject to certain exempt
issuances): (i) until the 24 month anniversary of the second closing or the applicable date of termination of the Alpha Purchaser Agreement
pursuant to the terms therein, if applicable, (as the case may be), we are prohibited from effecting a variable rate transaction, (iii) until the
12 month anniversary of the third closing or April 30, 2018 (as the case may be), we are prohibited from issuing any equity securities that
include any anti-dilution protection (other than customary anti-dilution protection for share splits, dividends and the like), and (iv) until the
12 month anniversary of the second closing or the applicable date of termination of the Alpha Purchaser Agreement pursuant to the terms
therein, if applicable, (as the case may be), we are prohibited from issuing any equity securities for an effective price per share less than the
effective per ordinary purchase price, subject to adjustment for share splits, dividends and the like.
The Alpha Purchase Agreement further provides for certain board appointment rights. On the first closing, we are required to
appoint two directors selected by Alpha (out of a seven-member board) and on the second closing, we are required to appoint one director
selected by Alpha (out of an eight-member board), each who shall serve as directors at least until the end of our 2018 annual general
meeting. At the first closing, Alpha selected Scott Burell to serve on the board and is yet to select an additional director.
We have been required under the Alpha Purchase Agreement to use commercially reasonable efforts to take the necessary steps to
transition to dual-listing reporting format with a view to delisting our ordinary shares form the TASE and to list the ADSs on the Nasdaq
Capital Market.
If we fail to timely effect a legend removal in accordance with the Alpha Purchase Agreement, the Alpha Purchase Agreement
provides for certain liquidated damages and customary buy-in provisions. In addition, the Alpha Purchase Agreement provides for certain
liquidated damages in the case of a failure to satisfy certain current public information requirements under Rule 144.
The Alpha Purchase Agreement may be terminated by the purchasers or by us partially with respect to the third closing if the third
closing does not occur on or before April 30, 2018.
123
Table of Contents
The Alpha Purchase Agreement also contains representations and warranties, covenants and indemnification provisions customary
in transactions of this nature.
Debentures
The Debenture issuable had a maturity date of five years from the date of issuance and is interest-free. The Debenture was
convertible at any time at the option of the holder into ADSs at a conversion price of the US dollar equivalent, as for the Debenture issued
in the first and second closing, of NIS 15.3897 and, for the Debenture to be issued in the third closing, of NIS 18.0719 (each calculated in
accordance with the rate of exchange of NIS 3.586 per US$1.00) per ADS. In addition, the Debenture was mandatorily convertible at the
then effective conversion price without regard to any beneficial ownership limitation if (i) the ADSs or our ordinary shares are approved
for listing on the Nasdaq Capital Market, and (ii) certain equity conditions are met, including, among other things, an effective registration
covering a minimum number of ordinary shares held by the holder or that all the ordinary shares or ADSs held by the holder may be sold
under Rule 144 without volume or manner-of-sale restrictions or current public information requirements; provided that the holder may
elect to convert the Debenture in whole or in part to a prepaid warrant to purchase such number of ADSs otherwise issuable upon
mandatory conversion of the Debenture. The prepaid warrant may be exercised on a cashless basis at any time. The prepaid warrant is
subject to certain anti-dilution adjustments upon certain events, including share splits, share dividends, subsequent rights offerings, pro-rata
distributions and fundamental transactions. In addition, we entered into a side letter with Alpha pursuant to which any ordinary shares or
ADSs issued upon exercise of the prepaid warrant are subject to full-ratchet anti-dilution protection until October 26, 2019 in the event of
certain subsequent equity issuances at a price that is lower than the applicable conversion price of the Debenture.
The Debenture was subject to certain anti-dilution adjustments upon certain events, including share splits, share dividends,
subsequent rights offerings, pro-rata distributions and fundamental transactions. In addition, the Debenture contained full-ratchet anti-
dilution protection until October 26, 2019 in the event of certain subsequent equity issuances at a price that is lower than the then
applicable conversion price.
Upon the occurrence of certain events of default, the outstanding principal amount of the Debenture, together with other amounts
due, would become, at the election of the holder, immediately due and payable in cash at the “Mandatory Default Amount” as defined in
the Debenture. In addition, if we fail to timely effectuate a conversion under the terms of the Debenture, the Debenture provided for certain
liquidated damages and customary buy-in provisions.
The Debenture was an unsecured, general obligation, and ranks pari passu with other unsecured and unsubordinated liabilities. As
stated above, upon the listing of our ADSs on The NASAQ Capital Market, the Debentures automatically converted into pre-paid warrants
to purchase 786,455 ADSs representing approximately 39,322,742 ordinary shares.
Warrant
At the third closing, we are required to issue the Alpha Warrant to purchase 49,607,407 ordinary shares represented by 992,148
ADSs. The Alpha Warrant may be exercised for a period of five years from issuance at an exercise price of the US dollar equivalent of NIS
36.14379 per ADS (calculated in accordance with the known representative rate of exchange on the date of the notice of exercise). The
Alpha Warrant may be exercised on a cashless basis if after the one-year anniversary of issuance there is no effective registration statement
covering the resale of the ADSs underlying the Alpha Warrant.
The Alpha Warrant is subject to certain anti-dilution adjustments upon certain events, including share splits, share dividends,
subsequent rights offerings, pro-rata distributions and fundamental transactions (which, in the case of fundamental transactions, is subject to
certain limitations). In addition, the Alpha Warrant contains full-ratchet anti-dilution protection until October 26, 2019 in the event of
certain subsequent equity issuances at a price that is lower than the applicable exercise price of the Alpha Warrant.
If we fail to timely effectuate an exercise under the terms of the Alpha Warrant, the Alpha Warrant provides for certain liquidated
damages and customary buy-in provisions.
124
Table of Contents
Registration Rights Agreement
In connection with the first closing, we entered into a Registration Rights Agreement with Alpha. Pursuant to the Registration
Rights Agreement, we agreed to file a registration statement with the SEC within 45 days from the date of the Registration Rights
Agreement to register the resale of our ordinary shares held by Alpha that were issued in the private placement including ordinary shares
underlying the Debentures, Alpha Warrant and Pre-Funded Warrants and to maintain the effectiveness thereunder. We also agreed to use
best efforts to have the registration statement declared effective within 105 days from the date of the Registration Rights Agreement and
use best efforts to keep the registration statement continuously effective until the earlier of (i) the date after which all of the securities to be
registered thereunder have been sold, or (ii) the date on which all the securities to be registered thereunder may be sold without volume or
manner-of-sale restrictions and without current public information pursuant to Rule 144 under the Securities Act.
Meitav Dash Financing
On November 8, 2017, we entered into the Meitav Purchase Agreement with Meitav Dash, pursuant to which we agreed, upon the
terms and subject to the conditions of the Meitav Purchase Agreement, to issue and sell to Meitav Dash in a private placement, certain of
our securities in three tranches, as follows: (i) at the first closing, 9,500,000 ordinary shares, for a purchase price of NIS 3,800,000
($1,096,048), (ii) at the second closing, 2,400,000 ordinary shares for a purchase price of NIS 960,000 ($272,032), provided that Meitav
Dash shall not be obligated to buy or hold, immediately following the second closing, 20% or more of our share capital, and (iii) at the
third closing for no additional consideration, warrants exercisable into 11,900,000 ordinary shares, or the Meitav Warrants.
Meitav Purchase Agreement
We completed the first and second closings on December 26, 2017 which resulted in the issuance to Meitav Dash of an aggregate
of 11,900,000 ordinary shares for gross proceeds of NIS 4,760,000 ($1,372,945) and we completed the third closing on March 7, 2018
which resulted in the issuance to Meitav Dash of a warrant to purchase 11,900,000 ordinary shares represented by 238,000 ADSs.
The Meitav Purchase Agreement contains full-ratchet anti-dilution protection until the second anniversary of the first closing in
the event of certain subsequent equity issuances at a price that is lower than the then applicable per ordinary share purchase price.
The Meitav Purchase Agreement also contains representations and warranties and covenants provisions customary in transactions
of this nature.
Meitav Warrant
At the third closing, we issued the Meitav Warrants exercisable into 11,900,000 ordinary shares, represented by 238,000 ADSs.
The warrants may be exercised for a period of five years from issuance at an exercise price of the US dollar equivalent of NIS 40 per ADS
(calculated in accordance with the known representative rate of exchange on the date of the notice of exercise).
The warrants are subject to certain anti-dilution adjustments upon certain events, including share splits, share dividends,
subsequent rights offerings, and fundamental transactions. In addition, pursuant to a side letter, the ordinary shares or ADSs issuable upon
exercise of the warrants are subject to full-ratchet anti-dilution protection until the second anniversary of the first closing in the event of
certain subsequent equity issuances at a price that is lower than the then applicable per ordinary share purchase price.
125
Table of Contents
Ami Sagi Financing
On November 9, 2017, we entered into the Sagi Purchase Agreement with Ami Sagi, pursuant to which we agreed, upon the terms
and subject to the conditions of the Sagi Purchase Agreement, to issue and sell to Ami Sagi in a private placement, certain of our securities
in two tranches, as follows: (i) at the first closing, 9,300,000 ordinary shares, for a purchase price of NIS 3,720,000 ($1,072,974), and (ii) at
the second closing for no additional consideration, the Sagi Warrants exercisable into 9,300,000 ordinary shares.
Sagi Purchase Agreement
We completed the first closing on December 26, 2017 which resulted in the issuance to Ami Sagi of an aggregate of 9,300,000
ordinary shares for gross proceeds of NIS 3,720,000 ($1,072,974) and we completed the second closing on March 7, 2018 which resulted in
the issuance to Ami Sagi of a warrant to purchase 9,300,000 ordinary shares represented by 186,000 ADSs.
The Sagi Purchase Agreement contains full-ratchet anti-dilution protection until the second anniversary of the first closing in the
event of certain subsequent equity issuances at a price that is lower than the then applicable per ordinary share purchase price.
The Sagi Purchase Agreement also contains representations and warranties and covenants provisions customary in transactions of
this nature.
Sagi Warrant
At the second closing, we issued warrants exercisable into 9,300,000 ordinary shares. The warrants may be exercised for a period
of five years from issuance at an exercise price of the US dollar equivalent of NIS 40 per ADS (calculated in accordance with the known
representative rate of exchange on the date of the notice of exercise).
The warrants are subject to certain anti-dilution adjustments upon certain events, including share splits, share dividends,
subsequent rights offerings, and fundamental transactions. In addition, pursuant to a side letter, the ordinary shares or ADSs issuable upon
exercise of the warrants are subject to full-ratchet anti-dilution protection until the second anniversary of the first closing in the event of
certain subsequent equity issuances at a price that is lower than the then applicable per ordinary share purchase price.
January 2018 Financing
On January 18, 2018, we entered into Security Purchase Agreements for the purchase and sale, in a private placement, of an
aggregate of 4,344,340 ordinary shares for an aggregate of NIS 2,172,170 ($615,520) to the following three investors as follows: (i) Alpha
entered into a Security Purchase Agreement for the purchase and sale of 1,275,340 ordinary shares for NIS 637,670 ($183,926); (ii) Ami
Sagi entered into a Security Purchase Agreement for the purchase and sale of 2,046,000 ordinary shares for NIS 1,023,000 ($295,068); and
(iii) Docor International BV entered into a Security Purchase Agreement for the purchase and sale of 1,023,000 ordinary shares for NIS
511,500 ($147,534). Closing occurred on January 25, 2018.
D. Exchange Controls
There are currently no Israeli currency control restrictions on remittances of dividends on our ordinary shares, proceeds from the
sale of the shares or interest or other payments to non-residents of Israel, except for shareholders who are subjects of countries that are, or
have been, in a state of war with Israel.
E. Taxation.
The following description is not intended to constitute a complete analysis of all tax consequences relating to the acquisition,
ownership and disposition of our ordinary shares and ADSs. You should consult your own tax advisor concerning the tax consequences of
your particular situation, as well as any tax consequences that may arise under the laws of any state, local, foreign, or other taxing
jurisdiction.
126
Table of Contents
Israeli Tax Considerations and Government Programs
The following is a brief summary of the material Israeli tax laws applicable to us, and certain Israeli Government programs that
benefit us. This section also contains a discussion of material Israeli tax consequences concerning the ownership and disposition of our
ordinary shares. This summary does not discuss all the aspects of Israeli tax law that may be relevant to a particular investor in light of his
or her personal investment circumstances or to some types of investors subject to special treatment under Israeli law. Examples of such
investors include residents of Israel or traders in securities who are subject to special tax regimes not covered in this discussion. To the
extent that the discussion is based on new tax legislation that has not yet been subject to judicial or administrative interpretation, we cannot
assure you that the appropriate tax authorities or the courts will accept the views expressed in this discussion. The discussion below is
subject to change, including due to amendments under Israeli law or changes to the applicable judicial or administrative interpretations of
Israeli law, which change could affect the tax consequences described below.
General Corporate Tax Structure in Israel
Israeli resident (as defined below) companies, such as us, are generally subject to corporate tax at the rate of 24% as of 2017. This
rate is scheduled to be reduced to 23% as of January 1, 2018. However, the effective tax rate payable by a company that derives income
from a Preferred Enterprise or a Preferred Technology Enterprise (as discussed below) may be considerably lower. Capital gains derived by
an Israeli company are generally subject to tax at the prevailing corporate tax rate.
Law for the Encouragement of Industry (Taxes), 5729-1969
The Law for the Encouragement of Industry (Taxes), 5729-1969, or the Industry Encouragement Law, provides several tax
benefits for “Industrial Companies.”
The Industry Encouragement Law defines an “Industrial Company” as a company resident in Israel, of which 90% or more of its
income in any tax year, other than income from defense loans, is derived from an “Industrial Enterprise” owned by it. An “Industrial
Enterprise” is defined as an enterprise whose principal activity in a given tax year is industrial production.
The following corporate tax benefits, among others, are available to Industrial Companies:
● amortization over an eight-year period of the cost of patents and rights to use a patent and know-how which were purchased in
good faith and are used for the development or advancement of the Industrial Enterprise;
● deduction over a three-year period of expenses incurred in connection with the issuance and listing of shares on a stock market;
and
● under certain conditions, an election to file consolidated tax returns with related Israeli Industrial Companies.
There can be no assurance that we currently qualify, or will continue to qualify, as an Industrial Company or that the benefits
described above will be available in the future.
Law for the Encouragement of Capital Investments, 5719-1959
Tax Benefits for Income from Preferred Enterprise
The Law for the Encouragement of Capital Investments, 5719-1959, or the Investment Law, currently provides certain tax benefits
for income generated by “Preferred Companies” from their “Preferred Enterprises.” The definition of a Preferred Company includes, inter
alia, a company incorporated in Israel that is not wholly owned by a governmental entity, which:
● owns a Preferred Enterprise, which is defined as an “Industrial Enterprise” (as defined under the Investment Law) that is
classified as either a “Competitive Enterprise” (as defined under the Investment Law) or a “Competitive Enterprise in the Field
of Renewable Energy” (as defined under the Investment Law);
127
Table of Contents
● is controlled and managed from Israel;
● is not a “Family Company,” a “Home Company,” or a “Kibbutz” (collective community) as defined under the Income Tax
Ordinance;
● keeps acceptable books of account and files reports in accordance with the provisions of the Investment Law and the Income
Tax Ordinance; and
● was not, and certain officers of which were not, convicted of certain crimes in the 10 years prior to the tax year with respect to
which benefits are being claimed.
As of January 1, 2017, a Preferred Company is currently entitled to a reduced corporate tax rate of 16% with respect to its income
derived by its Preferred Enterprise, unless the Preferred Enterprise is located in development area A, in which case the rate is currently
7.5% (our operations are currently not located in development area A).
Dividends paid out of income attributed to a Preferred Enterprise are generally subject to tax at the rate of 20% or such lower rate
as may be provided in an applicable tax treaty. However, if such dividends are paid to an Israeli company, such dividends should be exempt
from tax (although, if such dividends are subsequently distributed to individuals or a non-Israeli company, tax at a rate of 20% or such
lower rate as may be provided in an applicable tax treaty will apply).
If in the future we generate taxable income, to the extent that we qualify as a “Preferred Company,” the benefits provided under
the Investment Law could potentially reduce our corporate tax liabilities. Therefore, the termination or substantial reduction of the benefits
available under the Investment Law could materially increase our tax liabilities.
Tax Benefits for Income from Preferred Technology Enterprise
An amendment to the Investment Law was enacted as part of the Economic Efficiency Law that was published on December 29,
2016, and became effective as of January 1, 2017 (and is referred to herein as the “2017 Amendment”). The 2017 Amendment provides
new tax benefits to Preferred Companies for “Technology Enterprises,” as described below, and is in addition to the Preferred Enterprise
regime provided under the Investment Law.
The 2017 Amendment provides that a technology company satisfying certain conditions will qualify as a “Preferred Technology
Enterprise” and may thereby enjoy a reduced corporate tax rate of 12% on income that qualifies as “Preferred Technology Income,” as
defined in the Investment Law. The tax rate is further reduced to 7.5% for a Preferred Technology Enterprise located in development area
A. In addition, a Preferred Technology Enterprise may enjoy a reduced capital gains tax rate of 12% on capital gain derived from the sale
of certain “Benefited Intangible Assets” (as defined in the Investment Law) to a related foreign company if the Benefited Intangible Assets
were acquired from a foreign company on or after January 1, 2017 for at least NIS 200 million, and the sale receives prior approval from
the IIA.
Dividends distributed by a Preferred Technology Enterprise that are paid out of Preferred Technology Income are subject to tax at
the rate of 20%, but if they are distributed to a foreign company and at least 90% of the shares of the distributing company are held by
foreign resident companies then the tax rate may be as low as 4%, subject to the fulfillment of certain conditions.
128
Table of Contents
As we have not yet generated taxable income, there is no assurance that we qualify as a Preferred Technology Enterprise or that
the benefits described above will be available to us in the future.
If in the future we generate taxable income, to the extent that we qualify as a “Preferred Company,” the benefits provided under
the Investment Law could potentially reduce our corporate tax liabilities. Therefore, the termination or substantial reduction of the benefits
available under the Investment Law could materially increase our tax liabilities.
The Encouragement of Research, Development and Technological Innovation in the Industry Law 5744
Under the Encouragement of Research, Development and Technological Innovation in the Industry Law 5744-1984 (formerly
known as the Law for the Encouragement of Research and Development in Industry 5744-1984), or Innovation Law and the regulations and
guidelines promulgated thereunder, research and development programs which meet specified criteria and are approved by a committee of
the IIA, are eligible for grants. The grants awarded are typically up to 50% of the project’s expenditures, as determined by the research
committee. The grantee is required to pay royalties to the State of Israel from the sale of products developed under the program.
Regulations under the Innovation Law generally provide for the payment of royalties of 3% to 6% on income generated from products and
services based on technology developed using grants, until 100% of the grant, linked to the dollar and bearing interest at the LIBOR rate, is
repaid. In July 2017, new regulations came into force. According to the new regulations the royalties range between 1.3-5% depending on
the company’s size and sector. The terms of the IIA participation also require that products developed with IIA grants be manufactured in
Israel and that the know-how developed thereunder may not be transferred outside of Israel, unless approval is received from the IIA and
additional payments are made to the IIA. However, this does not restrict the export of products that incorporate the funded know-how. The
royalty repayment ceiling can reach up to three times the amount of the grant received (plus interest) if manufacturing is transferred outside
of Israel, and repayment of up to six times the amount of the grant (plus interest) may be required if the technology itself is transferred
outside of Israel or license to use it was granted to a foreign entity.
Taxation of our Shareholders
Capital Gains Tax
Israeli law generally imposes a capital gains tax (i) on the sale of any capital assets by residents of Israel, as defined for Israeli tax
purposes, and (ii) on the sale of capital assets located in Israel, including shares of Israeli companies, by non-residents of Israel, unless a
specific exemption is available or unless a tax treaty between Israel and the shareholder’s country of residence provides otherwise. The law
distinguishes between real gain and inflationary surplus. The inflationary surplus is a portion of the total capital gain that is equivalent to
the increase of the relevant asset’s purchase price which is attributable to the increase in the Israeli consumer price index or a foreign
currency exchange rate between the date of purchase and the date of sale. The real gain is the excess of the total capital gain over the
inflationary surplus.
Israeli Residents
Generally, as of January 1, 2012, the tax rate applicable to real capital gains derived from the sale of shares, whether listed on a
stock market or not, is 25% for Israeli individuals, unless such shareholder claims a deduction for financing expenses in connection with
such shares, in which case the gain will generally be taxed at a rate of 30%. Additionally, if such shareholder is considered a “substantial
shareholder” at the time of the sale or at any time during the 12-month period preceding such sale, the tax rate will be 30%. A “substantial
shareholder” is defined as one who holds, directly or indirectly, alone or “together with another” (i.e., together with a relative, or together
with someone who is not a relative but with whom, according to an agreement, there is regular cooperation in material matters of the
company, directly or indirectly), holds, directly or indirectly, at least 10% of any of the “means of control” in the company. “Means of
control” generally include the right to vote, receive profits, nominate a director or an executive officer, receive assets upon liquidation, or
instruct someone who holds any of the aforementioned rights regarding the manner in which such rights are to be exercised. However,
different tax rates will apply to dealers in securities. Israeli companies are subject to capital gains tax at the regular corporate tax rate
(i.e., currently 24%, but scheduled to be reduced to 23% as of January 1, 2018) on real capital gains derived from the sale of listed shares.
129
Table of Contents
As of January 1, 2017, Israeli resident shareholders who are individuals with taxable income that exceeds NIS 640,000 in a tax
year (linked to the Israeli consumer price index each year) will be subject to an additional tax at the rate of 3% on the portion of their
taxable income for such tax year that is in excess of NIS 640,000 (linked to the Israeli consumer price index each year). For this purpose,
taxable income includes taxable capital gains from the sale of our shares and taxable income from dividend distributions.
In some instances where our shareholders are liable for Israeli tax on the sale of their ordinary shares, the payment of the
consideration may be subject to the withholding of Israeli tax at source.
Non-Israeli Residents
A non-Israeli resident who derives capital gains from the sale of shares in an Israeli resident company that were purchased after
the company was listed for trading on a stock exchange outside of Israel will be exempt from Israeli tax so long as the shares were not held
through a permanent establishment that the non-resident maintains in Israel. However, non-Israeli resident corporations will not be entitled
to the foregoing exemption if (i) an Israeli resident has a controlling interest, directly or indirectly, alone, “together with another” (as
defined above), or together with another Israeli resident, of more than 25% in one or more of the “means of control” (as defined above) in
such non-Israeli resident corporation, or (ii) Israeli residents are the beneficiaries of, or are entitled to, 25% or more of the revenues or
profits of such non-Israeli resident corporation, whether directly or indirectly.
In addition, a sale of securities by a non-Israeli resident may be exempt from Israeli capital gains tax under the provisions of an
applicable tax treaty. For example, pursuant to the provisions of the Convention between the Government of the United States of America
and the Government of the State of Israel with respect to Taxes on Income, as amended, or the U.S.-Israel Tax Treaty, capital gains arising
from the sale, exchange or disposition of our ordinary shares by (i) a person who qualifies as a resident of the United States within the
meaning of the U.S.-Israel Tax Treaty, (ii) who holds the shares as a capital asset, and (iii) who is entitled to claim the benefits afforded to
such person by the U.S.-Israel Tax Treaty generally is generally exempt from Israeli capital gains tax. Such exemption will not apply if:
(i) such person holds, directly or indirectly, shares representing 10% or more of our voting power during any part of the 12-month period
preceding such sale, exchange, or disposition, subject to particular conditions; (ii) the capital gains from such sale, exchange, or disposition
are attributable to a permanent establishment in Israel; or (iii) such person is an individual and was present in Israel for 183 days or more
during the relevant tax year. In such case, the capital gain arising from the sale, exchange, or disposition of our ordinary shares would be
subject to Israeli tax, to the extent applicable; however, under the U.S.-Israel Tax Treaty, the taxpayer may be permitted to claim a credit
for such taxes against the U.S. federal income tax imposed with respect to such sale, exchange, or disposition, subject to the limitations
under U.S. law applicable to foreign tax credits. The U.S.-Israel Tax Treaty does not relate to U.S. state or local taxes.
Shareholders may be required to demonstrate that they are exempt from tax on their capital gains in order to avoid withholding at
source at the time of sale.
It should be noted that in the event that the real capital gain realized by an individual shareholder is not exempt from tax in Israel,
the tax rates applicable to Israeli resident individual shareholders should generally apply.
In some instances where our shareholders may be liable for Israeli tax on the sale of their ordinary shares, the payment of the
consideration may be subject to the withholding of Israeli tax at source.
Taxation of Dividend Distributions
Israeli Residents
Israeli resident individuals are generally subject to Israeli income tax on the receipt of dividends paid on our ordinary shares, other
than bonus shares (share dividends). As of January 1, 2012, the tax rate applicable to such dividends is generally 25%. With respect to a
person who is a “substantial shareholder” (as defined above) at the time the dividend is received or at any time during the preceding 12-
month period, the applicable tax rate is 30%. Dividends paid from income derived from Preferred Enterprises and Preferred Technology
Enterprises will generally be subject to income tax at a rate of 20%.
130
Table of Contents
As of January 1, 2017, Israeli resident shareholders who are individuals with taxable income that exceeds NIS 640,000 in a tax
year (linked to the Israeli consumer price index each year) will be subject to an additional tax at the rate of 3% on the portion of their
taxable income for such tax year that is in excess of NIS 640,000 (linked to the Israeli consumer price index each year). For this purpose,
taxable income includes taxable capital gains from the sale of our shares and taxable income from dividend distributions.
Dividends paid to an Israeli resident individual shareholder on our ordinary shares will generally be subject to withholding tax at
the rates corresponding with the income tax rates detailed above unless we are provided in advance with a withholding tax certificate
issued by the Israel Tax Authority stipulating a different rate.
Notwithstanding the above, dividends paid to an Israeli resident “substantial shareholder” (as defined above) on publicly traded
shares, like our ordinary shares, which are held via a “nominee company” (as defined under the Israeli Securities Law) are generally
subject to Israeli withholding tax at a rate of 25%, unless a different rate is provided under an applicable tax treaty, provided that a
certificate from the Israel Tax Authority allowing for a reduced withholding tax rate is obtained in advance.
If the dividend is attributable partly to income derived from a Preferred Enterprise or a Preferred Technology Enterprise and partly
to other sources of income, the tax rate will be a blended rate reflecting the relative portions of the various types of income. We cannot
assure you that we will designate the profits that are being distributed in a way that will reduce shareholders’ tax liability.
Israeli resident companies are generally exempt from tax on the receipt of dividends paid on our ordinary shares.
Non-Israeli Residents
Unless relief is provided in a treaty between Israel and the shareholder’s country of residence, non-Israeli residents are generally
subject to Israeli income tax on the receipt of dividends paid on our ordinary shares at the rate of 25%. With respect to a person (including
a corporation) who is a “substantial shareholder” (as defined above) at the time of receiving the dividend or at any time during the
preceding 12-month period, absent treaty relief as mentioned above, the applicable Israeli income tax rate is 30%. Notwithstanding the
above, dividends paid from income derived from Preferred Enterprises will be subject to Israeli income tax at a rate of 20%. In addition,
dividends distributed by a Preferred Technology Enterprise that are paid out of Preferred Technology Income, are subject to tax at the rate
of 20%, but if they are distributed to a foreign company and at least 90% of the shares of the distributing company are held by foreign
resident companies then the tax rate may be as low as 4%, subject to the fulfillment of certain conditions.
In this regard, dividends paid to a non-Israeli resident shareholder on our ordinary shares will generally be subject to withholding
tax at the rates corresponding with the income tax rates detailed above unless we are provided in advance with a withholding tax certificate
issued by the Israel Tax Authority stipulating a different rate (e.g., in accordance with the provisions of an applicable tax treaty).
Notwithstanding the above, dividends paid to a non-Israeli resident “substantial shareholder” (as defined above) on publicly traded
shares, like our ordinary shares, which are held via a “nominee company” (as defined under the Israeli Securities Law) are generally
subject to Israeli withholding tax at a rate of 25%, unless a different rate is provided under an applicable tax treaty, provided that a
certificate from the Israel Tax Authority allowing for a reduced withholding tax rate is obtained in advance.
In addition, it should be noted that an additional 3% tax might be applicable to individual shareholders if certain conditions are
met.
131
Table of Contents
Under the U.S.-Israel Tax Treaty, the maximum Israeli tax on dividends paid to a holder of ordinary shares who qualifies as a
resident of the United States within the meaning of the U.S.-Israel Tax Treaty is 25%. Such tax rate is generally reduced to 12.5% if: (i) the
shareholder is a U.S. corporation and holds at least 10% of the outstanding shares of our voting stock during the part of our tax year that
precedes the date of payment of the dividends and during the whole of our prior tax year; (ii) not more than 25% of our gross income in the
tax year preceding the payment of the dividends consists of interest or dividends, other than dividends or interest received from subsidiary
corporations 50% or more of the outstanding shares of voting stock of which is owned by us at the time such dividends or interest are
received by us; and (iii) the dividends are not sourced from income derived during a period for which we were entitled to the reduced tax
rate applicable to a Preferred Enterprise under the Investment Law. If the dividends are sourced from income derived during a period for
which we are entitled to the reduced tax rate applicable to a Preferred Enterprise or a Preferred Technology Enterprise under the Investment
Law, to the extent that the first two conditions detailed above are met, the Israeli tax rate applicable to such dividends should be 15%.
If the dividend is attributable partly to income derived from a Preferred Enterprise or a Preferred Technology Enterprise and partly
to other sources of income, the tax rate will be a blended rate reflecting the relative portions of the various types of income. We cannot
assure you that we will designate the profits that are being distributed in a way that will reduce shareholders’ tax liability.
Estate and gift tax
Israeli law presently does not impose estate tax.
Israeli law also does not presently impose gift taxes upon the transfer of assets to Israeli resident individuals so long as it is
demonstrated to the satisfaction of the Israel Tax Authority that the transfer was executed in good faith.
Material U.S. Federal Income Tax Consequences
The following summary describes certain material U.S. federal income tax consequences relating to an investment in the ADSs
and ordinary shares. This summary deals only with ADSs and ordinary shares that are held as capital assets within the meaning of
section 1221 of the U.S. Internal Revenue Code of 1986, as amended, or the Code, and does not address tax considerations of holders that
may be subject to special tax rules, such as dealers or traders in securities or currencies, financial institutions, tax-exempt organizations,
insurance companies, regulated investment companies, real estate investment trusts, individual retirement and tax-deferred accounts,
persons holding ADSs or ordinary shares as part of a hedging, integrated, conversion or constructive sale transaction or a straddle, persons
subject to the alternative minimum tax, or persons who have a functional currency other than the U.S. dollar. In addition, this discussion
does not address the tax treatment of U.S. holders (as defined below) who own, directly, indirectly, or constructively, 10% or more of our
outstanding stock, by vote or value. The summary set forth below relating to U.S. holders (as defined below) is applicable only to such U.S.
holders (i) who are residents of the United States for purposes of the United States-Israel Tax Treaty, (ii) whose ordinary shares or ADSs
are not, for purposes of the United States-Israel Tax Treaty, effectively connected with or attributable to a permanent establishment in
Israel, and (iii) who otherwise qualify for the full benefits of the United States-Israel Tax Treaty. The discussion below is based upon the
Code, final, temporary and proposed Treasury regulations promulgated thereunder, applicable administrative rulings and judicial
interpretations thereof, and the United States-Israel Tax Treaty, all as in effect as of the date hereof and all of which are subject to change,
possibly on a retroactive basis, and all of which are open to differing interpretations. In addition, this summary does not consider the
possible application of U.S. federal gift or estate taxes or any aspect of state, local, or non-U.S. tax laws. Furthermore, we will not seek a
ruling from the IRS with regard to the U.S. federal income tax treatment of an investment in our ADSs or ordinary shares and can provide
no assurance that the tax consequences contained in this summary will not be challenged by the IRS or will be sustained in a court if
challenged.
132
Table of Contents
As used in this summary the term “U.S. holder” means a beneficial owner of ADSs or ordinary shares that is, for U.S. federal
income tax purposes: (i) an individual citizen or resident of the United States, (ii) a corporation (or other entity taxable as a corporation for
U.S. federal income tax purposes) created or organized in or under the laws of the United States or any political subdivision thereof, (iii) an
estate the income of which is subject to U.S. federal income taxation regardless of its source, or (iv) a trust if either (a) a court within the
United States is able to exercise primary supervision over the administration of the trust and one or more U.S. persons have the authority to
control all substantial decisions of the trust, or (b) the trust has a valid election in effect under applicable Treasury regulations to be treated
as a U.S. person. Except to the limited extent discussed below, this summary does not consider the U.S. federal tax considerations to a
person that is not a U.S. holder (a “non-U.S. holder”). In addition, the tax treatment of persons who hold ADSs or ordinary shares through a
partnership or other pass-through entity treated as a partnership for U.S. federal income tax purposes generally depends upon the status of
the partner and the activities of the partnership. The tax consequences to such a partner or partnership are not considered in this summary
and partners and partnerships should consult their tax advisors with respect to the U.S. federal tax consequences of investing in the ADSs
or ordinary shares.
This summary does not discuss all aspects of U.S. federal income taxation that may be relevant to a particular investor in light of
its circumstances. Prospective purchasers of the ADSs or ordinary shares should consult their own tax advisors with respect to the
specific U.S. federal income tax consequences to such person of purchasing, holding, or disposing of the ADSs or ordinary shares,
as well as the effect of any state, local, or other tax laws.
ADSs
If you hold ADSs, for U.S. federal income tax purposes, you generally will be treated as the owner of the underlying ordinary
shares that are represented by such ADSs. Accordingly, deposits or withdrawals of ordinary shares for ADSs will not be subject to U.S.
federal income tax.
Distributions on ADSs
Subject to the discussion under the heading “Passive Foreign Investment Company Consequences,” U.S. holders are required to
include in gross income the amount of any distribution paid on ordinary shares to the extent the distribution is paid out of our current and
accumulated earnings and profits, as determined for U.S. federal income tax purposes. To the extent a distribution paid with respect to our
ordinary shares exceeds our current and accumulated earnings and profits, such amount will be treated first as a non-taxable return of
capital, reducing a U.S. holder’s tax basis for the ordinary shares to the extent thereof, and thereafter as either long-term or short-term
capital gain depending upon whether the U.S. holder has held our ordinary shares for more than one year as of the time such distribution is
received. Preferential tax rates for long-term capital gains are applicable for U.S. holders that are individuals, estates, or trusts. However,
we do not expect to maintain calculations of our earnings and profits under United States federal income tax principles. Therefore, U.S.
holders should expect that the entire amount of any distribution generally will be reported as dividend income. The amount of the dividend
will generally be treated as foreign-source dividend income to U.S. holders. A non-corporate U.S. holder that meets certain eligibility
requirements may qualify for a lower rate of U.S. federal income taxation on dividends paid if we are a “qualified foreign corporation” for
U.S. federal income tax purposes. We generally will be treated as a qualified foreign corporation if we are not a passive foreign investment
company, or PFIC, in the taxable year in which such dividends are paid or in the preceding taxable year (see discussion below), and (i) we
are eligible for benefits under the United States-Israel income tax treaty or (ii) our ordinary shares are listed on an established securities
market in the United States (which includes The Nasdaq Capital Market). We may be classified as a PFIC for U.S. federal income tax
purposes, and we would not be treated as a qualified foreign corporation if we are classified as a PFIC. In addition, a non-corporate U.S.
holder will not be eligible for a reduced U.S. federal income tax rate with respect to dividend distributions on ordinary shares if (a) such
U.S. holder has not held the ordinary shares for at least 61 days during the 121-day period starting on the date which is 60 days before, and
ending 60 days after the ex-dividend date, (b) to the extent the U.S. holder is under an obligation to make related payments on substantially
similar or related property, or (c) with respect to any portion of a dividend that is taken into account by the U.S. holder as investment
income under Section 163(d)(4)(B) of the Code. Any days during which the U.S. holder has diminished its risk of loss with respect to
ordinary shares (for example, by holding an option to sell the ordinary shares) are not counted towards meeting the 61-day holding period.
Non-corporate U.S. holders should consult their own tax advisors concerning whether dividends received by them qualify for the reduced
rate of tax.
133
Table of Contents
Corporate U.S. holders will not be allowed a deduction for dividends received from us.
The amount of a distribution with respect to our ordinary shares equals the amount of cash and the fair market value of any
property distributed plus the amount of any Israeli taxes withheld therefrom. The amount of any cash distributions paid in NIS equals the
U.S. dollar value of the NIS on the date of distribution based upon the exchange rate in effect on such date, regardless of whether the NIS
are converted into U.S. dollars at that time, and U.S. holders who include such distribution in income on such date will have a tax basis in
such NIS for U.S. federal income tax purposes equal to such U.S. dollar value. If the dividend is converted to U.S. dollars on the date of
receipt, a U.S. holder generally will not recognize a foreign currency gain or loss. However, if the U.S. holder converts the NIS into U.S.
dollars on a later date, the U.S. holder must include, in computing its income, any gain or loss resulting from any exchange rate fluctuations.
The gain or loss will be equal to the difference between (i) the U.S. dollar value of the amount included in income when the dividend was
received and (ii) the amount received on the conversion of the NIS into U.S. dollars. Such gain or loss will generally be ordinary income or
loss and United States source income for U.S. foreign tax credit purposes. U.S. holders should consult their own tax advisors regarding the
tax consequences to them if we pay dividends in NIS or any other non-U.S. currency.
Subject to certain significant conditions and limitations, including potential limitations under the U.S.-Israel Tax Treaty, U.S.
holders may be entitled to a credit against their U.S. federal income tax liability or a deduction against U.S. federal taxable income in an
amount equal to the Israeli tax withheld on distributions on our ordinary shares. U.S. holders should consult their own tax advisors to
determine whether and to what extent they would be entitled to such credit. Distributions paid on our ordinary shares will generally be
treated as passive income that is foreign source for U.S. foreign tax credit purposes, which may be relevant in calculating a U.S. holder’s
foreign tax credit limitation.
Disposition of ADSs
Subject to the discussion under the heading “Passive Foreign Investment Company Consequences,” upon the sale, exchange or
other disposition of ADSs, a U.S. holder generally will recognize capital gain or loss in an amount equal to the difference between the
amount realized on the disposition and such U.S. holder’s adjusted tax basis in the ADSs. The adjusted tax basis in an ADS generally will
be equal to the cost of such ADS. The capital gain or loss realized on the sale, exchange, or other disposition of ADSs will be long-term
capital gain or loss if the U.S. holder held the ADSs for more than one year as of the time of disposition. Preferential tax rates for long-
term capital gain will generally apply to non-corporate U.S. holders. Any gain or loss realized by a U.S. holder on the sale, exchange, or
other disposition of ADSs generally will be treated as from sources within the United States for U.S. foreign tax credit purposes, except for
certain losses which will be treated as foreign source to the extent certain dividends were received (or certain inclusion amounts were taken
into account) by the U.S. holder within the 24-month period preceding the date on which the U.S. holder recognized the loss. The
deductibility of capital losses for U.S. federal income tax purposes is subject to limitations.
Disclosure of Reportable Transactions
If a U.S. holder sells or disposes of the ADSs at a loss or otherwise incurs certain losses that meet certain thresholds, such U.S.
holder may be required to file a disclosure statement with the IRS. Failure to comply with these and other reporting requirements could
result in the imposition of significant penalties.
134
Table of Contents
Passive Foreign Investment Company Consequences
Generally, a non-U.S. corporation will be a PFIC for U.S. federal income tax purposes in any taxable year in which either (i) 75%
or more of its gross income for such year consists of certain types of “passive” income or (ii) 50% or more of the average fair market value
of its assets during such year (based on quarterly valuations) produce or are held for the production of passive income. Passive income for
this purpose generally includes dividends, interest, rents, royalties, annuities, income from certain commodities transactions and from
notional principal contracts, and the excess of gains over losses from the disposition of assets that produce passive income. Passive income
also includes amounts derived by reason of the temporary investment of funds, including those raised in a public offering. Assets that
produce or are held for the production of passive income include cash, even if held as working capital or raised in a public offering,
marketable securities, and other assets that may produce passive income. In determining whether a non-U.S. corporation is a PFIC, a
proportionate share of the income and assets of each corporation in which it owns, directly or indirectly, at least a 25% interest (by value) is
taken into account.
A foreign corporation’s PFIC status is an annual determination that is based on tests that are factual in nature, and our PFIC status
for any year will depend on the composition of our income, fair market value of our assets, and our activities for such year. Based on our
non-passive revenue-producing operations for the year ended December 31, 2017, we do not expect to be a PFIC for our 2017 taxable year.
Because the PFIC determination is highly fact intensive, there can be no assurance that we will not be a PFIC in 2018 or any other year.
Even if we determine that we are not a PFIC after the close of a taxable year, there can be no assurance that the IRS or a court will agree
with our conclusion.
If we were a PFIC for any taxable year during which a U.S. holder held ADSs, then unless an election has been made by a U.S.
holder to be taxed under one of the alternative regimes discussed below, gain recognized by a U.S. holder on a sale or other disposition
(including certain pledges) of the ADSs would be allocated ratably over the U.S. holder’s holding period for the ADSs. The amounts
allocated to the taxable year of the sale or other disposition and to any year before we became a PFIC would be taxed as ordinary income.
The amount allocated to each other taxable year would be subject to tax at the highest rate in effect for individuals or corporations, as
appropriate, for that taxable year, and an interest charge would be imposed on the amount allocated to that taxable year. Similar rules would
apply to any distribution with respect to the ADSs in excess of 125% of the average of the annual distributions received by a U.S. holder
during the preceding three years or such U.S. holder’s holding period, whichever is shorter. In addition, non-corporate U.S. holders will not
be eligible for reduced rates of taxation on any dividends received from us if we are a PFIC in the taxable year in which such dividends are
paid or in the preceding taxable year.
If we are a PFIC for any taxable year during which you hold the ADSs and our non-United States subsidiary is also a PFIC, a U.S.
holder would be treated as owning a proportionate amount (by value) of the shares of the lower-tier PFIC for purposes of the application of
these rules. U.S. holders are urged to consult their tax advisors about the application of the PFIC rules to our subsidiary.
If we are treated as a PFIC for any taxable year during the holding period of a non-electing U.S. holder (i.e., a U.S. holder that
does not elect to be taxed under one of the alternative regimes discussed below), we will continue to be treated as a PFIC for all succeeding
years during which such non-electing U.S. holder is treated as a direct or indirect holder even if we are not a PFIC for such years. A U.S.
holder is encouraged to consult its tax advisor with respect to any available elections that may be applicable in such a situation, including
the “deemed sale” election of Section 1298(b)(1) of the Code.
135
Table of Contents
Notwithstanding the default PFIC rules described in the preceding paragraphs, certain elections may be available that would result
in alternative tax consequences; i.e., the “qualified electing fund” or “QEF” election and the “mark to market” election. If a U.S. holder
makes a timely and valid mark-to-market election, the U.S. holder generally will recognize as ordinary income any excess of the fair
market value of the ADSs at the end of each taxable year over their adjusted tax basis, and will recognize an ordinary loss in respect of any
excess of the adjusted tax basis of the ADSs over their fair market value at the end of the taxable year (but only to the extent of the net
amount of income previously included as a result of the mark-to-market election). The U.S. holder’s tax basis in the ADSs will be adjusted
to reflect the income or loss resulting from the mark-to-market election. Any gain recognized on the sale or other disposition of ADSs in a
year when we are a PFIC will be treated as ordinary income and any loss will be treated as an ordinary loss (but only to the extent of the net
amount of income previously included as a result of the mark-to-market election and any loss in excess of such amount will be treated as
capital loss). The mark-to-market election is available only if we are a PFIC and the ADSs are “regularly traded” on a “qualified exchange”
within the meaning of applicable U.S. Treasury regulations. The ADSs will be treated as “regularly traded” in any calendar year in which
more than a de minimis quantity of the ADSs are traded on a qualified exchange on at least 15 days during each calendar quarter. Although
the IRS has not published any authority identifying specific exchanges that may constitute “qualified exchanges,” Treasury Regulations
provide that a qualified exchange is (i) a U.S. securities exchange that is registered with the Securities and Exchange Commission, (ii) the
U.S. market system established pursuant to section 11A of the Securities and Exchange Act of 1934, or (iii) a non-U.S. securities exchange
that is regulated or supervised by a governmental authority of the country in which the market is located, provided that: (a) such non-U.S.
exchange has trading volume, listing, financial disclosure, surveillance, and other requirements designed to prevent fraudulent and
manipulative acts and practices, to remove impediments to and perfect the mechanism of a free and open, fair and orderly, market, and to
protect investors, and the laws of the country in which such non-U.S. exchange is located and the rules of such non-U.S. exchange ensure
that such requirements are actually enforced; and (b) the rules of such non-U.S. exchange effectively promote active trading of listed
shares. No assurance can be given that the ADSs will meet the requirements to be treated as “regularly traded” for purposes of the mark-to-
market election. The Nasdaq Capital Market is a qualified exchange for this purpose and, consequently, if the ADSs are regularly traded,
the mark-to-market election will be available to a U.S. holder. Our ordinary shares currently trade on the Tel Aviv Stock Exchange, which
must meet the requirements described above in order to allow for a mark-to-market election with respect to our ordinary shares. A mark-to-
market election will not apply to ADSs held by a U.S. holder for any taxable year during which we are not a PFIC, but will remain in effect
with respect to any subsequent taxable year in which we become a PFIC unless the ADSs are no longer regularly traded on a qualified
exchange or the IRS consents to the revocation of the election. Such election will not apply to any PFIC subsidiary that we own. Each U.S.
holder is encouraged to consult its own tax advisor with respect to the availability and tax consequences of a mark-to-market election with
respect to the ADSs.
Another way in which certain of the adverse consequences of PFIC status can be mitigated is for a U.S. holder to make a QEF
election. Generally, a shareholder making the QEF election is required for each taxable year to include in income a pro rata share of the
ordinary earnings and net capital gain of the QEF, subject to a separate election to defer payment of taxes, which deferral is subject to an
interest charge. An election to treat us as a QEF will not be available if we do not provide the information necessary to make such an
election. We are not obligated and do not currently intend to provide the information necessary to make a QEF election and thus it is not
expected that a QEF election will be available for U.S. holders of the ADSs if we were a PFIC in any prior year, the current year or any
future year.
U.S. holders should consult their tax advisors to determine under what circumstances these elections would be available and, if
available, what the consequences of the alternative treatments would be in their particular circumstances.
If a U.S. holder holds ADSs in any year in which we are treated as a PFIC, the U.S. holder will be required to file IRS Form 8621
and may be subject to certain other information reporting requirements.
The U.S. federal income tax rules relating to PFICs are complex. Prospective U.S. holders are urged to consult their own tax
advisors with respect to the consequences to them of an investment in a PFIC, any elections available with respect to the ADSs or ordinary
shares and the IRS information reporting obligations with respect to the purchase, ownership, and disposition of the ADSs or ordinary
shares in the event we are determined to be a PFIC.
Medicare Tax on Investment Income
In addition to the income taxes described above, U.S. holders that are individuals, estates, or trusts and whose income exceeds
certain thresholds will be subject to a 3.8% tax on all or a portion of their “net investment income,” which generally results from dividends
and dispositions of ADSs. U.S. holders should consult their tax advisors with respect to the applicability of the 3.8% Medicare tax to their
income and gains, if any, resulting from their investment in the ADSs.
136
Table of Contents
Information Reporting and Backup Withholding
A U.S. holder may be subject to backup withholding and information reporting requirements with respect to cash distributions and
proceeds from a disposition of ADSs or ordinary shares. In general, backup withholding will apply only if a U.S. holder fails to comply
with certain identification procedures. Information reporting and backup withholding will not apply with respect to payments made to
certain exempt recipients, such as corporations and tax-exempt organizations. Backup withholding is not an additional tax and may be
claimed as a credit against the U.S. federal income tax liability of a U.S. holder, provided that the required information is furnished to the
IRS.
Tax Reporting
Certain U.S. holders will be required to file an IRS Form 926 (Return by a U.S. Transferor of Property to a Foreign Corporation) to
report a transfer of cash or other property to us. Substantial penalties may be imposed on a U.S. holder that fails to comply with this
reporting requirement. Each U.S. holder is urged to consult with its own tax advisor regarding this reporting obligation.
Foreign Asset Reporting
Certain U.S. holders who are individuals may be required to report information relating to an interest in the ADSs or ordinary
shares, subject to certain exceptions. For example, individuals that own “specified foreign financial assets” with an aggregate value in
excess of $50,000 are generally required to file IRS Form 8938 with respect to such assets with their tax returns. “Specified foreign
financial assets” include any financial accounts maintained by foreign financial institutions, as well as any of the following, but only if they
are not held in accounts maintained by financial institutions: (i) stocks and securities issued by non-U.S. persons; (ii) financial instruments
and contracts held for investment that have non-U.S. issuers or counterparties; and (iii) interests in foreign entities. Certain domestic
entities that are U.S. holders may also be required to file Form 8938 in the near future. In addition, a U.S. holder should consider the
possible obligation to file FinCEN Form 114, Report of Foreign Bank and Financial Accounts, as a result of holding ADSs or ordinary
shares. U.S. holders are urged to consult their tax advisors regarding the application of these and other reporting requirements that may
apply to their ownership of ADSs or ordinary shares.
Non-U.S. Holders of Ordinary Shares
Except as provided below, a non-U.S. holder of ordinary shares or ADSs generally will not be subject to U.S. income or
withholding tax on the payment of dividends on and the proceeds from the disposition of ADSs or ordinary shares.
A non-U.S. holder may be subject to U.S. federal income tax on dividends received on ADSs or ordinary shares or upon the
receipt of income from the disposition of ADSs or ordinary shares if: (i) such income is effectively connected with the conduct by the non-
U.S. holder of a trade or business in the United States or, in the case of a resident of a country which has an applicable income tax treaty
with the United States, such item is attributable to a permanent establishment or a fixed place of business of the non-U.S. holder in the
United States; (ii) with respect to a U.S. holder that is an individual, the non-U.S. holder is an individual who is present in the United States
for 183 days or more in the taxable year of the sale and certain other conditions are met; or (iii) the non-U.S. holder is subject to tax
pursuant to the provisions of the U.S. tax laws applicable to U.S. expatriates.
Payments to non-U.S. holders of distributions on, or proceeds from the disposition of, ADSs or ordinary shares are generally
exempt from information reporting and backup withholding. However, a non-U.S. holder may be required, under certain circumstances, to
establish that exemption by providing certification of non-U.S. status on an appropriate IRS Form W-8.
THE DISCUSSION ABOVE IS A GENERAL SUMMARY AND IS NOT INTENDED TO CONSTITUTE A COMPLETE
ANALYSIS OF ALL TAX CONSEQUENCES RELATING TO THE PURCHASE, OWNERSHIP AND DISPOSITION OF THE
ADSs OR ORDINARY SHARES. IT DOES NOT COVER ALL TAX MATTERS THAT MAY BE OF IMPORTANCE TO A
PROSPECTIVE INVESTOR. EACH PROSPECTIVE INVESTOR IS URGED TO CONSULT ITS OWN TAX ADVISOR
ABOUT THE TAX CONSEQUENCES TO IT RELATING TO THE PURCHASE, OWNERSHIP, AND DISPOSITION OF ADSs
OR ORDINARY SHARES IN LIGHT OF THE INVESTOR’S OWN CIRCUMSTANCES.
137
Table of Contents
F. Dividends and Paying Agents
Not applicable.
G. Statement by Experts
Not applicable.
H. Documents on Display
We are subject to certain information reporting requirements of the Exchange Act, applicable to foreign private issuers and under
those requirements will file reports with the SEC. You may read and copy the annual report on Form 20-F, including the related exhibits
and schedules, and any document we file with the SEC without charge at the SEC's public reference room at 100 F Street, N.E.,
Room 1580, Washington, DC 20549. You may also obtain copies of the documents at prescribed rates by writing to the Public Reference
Section of the SEC at 100 F Street, N.E., Room 1580, Washington, DC 20549. Please call the SEC at 1-800-SEC-0330 for further
information on the public reference room. The SEC also maintains an Internet website that contains reports and other information regarding
issuers that file electronically with the SEC. Our filings with the SEC will also available to the public through the SEC's website at
www.sec.gov.
As a foreign private issuer, we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy
statements, and our officers, directors and principal shareholders will be exempt from the reporting and short-swing profit recovery
provisions contained in Section 16 of the Exchange Act. In addition, we are not required under the Exchange Act to file annual, quarterly
and current reports and financial statements with the SEC as frequently or as promptly as U.S. domestic companies whose securities are
registered under the Exchange Act. However, we will file with the SEC, within 120 days after the end of each fiscal year, or such
applicable time as required by the SEC, an annual report on Form 20-F containing financial statements audited by an independent
registered public accounting firm, and may submit to the SEC, on a Form 6-K, unaudited quarterly financial information.
In addition, we have filed Hebrew language periodic and immediate reports with, and furnish information to, the TASE and the
ISA, as required under Chapter Six of the Israel Securities Law, 1968. Copies of our filings with the ISA can be retrieved electronically
through the MAGNA distribution site of the ISA (www.magna.isa.gov.il) and the TASE website (www.maya.tase.co.il).
I.
Subsidiary Information.
Not applicable.
ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are exposed to market risk in the ordinary course of our business. Market risk represents the risk of loss that may impact our
financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of fluctuations
in foreign currency exchange rates and interest rates.
Foreign Currency Exchange Risk
Our functional and reporting currency is the New Israeli Shekel (NIS) which is the local currency in Israel. Our foreign currency
exposures give rise to market risk associated with exchange rate movements of the NIS, mainly against the U.S. dollar and the Euro.
Although the NIS is our functional currency, a small portion of our expenses consist principally of payments made to subcontractors and
consultants for clinical trials, other research and development activities, and purchase of new equipment. A material portion of our research
and development is conducted through collaboration agreements denominated in U.S. dollars, and therefore our net research and
development expenses are subject to significant foreign currency risk. If the NIS fluctuates significantly against either the U.S. dollar or the
Euro, it may have a negative impact on our results of operations. To date, such fluctuations in exchange rates have not materially affected
our results of operations or financial condition for the periods under review.
138
Table of Contents
To date, we have not entered into any hedging arrangements with respect to foreign currency risk or other derivative financial
instruments. In the future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in
the operating currencies. These measures, however, may not adequately protect us from the material adverse effects of such fluctuations.
Interest Rate Risk
At present, our investments consist primarily of cash and cash equivalents in short-term deposits. The primary objective of our
investment activities is to preserve our capital to fund our operations. Our investments are exposed to market risk due to fluctuation in
interest rates, which may affect our interest income and the fair market value of our investments, if any. We manage this exposure by
performing ongoing evaluations of our investments. Due to the short-term maturities, if any, of our investments to date, their carrying value
has always approximated their fair value. We believe that our exposure to interest rate risk is not significant and a 1% change in market
interest rates would not have a material impact on our assets.
ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES
A. Debt Securities.
Not applicable.
B. Warrants and rights.
Not applicable.
C. Other Securities.
Not applicable.
D. American Depositary Shares
Persons depositing or withdrawing ordinary shares or ADS holders
For:
must pay:
$5.00 (or less) per ADSs (or portion of ADSs)
$0.05 (or less) per ADS
A fee equivalent to the fee that would be payable if securities
distributed to you had been ordinary shares and the ordinary shares
had been deposited for issuance of ADSs
$0.05 (or less) per ADS per calendar year
Registration or transfer fees
Expenses of the depositary
Taxes and other governmental charges the depositary or the custodian
has to pay on any ADSs or ordinary shares underlying ADSs, such
as stock transfer taxes, stamp duty, or withholding taxes
Issuance of ADSs, including issuances resulting from a distribution
of ordinary shares or rights or other property; or cancellation of
ADSs for the purpose of withdrawal, including if the deposit
agreement terminates
Any cash distribution to ADS holders
Distribution of securities distributed to holders of deposited
securities which are distributed by the depositary to ADS holders
Depositary services
Transfer and registration of ordinary shares on our share register to
or from the name of the depositary or its agent when you deposit or
withdraw ordinary shares
Cable (including SWIFT) and facsimile transmissions (when
expressly provided in the deposit agreement); conversion of foreign
currency to U.S. dollars
As necessary
Any charges incurred by the depositary or its agents for servicing the
As necessary
deposited securities
The depositary collects its fees for delivery and surrender of ADSs directly from investors depositing shares or surrendering ADSs
for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by
deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may
collect its annual fee for depositary services by deduction from cash distributions or by directly billing investors or by charging the book-
entry system accounts of participants acting for them. The depositary may collect any of its fees by deduction from any cash distribution
payable (or by selling a portion of securities or other property distributable) to ADS holders that are obligated to pay those fees. The
depositary may generally refuse to provide fee-attracting services until its fees for those services are paid.
From time to time, the depositary may make payments to us to reimburse us for costs and expenses generally arising out of
establishment and maintenance of the ADS program, waive fees and expenses for services provided to us by the depositary, or share
revenue from the fees collected from ADS holders. In performing its duties under the deposit agreement, the depositary may use brokers,
dealers, or other service providers that are affiliates of the depositary and that may earn or share fees or commissions.
139
Table of Contents
ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES
PART II
None.
ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS
There are no material modifications to the rights of security holders.
E. Use of Proceeds
We will not receive any proceeds from the sale of the ordinary shares represented by ADSs by the selling shareholder of ordinary
shares registered pursuant to a registration statement on Form F-1, Registration Number 333-214188, which was declared effective on
January 30, 2018. All net proceeds from the sale of the ordinary shares represented by ADSs will go to the selling shareholder. We may
receive proceeds from the exercise of a warrant to purchase 49,607,407 ordinary shares represented by ADSs, or the Alpha Warrant, and
issuance of the underlying ADSs to the extent that the Alpha Warrant is exercised for cash. The Alpha Warrant may however, be
exercisable on a cashless basis under certain circumstances. If the entire Alpha Warrant were exercised for cash in full, the proceeds would
be approximately $10.3 million.
ITEM 15. CONTROLS AND PROCEDURES
(a) Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Deputy CEO & Chief Financial Officer, has evaluated
the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange
Act) as of December 31, 2017, or the Evaluation Date. Based on such evaluation, those officers have concluded that, as of the Evaluation
Date, our disclosure controls and procedures are effective in recording, processing, summarizing and reporting, on a timely basis,
information required to be included in periodic filings under the Exchange Act and that such information is accumulated and communicated
to management, including our principal executive and financial officers, as appropriate to allow timely decisions regarding required
disclosure.
(b) Management's Annual Report on Internal Control over Financial Reporting
This annual report does not include a report of management’s assessment regarding internal control over financial reporting due to
a transition period established by rules of the SEC for newly public companies.
(c) Attestation Report of the Registered Public Accounting Firm
This annual report does not include an attestation report of our independent registered public accounting firm regarding internal
control over financial reporting due to an exemption for emerging growth companies provided in the JOBS Act.
(d) Changes in Internal Control over Financial Reporting
During the year ended December 31, 2017, there were no changes in our internal control over financial reporting that have
materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
140
Table of Contents
ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT
Our board of directors has determined that each of two members of our audit committee, Mr. Scott Burell and Dr. Elan Penn, is an
audit committee financial expert, as defined under the rules under the Exchange Act, and is independent in accordance with applicable
Exchange Act rules and the Nasdaq Listing Rules.
ITEM 16B. CODE OF ETHICS
Our board of directors has adopted a Code of Ethics applicable to all of our directors and employees, including our Chief
Executive Officer, Chief Financial Officer, controller or principal accounting officer, or other persons performing similar functions, which
is a “code of ethics” as defined in Item 16B of Form 20-F promulgated by the SEC. The full text of the Code of Ethics is posted on our
website at www.collplant.com. Information contained on, or that can be accessed through, our website does not constitute a part of this a
part of this annual report on Form 20-F and is not incorporated by reference herein. If we make any amendment to the Code of Ethics or
grant any waivers, including any implicit waiver, from a provision of the Code of Ethics, we will disclose the nature of such amendment or
waiver on our website to the extent required by the rules and regulations of the SEC. We have not granted any waivers under our Code of
Business Conduct and Ethics.
ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES
Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, an independent registered public
accounting firm, has served as our principal independent registered public accounting firm for each of the two years ended December 31,
2017 and 2016.
The following table provides information regarding fees paid by us to Kesselman & Kesselman and/or other member firms of
PricewaterhouseCoopers International Limited for all services, including audit services, for the years ended December 31, 2017 and 2016:
Year Ended
December 31,
2016
2017
120
—
—
120
135
8
—
143
(USD in thousands)
Audit fees (1)
Tax fees
All other fees
Total
(1)
Includes professional services rendered in connection with the audit of our annual financial statements and the review of our
interim financial statements.
Pre-Approval of Auditors' Compensation
Our audit committee has a pre-approval policy for the engagement of our independent registered public accounting firm to
perform certain audit and non-audit services. Pursuant to this policy, which is designed to assure that such engagements do not impair the
independence of our auditors, the audit committee pre-approves annually a catalog of specific audit and non-audit services in the categories
of audit services, audit-related services and tax services that may be performed by our independent registered public accounting firm. If a
type of service, that is to be provided by our auditors, has not received such general pre-approval, it will require specific pre-approval by
our audit committee. The policy prohibits retention of the independent registered public accounting firm to perform the prohibited non-
audit functions defined in applicable SEC rules.
141
Table of Contents
ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES
Not applicable.
ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS
Not applicable.
ITEM 16F. CHANGE IN REGISTRANT’S CERTIFYING ACCOUNTANT
Not applicable.
ITEM 16G. CORPORATE GOVERNANCE
Under the Companies Law, companies incorporated under the laws of the State of Israel, whose shares are publicly traded,
including companies whose shares are listed on The Nasdaq Capital Market are considered public companies under Israeli law and are
required to comply with various corporate governance requirements under Israeli law relating to such matters as external directors, the audit
committee, compensation, policy, company’s auditors, and an internal auditor. This is the case even if our shares are not listed on the Tel
Aviv Stock Exchange. These requirements are in addition to the corporate governance requirements imposed by the Nasdaq Listing Rules,
and other applicable provisions of U.S. securities laws to which we will become subject (as a foreign private issuer) upon the listing of the
ADSs on The Nasdaq Capital Market. Under the Nasdaq Listing Rules, a foreign private issuer, such as us, may generally follow its home
country rules of corporate governance in lieu of the comparable requirements of The Nasdaq Capital Market, except for certain matters
including (among others) the composition and responsibilities of the audit committee and the independence of its members within the
meaning of the rules and regulations of the SEC.
We intend to rely on this “home country practice exemption” with respect to the following Nasdaq Listing Rules:
● Quorum requirements. As permitted under the Companies Law pursuant to our articles of association, the quorum required for
an ordinary meeting of shareholders will consist of at least two shareholders present in person, by proxy or by other voting
instrument in accordance with the Companies Law, who hold at least 20% of the voting power of our shares (and in an
adjourned meeting, with some exceptions, any number of participating shareholders), instead of 331/
% of the issued share
3
capital required under the Nasdaq Listing Rules.
● Distribution of certain reports to shareholders. As opposed to the Nasdaq Listing Rules, which require listed issuers to make
its annual reports available to shareholders in one of a number of specific manners, Israeli law does not require that we
distribute annual reports, including our financial statements. As such, the generally accepted business practice in Israel is to
distribute such reports to shareholders through a public regulated distribution website. In addition to making such reports
available on a public regulated distribution website, we plan to make our audited financial statements available to our
shareholders at our offices and will only mail such reports to shareholders upon request. As a foreign private issuer, we are
generally exempt from the SEC’s proxy solicitation rules.
142
Table of Contents
● Shareholder approval. We will seek shareholder approval for all corporate actions requiring such approval under the
requirements of the Companies Law, rather than seeking approval for corporate actions in accordance with Nasdaq Listing
Rule 5635. In particular, under this Nasdaq Listing Rule, shareholder approval is generally required for: (i) an acquisition of
shares or assets of another company that involves the issuance of 20% or more of the acquirer’s shares or voting rights or if a
director, officer or 5% shareholder has greater than a 5% interest in the target company or the consideration to be received;
(ii) the issuance of shares leading to a change of control; (iii) adoption or amendment of equity compensation arrangements; and
(iv) issuances of 20% or more of the shares or voting rights (including securities convertible into, or exercisable for, equity) of
a listed company via a private placement (or via sales by directors, officers or 5% shareholders) if such equity is issued (or sold)
at below the greater of the book or market value of shares. By contrast, under the Companies Law, shareholder approval is
required (subject to certain limited exceptions) for, among other things: (a) transactions with directors concerning the terms of
their service (including indemnification, exemption, and insurance for their service or for any other position that they may hold
at a company), for which approvals of the compensation committee, board of directors, and shareholders are all required;
(b) extraordinary transactions with controlling shareholders of publicly held companies, which require the special approval
described below under “Disclosure of Personal Interests of Controlling Shareholders and Approval of Certain Transactions”;
(c) terms of office and employment or other engagement of our controlling shareholder, if any, or such controlling
shareholder’s relative, which require the special approval described below under “Disclosure of Personal Interests of
Controlling Shareholders and Approval of Certain Transactions”; (d) approval of transactions with Company’s Chief Executive
Officer with respect to his or hers compensation, whether in accordance with the approved compensation policy of the
Company or not in accordance with the approved compensation policy of the Company, or transactions with officers of the
Company not in accordance with the approved compensation policy; and (e) approval of the compensation policy of the
Company for office holders. In addition, under the Companies Law, a merger requires approval of the shareholders of each of
the merging companies.
Except as stated above, we intend to comply with the rules generally applicable to U.S. domestic companies listed on The Nasdaq
Capital Market, subject to certain exemptions the JOBS Act provides to emerging growth companies. We may in the future decide to use
other foreign private issuer exemptions with respect to some or all of the other Nasdaq Listing Rules. Following our home country
governance practices, as opposed to the requirements that would otherwise apply to a company listed on The Nasdaq Capital Market, may
provide less protection than is accorded to investors under the Nasdaq Listing Rules applicable to domestic issuers.
ITEM 16H. MINE SAFETY DISCLOSURE
Not applicable.
143
Table of Contents
ITEM 17. FINANCIAL STATEMENTS
PART III
We have elected to provide financial statements and related information pursuant to Item 18.
ITEM 18. FINANCIAL STATEMENTS
The consolidated financial statements and the related notes required by this Item are included in this annual report on Form 20-F
beginning on page F-1.
ITEM 19. EXHIBITS.
Exhibit No.
1.1
Exhibit Description
Memorandum of Association of the Company (unofficial English translation from Hebrew original) (included as Exhibit 3.1
to our Registration Statement on Form F-1 as filed with the Securities and Exchange Commission on October 21, 2016, and
incorporated herein by reference).
1.2
2.1
2.2
4.1
4.2†
4.3#
4.4
4.5#
Amended and Restated Articles of Association of the Company, as currently in effect (unofficial English translation from
Hebrew original) (included as Exhibit 3.2 to our Registration Statement on Form F-1 as filed with the Securities and
Exchange Commission on October 21, 2016, and incorporated herein by reference).
Form of Deposit Agreement by and between the Company and Bank of New York Mellon (included as Exhibit to the
Registration Statement on Form F-6 as filed with the Securities and Exchange Commission on February 20, 2015, as
amended, and incorporated herein by reference).
Specimen ADR Certificate (included as Exhibit to the Registration Statement on Form F-6 as filed with the Securities and
Exchange Commission on February 20, 2015, as amended, and incorporated herein by reference)
Form of Letter of Exemption and Form of Letter of Indemnification (unofficial English translation from Hebrew original)
(included as Exhibit 10.1 to our Registration Statement on Form F-1 as filed with the Securities and Exchange Commission
on October 21, 2016, and incorporated herein by reference)
Agreement, dated July 13, 2004, by and among Meytav—Technological Innovation Center Ltd., Yehuda Zafrir Fagin,
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., or Yissum, and Prof. Oded Shoseyov
(includes unofficial English translation of certain exhibits from Hebrew original) (included as Exhibit 10.2 to our
Registration Statement on Form F-1 as filed with the Securities and Exchange Commission on October 21, 2016, and
incorporated herein by reference)
Employee Share Ownership and Option Plan (2010) (included as Exhibit 10.3 to our Registration Statement on Form F-1 as
filed with the Securities and Exchange Commission on October 21, 2016, and incorporated herein by reference)
Lease Agreement, dated June 19, 2008, by and between the Company and Africa Israel Properties, Ltd., as amended
(unofficial English translation from Hebrew original) (included as Exhibit 10.4 to our Registration Statement on Form F-1 as
filed with the Securities and Exchange Commission on October 21, 2016, and incorporated herein by reference)
Employment Agreement dated September 30, 2009 between CollPlant Ltd. and Yehiel Tal (includes unofficial English
translation of an exhibit from Hebrew original) (included as Exhibit 10.5 to our Registration Statement on Form F-1 as filed
with the Securities and Exchange Commission on October 21, 2016, and incorporated herein by reference)
144
Table of Contents
4.6#
4.7#
4.8
4.9
4.10
4.11
4.12
4.13
4.14
4.15
4.16
Employment Agreement dated October 30, 2011 between CollPlant Ltd. and Eran Rotem (includes unofficial English
translation of certain exhibits from Hebrew original) (included as Exhibit 10.6 to our Registration Statement on Form F-1 as
filed with the Securities and Exchange Commission on October 21, 2016, and incorporated herein by reference)
Consulting and Services Agreement dated as of August 10, 2008 between CollPlant Ltd. and Prof. Oded Shoseyov (included
as Exhibit 10.7 to our Registration Statement on Form F-1 as filed with the Securities and Exchange Commission on October
21, 2016, and incorporated herein by reference)
Waiver dated September 10, 2017 to Agreement, dated July 13, 2004, by and among Meytav—Technological Innovation
Center Ltd., Yehuda Zafrir Fagin, Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., or
Yissum, and Prof. Oded Shoseyov (included as Exhibit 10.8 to our Amendment No. 3 to the Registration Statement on Form
F-1 as filed with the Securities and Exchange Commission on November 22, 2017, and incorporated herein by reference)
Securities Purchase Agreement dated as of September 6, 2017, between the Company and Alpha Capital Anstalt (included as
Exhibit 10.9 to our Amendment No. 3 to the Registration Statement on Form F-1 as filed with the Securities and Exchange
Commission on November 22, 2017, and incorporated herein by reference)
Convertible Debenture dated October 26, 2017 issued by the Company to Alpha Capital Anstalt under the Securities
Purchase Agreement dated as of September 6, 2017 (included as Exhibit 10.10 to our Amendment No. 5 to the Registration
Statement on Form F-1 as filed with the Securities and Exchange Commission on January 23, 2018, and incorporated herein
by reference)
Convertible Debenture dated December 31, 2017 issued by the Company to Alpha Capital Anstalt under the Securities
Purchase Agreement dated as of September 6, 2017 (included as Exhibit 10.11 to our Amendment No. 5 to the Registration
Statement on Form F-1 as filed with the Securities and Exchange Commission on January 23, 2018, and incorporated herein
by reference)
Form of Convertible Debenture to be issued by the Company to Alpha Capital Anstalt under the Securities Purchase
Agreement dated as of September 6, 2017 (included as Exhibit 10.12 to our Amendment No. 5 to the Registration Statement
on Form F-1 as filed with the Securities and Exchange Commission on January 23, 2018, and incorporated herein by
reference)
Form of Warrant to be issued by the Company to Alpha Capital Anstalt in the third closing under the Securities Purchase
Agreement dated as of September 6, 2017 (included as Exhibit 10.13 to our Amendment No. 3 to the Registration Statement
on Form F-1 as filed with the Securities and Exchange Commission on November 22, 2017, and incorporated herein by
reference)
Form of Pre-Funded Warrant to be issued by the Company to Alpha Capital Anstalt under the Securities Purchase
Agreement dated as of September 6, 2017 (included as Exhibit 10.14 to our Amendment No. 5 to the Registration Statement
on Form F-1 as filed with the Securities and Exchange Commission on January 23, 2018, and incorporated herein by
reference)
Form of Side Agreement between the Company and Alpha Capital Anstalt (included as Exhibit 10.15 to our Amendment
No. 5 to the Registration Statement on Form F-1 as filed with the Securities and Exchange Commission on January 23,
2018, and incorporated herein by reference)
Registration Rights Agreement dated as of October 26, 2017, between the Company and Alpha Capital Anstalt (included as
Exhibit 10.11 to our Amendment No. 3 to the Registration Statement on Form F-1 as filed with the Securities and Exchange
Commission on November 22, 2017, and incorporated herein by reference)
145
Table of Contents
4.17
4.18
Securities Purchase Agreement dated as of November 8, 2017, between the Company and Meitav Dash Provident Funds
and Pension Ltd. (included as Exhibit 10.14 to our Amendment No. 3 to the Registration Statement on Form F-1 as filed
with the Securities and Exchange Commission on November 22, 2017, and incorporated herein by reference)
Warrant dated March 7, 2018 issued to Meitav Dash Provident Funds and Pension Ltd. in the third closing under the
Securities Purchase Agreement dated as of November 8, 2017 between the Company and Meitav Dash Provident Funds and
Pension Ltd.*
4.19
Side Agreement between the Company and Meitav Dash Provident Funds and Pension Ltd.*
4.20
4.21
Securities Purchase Agreement dated as of November 9, 2017, between the Company and Ami Sagi (included as Exhibit
10.16 to our Amendment No. 3 to the Registration Statement on Form F-1 as filed with the Securities and Exchange
Commission on November 22, 2017, and incorporated herein by reference)
Warrant dated March 7, 2018 issued to Ami Sagi in the third closing under the Securities Purchase Agreement dated as of
November 9, 2017 between the Company and Ami Sagi and Pension Ltd.*
4.22
Side Agreement between the Company and Ami Sagi*
8.1
Subsidiaries of the Company (included as Exhibit 21.1 to our Registration Statement on Form F-1 as filed with the Securities
and Exchange Commission on October 21, 2016, and incorporated herein by reference)
12.1
Certification of the Chief Executive Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934*
12.2
Certification of the Chief Financial Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934*
13.1
Certification of the Chief Executive Officer pursuant to 18 U.S.C. 1350*
13.2
Certification of the Chief Financial Officer pursuant to 18 U.S.C. 1350*
101
The following financial information from Collplant Holdings Ltd.’s annual report on Form 20-F for the year ended
December 31, 2017, formatted in Extensible Business Reporting Language (XBRL): (i) Consolidated Statement of Financial
Position, (ii) Consolidated Statements of Comprehensive Loss, (iii) Statements of Changes in Equity (iv) Consolidated
Statements of Cash Flows, and (iv) Notes to Consolidated Financial Statements.*
Filed herewith.
Portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission pursuant to a
confidential treatment request.
Management contract or compensatory plan.
146
*
†
#
Table of Contents
SIGNATURES
The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and
authorized the undersigned to sign this annual report on Form 20-F filed on its behalf.
Date: March 20, 2018
COLLPLANT HOLDINGS LTD.
By:
/s/ Eran Rotem
Eran Rotem
Deputy CEO and Chief Financial Officer
147
Table of Contents
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the shareholders of
CollPlant Holdings Ltd.
Opinion on the Financial Statements
We have audited the accompanying consolidated statements of financial position of CollPlant Holdings Ltd. and its subsidiary as of
December 31, 2017 and 2016, and the related consolidated statements of comprehensive loss, changes in equity and cash flows for each of
the three years in the period ended December 31, 2017, including the related notes (collectively referred to as the “consolidated financial
statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the
Company and its subsidiary as of December 31, 2017 and 2016, and the results of their operations and their cash flows for each of the three
years in the period ended December 31, 2017 in conformity with International Financial Reporting Standards as issued by the International
Accounting Standards Board.
Basis for Opinion
These consolidated financial statements are the responsibility of the Company’s management and board of directors. Our responsibility is
to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered
with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the
Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange
Commission and the PCAOB.
We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards
require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of
material misstatement, whether due to error or fraud.
Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether
due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting
principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial
statements. We believe that our audits provide a reasonable basis for our opinion.
Tel-Aviv, Israel
March 20, 2018
/s/ Kesselman & Kesselman
Certified Public Accountants (lsr.)
A member firm of PricewaterhouseCoopers International Limited
We have served as the Company’s auditor since 2005.
F-1
Table of Contents
CollPlant Holdings Ltd.
Consolidated Statements of Financial Position
Assets
Current assets:
Cash and cash equivalents
Accounts receivables:
Trade receivables
Other
Inventory
Non-current assets:
Restricted deposit
Long term-receivables
Property and equipment, net
Intangible assets, net
Total assets
Liabilities and equity
Current liabilities:
Accounts payable:
Trade payables
Accrued liabilities and other
Non-current liabilities:
Debentures at fair value
Derivatives
Royalties to the Israel Innovation Authority
Long-term payables
Commitments and contingent liabilities
Total liabilities
Equity:
Ordinary shares
Additional paid in capital and warrants
Accumulated deficit
Total equity
Total liabilities and equity
December 31,
Note
2016
2017
NIS in thousands
Convenience
translation
into USD
(Note 1B)
December 31,
2017
In thousands
5
6
2(I)
7
8
10
4,12
4,12
13(A)(2)
13
14
3,797
17,817
217
3,568
487
8,069
557
168
4,008
1,631
6,364
14,433
5,189
1,617
6,806
—
—
2,181
286
2,467
354
3,543
700
22,414
503
92
3,582
1,454
5,631
28,045
2,922
1,996
4,918
12,639
141
1,203
61
14,044
9,273
18,962
5,139
102
1,022
202
6,465
145
27
1,033
419
1,624
8,089
843
576
1,419
3,645
41
345
18
4,049
5,468
3,207
159,864
(157,911)
5,160
14,433
4,998
178,467
(174,382)
9,083
28,045
1,442
51,476
(50,297)
2,621
8,089
The accompanying notes are an integral part of the consolidated financial statements
F-2
Table of Contents
CollPlant Holdings Ltd.
Consolidated Statements of Comprehensive Loss
Note
2015
Year ended December 31,
2016
NIS in thousands
2017
Revenue
Cost of Revenue
Gross Profit
Research and development expenses:
Research and development expenses
Participation in research and development expenses
Research and development expenses, net
General, administrative and marketing expenses
Operating loss
Financial income
Financial expenses
Financial expenses (income), net
Comprehensive loss
Basic and diluted loss per ordinary share (NIS/USD)
Weighted average ordinary shares outstanding
15
16
17
17
18
—
—
—
292
—
292
1,668
52
1,616
22,919
(11,055)
11,864
6,950
18,814
(215)
51
(164)
18,650
0.22
16,921
(2,855)
14,066
8,303
20,753
(253)
380
127
20,880
0.16
84,672,767 100,624,945 133,187,048
29,200
(12,411)
16,789
11,048
27,545
(93)
441
348
27,893
0.28
4,881
(823)
4,058
2,394
5,986
(74)
110
36
6,022
0.05
Convenience
translation
into
USD
(Note 1B)
2017
In thousands
481
15
466
The accompanying notes are an integral part of the consolidated financial statements.
F-3
Table of Contents
CollPlant Holdings Ltd.
Consolidated Statements of Changes in Equity
Balance as at January 1, 2015
Movement in 2015:
Comprehensive loss
Share-based compensation to employees and consultants
Proceeds from issue of shares and options, less issue expenses of NIS
1,297 thousand
Exercise of options into shares
Balance as at December 31, 2015
Movement in 2016:
Comprehensive loss
Share-based compensation to employees and consultants
Proceeds from issue of shares and warrants, net of issue expenses of
NIS 1,327 thousand
Issue of shares, See Note 13(A)(1)(C)
Balance as at December 31, 2016
Movement in 2017:
Comprehensive loss
Share-based compensation to employees and consultants
Proceeds from issue of shares and warrants, net of issue expenses of
NIS 634 thousand
Exercise of warrants into shares
Balance as at December 31, 2017
Balance as at January 1, 2017
Movement in 2017:
Comprehensive loss
Share-based compensation to employees and consultants
Proceeds from issue of shares and warrants, net of issue expenses of
$182 thousand
Exercise of warrants into shares
Balance as at December 31, 2017
Additional
paid in
capital
and
warrants
Accumulated
deficit
Total equity
NIS in thousands
130,918
(119,021)
14,311
—
—
(18,650)
4,081
(18,650)
4,081
Ordinary
shares
2,414
—
—
250
1
2,665
9,760
26
140,704
—
—
(133,590)
10,010
27
9,779
—
—
510
32
3,207
—
32
1,457
302
4,998
—
—
(27,893)
3,572
(27,893)
3,572
17,995
1,165
159,864
—
—
(157,911)
—
529
14,758
(20,880)
4,409
—
3,316
178,467
—
(174,382)
18,505
1,197
5,160
(20,880)
4,970
16,215
3,618
9,083
Convenience translation into USD
(Note 1B) in thousands
925
46,110
(45,547)
1,488
—
9
421
87
1,442
—
153
(6,022)
1,272
4,256
957
51,476
—
—
(50,297)
(6,022)
1,434
4,677
1,044
2,621
The accompanying notes are an integral part of the consolidated financial statements
F-4
Table of Contents
CollPlant Holdings Ltd.
Consolidated Statements of Cash Flows
2015
Year ended December 31,
2016
NIS in thousands
2017
Convenience
translation
into USD
(Note 1B)
2017
In thousands
(14,498)
1
(14,497)
(1,389)
(1,389)
10,010
27
—
10,037
(5,849)
11,062
104
5,317
(19,357)
—
(19,357)
(17,884)
—
(17,884)
(492)
(492)
(447)
(447)
18,505
—
(19)
18,486
(1,363)
5,317
(157)
3,797
29,030
3,618
(253)
32,395
14,064
3,797
(44)
17,817
(5,158)
—
(5,158)
(129)
(129)
8,374
1,044
(73)
9,345
4,058
1,094
(13)
5,139
Cash flows from operating activities:
Net cash used in operations (see Appendix A)
Interest received
Net cash used in operating activities
Cash flows from investing activities:
Purchase of property and equipment
Net cash used in investing activities
Cash flows from financing activities:
Proceeds from issue of shares, warrants and debentures, less issue
expenses
Exercise of options and warrants into shares
Payments made for equipment on financing terms
Net cash provided by financing activities
Increase (Decrease) in cash and cash equivalents
Cash and cash equivalents at the beginning of the year
Exchange differences on cash and cash equivalents
Cash and cash equivalents at the end of the year
F-5
Table of Contents
CollPlant Holdings Ltd.
Appendices to the Consolidated Statements of Cash Flows
Appendix to the statement of cash flows
A. Net cash used in operations:
Comprehensive Loss
Adjustments for:
Depreciation and amortization
Share-based compensation to employees and consultants
Exchange differences on cash and cash equivalents
Interest received
Gain from changes in fair value of financial instruments
Exchange differences on restricted cash
Changes in operating asset and liability items:
Increase in trade receivables
Increase in inventory
Decrease (increase) in other receivables (including long-term
receivables)
Increase (decrease) in trade payables (including long-term payables)
Increase in accrued liabilities and other payables
Increase (decrease) in royalties to the IIA
Net cash used in operations
B. Non-cash investing and financing activities—
Acquisition of fixed assets against issue of shares and credit
See Note 13(A)(1)(C).
2015
Year ended December 31,
2016
NIS in thousands
2017
Convenience
translation
into USD
(Note 1B)
2017
In thousands
(18,650)
(27,893)
(20,880)
(6,022)
788
4,081
(104)
(1)
—
(1)
(13,887)
(1,693)
(21)
854
249
-
(611)
(14,498)
864
3,572
157
—
—
8
(23,292)
1,050
4,970
44
—
(35)
54
(14,797)
(544)
(487)
(137)
(213)
101
(2,239)
379
(978)
(3,087)
(17,884)
(95)
2,498
382
2,181
3,935
(19,357)
1,678
303
1,433
13
—
(10)
16
(4,267)
(40)
(61)
29
(646)
109
(282)
(891)
(5,158)
The accompanying notes are an integral part of the consolidated financial statements
F-6
Table of Contents
NOTE 1—GENERAL
CollPlant Holdings Ltd.
Notes to the Consolidated Financial Statements
A.
CollPlant Holdings Ltd. is a regenerative medicine company focused on developing and commercializing tissue repair products,
initially for three-dimensional bio-printing of tissues and organs, orthobiologics and advanced wound care markets. CollPlant’s
products are based on its rhCollagen, a form of human collagen produced with CollPlant’s proprietary plant-based genetic
engineering technology. Two of the Company’s products received during 2016 a CE approval that enables their marketing in
Europe. The Company commenced marketing of the said products.
The Company operates through CollPlant Ltd., a wholly-owned subsidiary (CollPlant Holdings Limited and CollPlant Ltd. will be
referred to hereinafter as “the Company” and “CollPlant”, respectively).
The address of the Company’s registered office is 3 Sapir St., Science Park, Ness Ziona, Israel and the Company is traded on the
Tel Aviv Stock Exchange (“TASE”) and since January 31, 2018, the Company’s American Depositary Shares (“ADSs”)
commenced trading on The NASDAQ Capital Market. Each ADS represents 50 ordinary shares.
The Company’s plans for the year 2018 include continuing to focus on the 3D bio-printing of tissues and organs, orthobiologics and
advanced wound healing. The plans include the following: (i) expanding the Company’s 3D bio-printing presence and pursuing
joint ventures to position CollPlant’s bioink as a key component in the field of 3D bioprinting (ii) increasing the sales in Europe of
VergenixFG, a product for the treatment of chronic and surgical wounds, and (iii) increasing the sales of VergenixSTR, a product
for the treatment of tendinopathy, under an exclusive distribution agreement with Arthrex for its distribution in Europe, the Middle-
East, India and certain African countries.
The Company plans to continue research and development, production and marketing during 2018, supported by funding sources
that include the Company’s cash balances, the Israel Innovation Authority (“IIA”) grants, additional future proceeds from securities
purchase agreements signed on September 6, 2017 with Alpha Capital Anstalt (“Alpha”) in amount of $1 million, and proceeds
received on January 2018 from securities purchase agreements signed on January 18, 2018, with Alpha, Ami Sagi and Docor
International BV., respectively, in the total amount of $0.6 million (see notes 12 and 21B).
Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned
development, manufacturing and marketing activities and the corresponding level of expenditures for at least the next 12 months,
although no assurance can be given that it will not need additional funds prior to such time. However, if there are unexpected
increases in sales general and administrative expenses or research and development expenses, the Company may need to seek
additional financing.
B.
Convenience translation into U.S. dollars (“dollars”, “USD” or “$”)
For the convenience of the reader, the reported New Israeli Shekel (“NIS”) amounts as of December 31, 2017 and for the year then
ended have been translated into U.S. dollars at the Bank of Israel’s representative rate of exchange for December 31, 2017 ($1 =
NIS 3.467). The dollar amounts presented in these financial statements should not be construed as representing amounts that are
receivable or payable in dollars or convertible into dollars, unless otherwise indicated.
C.
Approval of financial statements
These financial statements were approved by the board of directors on March 20, 2018.
F-7
Table of Contents
CollPlant Holdings Ltd.
Notes to the Consolidated Financial Statements
NOTE 2—SIGNIFICANT ACCOUNTING POLICIES
A.
Basis of presentation of the financial statements
The Company’s financial statements as of December 31, 2016 and 2017 and for each of the three years ended on December 31,
2017 comply with International Financial Reporting Standards (“IFRS”) and interpretations issued by the IFRS Interpretations
Committee (“IFRS IC”) applicable to companies reporting under IFRS, as issued by the International Accounting Standard Board
(“IASB”).
The significant accounting policies described below have been applied consistently to all the years presented, unless otherwise
stated.
The consolidated financial statements have been prepared on the basis of historical cost except for debentures and derivatives at fair
value.
The preparation of financial statements that comply with IFRS requires the use of certain critical accounting estimates. It also
requires management to exercise judgment when applying the Company’s accounting policies. Note 3 provides disclosure of areas
involving a considerable degree of judgment or complexity, or areas where assumptions and estimates have a material effect on the
financial statements. Actual results may differ materially from the estimates and assumptions used by the Company’s management.
B.
Consolidated financial statements
A subsidiary is an entity over which the Company has control. The Company controls an entity when the Company is exposed to, or
has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over
the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Company. The subsidiaries are
deconsolidated from the date that control ceases.
C.
Translation of foreign currency balances and transactions:
1)
Functional currency and presentation currency
Items included in the financial statements are measured using the currency of the primary economic environment in which
the Company operates (“Functional Currency”). The financial statements are stated in NIS, which is the Functional
Currency and presentation currency of the Company and its subsidiary.
2)
Transactions and balances
Transactions in currencies other than the functional currency (“Foreign Currencies”) are translated into the Functional
Currency at exchange rates at the dates of transaction. Foreign exchange gains and losses resulting from the settlement of
such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in
Foreign Currencies are recognized in the profit or loss for the year.
Gains and losses arising from changes in exchange rates are recognized in the statement of comprehensive loss under
“Financing expenses, net”.
F-8
Table of Contents
CollPlant Holdings Ltd.
Notes to the Consolidated Financial Statements
NOTE 2—SIGNIFICANT ACCOUNTING POLICIES (continued)
D.
Property and equipment
1)
All property and equipment (including leasehold improvements) are stated at historical cost less accumulated depreciation
and impairment. Historical cost of an item of property and equipment includes:
a.
b.
Its purchase price, including import duties and non-refundable purchase taxes, after deducting trade discount and
rebates.
Any costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of
operating in the manner intended by management.
Repairs and maintenance are charged to the statements of comprehensive loss during the period in which they are incurred.
2)
The assets are depreciated using the straight-line method to allocate their cost over their estimated useful lives, as follows:
Computer equipment
Greenhouse equipment*
Office furniture
Laboratory equipment
Leasehold improvements
Years
3
4 - 10
7 - 17
4 - 5
5
*
Greenhouse equipment—agricultural equipment used in the tobacco production greenhouse.
Leasehold improvements are depreciated over the lease period or the expected useful life of the improvements, whichever
is shorter.
Impairment of the asset to its recoverable amount is recognized as incurred, if the carrying amount of the asset is greater
than its estimated recoverable amount (see also section F below).
3)
Gains or losses on disposals are determined by comparing net proceeds with the carrying amount. These are included in
the statement of comprehensive loss.
E.
Intangible assets
1)
In process research and development (“IPR&D”)
Acquired IPR&D is presented based on the fair value at the date of the acquisition and up to December 31, 2015 (see
below), was not depreciated. Such asset was tested annually for impairment, see section F below. The assessment was
carried out more frequently if there were indications of impairment.
Up to December 31, 2015, during the research and development period, this intangible asset was not amortized.
Commencing 2016, the said asset is available for use and therefore is amortized on a straight-line basis until the end of the
period of the patent for the know-how (approximately 10 years).
For information about impairment of non-monetary assets, see F below.
F-9
Table of Contents
CollPlant Holdings Ltd.
Notes to the Consolidated Financial Statements
NOTE 2—SIGNIFICANT ACCOUNTING POLICIES (continued)
2)
Software
Acquired software licenses are capitalized on the basis of the cost incurred to acquire and implement the specific software.
These costs are amortized on a straight-line basis over the estimated useful life of licenses (3 years).
3)
Research and development (“R&D”)
Research expenses are recognized as an expense as incurred. Costs incurred for development projects (referring to design
and testing of new or improved products) are recognized as intangible assets when the following conditions exist:
● It is technically feasible to complete the intangible asset so that it will be available for use;
● Management intends to complete the development of the intangible asset and to use or sell the asset;
● The intangible asset can be used or sold;
● It can be demonstrated how the intangible asset will generate probable future economic benefits;
● There are adequate technical, financial and other resources to complete development and to use or sell the intangible
asset;
● The expenditure attributable to the intangible asset can be reliably measured during its development.
Other development costs that do not meet these criteria are recognized as an expense when incurred. Development costs
previously recognized as an expense are not recognized as an asset in subsequent periods.
As of December 31, 2017, the Company has not met the rules for capitalizing development costs as an intangible asset and
accordingly, no asset whatsoever has been recognized in the financial statements for such costs.
F.
Impairment of non-monetary assets
Assets that have indefinite useful life are not subject to amortization and are tested annually (or when there are indicators for
impairment-see below) for impairment.
All non-monetary assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying
amount may not be recoverable. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its
recoverable amount. The recoverable amount of an asset is the higher of its fair value less costs to sell and value in use. For the
purpose of assessing impairment, assets are grouped together at the lowest levels for which there are separately identifiable cash
flows (cash-generating units). Non-financial assets other than goodwill that suffered impairment are reviewed for possible reversal
of the impairment at each reporting date.
For the years ended December 31, 2015, 2016 and 2017, no impairment has been recognized.
F-10
Table of Contents
CollPlant Holdings Ltd.
Notes to the Consolidated Financial Statements
NOTE 2—SIGNIFICANT ACCOUNTING POLICIES (continued)
G.
Government grants
Government grants, which are received from the Israel Innovation Authority (“IIA”) (formerly known as the Israeli Office of Chief
Scientist or OCS) by way of participation in research and development that is conducted by the Company, fall within the scope of
“forgivable loans,” as set forth in International Accounting Standard 20 “Accounting for Government Grants and Disclosure of
Government Assistance” (“IAS 20”).
As approved by the IIA, the grants are received in installments as the program progresses. The Company recognizes each
forgivable loan on a systematic basis at the same time the Company records, as an expense, the related research and development
costs for which the grant is received, provided that there is reasonable assurance that: (a) the Company complies with the conditions
attached to the grant, and (b) the grant will be received (usually upon receipt of approval notice). The amount of the forgivable loan
is recognized based on the participation rate approved by the IIA; thus, a forgivable loan is recognized as a receivable when
approved research and development costs have been incurred before grant funds are received.
If at the time of grant approval there is reasonable assurance that the Company will comply with the forgivable loan conditions
attached to the grant, and that the Company will not pay royalties to IIA, grant income is recorded against the related research and
development expenses in the statements of comprehensive loss.
If at the time of grant or in subsequent periods, it is not reasonably assured that royalties will not be paid to the IIA, the Company
recognizes a liability that is measured based on the Company’s best estimate of the amount required to settle the Company’s
obligation at the end of each reporting period.
H.
Cash and cash equivalents
Cash and cash equivalents include cash on hand and short-term bank deposits, and other short-term highly liquid investments with
original maturities of three months or less.
I.
Inventory
Inventory is measured at the lower of cost and net realizable value.
The cost of inventories is based on the first-in first-out (FIFO) principle. In the case of purchased goods and work in process, costs
include design, raw materials, direct labor, other direct costs and fixed production overheads (based on the normal operating
capacity of the production facilities).
Net realizable value is the estimated selling price in the ordinary course of business, less variable attributable selling expenses.
J.
Share capital
The Company’s ordinary shares are classified as share capital. Incremental costs directly attributable to the issue of new shares or
warrants are recognized in equity as a deduction of issue proceeds. See also note 14A(8).
K.
Trade payables
Trade payables include the Company’s liabilities to pay for goods or services purchased from suppliers in the ordinary course of
business. Trade payables are classified as current liabilities if payment is due within one year, otherwise they are recognized as non-
current liabilities.
Trade payables are recognized initially at fair value and subsequently measured at amortized cost based on the effective interest
method.
F-11
Table of Contents
CollPlant Holdings Ltd.
Notes to the Consolidated Financial Statements
NOTE 2—SIGNIFICANT ACCOUNTING POLICIES (continued)
L.
Deferred taxes
The Company recognizes deferred taxes based on the liability method, for temporary differences between the carrying amounts of
assets and liabilities included in the consolidated financial statements and the amounts used for tax purposes. However, deferred tax
liabilities are not recognized if they arise from the initial recognition of goodwill. In addition, deferred taxes are not recognized if
the temporary differences arise on initial recognition of an asset or a liability, other than in a business combination, which, at the
time of the transaction, have no effect on profit or loss—whether for accounting or tax purposes. The amount of deferred taxes is
determined in accordance with the tax rates (and tax laws) that have been enacted or substantively enacted as at the date of the
statement of financial position and are expected to apply when the deferred tax assets will be realized or when the deferred tax
liabilities will be settled.
Deferred tax assets are recognized for deductible temporary differences, to the extent that it is probable that future taxable profits
will be available against which they can be utilized.
In the absence of a forecast of future taxable income, a deferred tax asset was not recognized in the Company’s financial statements.
M.
Employee benefits
1)
Liability for severance pay
In accordance with labor laws and labor agreements in effect, the Company and its subsidiary are required to pay severance
and pension benefits to employees who are dismissed or retire under certain circumstances.
The said liability to pay pension and severance pay is related to employees in Israel who are covered by Section 14 of the
Severance Pay Law, and is covered by regular contributions to defined contribution plans. The amounts contributed are not
included in the statement of financial position.
2)
Vacation and recreation pay
By law, all employees are entitled to vacation and recreation pay, calculated on a monthly basis. The right is based on the
employment period.
N.
Revenue recognition
The Company’s revenues are measured at fair value of the consideration received or receivable for the sale of goods in the ordinary
course of business. Revenues are recognized to the extent that it is probable that the economic benefits will flow to the Company
and the revenues can be reliably measured. Revenues from the sale of products are recognized when all the significant risks and
rewards of ownership of the products have passed to the buyer and the Company does not retain continuing managerial involvement
to the degree usually associated with ownership nor effective control over the goods sold.
F-12
Table of Contents
CollPlant Holdings Ltd.
Notes to the Consolidated Financial Statements
NOTE 2—SIGNIFICANT ACCOUNTING POLICIES (continued)
O.
Share-based payment
The Company has a share-based payment plan for employees and service providers, settled by the Company’s equity instruments,
whereby the Company receives services from employees and service providers in exchange for the Company’s equity instruments
(options). The fair value of services received from employees and service providers in exchange for the options is recognized as an
expense in the statements of comprehensive loss. With respect to option granted to employees the total amount recognized as an
expense in statements of the comprehensive loss is based on the fair value of the options granted, without taking into account the
effect of service conditions and non-market vesting conditions.
With respect to options granted to service providers and suppliers, the fair value of the grant is determined in accordance with the
fair value of the service or goods received.
Non-market vesting conditions are included in the assumptions used to estimate the number of options expected to vest. The total
expense is recognized in the vesting period, which is the period for fulfillment of all the defined vesting terms of the share-based
payment arrangement.
At each reporting date, the Company adjusts its estimates of the number of options that are expected to vest, based on the non-
market vesting conditions, and recognizes the effect of the change compared to original estimates, if any, in the statement of
comprehensive loss, and a corresponding adjustment in equity.
When exercising the options, the Company issues new shares, the proceeds, net of directly attributable transaction costs, are
recognized in share capital (par value) and additional paid in capital.
P.
Segment reporting
Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker,
who is responsible for allocating resources and assessing performance of the operating segments. The Company operates in one
operating segment.
Q.
Leases
Lease agreements in which a significant portion of the risks and rewards of ownership are retained by the lessor are classified as
operating leases. Payments made in connection with operating leases are recognized in profit or loss using the straight-line basis
over the term of the lease.
R.
Financial instruments:
1)
Classification
The Company classifies its financial assets to the category of Loan and receivables. The classification depends, among
other things, on the purpose for which the financial assets were purchased. Management determines the classification of
financial assets upon initial recognition.
(a) Loan and receivables
Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted on
an active market. These assets are classified as current assets, except for maturities longer than 12 months following
the date of the balance sheet which are classified as non-current assets. The Company’s loans and receivables are
included in “accounts receivable” and “cash and cash equivalents” in the consolidated statements of financial
position.
F-13
Table of Contents
CollPlant Holdings Ltd.
Notes to the Consolidated Financial Statements
NOTE 2—SIGNIFICANT ACCOUNTING POLICIES (continued)
The Company classifies its financial liabilities to the following categories: financial liabilities at fair value through
profit or loss and financial liabilities at amortized cost. The Company’s management determines the classification of
financial liabilities upon initial recognition.
(a) Financial liabilities at fair value through profit or loss.
Convertible debentures allotted to investors that contain an anti-dilution protection right and other rights, as well as
anti-dilution derivative related to shares issued (see also Notes 12 and 14) are classified, in accordance with IAS 32 as
“financial Liabilities” since the amount of shares that will be issued upon their settlement is not fixed. As the
aforementioned liabilities are non-equity derivative financial instruments, they are measured, in accordance with IAS
39, as financial liabilities at fair value through profit or loss.
In accordance with IAS 39, the company elected to designate, upon initial recognition, the entire hybrid (combined)
debenture (that includes the host debenture contract and the anti-dilution protection) as a financial liability at fair
value through profit or loss.
The said liabilities are measured at their fair value at each date of the balance sheet, with changes in their fair value
recorded to “Financial expenses, net” in the consolidated statements of comprehensive loss.
For those liabilities for which, upon initial recognition, the transaction price is different than their fair value – the
liability is initially recognized at fair value adjusted to defer the difference between the fair value at initial
recognition and the transaction price (“Day 1 Loss”), as the Company uses valuation techniques that incorporate data
not obtained from observable markets. After initial recognition, the unrecognized Day 1 Loss of the said liabilities is
amortized on a straight line basis over the term that market participants would take into account when pricing the
liability. Any unrecognized Day 1 Loss is immediately recognized in profit or loss if the fair value of the financial
instrument in question can be determined either by using only market observable model inputs or by reference to a
quoted price for the same product in an active market. Upon exercise of convertible debenture for which an
unrecognized a Day 1 Loss exists, the carrying amount of the convertible debenture (which is presented net of the
unrecognized Day 1 Loss) is reclassified to equity with no impact on profit or loss.
Transaction costs allocated to financial liabilities measured at fair value through profit or loss are recognized
immediately in profit or loss.
(b) Financial liabilities at amortized cost
Trade payables and financial liabilities included in “accrued liabilities and other” are recognized initially at fair value
and subsequently measured at amortized cost using the effective interest method.
2)
Recognition and measurement
Regular purchases and sales of financial assets are recorded at the date of the settlement which is the date on which the
asset was delivered to the Company or delivered from the Company.
Investments are initially recognized at fair value plus transaction costs for all financial assets not carried at fair value
through profit or loss. Financial assets are derecognized when the rights to receive cash flows from the investments have
expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership
associated with these assets. Receivables are subsequently carried at amortized cost using the effective interest method.
As to methods for measurement of the Company’s financial instruments, see note 4.
F-14
Table of Contents
CollPlant Holdings Ltd.
Notes to the Consolidated Financial Statements
NOTE 2—SIGNIFICANT ACCOUNTING POLICIES (continued)
3)
Impairment of financial assets
The Company assesses at each date of the balance sheet whether there is objective evidence that a financial asset or group
of financial assets measured at amortized cost is impaired. A financial asset or a group of financial assets is impaired and
impairment losses are incurred only if there is objective evidence of impairment as a result of one or more events that
occurred after the initial recognition of the asset (a ‘loss event’) and that loss event (or events) has an impact on the
estimated future cash flows of the financial asset or group of financial assets that can be reliably estimated.
S.
Loss per share
Basic loss per share is generally based on the distributable loss to ordinary shareholders, divided by the weighted average number
of ordinary shares outstanding in the period, net of shares held by the Company.
When calculating diluted loss per share, the Company adjusts the loss attributable to ordinary shareholders of the Company and the
weighted average number of ordinary shares outstanding, for the effects of all dilutive potential ordinary shares.
Potential shares are only taken into account if their effect is dilutive (reduces earnings per share or increases loss per share).
T.
New standards and interpretations not yet adopted:
1)
IFRS 9 “Financial Instruments” (“IFRS 9”)
The complete version of IFRS 9 replaces most of the guidance in IAS 39. IFRS 9 retains but simplifies the mixed
measurement model and establishes three primary measurement categories or financial assets: amortized cost, fair value
through other comprehensive income (“OCI”) and fair value through profit and loss (P&L). The basis of classification
depends on the entity’s business model and the contractual cash flow characteristics of the financial asset. Investments in
equity instruments are required to be measured at fair value through profit or loss with the irrevocable option at inception
to present changes in fair value in OCI. There is now a new expected credit losses model that will replace the incurred loss
impairment model used in IAS 39.
For financial liabilities there were no changes to classification and measurement except for the recognition in other
comprehensive income of changes, resulting from its own credit risk, in liabilities designated at fair value through profit or
loss.
The standard is effective for accounting periods beginning on or after 1 January 2018. Early adoption is permitted. The
Company concluded that the adoption of the new standard as of its initial application will not have a material effect on its
consolidated financial statement.
2)
IFRS 16 “Leases” (“IFRS 16 ”)
In January 2016, the IASB issued IFRS 16—Leases which sets out the principles for the recognition, measurement,
presentation and disclosure of leases for both parties to a contract and replaces the previous leases standard, IAS 17—
Leases.
IFRS 16 eliminates the classification of leases for the lessee as either operating leases or finance leases as required by
IAS 17 and instead introduces a single lessee accounting model whereby a lessee is required to recognize assets and
liabilities for all leases with a term that is greater than 12 months, unless the underlying asset is of low value, and to
recognize depreciation of leases assets separately from interest on lease liabilities in the statements of comprehensive loss.
As IFRS 16 substantially carries forward the lessor accounting requirements in IAS 17, a lessor will continue to classify its
leases as operating leases or finance leases and to account for those two types of leases differently. IFRS 16 is effective
from January 1, 2019 with early adoption allowed only if IFRS 15—Revenue from Contracts with Customers is also
applied. The Company is currently evaluating the impact of adoption on its consolidated financial statements.
F-15
Table of Contents
CollPlant Holdings Ltd.
Notes to the Consolidated Financial Statements
NOTE 2—SIGNIFICANT ACCOUNTING POLICIES (continued)
T.
New standards and interpretations not yet adopted:
3)
IFRS 15 “Revenues from Contracts with Customers” - ( “IFRS 15”).
IFRS 15 will replace, on its first implementation, the directives on the subject of recognizing revenues existing today under
International Financial Reporting Standards.
The core principle of IFRS 15 is that revenues from contracts with customers must be recognized in a way that reflects the
transfer of control of goods or services supplied to customers in the framework of the contracts by amounts which reflect
the proceeds that the entity expects that it will be entitled to receive for those goods or services.
IFRS 15 sets forth a single model for recognizing revenues, according to which the entity will recognize revenues
according to the said core principle by implementing five stages:
(1)
(2)
(3)
(4)
(5)
Identifying the contract(s) with the customer.
Identifying the separate performance obligations in the contract.
Determining the transaction price.
Allocating the transaction price to separate performance obligations in the contract.
Recognizing revenue when (or as) each of the performance obligations is satisfied.
The Company examined the expected effects of the application of IFRS 15 on its consolidated financial statements. The
Company intends to apply IFRS 15 on the date it becomes effective as from the first quarter of 2018, in accordance with
the transitional directive, which allows recognition of the cumulative effect of the initial application as an adjustment to the
opening balance of equity as of January 1, 2018.
Based on such examination, management concluded that the implementation of IFRS 15 will not have a material effect on
its consolidated financial statements.
NOTE 3—SIGNIFICANT ACCOUNTING ESTIMATES AND JUDGMENTS
Estimates and judgments are reviewed on an ongoing basis and are based on past experience and other factors, including
expectations of future events, which are considered reasonable in view of current circumstances.
A.
Significant accounting estimates
The Company makes estimates and assumptions with respect to the future. By nature, accounting estimates are rarely identical to
actual results. The estimate that has a significant risk of resulting in a material adjustment to carrying amounts of assets and
liabilities in the next financial year are discussed below:
1)
Impairment indicators of IPR&D.
The Company reviews whether events or changes in circumstances have occurred that indicate that the carrying amount of
IPR&D may not be recoverable. In such cases an impairment test is performed. See also Note 2E(1).
F-16
Table of Contents
CollPlant Holdings Ltd.
Notes to the Consolidated Financial Statements
NOTE 3—SIGNIFICANT ACCOUNTING ESTIMATES AND JUDGMENTS (continued)
2)
Fair value measurement of debentures
The fair value of the debentures is measured on the basis of accepted valuation models and assumptions regarding
unobservable inputs used in the valuation models, see also Note 12.
Significant judgments made when applying the Company’s accounting policy:
1)
Grants from the IIA
In accordance with the accounting treatment prescribed in Note 2G, The Company’s management is required to examine
whether there is reasonable assurance that the grant that was received will be repaid. In addition, if, at the date of initial
recognition, the grant is recognized in the statement of comprehensive loss, the Company’s management is required to
evaluate whether there is reasonable assurance of the project’s success and of payment of royalties to the IIA. The
Company’s management believes that as of December 31, 2017, there is reasonable assurance that royalties will be paid to
the IIA and that their present value is NIS 1.2 million. This amount was recognized as a financial liability in the statement
of financial position.
2)
Development costs
Development costs are capitalized in accordance with the accounting policy described in Note 2E(3). Capitalization of
costs is based on management’s judgment about technological and economic feasibility. The Company’s management
believes that as of December 31, 2017, the above conditions were not met, therefore development costs were not
capitalized.
NOTE 4—FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT
Financial risk management:
1)
Financial risk factors
The Company’s activities expose it to diverse financial risks: currency risk, credit risk, and liquidity risk. The Company’s
comprehensive risk management plan focuses on the unpredictability of financial markets and the attempt to minimize
potential adverse effects on the Company’s financial performance.
The Company’s CFO is responsible for risk management in accordance with the policy approved by the board of directors.
A)
Market risks
Exchange rate risk
F-17
Table of Contents
CollPlant Holdings Ltd.
Notes to the Consolidated Financial Statements
NOTE 4—FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (continued)
The Company is exposed to exchange rate risks arising from exposure to various currencies, primarily the U.S.
dollar. The exchange rate risk is due to future commercial transactions and assets or liabilities denominated in
foreign currency.
As of December 31, 2017, if the Company’s Functional Currency had depreciated by 5% against the U.S. dollar,
and if all the other variables had remained constant, the loss for the year would have been higher by NIS 350,000
(December 31, 2016, NIS 126,000), mainly due to losses from exchange rate differences for translation of cash
balances, other receivables and trade payables.
B)
Liquidity risk
The Company has not yet generated profits or positive cash flows from its operating activities, and the
continuation of its operations in the current format is subject to raising financing sources until a positive cash flow
is generated from its operations. See also Note 1A.
2)
Capital risk management
The objectives of the Company’s capital risk management are to maintain the Company’s ability to continue as a going
concern in order to provide shareholders with a return on their investment and to maintain an optimal capital structure to
minimize the cost of capital. See also Note 1A.
3)
Estimates of fair value
A.
Fair value measurement
The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is
based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes
observable and unobservable inputs used to measure fair value into three broad levels, which are described below:
Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities.
The fair value hierarchy gives the highest priority to Level 1 inputs.
Level 2: Observable inputs that are based on inputs not quoted on active markets but corroborated by market data.
Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest
priority to Level 3 inputs.
In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and
minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of
fair value.
B.
Estimates of fair value
The following is an analysis of the financial instruments measured at fair value, according to valuation methods. Inputs for
the assets and liabilities that are not based on observable market data (unobservable inputs) (Level 3).
F-18
Table of Contents
CollPlant Holdings Ltd.
Notes to the Consolidated Financial Statements
NOTE 4—FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (continued)
The Company’s financial liability at fair value through profit or loss is the obligation for debentures and anti-dilution
derivatives.
The following table presents the group’s financial liabilities measured at fair value, net of unrecognized Day 1 Loss:
Fair value of convertible debentures
Unrecognized Day 1 Loss
Debentures, net
C.
Financial instruments in level 3
The following table presents the Level 3 instruments roll-forward during 2017:
Opening balance as of January 1, 2017
Issuance of Debentures
Profit from changes in fair value of debentures
Closing balance as of December 31, 2017
NOTE 5—CASH AND CASH EQUIVALENTS
Breakdown by currency:
NIS
In foreign currency (mainly U.S. dollars)
F-19
December 31,
2017
NIS
in thousands
14,015
(1,376)
12,639
2017
NIS
in thousands
—
(14,049)
34
(14,015)
December 31
2016
2017
NIS
in thousands
2,473
1,324
3,797
9,654
8,163
17,817
Table of Contents
NOTE 6—OTHER RECEIVABLES
CollPlant Holdings Ltd.
Notes to the Consolidated Financial Statements
Value added tax
Receivables for participation in R&D expenses
Prepaid expenses
Other
Most financial balances are in NIS and are unlinked.
December 31
2016
2017
NIS
in thousands
624
2,781
131
32
3,568
464
1,294
1,717
68
3,543
The carrying amount of receivables is a reasonable approximation of their fair value since the effect of discounting is insignificant.
The maximum exposure to credit risk as of December 31, 2017 for receivables that are financial assets is their carrying amount. The
Company does not hold any collateral for these receivables.
NOTE 7—PROPERTY AND EQUIPMENT
Composition of property and equipment and accumulated depreciation, by principal groups, and the movements therein in
2015:
Cost
Accumulated depreciation
Carrying
amount at
beginning
Carrying
amount at
end
Carrying
amount at
beginning
Carrying
amount at
end
of year Additions
of year
of year Additions
of year
Computer equipment
Office furniture
Laboratory equipment
Greenhouse equipment
Leasehold improvements
NIS in thousands
64
58
1,200
—
67
1,389
598
438
3,983
2,982
976
8,977
662
496
5,183
2,982
1,043
10,366
NIS in thousands
49
26
355
260
94
784
520
161
3,371
2,199
719
6,970
F-20
Depreciated
balance as at
December 31,
2015
NIS
in thousands
93
309
1,457
523
230
2,612
569
187
3,726
2,459
813
7,754
Table of Contents
CollPlant Holdings Ltd.
Notes to the Consolidated Financial Statements
NOTE 7—PROPERTY AND EQUIPMENT (continued)
Composition of property and equipment and accumulated depreciation, by principal groups, and the movements therein in
2016:
Costs
Accumulated depreciation
Carrying
amount at
beginning
Carrying
amount at
end
Carrying
amount at
beginning
Carrying
amount at
end
of year Additions
of year
of year Additions
of year
Computer equipment
Office furniture
Laboratory equipment
Greenhouse equipment
Leasehold improvements
NIS in thousands
40
4
284
—
1,842
2,170
662
496
5,183
2,982
1,043
10,366
702
500
5,467
2,982
2,885
12,536
NIS in thousands
54
27
400
254
39
774
569
187
3,726
2,459
813
7,754
623
214
4,126
2,713
852
8,528
Composition of property and equipment and accumulated depreciation, by principal groups, and the movements therein in
2017:
Costs
Accumulated depreciation
Carrying
amount at
beginning
Carrying
amount at
end
Carrying
amount at
beginning
Carrying
amount at
end
of year Additions
of year
of year Additions
of year
Computer equipment
Office furniture
Laboratory equipment
Greenhouse equipment
Leasehold improvements
NIS in thousands
16
1
68
—
362
447
702
500
5,467
2,982
2,885
12,536
718
501
5,535
2,982
3,247
12,983
NIS in thousands
44
27
420
207
175
873
623
214
4,126
2,713
852
8,528
F-21
Depreciated
balance as at
December 31,
2016
NIS
in thousands
79
286
1,341
269
2,033
4,008
Depreciated
balance as at
December 31,
2017
NIS
in thousands
51
260
989
62
2,220
3,582
667
241
4,546
2,920
1,027
9,401
Table of Contents
NOTE 8—INTANGIBLE ASSETS
CollPlant Holdings Ltd.
Notes to the Consolidated Financial Statements
Composition of intangible assets and accumulated amortization, by principal groups, and the movements therein in 2015:
Cost
Accumulated depreciation
Carrying
amount at
beginning
of year
Carrying
amount at
end
of year
Carrying
amount at
beginning
of year
Additions
Carrying
amount at
end
of year
Depreciated
balance as at
December 31,
2015
NIS in
thousands
1
1,720
1,721
103
—
103
Software
IPR&D
NIS in thousands
NIS in thousands
104
1,720
1,824
104
1,720
1,824
99
—
99
4
—
4
Composition of intangible assets and accumulated amortization, by principal groups, and the movements therein in 2016:
Costs
Accumulated amortization
Software
IPR&D
NIS
in thousands
104
1,720
1,824
Carrying
amount at
beginning
of year
Carrying
amount at
end
of year
Carrying
amount at
beginning
of year
Carrying
amount at
end of
year
Addition
NIS
in thousands
104
1,720
1,824
103
—
103
1
89
90
104
89
193
Amortized
balance as at
December 31,
2016
NIS
in thousands
—
1,631
1,631
Composition of intangible assets and accumulated amortization, by principal groups, and the movements therein in 2017:
Costs
Accumulated amortization
Carrying
amount at
beginning
of year
Carrying
amount at
end
of year
Carrying
amount at
beginning
of year
Carrying
amount at
end
of year
Amortized
balance as at
December 31,
2017
NIS
in thousands
Addition
NIS
in thousands
104
1,720
1,824
104
89
193
—
177
177
104
266
370
1,454
1,454
Software
IPR&D
NIS
in thousands
104
1,720
1,824
NOTE 9—INCOME TAX
A.
Taxation of the Company and its subsidiary:
Tax rates
The income of the Company and its subsidiary is taxable at the regular rate of corporate tax in Israel.
The rate of corporate tax in 2015 was 26.5%.
In January 2016, the Law for the Amendment of the Income Tax Ordinance (No. 216) was published, enacting a reduction of
corporate tax rate beginning in 2016, from 26.5% to 25%.
F-22
Table of Contents
NOTE 9—INCOME TAX (continued)
CollPlant Holdings Ltd.
Notes to the Consolidated Financial Statements
In December 2016, the Economic Efficiency Law (Legislative Amendments for Achieving Budget Objectives in 2017 and 2018),
2016 was published. The Law stipulates a further reduction in the rate of corporate tax, from 25% to 23%. However, the Law
establishes a temporary order by which the corporate tax rate in 2017 will be 24%. As a result, the corporate tax rate applicable in
2017 was 24% and the corporate tax rate that will apply from 2018 onwards will be 23%. The changes in the above tax rates has no
effect on the Company’s financial statements.
B.
Carry-forward tax losses
Deferred tax assets for carry-forward tax losses are recognized if it is probable that the tax benefit will be realized through the
existence of future taxable profits.
The carry-forward losses of CollPlant Holdings Ltd. (without capital losses) as at December 31, 2017 and 2016 amounted to
approximately NIS 10 .9 million and NIS 9.9 million, respectively.
The carry-forward losses of CollPlant Ltd. (without capital losses) as at December 31, 2017 and 2016 amounted to approximately
NIS 149 million and NIS 136.5 million, respectively.
Under Israeli tax laws, carryforward tax losses have no expiration date.
The Company did not recognize deferred taxes on the losses of the Company and the subsidiary, as it is not probable that the carry-
forward losses will be realized in the foreseeable future.
C.
Tax assessments
In accordance with the Israeli Income Tax Ordinance, tax assessments filed by the Company and its subsidiary up to 2013 are
considered final.
D.
Value added tax
The Company and its subsidiary, are registered as authorized dealers in Israel for VAT purposes.
NOTE 10—ACCOUNTS PAYABLE
A. Trade payables:
Breakdown by currency:
NIS
In foreign currency (mainly U.S. dollars)
B. Composition of other payables:
Employees and institutions for employees
Provisions for vacation and others
Other
December 31
2016
2017
NIS in thousands
3,686
1,503
5,189
775
842
—
1,617
1,923
999
2,922
1,148
784
64
1,996
The carrying amount of accounts payable is a reasonable approximation of their fair value since the effect of discounting is
insignificant.
F-23
Table of Contents
CollPlant Holdings Ltd.
Notes to the Consolidated Financial Statements
NOTE 11—RETIREMENT BENEFIT OBLIGATION
The amount recognized as an expense for defined contribution plans in 2015, 2016 and 2017 is NIS 1,159 thousand NIS
1,558 thousand and NIS 1,378 thousand, respectively.
NOTE 12—FINANCING AGREEMENT
On September 6, 2017, the Company signed a securities purchase agreement (the “Alpha Purchase Agreement”) with Alpha ,
pursuant to which the Company agreed, upon the terms and subject to the conditions of the Alpha Purchase Agreement, to issue to
Alpha, in a private placement, certain securities, in three tranches, as follows: (i) at the first closing, which was completed on
October 26, 2017, ordinary shares and a Convertible Debenture (“Debenture”), for a purchase price of $2 million, (ii) at the second
closing, which was completed on December 31, 2017 and which was subject, among other things, to approval of the private
placement by the Company’s shareholders, Debenture for a purchase price of $2 million, and (iii) at the third closing, which is
subject, among other things, to the listing of the Company’s ADSs for trading on the NASDAQ and to the receipt of shareholder
and option holder approval to adopt the provisions of Chapter E3 of the Israeli Securities Law of 1968 (which allows the Company
to report in Israel in accordance with U.S. reporting requirements) (“Dual Reporting Approval”), ordinary shares and/or a Pre-
Funded warrants for a purchase price of $1 million, and a warrant to purchase 49,607,407 ordinary shares represented by 992,148
ADSs exercisable for a period of five years from the date of issuance at an exercise price of the US dollar equivalent of NIS
36.14379 per ADS (calculated in accordance with the known representative rate of exchange on the date of the notice of exercise).
On October 26, 2017, upon the completion of the first closing, the Company issued to Alpha 7,280,000 ordinary shares and a
Debenture in the principal amount of $1,375,144, for gross proceeds of $2,000,000. On December 31, 2017, upon completion of the
second closing, the Company issued a Debenture in the principal amount of $2,000,000 for gross proceeds of $2,000,000. The
Debentures were convertible at any time at the option of the holder into ADSs at a conversion price of the US dollar equivalent of
NIS 15.3897 (calculated in accordance with the rate of exchange of NIS 3.586 per $1.00) per ADS. In addition, the Debenture was
mandatorily convertible at the then effective conversion price without regard to any beneficial ownership limitation if (i) the ADSs
or the Company’s ordinary shares are approved for listing on the NASDAQ stock market, and (ii) certain equity conditions are met,
and provided that the holder may elect to convert the Debenture in whole or in part to a Pre-Funded Warrant to purchase such
number of ADSs otherwise issuable upon mandatory conversion of the Debenture. On January 31, 2018, Debentures in the
aggregate principal amount of $3,375,144 were automatically converted into a Pre-Funded Warrant to purchase 39,322,742 ordinary
shares represented by 786,455 ADSs.
As part of the first and second closings, and included within the ordinary shares and Debentures issued at the first and second
closings, we issued an aggregate of 1,080,503 ordinary shares and Debentures convertible into 5,836,313 ordinary shares in
connection with services Alpha provided to the Company. These issuances, in fair market value of NIS 3.0 million, were accounted
as share based compensation. NIS 1.5 million was recognized as an expense within “general, administrative and marketing
expenses” in the statements of comprehensive loss and NIS 1.5 million was recognized as a prepaid expense within “accounts
receivables - other” in the statements of financial position.
Under the Alpha Purchase Agreement, Alpha was also granted certain rights, including, among other things, anti-dilution protection
in the event of certain subsequent equity issuances at a price that is lower than the then applicable per ordinary share purchase price.
This right is accounted for as a derivative liability. Accordingly, it is presented as a component of non-current liabilities and is
measured at fair value each reporting period and presented in the statements of financial position within non-current liabilities, see
Note 2R.
F-24
Table of Contents
CollPlant Holdings Ltd.
Notes to the Consolidated Financial Statements
NOTE 12—FINANCING AGREEMENT (continued)
As the Debentures includes an anti-dilution protection and other rights, they are classified as financial liabilities measured at fair
value through profit or loss at each reporting period. The Debentures are initially recognized at fair value adjusted to defer the
difference between the fair value at initial recognition and the transaction price (“Day 1 Loss”), as the Company uses valuation
techniques that incorporate data not obtained from observable markets. On February 1, 2018, all of the debentures were converted
into Pre-Funded warrants and reclassified as equity.
As for the accounting treatment of the Day 1 Loss - see Note 2R.
The financial instruments recognized on the Company’s statement of financial position as of December 31, 2017, are as follows:
1) Derivatives – comprised of an anti-dilution protection on 27,399,497 ordinary shares. The derivative is presents in the
Company’s statements of financial position on a fair value basis in the amount of NIS 140,875.
The derivative’s fair value is determined by using a Put option Model.
The following table presents the assumptions that were used for the models as of December 31, 2017:
Probability
Expected volatility
Risk free interest rate
Expected term (years)
Meitav Dash
and Ami
Sagi
Alpha
5%
5%
64.35%
0.185%
2
65.64%
0.187%
2
2) Debentures - convertible debentures which are convertible into 39,322,742 Pre-Funded warrants and contain an anti-dilution
protection right and other rights. The debentures are presented in the Company’s statement of financial position at fair value basis
in the amount of NIS 12,639 thousand, net of unrecognized Day 1 Loss in the amount of NIS 1,376 thousands.
The debentures fair value is determined by using an Asian put option model.
F-25
Table of Contents
CollPlant Holdings Ltd.
Notes to the Consolidated Financial Statements
NOTE 12—FINANCING AGREEMENT (continued)
The following table presents the assumptions that were used for the models as of December 31, 2017:
Fair value of shares of common stock - NIS
Expected volatility
Discount on lack of marketability
Risk free interest rate
Expected term (years)
Expected dividend yield
NOTE 13—COMMITMENTS AND CONTINGENT LIABILITIES
A.
Agreements:
1)
Operating lease agreements:
First
closing
Debenture
0.43
64.56%
20.4%
0.17%
1.82
Second
closing
Debenture
0.43
61.29%
20.2%
0.19%
2
0%
0%
A)
B)
C)
In 2017, an agreement was signed to extend the lease of the Company’s offices, which commenced in June 2008.
The lease term ends on August 18, 2018, and the monthly rent amounts to NIS 54 thousand. The Company is in a
dialog for the extension of the rent for additional period.
As collateral for the lease agreement, a restricted deposit was pledged in favor of the property owner. The balance
of the restricted deposit as of December 31, 2017 amounts to NIS 503 thousand. The deposit is classified as a non-
current asset.
In April 2007, the Company signed an agreement with a third party for lease of land in Yessod Hamaala. The
lease term ended on April 30, 2017. On July 4, 2017, the Company signed a new agreement for four years with an
option for extension of another 6 years. The lease term began on May 1, 2017. The annual rent amount is NIS
120 thousand.
On July 28, 2016, the Company signed a lease agreement for additional space designated for its development and
production activities. The lease is for three years with an option to extend for four additional years, in return for a
monthly payment of NIS 30 thousand. In addition, as part of the lease agreement, the Company acquired
equipment and clean rooms for the Company’s operations for NIS 1,849 thousand. Out of the aforementioned total
consideration an amount of NIS 1,197 thousand was paid by issuing 1,067,916 ordinary shares of the Company
and a total of NIS 525 thousand was on credit and will be repaid in cash over the term of the lease.
2)
Commitment to pay royalties to the Government of Israel
The Company is committed to pay royalties to the Government of Israel on proceeds from sales of products in the research
and development of which the Government participates by way of grants through the IIA.
At the time the grants were received, successful development of the related project was not assumed. In the case of failure
of the project that was partly financed by the Government of Israel, the Company is not obligated to pay any such royalties.
Under the terms of Company’s funding from the Israeli Government, royalties of 3%-3.5% are payable on sales of products
developed from projects so funded up to 100% of the amount of the grant received by the Company (dollar linked) with
the addition of an annual interest based on Libor.
F-26
Table of Contents
CollPlant Holdings Ltd.
Notes to the Consolidated Financial Statements
NOTE 13—COMMITMENTS AND CONTINGENT LIABILITIES (continued)
Following the marketing agreements that the Company signed, the updated estimate of the Company as of December 31,
2017 is that royalties will be paid to the IIA and that their present value is NIS 1,234 thousand. This amount was
recognized as a financial liability in the statement of financial position (NIS 1,203 thousand within long-term liabilities,
and the remainder within current liabilities). As of December 31, 2017, the fair value of that liability is not materially
different from its carrying amount. As of December 31, 2017, the maximum royalty amount that would be payable by the
Company, before additional Libor interest, is approximately NIS 31.7 million (assuming 100% of the funds are payable).
During 2017, grants amounting to NIS 550,000 were received from the IIA. The participation of IIA in research and
development expenses is presented net of the expenses to pay royalties and expenses of remeasurement of the liability and
amounted to NIS 2.3 million.
B.
Development agreements with pharmaceutical and orthobiologic companies
On November 17, 2010, CollPlant Ltd. and Pfizer signed an agreement for joint development of prototype products for the
treatment of orthopedic problems. The agreement provided for, among other things, the allocation of the rights of the project
outcomes. In accordance with the agreement, Pfizer paid CollPlant immaterial amounts for the development of prototypes.
On December 22, 2011, CollPlant and Pfizer signed another joint development agreement for development of a product for the
orthopedic market (the “Development Agreement”). In accordance with the Development Agreement, the parties agreed to
collaborate in the development of a product that contained Pfizer’s therapeutic proteins and compounds based on CollPlant’s
recombinant human collagen (rhCollagen) (the “Product”).
To the best of the Company’s knowledge, based partially on public sources, in July 2013, Pfizer signed an agreement with
Bioventus LLC, a U.S. based company (“Bioventus”), which specializes in orthobiologics, whereby Pfizer granted Bioventus an
exclusive, global license for the portfolio of projects related to Pfizer’s bone morphogenetic protein (“BMP”). Between July 2013
and February 2017, the Company and Bioventus developed a bioactive implant for spinal fusion and orthopedic trauma, instead of
under the Pfizer agreement, which expired during 2014.
On July 9, 2015, the Company signed a non-binding term sheet with Bioventus. According to the term sheet, Bioventus agreed to
make payments to the Company for the full development plan.
On March 1, 2017, Bioventus informed the Company that it had decided to discontinue the joint development with CollPlant and to
complete product development at a subsidiary of Bioventus.
C.
Contingent liability
On September 6, 2017, the Company received a VAT assessment from the Israel Tax Authority according to which the Company is
required to pay tax in the amount of NIS 1.5 million (including linkage differentials and interest) for the years 2012-2016.
The Company disputes the position of the Israel Tax Authority and intends to appeal the entire assessment, in view of its position
that it is not liable for the additional tax requirement. The Company’s position relies, among other things, on an agreement signed
between the Company and the Israel Tax Authority in 2011, which allows the Company to deduct VAT as stated. It is
management’s view that its financial statements include an adequate provision in respect of the above.
F-27
Table of Contents
NOTE 14—EQUITY
A.
Ordinary shares and warrants:
1)
Composition
CollPlant Holdings Ltd.
Notes to the Consolidated Financial Statements
Number of shares
Ordinary shares of par value NIS 0.03
Ordinary shares of par value NIS 0.03
Registered
December 31
2017 and
2016
Issued and paid up
December 31
2017
500,000,000 166,816,328 107,128,864
2016
Amount in NIS
Issued and paid up
December 31
Registered
December 31
2017 and
2016
2017
15,000,000 5,004,490 3,213,866
2016
Traded on the Tel Aviv Stock Exchange (“TASE”) and on NASDAQ as of January 31, 2018.
On March 4, 2015, the Company announced that its ADR level 1 program became effective in the United States and traded
over the counter (OTC) under the symbol CQPTY.
On January 31, 2018 the Company’s ADSs commenced trading on The NASDAQ Capital Market, under the symbol
CLGN. Each ADS represents 50 ordinary shares.
The above table does not include 920,461 shares held by the Company. These shares are considered to be dormant.
The ordinary shares confer on their holders the right to vote and participate in shareholder meetings (with one vote for each
NIS 0.03 share), the right to receive profits and the right to participate in surplus assets on liquidation of the Company.
In 2016, warrants Series F and I expired without exercise.
On July 1, 2015, the Company completed a capital raise of NIS 11.3 million gross in gross proceeds in a non-uniform
offering to institutional investors (the issuance costs amounted to NIS 1.3 million). In consideration for this amount, the
Company issued 8,317,000 ordinary shares, 8,623,000 Series G warrants to purchase 2,874,333 shares at an exercise price
of NIS 0.80 per warrant for an exercise period of three years, and 3,852,000 Series H warrants to purchase 1,284,000 shares
at an exercise price of NIS 0.85 per warrant for an exercise period of three years. In addition, in accordance with the terms
of the broker agreement, the Company issued 673,284 Series G warrants and 300,764 Series H warrants for the transaction
broker under the same terms as above.
On February 2, 2016, the Company completed a capital raise of NIS 8.2 million in gross proceeds to two institutional
investors and to the public (the issuance expenses amounted to NIS 643 thousand). In consideration, the Company issued
5,745,903 ordinary shares, 12,930,505 Series I warrants exercisable into 4,310,168 ordinary shares at an exercise price of
NIS 0.80 per warrant, for three years, and 8,618,855 Series J warrants exercisable into 2,872,952 ordinary shares at an
exercise price of NIS 0.575 per warrant, exercisable until July 31, 2016. In addition, under the terms of the broker
agreement, the Company issued to the Israeli broker 814,520 Series I warrants exercisable into 271,507 ordinary shares at
an exercise price of NIS 0.80 per warrant, for three years. On July 31, 2016, 8,618,855 Series J warrants expired.
2)
3)
4)
5)
F-28
Table of Contents
NOTE 14—EQUITY (continued)
CollPlant Holdings Ltd.
Notes to the Consolidated Financial Statements
6)
7)
8)
9)
10)
On June 9, 2016, the Company completed a capital raise of NIS 11.8 million in gross proceeds by way of a non-uniform
offering to institutional investors and a uniform offer to the public (the issuance expenses amounted to NIS 684 thousand).
In consideration, the Company issued 11,267,833 ordinary shares and 33,803,500 Series K warrants exercisable into
11,267,833 ordinary shares at an exercise price of NIS 0.60 per warrant, for three years. In addition, in consideration, the
Company issued to the broker under the terms of the broker agreement, 2,728,000 Series K warrants exercisable into
909,333 ordinary shares at an exercise price of NIS 0.60 per warrant, for three years.
On July 28, 2016, as part of the lease agreement described in note 12A(1)(c), the Company acquired equipment and clean
rooms for the Company’s operations for NIS 1,849 thousand (present value). Of this amount, NIS 1,197 thousand was paid
by issuing 1,067,916 ordinary shares and a total of NIS 525 thousand was a credit that will be repaid in cash over the term
of the lease.
On November 17, 2016, the general meeting of shareholders approved a reverse share split of the Company’s shares that
was effected on November 20, 2016. Pursuant to the reverse split each 3 ordinary shares of NIS 0.01 par value were
converted into one share of NIS 0.03 par value of the Company.
Additionally, according to the share option plan of the Company, every 3 unlisted options that were allocated through
private offers to directors, employees, consultants and officers under the option plan are exercisable into one ordinary share
of the Company of NIS 0.03 par value. No change took place in the exercise price of the options, as above; however, the
total exercise price for one share of NIS 0.03 par value will be the former exercise price for one share of NIS 0.01 par value
multiplied by 3.
Further, according to the terms and conditions of the marketable warrants of the Company, each 3 marketable warrants that
the Company issued are exercisable into one ordinary share of the Company of NIS 0.03 par value. There will be no
change in the exercise price of those warrants; however, the total exercise price for one share of NIS 0.03 par value will be
the former exercise price for one share of NIS 0.01 par value multiplied by 3.
Following the reverse split, the Company retrospectively reflected the change in the share capital of the Company for all
periods presented. Unless otherwise indicated, all of the share numbers, losses per share, share prices, options and warrants
in these financial statements have been adjusted, on a retroactive basis, to reflect this 1 to 3 reverse share split.
On February 12, 2017, the Company completed a capital raise of NIS 7.2 million in gross proceeds from institutional
investors and from the public (the issuance expenses amounted to NIS 404 thousand). In consideration, the Company
issued 21,152,000 ordinary shares and 10,576,000 Series L warrants exercisable into 10,576,000 ordinary shares at an
exercise price of NIS 0.36 per warrant, until June 13, 2017. In addition, under the terms of the broker agreement, the
Company issued to the broker 941,400 Series L warrants exercisable into 941,400 ordinary shares at an exercise price of
NIS 0.36 per warrant.
During the second quarter of 2017, 10,055,464 Series L warrants were exercised into 10,055,464 ordinary shares, at an
exercise price of NIS 0.36 for each warrant. The total consideration amounted to NIS 3,618 thousand. 1,461,936 Series L
warrants that were not exercised expired on June 14, 2017.
F-29
Table of Contents
NOTE 14—EQUITY (continued)
CollPlant Holdings Ltd.
Notes to the Consolidated Financial Statements
On November 8, 2017, the Company signed a securities purchase agreement (the “Meitav Dash Purchase Agreement”)
with Meitav Dash, a company held by Meitav Dash Ltd., one of the Company’s shareholders pursuant to which the
Company agreed, upon the terms and subject to the conditions of the Meitav Dash Purchase Agreement, to issue to Meitav
Dash in a private placement certain securities in three tranches as follows: (i) at the first closing, which was completed on
December 26, 2017, 9,500,000 ordinary shares, for a purchase price of NIS 3.8 million, (ii) at the second closing, which
was completed on December 26, 2017, 2,400,000 ordinary shares for a purchase price of NIS 960 thousand provided that
Meitav Dash shall not be obligated to buy or hold, immediately following the second closing, 20% or more of the
Company’s share capital, and (iii) at the third closing, which was completed on March 7, 2018 and which was subject,
among other things, to the listing of the Company’s ADSs for trading on the NASDAQ and Dual Reporting Approval, for
no additional consideration, warrants exercisable into 11,900,000 ordinary shares.
The Company completed the first and second closings on December 26, 2017 which resulted in the issuance to Meitav
Dash of an aggregate of 11,900,000 ordinary shares for gross proceeds of NIS 4,760,000 ($1,384,824) and on March 7,
2018, the Company completed the third closing which resulted in the issuance to Meitav Dash of a warrant to purchase
11,900,000 ordinary shares.
The warrant may be exercised for a period of five years from issuance at an exercise price of the US dollar equivalent of
NIS 40 per ADS (calculated in accordance with the known representative rate of exchange on the date of the notice of
exercise).
Under the Meitav Dash Purchase Agreement, Meitav Dash was also granted certain rights, including, among others, anti-
dilution protection in the event of certain subsequent equity issuances at a price that is lower than the then applicable per
ordinary share purchase price. This component accounted for derivatives and presented in the statements of financial
position within non-current liabilities, see Note 2R.
12)
On November 9, 2017, the Company signed a securities purchase agreement (the “Sagi Purchase Agreement”) with Ami
Sagi, one of the Company’s shareholders, pursuant to which the Company agreed, upon the terms and subject to the
conditions of the Sagi Purchase Agreement, to issue to Ami Sagi in a private placement certain securities in two tranches as
follows: (i) at the first closing, which closed on December 26, 2017, 9,300,000 ordinary shares, for a purchase price of NIS
3.7 million, and (ii) at the second closing, which closed on March 7, 2018 and which was subject, among other things, to
the listing of the Company’s ADSs for trading on the NASDAQ and to Dual Reporting Approval, for no additional
consideration, the Company will issue warrants exercisable into 9,300,000 of its ordinary shares.
The Company completed the first closing on December 26, 2017 which resulted in the issuance to Ami Sagi of an
aggregate of 9,300,000 ordinary shares for gross proceeds of NIS 3,720,000 ($1,054,122) and on March 7, 2018, the
Company completed the second closing which resulted in the issuance to Ami Sagi of a warrant to purchase 9,300,000
ordinary shares.
The warrant may be exercised for a period of five years from issuance at an exercise price of the US dollar equivalent of
NIS 40 per ADS (calculated in accordance with the known representative rate of exchange on the date of the notice of
exercise).
Under the Sagi Purchase Agreement, Ami Sagi was also granted certain rights, including, among other things, anti-dilution
protection in the event of certain subsequent equity issuances at a price that is lower than the then applicable per ordinary
share purchase price. This component accounted for derivatives and presented in the statements of financial position within
non-current liabilities, see Note 2R.
12)
On September 6, 2017, the Company signed a securities purchase agreement with Alpha, see note 12.
F-30
Table of Contents
NOTE 14—EQUITY (continued)
B.
Share-based payment:
CollPlant Holdings Ltd.
Notes to the Consolidated Financial Statements
In accordance with an option plan for employees and consultants (“the Option Plan”), as amended from time to time, employees and
consultants of the Company will be granted options, each exercisable into one ordinary share of the Company of NIS 0.03. The
ordinary shares that will be issued in accordance with the Option Plan will have the same rights as the other ordinary shares of the
Company, immediately subsequent to their issue. An option that is not exercised within 10 years from the allotment date will expire,
unless the board of directors extends its validity.
Grants to employees are made in accordance with the Option Plan, and are carried out within the provisions of Section 102 of the
Israel Income Tax Ordinance. In accordance with the track selected by the Company and these provisions, the Company is not
entitled to claim a tax deduction for the employee benefits.
For those who are not employees of the Company, and for the Company’s controlling shareholders (as defined in the Income Tax
Ordinance) options are granted in accordance with section 3(I) of the Income Tax Ordinance.
1)
2)
3)
4)
5)
On March 22, 2015, the Company’s Board of Directors approved the grant of 10,000,000 options to purchase 3,333,333
ordinary shares to its Director and Chief Scientific Officer. The options will vest over 5 years. One fifth will vest one year
after the grant date, and the balance will vest in equal parts at the end of each subsequent quarter. The exercise price of
each option is NIS 0.60.
On July 30, 2015, the Company’s general meeting approved the options grant. The fair value of the options at the date of
general meeting approval was NIS 4,758 thousand.
The fair value of each option, calculated according to the Black and Scholes formula as of the grant date, amounted to NIS
0.48. This value was based on the following assumptions: expected dividend at a rate of 0%, expected volatility at a rate of
56.49%, risk-free interest rate of 2%, and 4 years of expected term.
On May 18, 2015, the Company’s Board of Directors approved the grant of 5,670,000 options to purchase 1,890,000
ordinary shares to the Company’s CEO. The options will vest over 4 years. One quarter will vest one year after the grant
date, and the balance will vest in equal parts at the end of each subsequent quarter. The exercise price of each option is NIS
0.60.
On July 30, 2015, the Company’s general meeting approved the options grant. The fair value of the options at the date of
general meeting approval was NIS 2,698 thousand.
The fair value of each option, calculated according to the Black and Scholes formula as of the grant date, amounted to NIS
0.48. This value was based on the following assumptions: expected dividend at a rate of 0%, expected volatility at a rate of
56.49%, risk-free interest rate of 2%, and 4 years of expected term.
On May 18, 2015, the Company’s Board of Directors approved the grant of 7,450,000 options to purchase 2,483,333
ordinary shares to employees and officers of the Company (who are not the CEO and/or a director). The options will vest
over 4 years. One quarter will vest one year after the grant date, and the balance will vest in equal parts at the end of each
subsequent quarter. The exercise price of each option is NIS 0.60. The fair value of the options at the grant date was NIS
1,597 thousand.
The fair value of each option, calculated according to the Black and Scholes formula as of the grant date, amounted to NIS
0.22. This value was based on the following assumptions: expected dividend at a rate of 0%, expected volatility at a rate of
56.18%, risk-free interest rate of 2%, and 4 years of expected term.
On May 18, 2015, the Company’s Board of Directors approved the grant of 1,000,000 options to purchase 333,333
ordinary shares to a consultant of the Company. The options will vest according to certain milestones. The exercise price of
each option is NIS 0.60. The fair value of the options at the grant date was NIS 240 thousand.
F-31
Table of Contents
NOTE 14—EQUITY (continued)
CollPlant Holdings Ltd.
Notes to the Consolidated Financial Statements
6)
7)
8)
9)
On May 21, 2015, the Company’s Board of Directors approved the grant of 2,680,000 options to purchase a total of
893,333 ordinary shares to four Board members, 670,000 options to each. The options will vest over 4 years. Half of the
amount will vest two years after the date of the board of directors’ approval, and the balance will vest in equal parts at the
end of each subsequent month. The exercise price of each option is NIS 0.60.
On July 30, 2015, the Company’s general meeting approved the options grant. The fair value of the options at the date of
general meeting approval was NIS 1,275 thousand.
The fair value of each option, calculated according to the Black and Scholes formula as of the grant date, amounted to NIS
0.48. This value was based on the following assumptions: expected dividend at a rate of 0%, expected volatility at a rate of
56.49%, risk-free interest rate of 2%, and 4 years of expected term.
O n August 31, 2015, the Company’s Board of Directors approved a grant of 1,300,000 options to purchase 433,333
ordinary shares to two new officers of the Company (who are not the CEO and/or a director). The options will vest over
4 years. One quarter will vest one year after the grant date, and the balance will vest in equal parts at the end of each
subsequent quarter. The exercise price of each option is NIS 0.85. The fair value of the options at the grant date was NIS
331 thousand.
The fair value of each option, calculated according to the Black and Scholes formula as of the grant date, amounted to NIS
0.25. This value was based on the following assumptions: expected dividend at a rate of 0%, expected volatility at a rate of
56.36%, risk-free interest rate of 2%, and 4 years expected term.
On August 22 2017, the general meeting of shareholders approved the grant of 486,000 options to one director, exercisable
into 486,000 shares in two tranches. 221,000 options were granted without an exercise price and vested immediately on the
grant date. The fair value of each of these latter options is NIS 0.29 and is equal to the share price at the date of grant. The
remaining 265,000 options are exercisable at an exercise price of NIS 0.33 per option. The options will vest over four years
in which one quarter will vest one year after the grant date and the remaining balance will vest in equal parts at the end of
each subsequent quarter. The fair value of each option, at the grant date, calculated according to the Black and Scholes
formula, amounted to NIS 0.13. This value is based on the following assumptions: expected dividend at a rate of 0%,
expected volatility at a rate of 60.53%, risk-free interest rate of 2%, and 4 years expected term. The fair value of the grant
as calculated on the date of the shareholders’ approval is NIS 99 thousand.
On December, 2017, the board of directors approved the grant of an aggregate of 9,100,000 options to purchase 9,100,000
ordinary shares to certain officers and employees. Each of the foregoing options may be exercised at a price per option of
NIS 0.58 and the options will vest over four years in which one quarter will vest one year after the grant date and the
remaining balance will vest in equal parts at the end of each subsequent quarter.
The options will vest over four years in which one quarter will vest one year after the grant date and the remaining balance
will vest in equal parts at the end of each subsequent quarter.
The fair value of each option, at the grant date, calculated according to the Black and Scholes formula, amounted to NIS
0.23. This value is based on the following assumptions: expected dividend at a rate of 0%, expected volatility at a rate of
61.96%, risk-free interest rate of 2%, and 4 years expected term. The fair value of the grant as calculated at the grant date
was NIS 2,145 thousand.
Additionally, the board of directors approved the grant of an aggregate of 6,900,000 options to purchase 6,900,000
ordinary shares which was subject to shareholder approval, as further described in Note 19A.
F-32
Table of Contents
NOTE 14—EQUITY (continued)
Exercise of options
CollPlant Holdings Ltd.
Notes to the Consolidated Financial Statements
10)
11)
On June 24, 2015, 92,045 options were exercised to purchase 30,682 ordinary shares at an exercise price of NIS 0.30 per
option, for total consideration of NIS 27 thousand.
On August 15, 2016, 3,620,885 options were exercised for 235,413 ordinary shares of the Company. No cash was received
for the exercise.
Changes in number of options and weighted average exercise prices are as follows:
Year ended
December 31, 2015
Year ended
December 31, 2016
Year ended
December 31, 2017
Weighted
average of
exercise
price
Weighted
average of
exercise
price
Weighted
average of
exercise
price
No. of
options
No. of
options
0.56
0.61
0.44
0.84
0.3
0.59
0.49
45,532,659
—
(4,076,167)
(4,947,135)
(3,620,885)
32,888,472
14,350,118
0.59 32,888,472
— *9,586,000
(1,065,305)
0.6
(764,375)
0.35
0.26
—
0.65 40,644,792
0.56 20,922,506
0.65
0.56
0.58-1.39
0.6
—
0.63
0.57
No. of
options
17,963,346
28,100,000
(318,894)
(119,748)
(92,045)
45,532,659
11,700,665
Outstanding at the beginning of the
year
Granted
Expired
Forfeited
Exercised
Outstanding at the end of the year
Exercisable at the end of the year
*
Not including options to Directors and CEO which are subject to shareholder approval
The following is information about the exercise price and remaining contractual life of outstanding options:
December 31, 2015
December 31, 2016
December 31, 2017
Number of
outstanding
options
Exercise
price range
45,532,659 0.26 - 1.39
Weighted
average of the
remaining
contractual life
Number of
outstanding
options
Exercise
price range
8.28 32,888,472 0.26 - 1.39
Weighted
average of the
remaining
contractual life
Number of
outstanding
options at
the end of
the year
Exercise
price range
7.72 40,644,792 0.26 - 1.39
Weighted
average of the
remaining
contractual life
6.78
The expenses recognized in the Company’s statements of comprehensive loss in 2015, 2016 and 2017 for options granted
to employees and consultants amounted to NIS 4,081 thousand, NIS 3,572 thousand and NIS 1,910 thousand, respectively.
The total unrecognized compensation cost of stock options at December 31, 2017 is approximately NIS 5.2 million. The
unrecognized compensation cost of employee stock options is expected to be recognized over 4 years.
F-33
Table of Contents
CollPlant Holdings Ltd.
Notes to the Consolidated Financial Statements
NOTE 15—RESEARCH AND DEVELOPMENT EXPENSES, NET
2015
Payroll and related expenses
Share-based payments
Subcontractors and consultants
Consumables and materials
Depreciation and amortization
Rent and maintenance
Other
Less:
Participation in R&D expenses, See Note 13B
IIA participation in R&D expenses, See Note 13(A)(2)
NOTE 16—GENERAL, ADMINISTRATIVE AND MARKETING EXPENSES
2015
Payroll and related expenses
Share-based payments (1)
Directors’ salary and insurance
Rent and office maintenance
Professional services
Depreciation
Other
Year ended
December 31
2016
NIS in thousands
8,728
2,127
11,328
1,806
826
2,963
1,422
29,200
7,656
2,464
7,532
1,035
763
2,448
1,021
22,919
(6,428)
(4,627)
(11,055)
11,864
(9,257)
(3,154)
(12,411)
16,789
Year ended
December 31
2016
NIS in thousands
2,822
1,445
787
364
5,039
38
553
11,048
1,418
1,617
740
407
2,248
25
495
6,950
2017
7,687
1,197
2,554
698
1,002
2,700
1,083
16,921
(573)
(2,282)
(2,855)
14,066
2017
2,926
2,243
411
321
1,827
47
528
8,303
(1) Share-based payments expenses for the year ended December 31, 2017, include amount of NIS 1.5 million due to fair value estimate of
services received through the Alpha Purchase Agreement.
F-34
Table of Contents
CollPlant Holdings Ltd.
Notes to the Consolidated Financial Statements
NOTE 17—FINANCING EXPENSES (INCOME), NET
Financing expenses:
Financing expenses arising from liability to the IIA
Bank and other fees
Other financing expenses
Exchange rate differences
Total financing expenses
Financing income:
Interest income on cash equivalents and deposits
Remeasurement of financial instruments
Exchange rate differences
Total financing income
Financing expenses (income), net
NOTE 18—LOSS PER SHARE
Year ended
December 31
2016
NIS in thousands
2015
2017
—
51
—
—
51
1
—
214
215
(164)
129
61
—
158
190
—
—
—
—
348
273
32
75
—
380
—
35
218
253
127
Basic loss per share is calculated by dividing the loss attributable to the Company’s shareholders by the weighted average number
of ordinary shares issued. The calculation of the diluted loss per share did not take into account 40,544,792 options for employees
and consultants, 9,296,284 Series G warrants, 4,152,764 Series H warrants, 13,745,025 Series I warrants, and 36,531,500 Series K
warrants, since their effect is anti-dilutive.
NOTE 19—TRANSACTIONS AND BALANCES WITH RELATED PARTIES
The Company’s key management personnel include members of the executive management and board of directors, in accordance
with the definition of Related Parties in IAS 24.
A.
Transactions with and benefits to related parties
CEO’s salary*
Share-based payments portion
Remuneration of directors**
Share-based payments portion
Number of directors
2015
Year ended
December 31
2016
NIS in thousands
2,010
1,066
1,214
558
6
1,804
963
3,513
2,455
5
2017
1,988
455
613
279
6
Regarding benefits to other key management personnel—see C below.
*
**
I n accordance with the CEO’s employment agreement, the CEO will be eligible for a bonus based on qualitative criteria and
parameters determined by the Company, which will amount to a maximum of four salaries, plus a special bonus based on the
fulfillment of additional conditions.
Including, in 2015, the effect of an agreement with one of the Company’s shareholders (who also serves as a director of the
Company as from until 2016) for research consulting services, in consideration of a monthly amount of NIS 32 thousand.
F-35
Table of Contents
CollPlant Holdings Ltd.
Notes to the Consolidated Financial Statements
NOTE 19—TRANSACTIONS AND BALANCES WITH RELATED PARTIES (continued)
B.
Balances with related parties:
For salary, incidentals and other benefits, the balance is stated in other payables under current
liabilities
C.
Benefits for key officers
December 31
2016
2017
NIS
in thousands
(235)
(577)
Compensation for the CFO, VP Research and Development, COO (from October 2015), VP commercialization, Chief Scientist, and
VP Quality Assurance, defined as key management personnel, for their services provided to the Company, is as follows:
Salary and other short-term benefits
Share-based payments
Number of key managers
NOTE 20—ENTITY LEVEL DISCLOSURES:
A.
Revenues by geographical area (based on the location of customers):
United states and Canada
Europe
B.
Major customers
2015
Year ended
December 31
2016
NIS in thousands
3,917
2,147
6,064
6
2,545
500
3,045
5
2017
4,119
1,051
5,170
6
2017
NIS in
thousands
802
866
1,668
Set forth below is a breakdown of Company’s revenue by major customers (major customer –revenues from these customers
constitute at least 10% of total revenues in a certain year):
Customer A
Customer B
Customer C
F-36
2017
NIS in
thousands
688
521
295
Table of Contents
CollPlant Holdings Ltd.
Notes to the Consolidated Financial Statements
NOTE 21—SUBSEQUENT EVENTS
A.
B.
C.
D.
O n January 14, 2018, at a shareholder’s meeting, the Company’s shareholders approved (i) the grant of 3,750,000 options to
purchase 3,750,000 ordinary shares to Yehiel Tal, the chief executive officer, (ii) the grant of 650,000 options to purchase 650,000
ordinary shares to Adi Goldin, a director and former chairman, (iii) the grant to each of the directors, Abraham Havron, David Tsur
and Scott Burell, of 500,000 options to purchase 500,000 ordinary shares, (iv) the grant to each of Gili Hart, external director, and
Elan Penn, external director, of 500,000 options to purchase 500,000 ordinary shares, and (v) the annual and attendance
compensation to David Tsur, in accordance with the fixed amounts in accordance with the Companies Law. Following their
approval, each of the foregoing options may be exercised at a price per option of NIS 0.58 and the options will vest over four years
in which one quarter will vest one year after the grant date and the remaining balance will vest in equal parts at the end of each
subsequent quarter.
On January 18, 2018, the Company signed a Security Purchase Agreements for the purchase and sale, in a private placement, of an
aggregate of 4,344,340 ordinary shares for an aggregate of NIS 2.2 million to the following three investors as follows: (i) Alpha
entered into a Security Purchase Agreement for the purchase of 1,275,340 ordinary shares for NIS 638 thousands; (ii) Ami Sagi
entered into a Security Purchase Agreement for the purchase of 2,046,000 ordinary shares for NIS 1 million; and (iii) Docor
International BV entered into a Security Purchase Agreement for the purchase of 1,023,000 ordinary shares for NIS 511 thousand.
Closing occurred on January 25, 2018.
On March 1, 2018, at an extraordinary general meeting of the shareholders of the Company, the authorized share capital of the
Company was increased by 250,000,000 ordinary shares, par value NIS 0.03 per share, to 750,000,000 ordinary shares, par value
NIS 0.03 per share.
On March 20, 2018, the Company's board of directors agreed to issue to Alpha an additional 1,060,000 ordinary shares, subject to
shareholder approval.
F-37
EXECUTION VERSION
Exhibit 4.18
EXHIBIT A
NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN
REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE
IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR
IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN
ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON
EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER
LOAN SECURED BY SUCH SECURITIES.
WARRANT TO PURCHASE ORDINARY SHARES
REPRESENTED BY AMERICAN DEPOSITARY SHARES
COLLPLANT HOLDINGS LTD.
Warrant ADSs: 238,000
Initial Exercise Date: March 7, 2018
THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY
SHARES (the “Warrant”) certifies that, for value received, Meitav Dash Provident Funds And Pension Ltd., or its assigns (the “ Holder”) is
entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date
hereof (the “Initial Exercise Date”) and on or prior to the close of business at 5:00 p.m. (New York City time) on the five (5) year
anniversary of the Initial Exercise Date (the “Termination Date) but not thereafter, to subscribe for and purchase from CollPlant Holdings
Ltd., a company organized under the laws of the State of Israel (the “Company”), up to 11,900,000 Ordinary Shares (the “Warrant Shares”)
represented by 50 American Depositary Shares (“ADSs”), as subject to adjustment hereunder (the “Warrant ADSs”). The purchase price of
one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). Notwithstanding anything herein to
the contrary, in lieu of receiving ADS Warrant Shares, the Holder may choose to receive Ordinary Shares and for such purposes ADS
“Warrant Shares” shall be deemed Ordinary Shares, taking into consideration the applicable ratio and necessary adjustments to the Exercise
Price, if required.
Section 1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain
Securities Purchase Agreement (the “Purchase Agreement”), dated November 7, 2017, between the Company and the Holder.
1
Section 2. Exercise.
a) Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any
time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed
facsimile copy or PDF copy as e-mail attachment of the Notice of Exercise in the form annexed hereto (“Notice of Exercise”). Within the
earlier of (i) three (3) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section
2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant ADSs
specified in the applicable Notice of Exercise by wire transfer. No ink-original Notice of Exercise shall be required, nor shall any medallion
guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required. Notwithstanding anything herein to the
contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the
Warrant ADSs available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the
Company for cancellation within three (3) Trading Days of the date the final Notice of Exercise is delivered to the Company. Partial
exercises of this Warrant resulting in purchases of a portion of the total number of Warrant ADSs available hereunder shall have the effect
of lowering the outstanding number of Warrant ADSs purchasable hereunder in an amount equal to the applicable number of Warrant
ADSs purchased. The Holder and the Company shall maintain records showing the number of Warrant ADSs purchased and the date of
such purchases. The Company shall deliver any objection to any Notice of Exercise within two (2) Business Days of receipt of such notice.
The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this
paragraph, following the purchase of a portion of the Warrant ADSs hereunder, the number of Warrant ADSs available for
purchase hereunder at any given time may be less than the amount stated on the face hereof.
b ) Exercise Price. The exercise price per ADS under this Warrant shall be the amount in US Dollar equal to ILS 40
calculated in accordance with the known representative rate of exchange as published by the Bank of Israel on the date of the Notice of
Exercise, subject to adjustment hereunder (the “Exercise Price”).
c) Mechanics of Exercise.
i. Delivery of Warrant ADSs Upon Exercise . The Company shall cause the Warrant ADSs purchased hereunder to be
transmitted by the Depository to the Holder by physical delivery of a certificate, registered in the Company’s share register
in the name of the Holder or its designee, for the number of Warrant ADSs to which the Holder is entitled pursuant to such
exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of (i) the earlier of
(A) three (3) Trading Days after the delivery to the Company of the Notice of Exercise and (B) one (1) Trading Day after
delivery of the aggregate Exercise Price to the Company three (3) trading days and (ii) the number of Trading Days
comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the
“Warrant ADS Delivery Date ”). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate
purposes to have become the holder of record of the Warrant ADSs with respect to which this Warrant has been exercised,
irrespective of the date of delivery of the Warrant ADSs, provided that payment of the aggregate Exercise Price is received
within the earlier of (i) three Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period
following delivery of the Notice of Exercise. As used herein, “Standard Settlement Period” means the standard settlement
period, expressed in a number of Trading Days, on the Company’s primary Trading Market with respect to the ADSs as in
effect on the date of delivery of the Notice of Exercise.
2
ii. Delivery of New Warrants Upon Exercise . If this Warrant shall have been exercised in part, the Company shall, at
the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant ADSs, deliver
to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant ADSs called for by
this Warrant, which new Warrant shall in all other respects be identical with this Warrant.
i i i . Rescission Rights. If the Company fails to cause the Depository to transmit to the Holder the Warrant ADSs
pursuant to Section 2(d)(i) by the Warrant ADS Delivery Date, then the Holder will have the right to rescind such exercise.
iv. No Fractional Shares or Scrip. No fractional Warrant Shares or Warrant ADSs shall be issued upon the exercise of
this Warrant. As to any fraction of an ADS which the Holder would otherwise be entitled to purchase upon such exercise,
the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such
fraction multiplied by the Exercise Price or round up to the next whole ADS.
v. Charges, Taxes and Expenses. Issuance of Warrant ADSs shall be made without charge to the Holder for any issue
or transfer tax or other incidental expense in respect of the issuance of such Warrant ADSs, all of which taxes and
expenses shall be paid by the Company, and such Warrant ADSs shall be issued in the name of the Holder or in such name
or names as may be directed by the Holder; provided, however, that in the event that Warrant ADSs are to be issued in a
name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the
Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the
payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Depository
fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another
established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant
ADSs. The Company shall pay all applicable fees and expenses of the Depositary in connection with the issuance of the
Warrant ADSs hereunder.
3
vi. Closing of Books. The Company will not close its shareholder books or records in any manner which prevents the
timely exercise of this Warrant, pursuant to the terms hereof.
d) Notwithstanding the provisions of this Warrants, the Purchaser may not exercise this Warrant on the record date of any one
of the following events: (i) distribution of bonus shares; (ii) rights offering; (iii) distribution of dividend; (iv) consolidation of share capital;
(v) split of share capital; (vi) reduction of capital (each of the above will be referred to below as a “Company Event”). In the event the ex-
day (as defined in the TASE’s regulations) of a Company Event precedes the record date of such Company Event, the Warrants may not be
exercised on such ex-day.
Section 3. Certain Adjustments.
a) Share Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a share dividend or
otherwise makes a distribution or distributions on its Ordinary Shares or ADSs or any other equity or equity equivalent securities payable in
Ordinary Shares or ADSs (which, for avoidance of doubt, shall not include any Ordinary Shares issued by the Company upon exercise of
this Warrant) as applicable, (ii) subdivides outstanding Ordinary Shares or ADSs, as applicable, into a larger number of Ordinary Shares or
ADSs, as applicable (iii) combines (including by way of reverse share split) outstanding Ordinary Shares or ADSs into a smaller number of
Ordinary Shares or ADSs, as applicable, or (iv) issues by reclassification of shares of the Ordinary Shares or ADSs any shares of the
Company, as applicable, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number
of Ordinary Shares or ADSs, as applicable (excluding treasury shares, if any), outstanding immediately before such event and of which the
denominator shall be the number of Ordinary Shares or ADSs, as applicable, outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall
remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the
determination of shareholders entitled to receive such dividend or distribution and shall become effective immediately after the effective
date in the case of a subdivision, combination or re-classification.
b) [intentionally deleted]
4
c) Subsequent Rights Offerings. Notwithstanding any adjustments in this Warrant, if at any time the Company grants, issues
or sells any Ordinary Share Equivalents or rights to purchase shares, warrants, securities or other property pro rata to the record holders of
any class of Ordinary Shares or ADSs (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the terms applicable to such
Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of
Ordinary Shares or ADSs acquirable upon complete exercise of this Warrant immediately before the date on which a record is taken for the
grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of Ordinary Shares or
ADSs are to be determined for the grant, issue or sale of such Purchase Rights.
d) Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one
or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or
indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one
or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or
another Person) is completed pursuant to which holders of Ordinary Shares or ADSs are permitted to sell, tender or exchange their shares
for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Ordinary Shares or ADSs,
(iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of
the Ordinary Shares or ADSs or any compulsory share exchange pursuant to which the Ordinary Shares or ADSs are effectively converted
into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions
consummates a share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization,
spin-off or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50%
of the outstanding Ordinary Shares or ADSs (not including any Ordinary Shares or ADSs held by the other Person or other Persons making
or party to, or associated or affiliated with the other Persons making or party to, such share purchase agreement or other business
combination) (each a “Fundamental Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to
receive, for each Warrant ADS that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental
Transaction, at the option of the Holder the number of Ordinary Shares or ADSs of the successor or acquiring corporation or of the
Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”) receivable as a result of such
Fundamental Transaction by a holder of the number of Ordinary Shares or ADSs for which this Warrant is exercisable immediately prior to
such Fundamental Transaction. For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted
to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one Ordinary Share or ADS
in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable
manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Ordinary Shares or ADSs are
given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same
choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The
Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor Entity”)
to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the
provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by
the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder
in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and
substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent
entity) equivalent to the ADSs acquirable and receivable upon exercise of this Warrant prior to such Fundamental Transaction, and with an
exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the
ADSs pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and
such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such
Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such
Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental
Transaction, the provisions of this Warrant and the other Transaction Documents referring to the “Company” shall refer instead to the
Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under
this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.
e) Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of an ADS, as
the case may be. For purposes of this Section 3, the number of Ordinary Shares deemed to be issued and outstanding as of a given date
shall be the sum of the number of Ordinary Shares (excluding treasury shares, if any) issued and outstanding.
f) Notice to Holder.
i. Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3,
the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such
adjustment and any resulting adjustment to the number of Warrant ADSs and setting forth a brief statement of the facts
requiring such adjustment.
5
ii. Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in
whatever form) on the Ordinary Shares, (B) the Company shall declare a special nonrecurring cash dividend on or a
redemption of the Ordinary Shares or ADSs, (C) the Company shall authorize the granting to all holders of the Ordinary
Shares or ADSs rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D)
the approval of any shareholders of the Company shall be required in connection with any reclassification of the Ordinary
Shares, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the
assets of the Company, or any compulsory share exchange whereby the Ordinary Shares are converted into other securities,
cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of
the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder
at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 20
calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a
record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be
taken, the date as of which the holders of the Ordinary Shares of record to be entitled to such dividend, distributions,
redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger,
sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that
holders of the Ordinary Shares of record shall be entitled to exchange their Ordinary Shares for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the
failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate
action required to be specified in such notice. The Holder shall remain entitled to exercise this Warrant during the period
commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be
expressly set forth herein.
Section 4. Transfer of Warrant.
a) Transferability. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof
and to the provisions of Section 4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any
registration rights) are transferable, in whole or in part, to investors listed on the first supplement of the Israeli Securities Law of 1968 who
are also “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933, only upon surrender of this
Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in
the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the
making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or
Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of
assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall
promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this
Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the
Company within three (3) Trading Days of the date the Holder delivers an assignment form to the Company assigning this Warrant full.
The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant ADSs without
having a new Warrant issued.
6
b) New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid
office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued,
signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such
division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be
divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Initial Exercise Date
and shall be identical with this Warrant except as to the number of Warrant ADSs issuable pursuant thereto.
c ) Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that
purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the
registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and
for all other purposes, absent actual notice to the contrary.
d) Transfer Restrictions. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the
transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under
applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public
information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or
transferee of this Warrant, as the case may be, comply with the provisions of Section 5.7 of the Purchase Agreement.
e ) Representation by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this
Warrant and, upon any exercise hereof, will acquire the Warrant ADSs issuable upon such exercise, for its own account and not with a view
to or for distributing or reselling such Warrant ADSs or any part thereof in violation of the Securities Act or any applicable state securities
law, except pursuant to sales registered or exempted under the Securities Act.
7
Section 5. Miscellaneous.
a) No Rights as Shareholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other
rights as a shareholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3.
b ) Loss, Theft, Destruction or Mutilation of Warrant . The Company covenants that upon receipt by the Company of
evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any share certificate relating to the
Warrant ADSs, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the
Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or share certificate, if mutilated,
the Company will make and deliver a new Warrant or share certificate of like tenor and dated as of such cancellation, in lieu of such
Warrant or share certificate.
c ) Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next
succeeding Business Day.
d) Authorized Shares.
The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued
Ordinary Shares and a sufficient number of shares to provide for the issuance of the Ordinary Shares underlying the Warrant ADSs
upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall
constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of
the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such
Warrant ADSs may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the
Trading Market upon which the Ordinary Shares and ADSs may be listed. The Company covenants that all Warrant Shares which
may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights
represented by this Warrant and payment for such Warrant ADSs in accordance herewith, be duly authorized, validly issued, fully
paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than
taxes in respect of any transfer occurring contemporaneously with such issue).
Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without
limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger,
dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of
the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such
actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without
limiting the generality of the foregoing, the Company will (i) take all such action as may be necessary or appropriate in order that
the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (ii)
use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body
having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.
Notwithstanding the foregoing, the Company will be authorized to conduct a reverse share split with respect to its Ordinary Shares
in order to meet TASE or Nasdaq requirements which shall increase the par value of the Ordinary Shares.
8
Before taking any action, which would result in an adjustment in the number of Warrant ADSs for which this Warrant is
exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as
may be necessary from any public regulatory body or bodies having jurisdiction thereof.
e ) Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be
determined in accordance with the provisions of the Purchase Agreement.
f) Restrictions. The Holder acknowledges that the Ordinary Shares underlying the Warrant ADSs acquired upon the exercise
of this Warrant will have restrictions upon resale imposed by state and federal securities laws.
g) Nonwaiver. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate
as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies.
h ) Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the
Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.
i) Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant ADSs, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder
for the purchase price of any Ordinary Shares or ADSs or as a shareholder of the Company, whether such liability is asserted by the
Company or by creditors of the Company.
j) Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted
assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall
be enforceable by the Holder or holder of Warrant ADSs.
k) Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the
Company and the Holder.
I) Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and
valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.
m) Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.
****** **** * **** * ****
(Signature Page Follows)
9
IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the
date first above indicated.
COLLPLANT HOLDINGS LTD.
By:
By:
/s/ Yehiel Tal
Name: Yehiel Tal
Title: CEO
/s/ Eran Rotem
Name: Eran Rotem
Title: Deputy CEO & CFO
10
TO: COLLPLANT HOLDINGS LTD.
NOTICE OF EXERCISE
(1) The undersigned hereby elects to purchase Warrant ADSs of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.
(2) Payment shall be in lawful money of the United States.
(3) Please issue said Warrant ADSs in the name of the undersigned or in such other name as is specified below:
The Warrant ADSs shall be delivered to the following DWAC Account Number:
( 4 ) Accredited Investor. The undersigned is an “accredited investor” as defined in Regulation D promulgated under the
Securities Act of 1933, as amended as well as meets one of the entities listed in the First Supplement of the Israeli Securities Law of 1968.
Evidence to the above is attached.
[SIGNATURE OF HOLDER]
Name of Investing Entity:____________________________________________________________________
Signature of Authorized Signatory of Investing Entity:_______________________________________________
Name of Authorized Signatory: _______________________________________________________________
Title of Authorized Signatory:_________________________________________________________________
Date:
ASSIGNMENT FORM
EXHIBIT B
(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase Warrant ADSs)
FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to Name:
(Please Print)
(Please Print)
Address:
Phone Number:
Email Address: Dated:
Holder’s Signature:____________________
Holder’s Address:_____________________
SIDE AGREEMENT
Exhibit 4.19
Reference is made to that certain Securities Purchase Agreement dated as of November 7, 2017 among CollPlant Holdings Ltd.
(the “Company”), and Meitav Dash Provident Funds And Pension Ltd., a company organized under the laws of the State of Israel
(including its successors and assigns, a “Purchaser”), including any Schedules, Annexes and Exhibits thereto, as may be amended,
supplemented or otherwise modified from time to time (“Purchase Agreement”).
WHEREAS, the Company and the Purchaser have entered into the Purchase Agreement in connection with the sale of securities of
the Company; and
WHEREAS, the Purchaser (the “Holder”) may hold Warrants to purchase Ordinary Shares represented by American Depositary
Shares issued to Holder on the Third Closing as such terms are defined in the Purchase Agreement (the “Warrants”); and
WHEREAS, the Warrants may be exercisable to an amount of up to 11,900,000 Ordinary Shares Ordinary Shares (the “Warrant
Shares”) represented by 238,000 American Depositary Shares (“ADSs”), as subject to adjustment as provided in the Warrants (the
“Warrant ADSs”); and
WHEREAS, the Company and the Holder wish to distinguish the “anti-dilution mechanism” detailed in Section 3(b) of the
Warrants into a separate right of Holder, independent from the terms of the Warrants;
NOW, THEREFORE, as set forth in this side agreement (“Side Agreement”) in consideration of the foregoing, the Company and
the Holder (collectively: “Parties”) agree as follows:
Section 1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in the Purchase
Agreement and the Warrant, as applicable.
Section 2. Subsequent Equity Sales. Until the two (2) year anniversary of the First Closing Date, if the Company or any Subsidiary
thereof, as applicable, shall sell or grant any option to purchase, or sell or grant any right to reprice, or otherwise dispose of or issue (or
announce any offer, sale, grant or any option to purchase or other disposition) any ADSs, Ordinary Shares or any Ordinary Share
Equivalents at a price per share or exercise price (whichever is lower) paid for the securities less than the Exercise Price then in effect (such
lower price, the “Base Share Price” and such issuances collectively, a “Dilutive Issuance”) (it being understood and agreed that if the
holder of the Ordinary Shares or ADSs or any Ordinary Share Equivalents so issued shall at any time, whether by operation of purchase
price adjustments, reset provisions, floating conversion, exercise or exchange prices or otherwise, or due to warrants, options or rights per
share which are issued in connection with such issuance, be entitled to receive Ordinary Shares or ADSs or any Ordinary Share Equivalents
at a Base Share Price that is less than the Exercise Price, such issuance shall be deemed to have occurred for less than the Exercise Price on
such date of the Dilutive Issuance at such effective price), then simultaneously with the consummation of each Dilutive Issuance the
Exercise Price shall be reduced and only reduced to equal the Base Share Price. Such adjustment shall be made whenever such Ordinary
Shares or ADSs or any Ordinary Share Equivalents are issued. Notwithstanding the foregoing, no adjustments shall be made, paid or issued
under this Section 2 in respect of an Exempt Issuance. The Company shall notify the Holder, in writing, no later than the Trading Day
following the issuance or deemed issuance of any Ordinary Shares or ADSs or any Ordinary Share Equivalents subject to this Section 2,
indicating therein the applicable issuance price, or applicable reset price, exchange price, conversion price and other pricing terms (such
notice, the “Dilutive Issuance Notice”). For purposes of clarification, whether or not the Company provides a Dilutive Issuance Notice
pursuant to this Section 2, upon the occurrence of any Dilutive Issuance, the Holder is entitled to receive a number of Warrant ADSs based
upon the Base Share Price regardless of whether the Holder accurately refers to the Base Share Price in the Notice of Exercise. The
provisions of this Section 2 shall be effective only on the date immediately following the date on which the Company becomes a
corporation reporting under Chapter E3 of the Israeli Securities Law and the provisions of this Section 2 shall apply on such day with
retroactive effect as of the Original Issue Date.
Section 3. Miscellaneous. The provisions of Section 3(a) (Share Dividends and Splits), Section 3(c) (Subsequent Rights Offerings),
Section 3(d) (Fundamental Transaction), Section 3(e) (Calculations), Section 3(f) (Notice to Holder), Section 4 (Transfer of Warrant) and
Section 5 (Miscellaneous) of the Warrants are hereby incorporated by reference, mutatis mutandis.
Section 4. Counterparts and Signature. This Side Agreement may be executed in two or more counterparts (including by fax or
electronic scan, such as PDF), each of which shall be deemed to be an original, with the same effect as if the signatures hereto were upon
the same instrument, and shall become effective when one or more counterparts have been signed by each of the Parties and delivered
(including by fax or electronic scan, such as PDF) to the other Party.
[Remainder of page intentionally left blank]
IN WITNESS WHEREOF, the parties hereto have caused this Side Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.
COLLPLANT HOLDINGS LTD.
Address for Notice:
By:
/s/ Yehiel Tal
Name: Yehiel Tal
Title: CEO
By:
/s/ Eran Rotem
Name: Eran Rotem
Title: Deputy CEO & CFO
With a copy to (which shall not constitute notice):
Fax:
E-Mail: yehiel@collplant.com;
eran@collplant.com
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK
SIGNATURE PAGE FOR HOLDER FOLLOWS]
[Signature Page to Side Agreement]
[HOLDER SIGNATURE PAGES TO SIDE AGREEMENT]
IN WITNESS WHEREOF, the undersigned have caused this Side Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.
Name of Holder:
Signature of Authorized Signatory of Holder:
Name of Authorized Signatory:
Title of Authorized Signatory:
Email Address of Authorized Signatory:
Facsimile Number of Authorized Signatory:
Address for Notice to Holder:
Address for Delivery of Securities to Holder (if not same as address for notice):
[Signature Page to Side Agreement]
EXECUTION VERSION
Exhibit 4.21
EXHIBIT A
NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN
REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE
IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR
IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN
ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON
EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER
LOAN SECURED BY SUCH SECURITIES.
WARRANT TO PURCHASE ORDINARY SHARES
REPRESENTED BY AMERICAN DEPOSITARY SHARES
COLLPLANT HOLDINGS LTD.
Warrant ADSs: 186,000
Initial Exercise Date: March 7, 2018
THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY
SHARES (the “Warrant”) certifies that, for value received, Ami Sagi XXXXX, an Israeli citizen or his successors or assigns (the “ Holder”)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date
hereof (the “Initial Exercise Date”) and on or prior to the close of business at 5:00 p.m. (New York City time) on the five (5) year
anniversary of the Initial Exercise Date (the “Termination Date) but not thereafter, to subscribe for and purchase from CollPlant Holdings
Ltd., a company organized under the laws of the State of Israel (the “Company”),up to 9,300,000 Ordinary Shares (the “Warrant Shares”)
represented by 50 American Depositary Shares (“ADSs”), as subject to adjustment hereunder (the “Warrant ADSs”). The purchase price of
one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). Notwithstanding anything herein to
the contrary, in lieu of receiving ADS Warrant Shares, the Holder may choose to receive Ordinary Shares and for such purposes ADS
“Warrant Shares” shall be deemed Ordinary Shares, taking into consideration the applicable ratio and necessary adjustments to the Exercise
Price, if required.
Section 1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain
Securities Purchase Agreement (the “Purchase Agreement”), dated November 9, 2017, between the Company and the Holder.
1
Section 2. Exercise.
a) Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any
time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed
facsimile copy or PDF copy as e-mail attachment of the Notice of Exercise in the form annexed hereto (“Notice of Exercise”). Within the
earlier of (i) three (3) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section
2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant ADSs
specified in the applicable Notice of Exercise by wire transfer. No ink-original Notice of Exercise shall be required, nor shall any medallion
guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required. Notwithstanding anything herein to the
contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the
Warrant ADSs available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the
Company for cancellation within three (3) Trading Days of the date the final Notice of Exercise is delivered to the Company. Partial
exercises of this Warrant resulting in purchases of a portion of the total number of Warrant ADSs available hereunder shall have the effect
of lowering the outstanding number of Warrant ADSs purchasable hereunder in an amount equal to the applicable number of Warrant
ADSs purchased. The Holder and the Company shall maintain records showing the number of Warrant ADSs purchased and the date of
such purchases. The Company shall deliver any objection to any Notice of Exercise within two (2) Business Days of receipt of such notice.
The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this
paragraph, following the purchase of a portion of the Warrant ADSs hereunder, the number of Warrant ADSs available for
purchase hereunder at any given time may be less than the amount stated on the face hereof.
b) Exercise Price. The exercise price per ADS under this Warrant shall be the amount in US Dollar equal to ILS 40 calculated
in accordance with the known representative rate of exchange as published by the Bank of Israel on the date of the Notice of Exercise,
subject to adjustment hereunder (the “Exercise Price”).
c) Mechanics of Exercise.
i . Delivery of Warrant ADSs Upon Exercise . The Company shall cause the Warrant ADSs purchased
hereunder to be transmitted by the Depository to the Holder by physical delivery of a certificate, registered in the Company’s
share register in the name of the Holder or its designee, for the number of Warrant ADSs to which the Holder is entitled
pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of (i) the
earlier of (A) three (3) Trading Days after the delivery to the Company of the Notice of Exercise and (B) one (1) Trading Day
after delivery of the aggregate Exercise Price to the Company three (3) trading days and (ii) the number of Trading Days
comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the “Warrant
ADS Delivery Date”). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have
become the holder of record of the Warrant ADSs with respect to which this Warrant has been exercised, irrespective of the
date of delivery of the Warrant ADSs, provided that payment of the aggregate Exercise Price is received within the earlier of (i)
three Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the
Notice of Exercise. As used herein, “ Standard Settlement Period” means the standard settlement period, expressed in a number
of Trading Days, on the Company’s primary Trading Market with respect to the ADSs as in effect on the date of delivery of the
Notice of Exercise.
2
ii. Delivery of New Warrants Upon Exercise . If this Warrant shall have been exercised in part, the Company
shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant ADSs,
deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant ADSs called for
by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.
iii. Rescission Rights, If the Company fails to cause the Depository to transmit to the Holder the Warrant
ADSs pursuant to Section 2(d)(i) by the Warrant ADS Delivery Date, then the Holder will have the right to rescind such
exercise.
iv. No Fractional Shares or Scrip. No fractional Warrant Shares or Warrant ADSs shall be issued upon the
exercise of this Warrant. As to any fraction of an ADS which the Holder would otherwise be entitled to purchase upon such
exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to
such fraction multiplied by the Exercise Price or round up to the next whole ADS.
v. Charges, Taxes and Expenses, Issuance of Warrant ADSs shall be made without charge to the Holder for
any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant ADSs, all of which taxes and
expenses shall be paid by the Company, and such Warrant ADSs shall be issued in the name of the Holder or in such name or
names as may be directed by the Holder; provided, however, that in the event that Warrant ADSs are to be issued in a name
other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form
attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum
sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Depository fees required for same-
day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing
corporation performing similar functions) required for same-day electronic delivery of the Warrant ADSs. The Company shall
pay all applicable fees and expenses of the Depositary in connection with the issuance of the Warrant ADSs hereunder.
3
prevents the timely exercise of this Warrant, pursuant to the terms hereof.
vi. Closing of Books. The Company will not close its shareholder books or records in any manner which
d) Notwithstanding the provisions of this Warrants, the Purchaser may not exercise this Warrant on the record date of any one
of the following events: (i) distribution of bonus shares; (ii) rights offering; (iii) distribution of dividend; (iv) consolidation of share capital;
(v) split of share capital; (vi) reduction of capital (each of the above will be referred to below as a “Company Event”). In the event the ex-
day (as defined in the TASE’s regulations) of a Company Event precedes the record date of such Company Event, the Warrants may not be
exercised on such ex-day.
Section 3. Certain Adjustments.
a) Share Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a share dividend or
otherwise makes a distribution or distributions on its Ordinary Shares or ADSs or any other equity or equity equivalent securities payable in
Ordinary Shares or ADSs (which, for avoidance of doubt, shall not include any Ordinary Shares issued by the Company upon exercise of
this Warrant) as applicable, (ii) subdivides outstanding Ordinary Shares or ADSs, as applicable, into a larger number of Ordinary Shares or
ADSs, as applicable (iii) combines (including by way of reverse share split) outstanding Ordinary Shares or ADSs into a smaller number of
Ordinary Shares or ADSs, as applicable, or (iv) issues by reclassification of shares of the Ordinary Shares or ADSs any shares of the
Company, as applicable, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number
of Ordinary Shares or ADSs, as applicable (excluding treasury shares, if any), outstanding immediately before such event and of which the
denominator shall be the number of Ordinary Shares or ADSs, as applicable, outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall
remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the
determination of shareholders entitled to receive such dividend or distribution and shall become effective immediately after the effective
date in the case of a subdivision, combination or re-classification.
b) [intentionally deleted]
4
c) Subsequent Rights Offerings. Notwithstanding any adjustments in this Warrant, if at any time the Company grants, issues or
sells any Ordinary Share Equivalents or rights to purchase shares, warrants, securities or other property pro rata to the record holders of any
class of Ordinary Shares or ADSs (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the terms applicable to such
Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of
Ordinary Shares or ADSs acquirable upon complete exercise of this Warrant immediately before the date on which a record is taken for the
grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of Ordinary Shares or
ADSs are to be determined for the grant, issue or sale of such Purchase Rights.
d) Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one
or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or
indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one
or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or
another Person) is completed pursuant to which holders of Ordinary Shares or ADSs are permitted to sell, tender or exchange their shares
for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Ordinary Shares or ADSs,
(iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of
the Ordinary Shares or ADSs or any compulsory share exchange pursuant to which the Ordinary Shares or ADSs are effectively converted
into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions
consummates a share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization,
spin-off or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50%
of the outstanding Ordinary Shares or ADSs (not including any Ordinary Shares or ADSs held by the other Person or other Persons making
or party to, or associated or affiliated with the other Persons making or party to, such share purchase agreement or other business
combination) (each a “Fundamental Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to
receive, for each Warrant ADS that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental
Transaction, at the option of the Holder the number of Ordinary Shares or ADSs of the successor or acquiring corporation or of the
Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”) receivable as a result of such
Fundamental Transaction by a holder of the number of Ordinary Shares or ADSs for which this Warrant is exercisable immediately prior to
such Fundamental Transaction. For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted
to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one Ordinary Share or ADS
in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable
manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Ordinary Shares or ADSs are
given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same
choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The
Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor Entity”)
to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the
provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by
the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder
in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and
substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent
entity) equivalent to the ADSs acquirable and receivable upon exercise of this Warrant prior to such Fundamental Transaction, and with an
exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the
ADSs pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and
such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such
Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such
Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental
Transaction, the provisions of this Warrant and the other Transaction Documents referring to the “Company” shall refer instead to the
Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under
this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.
5
e) Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of an ADS, as the
case may be. For purposes of this Section 3, the number of Ordinary Shares deemed to be issued and outstanding as of a given date shall be
the sum of the number of Ordinary Shares (excluding treasury shares, if any) issued and outstanding.
f) Notice to Holder.
i. Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this
Section 3, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after
such adjustment and any resulting adjustment to the number of Warrant ADSs and setting forth a brief statement of the facts
requiring such adjustment.
ii. Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution
in whatever form) on the Ordinary Shares, (B) the Company shall declare a special nonrecurring cash dividend on or a
redemption of the Ordinary Shares or ADSs, (C) the Company shall authorize the granting to all holders of the Ordinary Shares
or ADSs rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval
of any shareholders of the Company shall be required in connection with any reclassification of the Ordinary Shares, any
consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the
Company, or any compulsory share exchange whereby the Ordinary Shares are converted into other securities, cash or property,
or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the
Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile
number or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the
applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the
purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the
holders of the Ordinary Shares of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be
determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to
become effective or close, and the date as of which it is expected that holders of the Ordinary Shares of record shall be entitled
to exchange their Ordinary Shares for securities, cash or other property deliverable upon such reclassification, consolidation,
merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery
thereof shall not affect the validity of the corporate action required to be specified in such notice. The Holder shall remain
entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event
triggering such notice except as may otherwise be expressly set forth herein.
6
Section 4. Transfer of Warrant.
a) Transferability. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof
and to the provisions of Section 4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any
registration rights) are transferable, in whole or in part, to investors listed on the first supplement of the Israeli Securities Law of 1968 who
are also “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933, only upon surrender of this
Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in
the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the
making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or
Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of
assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall
promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this
Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the
Company within three (3) Trading Days of the date the Holder delivers an assignment form to the Company assigning this Warrant full.
The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant ADSs without
having a new Warrant issued.
7
b) New Warrants . This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid
office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued,
signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such
division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be
divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Initial Exercise Date
and shall be identical with this Warrant except as to the number of Warrant ADSs issuable pursuant thereto.
c) Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose
(the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered
Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all
other purposes, absent actual notice to the contrary.
d) Transfer Restrictions. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the
transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under
applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public
information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or
transferee of this Warrant, as the case may be, comply with the provisions of Section 5.7 of the Purchase Agreement.
e ) Representation by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this
Warrant and, upon any exercise hereof, will acquire the Warrant ADSs issuable upon such exercise, for its own account and not with a view
to or for distributing or reselling such Warrant ADSs or any part thereof in violation of the Securities Act or any applicable state securities
law, except pursuant to sales registered or exempted under the Securities Act.
Section 5. Miscellaneous.
a) No Rights as Shareholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other
rights as a shareholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3.
8
b) Loss, Theft, Destruction or Mutilation of Warrant . The Company covenants that upon receipt by the Company of evidence
reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any share certificate relating to the Warrant ADSs,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not
include the posting of any bond), and upon surrender and cancellation of such Warrant or share certificate, if mutilated, the Company will
make and deliver a new Warrant or share certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or share
certificate.
c) Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next
succeeding Business Day.
d) Authorized Shares.
The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized
and unissued Ordinary Shares and a sufficient number of shares to provide for the issuance of the Ordinary Shares underlying
the Warrant ADSs upon the exercise of any purchase rights under this Warrant. The Company further covenants that its
issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary
Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant ADSs may be issued as provided herein without violation of any applicable
law or regulation, or of any requirements of the Trading Market upon which the Ordinary Shares and ADSs may be listed. The
Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this
Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant ADSs in
accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges
created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously
with such issue).
Except and to the extent as waived or consented to by the Holder, the Company shall not by any action,
including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets,
consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the
observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all
such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in
this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) take all such action as
may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant
Shares upon the exercise of this Warrant and (ii) use commercially reasonable efforts to obtain all such authorizations,
exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the
Company to perform its obligations under this Warrant. Notwithstanding the foregoing, the Company will be authorized to
conduct a reverse share split with respect to its Ordinary Shares in order to meet TASE or Nasdaq requirements which shall
increase the par value of the Ordinary Shares.
9
Before taking any action which would result in an adjustment in the number of Warrant ADSs for which this
Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or
consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.
e) Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be
determined in accordance with the provisions of the Purchase Agreement.
f) Restrictions. The Holder acknowledges that the Ordinary Shares underlying the Warrant ADSs acquired upon the exercise
of this Warrant will have restrictions upon resale imposed by state and federal securities laws.
g) Nonwaiver. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate
as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies.
h ) Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the
Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.
i) Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant ADSs, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder
for the purchase price of any Ordinary Shares or ADSs or as a shareholder of the Company, whether such liability is asserted by the
Company or by creditors of the Company.
j) Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted
assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall
be enforceable by the Holder or holder of Warrant ADSs.
10
k) Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the
Company and the Holder.
l) Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and
valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.
m) Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.
*********************
(Signature Page Follows)
11
IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the
date first above indicated.
COLLPLANT HOLDINGS LTD.
By:
By:
/s/ Yehiel Tal
Name:Yehiel Tal
Title: CEO
/s/ Eran Rotem
Name: Eran Rotem
Title: Deputy CEO & CFO
12
TO: COLLPLANT HOLDINGS LTD.
NOTICE OF EXERCISE
(1) The undersigned hereby elects to purchase Warrant ADSs of the Company pursuant to the terms of the
attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer
taxes, if any.
(2) Payment shall be in lawful money of the United States.
(3) Please issue said Warrant ADSs in the name of the undersigned or in such other name as is specified below:
___________________________
The Warrant ADSs shall be delivered to the following DWAC Account Number:
___________________________
___________________________
___________________________
(4) Accredited Investor. The undersigned is an "accredited investor" as defined in Regulation D promulgated under the
Securities Act of 1933, as amended as well as meets one of the entities listed in the First Supplement of the Israeli Securities Law of 1968.
Evidence to the above is attached.
[SIGNATURE OF HOLDER]
Name of Investing Entity:____________________________________________________________________
Signature of Authorized Signatory of Investing Entity:______________________________________________
Name of Authorized Signatory: _______________________________________________________________
Title of Authorized Signatory:_________________________________________________________________
Date: ___________________________________________________________________________________
ASSIGNMENT FORM
EXHIBIT B
(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase Warrant
ADSs)
FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to Name:
(Please Print)
(Please Print)
Address:
Phone Number:
Email Address:
Dated: ,
Holder's Signature:
Holder's Address:
SIDE AGREEMENT
Exhibit 4.22
Reference is made to that certain Securities Purchase Agreement dated as of November 9, 2017 among CollPlant Holdings Ltd.
(the “Company”), and Ami Sagi 70291935, an Israeli citizen (“Ami”) (including its successors and assigns), including any Schedules,
Annexes and Exhibits thereto, as may be amended, supplemented or otherwise modified from time to time (“Purchase Agreement”).
WHEREAS, the Company and Ami have entered into the Purchase Agreement in connection with the sale of securities of the
Company; and
WHEREAS, Ami or his successors or assigns (the “ Holder”) may hold Warrants to purchase Ordinary Shares represented by
American Depositary Shares issued to Holder on the Second Closing as such terms are defined in the Purchase Agreement (the
“Warrants”); and
WHEREAS, the Warrants may be exercisable to an amount of up to 9,300,000 Ordinary Shares (the “Warrant Shares”) represented
by 186,000 American Depositary Shares (“ADSs”), as subject to adjustment as provided in the Warrants (the “Warrant ADSs”); and
WHEREAS, the Company and the Holder wish to distinguish the “anti-dilution mechanism” detailed in Section 3(b) of the
Warrants into a separate right of Holder, independent from the terms of the Warrants;
NOW, THEREFORE, as set forth in this side agreement (“Side Agreement”) in consideration of the foregoing, the Company and
the Holder (collectively: “Parties”) agree as follows:
Section 1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in the Purchase
Agreement and the Warrant, as applicable.
Section 2. Subsequent Equity Sales. Until the two (2) year anniversary of the First Closing Date, if the Company or any Subsidiary
thereof, as applicable, shall sell or grant any option to purchase, or sell or grant any right to reprice, or otherwise dispose of or issue (or
announce any offer, sale, grant or any option to purchase or other disposition) any ADSs, Ordinary Shares or any Ordinary Share
Equivalents at a price per share or exercise price (whichever is lower) paid for the securities less than the Exercise Price then in effect (such
lower price, the “Base Share Price” and such issuances collectively, a “Dilutive Issuance”) (it being understood and agreed that if the holder
of the Ordinary Shares or ADSs or any Ordinary Share Equivalents so issued shall at any time, whether by operation of purchase price
adjustments, reset provisions, floating conversion, exercise or exchange prices or otherwise, or due to warrants, options or rights per share
which are issued in connection with such issuance, be entitled to receive Ordinary Shares or ADSs or any Ordinary Share Equivalents at a
Base Share Price that is less than the Exercise Price, such issuance shall be deemed to have occurred for less than the Exercise Price on
such date of the Dilutive Issuance at such effective price), then simultaneously with the consummation of each Dilutive Issuance the
Exercise Price shall be reduced and only reduced to equal the Base Share Price. Such adjustment shall be made whenever such Ordinary
Shares or ADSs or any Ordinary Share Equivalents are issued. Notwithstanding the foregoing, no adjustments shall be made, paid or issued
under this Section 2 in respect of an Exempt Issuance. The Company shall notify the Holder, in writing, no later than the Trading Day
following the issuance or deemed issuance of any Ordinary Shares or ADSs or any Ordinary Share Equivalents subject to this Section 2,
indicating therein the applicable issuance price, or applicable reset price, exchange price, conversion price and other pricing terms (such
notice, the “Dilutive Issuance Notice”). For purposes of clarification, whether or not the Company provides a Dilutive Issuance Notice
pursuant to this Section 2, upon the occurrence of any Dilutive Issuance, the Holder is entitled to receive a number of Warrant ADSs based
upon the Base Share Price regardless of whether the Holder accurately refers to the Base Share Price in the Notice of Exercise. The
provisions of this Section 2 shall be effective only on the date immediately following the date on which the Company becomes a
corporation reporting under Chapter E3 of the Israeli Securities Law and the provisions of this Section 2 shall apply on such day with
retroactive effect as of the Original Issue Date.
Section 3. Miscellaneous. The provisions of Section 3(a) (Share Dividends and Splits), Section 3(c) (Subsequent Rights Offerings),
Section 3(d) (Fundamental Transaction), Section 3(e) (Calculations), Section 3(f) (Notice to Holder), Section 4 (Transfer of Warrant) and
Section 5 (Miscellaneous) of the Warrants are hereby incorporated by reference, mutatis mutandis.
Section 4. Counterparts and Signature. This Side Agreement may be executed in two or more counterparts (including by fax or
electronic scan, such as PDF), each of which shall be deemed to be an original, with the same effect as if the signatures hereto were upon
the same instrument, and shall become effective when one or more counterparts have been signed by each of the Parties and delivered
(including by fax or electronic scan, such as PDF) to the other Party.
[Remainder of page intentionally left blank]
IN WITNESS WHEREOF, the parties hereto have caused this Side Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.
COLLPLANT HOLDINGS LTD.
Address for Notice:
By:
/s/ Yehiel Tal
Name:Yehiel Tal
Title: CEO
By:
/s/ Eran Rotem
Name: Eran Rotem
Title: Deputy CEO & CFO
With a copy to (which shall not constitute notice):
Fax:
E-
Mail:
yehiel@collplant.corn;
eran@collplant.com
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK
SIGNATURE PAGE FOR HOLDER FOLLOWS]
[Signature Page to Side Agreement]
[HOLDER SIGNATURE PAGES TO SIDE AGREEMENT]
IN WITNESS WHEREOF, the undersigned have caused this Side Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.
Name of Holder:_______________________________________________________
Signature of Authorized Signatory of Holder:_________________________________
Name of Authorized Signatory: ___________________________________________________
Title of Authorized Signatory:_____________________________________________________
Email Address of Authorized Signatory:_____________________________________________
Facsimile Number of Authorized Signatory:__________________________________________
Address for Notice to Holder:
Address for Delivery of Securities to Holder (if not same as address for notice):
[Signature Page to Side Agreement]
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a)
Exhibit 12.1
I, Yehiel Tal, certify that:
1.
I have reviewed this Annual Report on Form 20-F of CollPlant Holdings Ltd.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;
4. The company's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) [language omitted in accordance with Exchange Act Rule 13a-14(a)] for the
company and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to
us by others within those entities, particularly during the period in which this report is being prepared;
(b) [paragraph omitted in accordance with Exchange Act Rule 13a-14(a)];
(c) Evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such
evaluation; and
(d) Disclosed in this report any change in the company's internal control over financial reporting that occurred during the period
covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company's internal control
over financial reporting; and
5. The company's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the company's auditors and the audit committee of the company’s board of directors:
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the company's
internal control over financial reporting.
Date: March 20, 2018
/s/ Yehiel Tal
Yehiel Tal
Chief Executive Officer
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a)
Exhibit 12.2
I, Eran Rotem, certify that:
1.
I have reviewed this Annual Report on Form 20-F of CollPlant Holdings Ltd.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;
4. The company's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) [language omitted in accordance with Exchange Act Rule 13a-14(a)] for the
company and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to
us by others within those entities, particularly during the period in which this report is being prepared;
(b) [paragraph omitted in accordance with Exchange Act Rule 13a-14(a)];
(c) Evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such
evaluation; and
(d) Disclosed in this report any change in the company's internal control over financial reporting that occurred during the period
covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company's internal control
over financial reporting; and
5. The company's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the company's auditors and the audit committee of the company’s board of directors:
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the company's
internal control over financial reporting.
Date: March 20, 2018
/s/ Eran Rotem
Eran Rotem
Deputy CEO and Chief Financial Officer
CERTIFICATION PURSUANT TO
18 U.S.C. Section 1350
Exhibit 13.1
In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2017 (the “Report”) by
CollPlant Holdings Ltd. (the “Company”), the undersigned, as Chief Executive Officer of the Company, hereby certifies pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
(1) the Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.
Date: March 20, 2018
/s/ Yehiel Tal
Name: Yehiel Tal
Title: Chief Executive Officer
CERTIFICATION PURSUANT TO
18 U.S.C. Section 1350
Exhibit 13.2
In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2017 (the “Report”) by
CollPlant Holdings Ltd. (the "Company"), the undersigned, as Chief Financial Officer of the Company, hereby certifies pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
(1) the Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.
Date: March 20, 2018
/s/ Eran Rotem
Name: Eran Rotem
Title: Deputy CEO and Chief Financial Officer